The O O
synthesis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
endo O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
adduct O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
[ O O
4aS O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5S O B_LOCATION/B_PROTEIN[GENE]
, O O
8R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
8aR O B_LOCATION/B_MEASURE
, O O
SS O B_MEASURE
] O I_MEASURE
- O O
9d O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulting O O
from O O
cycloaddition O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
substituted O O
C O B_PROTEIN[GENE]/B_LOCATION
( O O
2 O B_NUMBER[MEASURE]
) O O
- O O
C O B_PROTEIN[GENE]/B_LOCATION
( O O
3 O B_NUMBER[MEASURE]
) O O
double O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
bond O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
achieved O O
in O O
a O O
chemo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
and O O
diastereoselective O B_LOCATION
way O I_LOCATION
from O O
quinone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1d O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
presence O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
ZnBr O B_LOCATION
( O O
2 O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

Radioimmunoassay O O
of O O
plasma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gonadotropins I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
; O O
problems O O
of O O
specificity O O

Patients O B_PERSON
randomized O O
into O O
the O O
active O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
A30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O O
n O B_OTHER/B_MEASURE
= O O
49 O B_MEASURE
) O O
and O O
A60 O B_PROTEIN[GENE]/B_MEASURE
( O O
n O B_OTHER/B_MEASURE
= O O
48 O B_MEASURE
) O O
received O O
topical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
with O O
3 O B_MEASURE
. O O
0 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diclofenac O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
2 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
hyaluronan O I_MEASURE
gel O I_MEASURE
0 O I_MEASURE
. O O
5 O B_MEASURE
g O I_MEASURE
twice O O
daily O O
for O O
30 O B_MEASURE
or O O
60 O B_TIME[MEASURE]
days O I_TIME[MEASURE]
, O O
respectively O O
. O O

Previous O O
analysis O O
of O O
this O O
motif O O
in O O
the O O
lactose B B_SPECIES[BIO]/B_TIME[MEASURE]
permease I I_SPECIES[BIO]/I_TIME[MEASURE]
( O O
A O O
. O O

The O O
comparisons O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
swimming O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
performance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
before O O
and O O
after O O
treatments O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
deltamethrin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
have O O
shown O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
locomotory O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
ability O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
rainbow O B_BIO/B_PERSON
trout O I_BIO/I_PERSON
which O O
at O O
the O O
end O B_MEASURE/B_LOCATION
of O O
strong O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exposure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
e O B_DISEASE/B_LOCATION
. O O
g O B_PROTEIN[GENE]/B_MEASURE
. O O

In O O
Types O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O
and O O
II O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
capillary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
walls O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
became O O
thinner O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
more O O
capillary O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lumens O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
visiable O B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
the O O
non O O
- O O
competitive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NMDA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
+ O B_PROTEIN[GENE]/B_DISEASE
) O O
MK O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
801 O B_NUMBER[MEASURE]
on O O
the O O
behavioral O B_DISEASE_ADJECTIVE[DISEASE]
alterations O I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
repeated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
restraint O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stress O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
investigated O O
. O O

The O O
cDNA O O
clones O O
encode O O
a O O
polypeptide O O
of O O
657 O O
amino O O
acids O O
with O O
a O O
bHLH O O
( O O
basic O O
- O O
helix O O
- O O
loop O O
- O O
helix O O
) O O
domain O O
, O O
characteristic O O
of O O
a O O
large O O
family O O
of O O
transcription O O
factors O O
, O O
and O O
a O O
PAS B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
Per B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Arnt B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O O
Sim B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
domain O O
in O O
the O O
amino O O
- O O
terminal O O
half O O
region O O
. O O

Lumbar O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spine O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mineral O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
density O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
BMD O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
by O O
dual O B_MEASURE/B_LOCATION
- O O
energy O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
ray O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
absorptiometry O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DXA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
increased O O
by O O
0 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
3 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
8 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
after O O
48 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
L O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
M O B_LOCATION
and O O
H O B_OTHER/B_PROTEIN[GENE]
respectively O O
, O O
responses O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
groups O B_LOCATION/B_PERSON
M O I_LOCATION/I_PERSON
and O O
H O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
being O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
in O O
L O B_OTHER/B_PROTEIN[GENE]
( O O
p O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
0 O I_MEASURE/I_LOCATION
. O O
05 O B_MEASURE
, O O
Mann O B_PERSON
- O O
Whitney O B_PERSON
U O I_PERSON
- O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
. O O

The O O
S B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
typhimurium I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
aspartyl I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
asparaginyl I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hydroxylase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
homologue I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
designated O O
lpxO B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
was O O
cloned O O
into O O
pBluescriptSK O O
and O O
expressed O O
in O O
Escherichia O O
coli O O
K O O
- O O
12 O O
, O O
which O O
does O O
not O O
contain O O
lpxO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
highest O O
TTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
content O O
is O O
10 O O
. O O
0 O O
microg O O
/ O O
g O O
in O O
N O O
. O O
livescens O O
. O O

Soluble O O
fibrin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monomer O O
complexes O O
in O O
thromboembolism O O

Several O O
studies O O
have O O
demonstrated O O
that O O
the O O
corticotropin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
releasing I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
test O O
( O O
CRF B B_LOCATION/B_GENE
) O O
is O O
useful O O
for O O
the O O
aetiological O O
diagnosis O O
of O O
Cushing O O
' O O
s O O
syndrome O O
: O O
in O O
Cushing O O
' O O
s O O
disease O O
, O O
as O O
opposed O O
to O O
ectopic O O
ACTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
secretion O O
syndrome O O
, O O
the O O
hypothalamus O O
- O O
pituitary O O
- O O
adrenal O O
( O O
HPA O O
) O O
axis O O
can O O
still O O
be O O
stimulated O O
by O O
CRF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

To O O
test O O
this O O
hypothesis O O
, O O
we O O
developed O O
a O O
system O O
of O O
transient O O
transfection O O
of O O
rat O O
adipocytes O O
with O O
constructs O O
containing O O
glyceraldehyde B B_ENZYME[GENE]
- I I_ENZYME[GENE]
3 I I_ENZYME[GENE]
- I I_ENZYME[GENE]
phosphate I I_ENZYME[GENE]
dehydrogenase I I_ENZYME[GENE]
( O O
GAPDH B B_GENE/B_LOCATION
) O O
and O O
fatty B B_ENZYME[GENE]
acid I I_ENZYME[GENE]
synthetase I I_ENZYME[GENE]
( O O
FAS B B_DISEASE/B_LOCATION
) O O
promoters O O
fused O O
to O O
gene B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CAT I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Simvastatin O O
decreased O O
levels O O
of O O
total O O
cholesterol O O
by O O
20 O O
. O O
8 O O
% O O
, O O
LDL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cholesterol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
by O O
29 O O
. O O
7 O O
% O O
, O O
triglycerides O O
by O O
13 O O
. O O
6 O O
% O O
, O O
apolipoprotein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
by O O
22 O O
. O O
4 O O
% O O
, O O
alpha O O
- O O
tocopherol O O
by O O
16 O O
. O O
2 O O
% O O
, O O
beta O O
- O O
carotene O O
by O O
19 O O
. O O
5 O O
% O O
, O O
and O O
ubiquinol O O
- O O
10 O O
by O O
22 O O
. O O
0 O O
% O O
( O O
P O O
< O O
. O O
001 O O
for O O
all O O
) O O
and O O
increased O O
levels O O
of O O
HDL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cholesterol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
7 O O
. O O
0 O O
% O O
( O O
P O O
< O O
. O O
001 O O
) O O
and O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
13 O O
. O O
2 O O
% O O
( O O
P O O
= O O
. O O
005 O O
) O O
. O O

A O O
novel O O
Cdc42Hs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mutant I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
induces O O
cellular O O
transformation O O
. O O

BACKGROUND O O
- O O
- O O
Platelet B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activating I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PAF B B_LOCATION/B_GENE
) O O
has O O
been O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
airway O O
hyperresponsiveness O O
in O O
asthma O O
. O O

Our O O
results O O
show O O
that O O
unlike O O
the O O
case O O
for O O
sos1 B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
sos2 B B_GENE/B_PERSON
gene I I_GENE/I_PERSON
function O O
is O O
dispensable O O
for O O
normal O O
mouse O O
development O O
, O O
growth O O
, O O
and O O
fertility O O
. O O

This O O
inhibition O O
was O O
due O O
to O O
competition O O
from O O
the O O
EMC O O
virus O O
IRES O O
present O O
in O O
pEP B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
2A I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transcripts I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
as O O
well O O
as O O
the O O
expression O O
of O O
proteolytically O O
active O O
2Apro B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Some O O
may O O
affect O O
the O O
folding O O
pathway O O
or O O
the O O
affinity O O
for O O
chaperonins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

The O O
effect O O
on O O
FIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
of O O
progressively O O
deleting O O
these O O
nuclear O O
factor O O
binding O O
sites O O
was O O
examined O O
by O O
linking O O
LTR O O
deletion O O
mutants O O
to O O
the O O
chloramphenicol B B_ENZYME[GENE]
acetyltransferase I I_ENZYME[GENE]
( O O
CAT B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
gene O O
. O O

A O O
series O O
of O O
sequence O O
fragments O O
were O O
placed O O
5 O O
' O O
to O O
the O O
chloramphenicol B B_ENZYME[GENE]
acetyltransferase I I_ENZYME[GENE]
( O O
CAT B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
reporter O O
gene O O
and O O
ability O O
to O O
mediate O O
transcription O O
of O O
CAT B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
response O O
to O O
IFN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O O
LPS O O
treatment O O
was O O
studied O O
following O O
transient O O
transfection O O
in O O
the O O
macrophage O O
- O O
like O O
cell O O
line O O
RAW O O
264 O O
. O O
7 O O
. O O

Module O O
2 O O
of O O
RifA B B_SPECIES[BIO]/B_LOCATION
lacks O O
a O O
beta B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
ketoacyl I I_GENE/I_MEASURE
: I I_GENE/I_MEASURE
acyl I I_GENE/I_MEASURE
carrier I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
reductase I I_GENE/I_MEASURE
( O O
KR B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
domain O O
and O O
the O O
one O O
in O O
module O O
3 O O
has O O
an O O
apparently O O
inactive O O
NADPH B B_LOCATION/B_MEASURE
binding I I_LOCATION/I_MEASURE
motif I I_LOCATION/I_MEASURE
, O O
similar O O
to O O
one O O
found O O
in O O
the O O
Er B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PKS I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
while O O
the O O
other O O
eight O O
KR B B_LOCATION/B_PERSON
domains I I_LOCATION/I_PERSON
of O O
the O O
Rf B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
PKS I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
should O O
be O O
functional O O
. O O

In O O
accordance O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
Ann O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Arbor O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
classification O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
we O O
observed O O
12 O B_MEASURE
CS O I_MEASURE
IA O I_MEASURE
( O O
21 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
) O O
, O O
2 O B_PROTEIN[GENE]/B_LOCATION
CS O I_PROTEIN[GENE]/I_LOCATION
IB O I_PROTEIN[GENE]/I_LOCATION
( O O
3 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
) O O
, O O
14 O B_PROTEIN[GENE]/B_LOCATION
CS O I_PROTEIN[GENE]/I_LOCATION
IIA O I_PROTEIN[GENE]/I_LOCATION
( O O
25 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
27 O B_LOCATION/B_PERSON
CS O I_LOCATION/I_PERSON
IIB O I_LOCATION/I_PERSON
( O O
49 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

We O O
now O O
show O O
that O O
the O O
FRAP B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ser2035 O O
- O O
- O O
> O O
Ala O O
mutant O O
displays O O
similar O O
binding O O
affinity O O
when O O
compared O O
with O O
the O O
wild O O
- O O
type O O
protein O O
, O O
whereas O O
all O O
other O O
mutations O O
at O O
this O O
site O O
, O O
including O O
mimics O O
of O O
phosphoserine O O
, O O
abolish O O
binding O O
, O O
presumably O O
due O O
to O O
either O O
unfavorable O O
steric O O
interactions O O
or O O
induced O O
conformational O O
changes O O
. O O

Titres O O
of O O
antistreptolysin B B_VIRUS[BIO]/B_DISEASE
O I B_VIRUS[BIO]/I_DISEASE
in O O
mothers O O
of O O
children O O
affected O O
with O O
Down O O
' O O
s O O
syndrome O O
. O O

Defects O O
in O O
RT6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
coincide O O
with O O
increased O O
susceptibility O O
in O O
animal O O
models O O
for O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
dependent O O
diabetes O O
mellitus O O
and O O
other O O
autoimmune O O
diseases O O
. O O

The O O
unc B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
101 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
sli B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
1 I I_MEASURE/I_GENE
, O O
and O O
rok B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
genes I I_GENE/I_MEASURE
encode O O
a O O
distinct O O
set O O
of O O
negative O O
regulators O O
of O O
vulval O O
differentiation O O
. O O

Neuronal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
58 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dopaminergic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
DA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
and O O
200 O B_MEASURE/B_PROTEIN[GENE]
non O B_MEASURE/I_PROTEIN[GENE]
- O O
dopaminergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
non O B_DISEASE/B_LOCATION
- O O
DA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
in O O
the O O
ventral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tegmental O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
area O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
VTA O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
of O O
female O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
monkeys O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
recorded O O
, O O
and O O
correlation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
bar O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
press O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
feeding O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
sensory O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O O
change O B_DISEASE_ADJECTIVE[DISEASE]
in O O
motivation O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
investigated O O
. O O

We O O
demonstrate O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
2 O B_MEASURE
- O O
deoxyglucose O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
uptake O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
isolated O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
primary O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
rat O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
adipocytes O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
3T3 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
- O O
L1 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
adipocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
pretreated O O
with O O
U73122 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

RESULTS O O
: O O
BMK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
other O O
19 O O
contents O O
significantly O O
decreased O O
depolarization O O
parameters O O
Vmax O O
, O O
APA O O
, O O
OS O O
, O O
and O O
MDP O O
, O O
which O O
was O O
similar O O
to O O
that O O
of O O
TTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
different O O
from O O
that O O
of O O
Nim O O
and O O
BaCl2 O O
. O O

Serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prolactin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
oestradiol O O
levels O O
at O O
different O O
stages O O
of O O
puberty O O
. O O

Role O O
of O O
distinct O O
mitogen B B_GENE
- I I_GENE
activated I I_GENE
protein I I_GENE
kinase I I_GENE
pathways O O
and O O
cooperation O O
between O O
Ets B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
ATF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
, O O
and O O
Jun B B_GENE
family I I_GENE
members I I_GENE
in O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
urokinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasminogen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induction O O
by O O
interleukin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
tetradecanoyl O O
phorbol O O
acetate O O
. O O

Stability O O
of O O
125 O O
I O O
- O O
labeled O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
used O O
in O O
radioimmunoassay O O
of O O
insulin B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
Aspergillus B B_GENE/B_MEASURE
uvsH I I_GENE/I_MEASURE
gene I I_GENE/I_MEASURE
encodes O O
a O O
product O O
homologous O O
to O O
yeast B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
RAD18 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Neurospora B B_BIO/B_GENE
UVS I B_BIO/I_GENE
- I B_BIO/I_GENE
2 I B_BIO/I_GENE
. O O

Consequently O O
, O O
during O O
the O O
evolution O O
of O O
mammals O O
, O O
it O O
is O O
the O O
CKbeta4GT B B_DISEASE_ADJECTIVE[DISEASE]/B_SEQUENCE[MEASURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_SEQUENCE[MEASURE]
I I B_DISEASE_ADJECTIVE[DISEASE]/I_SEQUENCE[MEASURE]
gene I B_DISEASE_ADJECTIVE[DISEASE]/I_SEQUENCE[MEASURE]
lineage O O
that O O
has O O
been O O
recruited O O
for O O
the O O
biosynthesis O O
of O O
lactose O O
. O O

The O O
human O B_GENE
cDNA O I_GENE
was O O
cloned O O
and O O
sequenced O O
; O O
it O O
was O O
shown O O
to O O
have O O
an O O
open O B_GENE
reading O I_GENE
frame O I_GENE
encoding O O
a O O
296 O B_MEASURE
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
acid O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein O B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
which O O
could O O
be O O
identified O O
four O B_LOCATION/B_BIO
peptides O I_LOCATION/I_BIO
previously O O
identified O O
by O O
micro O B_GENE
- O O
sequencing O O
purified O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
preference O O
for O O
third O O
base O O
codon O O
in O O
Y O O
position O O
prolines O O
is O O
U O O
for O O
the O O
alpha B B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
2 I I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
( I I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
VI I I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
) I I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
collagen I I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
as O O
it O O
is O O
for O O
the O O
human B B_GENE/B_MEASURE
fibrillar I I_GENE/I_MEASURE
collagen I I_GENE/I_MEASURE
genes I I_GENE/I_MEASURE
. O O

Residues O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Stauffer O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
R O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3828 O B_MEASURE
and O O
its O O
oxygen O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analogue O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
the O O
body O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cattle O B_BIO/B_PERSON
fed O O
R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3828 O B_MEASURE
in O O
the O O
diet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
goals O O
of O O
these O O
experiments O O
were O O
to O O
determine O O
whether O O
lactational O O
anestrus O O
would O O
be O O
prolonged O O
by O O
a O O
48 O O
- O O
h O O
fast O O
at O O
days O O
13 O O
and O O
14 O O
postpartum O O
( O O
pp O O
) O O
and O O
, O O
if O O
so O O
, O O
to O O
determine O O
whether O O
this O O
effect O O
could O O
be O O
reversed O O
by O O
treatment O O
with O O
the O O
Ob B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
protein I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
leptin B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

However O O
, O O
electron O O
microscopy O O
revealed O O
that O O
while O O
sec4 B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
mutant I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
cells O O
accumulate O O
secretory O O
vesicles O O
, O O
ypt31 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
/ I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
32 I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mutant I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
cells O O
accumulate O O
aberrant O O
Golgi O O
structures O O
. O O

Moreover O O
, O O
a O O
hybrid O O
protein O O
composed O O
of O O
a O O
PvALF B B_GENE
activation I I_GENE
domain I I_GENE
and O O
the O O
DNA O O
binding O O
and O O
dimerization O O
domain O O
of O O
ROM2 B B_GENE
activated O O
gene O O
expression O O
, O O
indicating O O
that O O
ROM2 B B_GENE/B_MEASURE
recognizes O O
the O O
DLEC2 B B_GENE/B_LOCATION
enhancer I I_GENE/I_LOCATION
in O O
vivo O O
; O O
consequently O O
, O O
ROM2 B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
functions O O
as O O
a O O
DNA O O
binding O O
site O O
- O O
dependent O O
repressor O O
. O O

We O O
found O O
that O O
the O O
central O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
nonconserved O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
region O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
large O B_ENZYME[GENE]/B_LOCATION
subunit O I_ENZYME[GENE]/I_LOCATION
is O O
not O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
likely O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acts O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
spacer O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
between O O
the O O
conserved O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
and O O
C O B_PROTEIN[GENE]/B_LOCATION
- O O
terminal O B_LOCATION/B_BIO
regions O I_LOCATION/I_BIO
. O O

On O O
the O O
other O O
hand O O
, O O
NE O O
transport O O
and O O
antagonist O O
( O O
[ O O
125I O O
] O O
RTI O O
- O O
55 O O
) O O
binding O O
assays O O
on O O
whole O O
LLC O O
- O O
NET O O
cells O O
treated O O
with O O
tunicamycin O O
reveal O O
a O O
pronounced O O
reduction O O
in O O
NE O O
transport O O
activity O O
and O O
hNET B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
membrane O O
density O O
paralleled O O
by O O
an O O
inability O O
of O O
NET B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
replenish O O
the O O
higher O O
M O O
( O O
r O O
) O O
hNET B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pool O O
. O O

In O O
transient O O
transfections O O
using O O
luciferase B B_GENE/B_LOCATION
reporter I I_GENE/I_LOCATION
genes I I_GENE/I_LOCATION
driven O O
by O O
1 O O
kb O O
of O O
the O O
5 O O
' O O
flanking O O
DNA O O
of O O
the O O
three O O
CALM B B_GENE/B_LOCATION
genes I I_GENE/I_LOCATION
, O O
the O O
promoter O O
activity O O
correlated O O
with O O
the O O
endogenous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CALM I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
transcriptional O O
activity O O
, O O
but O O
only O O
when O O
the O O
5 O O
' O O
untranslated O O
regions O O
were O O
included O O
in O O
the O O
constructs O O
. O O

The O O
derepressed O O
expression O O
of O O
fixN B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
observed O O
in O O
a O O
purH B B_DISEASE/B_PERSON
mutant I I_DISEASE/I_PERSON
. O O

In O O
area O B_LOCATION/B_BIO
CA1 O I_LOCATION/I_BIO
of O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
numbers O B_MEASURE/B_LOCATION
of O O
normal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
increased O O
11 O B_NUMBER[MEASURE]
- O O
to O O
14 O B_MEASURE
- O O
fold O B_MEASURE/B_BIO
by O O
MK O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
801 O B_MEASURE
treatment O I_MEASURE
( O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
. O O

The O O
temporal O O
changes O O
in O O
the O O
plasma O O
concentration O O
of O O
immunoreactive B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
atrial I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
natriuretic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
iANF B B_GENE/B_LOCATION
) O O
were O O
studied O O
in O O
six O O
conscious O O
dogs O O
with O O
an O O
arteriovenous O O
( O O
AV O O
) O O
fistula O O
, O O
a O O
model O O
of O O
chronic O O
high O O
- O O
output O O
heart O O
failure O O
. O O

Genetic O O
analysis O O
places O O
CWH43 B B_LOCATION/B_GENE
upstream O O
of O O
the O O
BCK2 B B_GENE
branch O O
of O O
the O O
PKC1 B B_GENE
signalling O O
pathway O O
, O O
since O O
cwh43 B B_NUMBER[MEASURE]/B_LOCATION
mutations O O
were O O
synthetic O O
lethal O O
with O O
pkc1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
deletion O O
, O O
whereas O O
the O O
cwh43 B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defects O O
could O O
be O O
rescued O O
by O O
overexpression O O
of O O
BCK2 B B_GENE
and O O
not O O
by O O
high O O
- O O
copy O O
- O O
number O O
expression O O
of O O
genes O O
encoding O O
downstream O O
proteins O O
of O O
the O O
PKC1 B B_GENE/B_DISEASE
pathway O O
However O O
, O O
unlike O O
BCK2 B B_GENE/B_BIO
, O O
whose O O
disruption O O
in O O
a O O
cln3 B B_LOCATION/B_GENE
mutant I B_LOCATION/I_GENE
resulted O O
in O O
growth O O
arrest O O
in O O
G O O
( O O
1 O O
) O O
, O O
no O O
growth O O
defect O O
was O O
observed O O
in O O
a O O
double O O
cwh43 B B_DISEASE_ADJECTIVE[DISEASE]
cln3 B I_DISEASE_ADJECTIVE[DISEASE]
mutants I I_DISEASE_ADJECTIVE[DISEASE]
. O O

Therefore O O
, O O
a O O
structural O O
interaction O O
between O O
PsaL B B_GENE/B_BACTERIUM[BIO]
and O O
PsaI B B_GENE/B_BACTERIUM[BIO]
may O O
stabilize O O
the O O
association O O
of O O
PsaL B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
with O O
the O O
photosystem B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
I I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
core I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Reversal O O
of O O
' O O
refractory O O
septic O O
shock O O
' O O
by O O
infusion O O
of O O
amrinone O O
and O O
angiotensin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
II I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
an O O
anthracycline O O
- O O
treated O O
patient O O
. O O

Rv O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
7 O B_MEASURE
. O O
7 O B_MEASURE
+ O O
/ O O
- O O
1 O B_MEASURE
. O O
4 O B_MEASURE
mmHg O I_MEASURE
. O O
ml O B_MEASURE/B_PERSON
- O O
1 O B_MEASURE/B_LOCATION
. O O
min O B_MEASURE/B_PERSON
. O O
100 O B_MEASURE/B_LOCATION
g O B_MEASURE/I_LOCATION
- O O
1 O B_MEASURE/B_LOCATION
and O O
Cv O B_PROTEIN[GENE]/B_BIO
was O O
0 O B_MEASURE
. O O
59 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
25 O B_MEASURE
ml O I_MEASURE
/ O O
mmHg O B_MEASURE
, O O
tau O B_PROTEIN[GENE]
v O O
calculated O O
from O O
the O O
product O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Rv O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Cv O B_PROTEIN[GENE]/B_BIO
was O O
4 O B_MEASURE
. O O
20 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE/B_LOCATION
. O O
58 O B_MEASURE
s O I_MEASURE
and O O
from O O
the O O
ratio O B_MEASURE
of O O
delta O B_PROTEIN[GENE]/B_MEASURE
V O O
to O O
delta O B_MEASURE/B_PROTEIN[GENE]
Q O B_MEASURE/I_PROTEIN[GENE]
was O O
4 O B_MEASURE
. O O
95 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_NUMBER[MEASURE]
. O O
53 O B_MEASURE
s O I_MEASURE
( O O
P O B_OTHER/B_MEASURE
= O O
NS O B_MEASURE
) O O
at O O
a O O
mean O B_MEASURE/B_PERSON
Pel O I_MEASURE/I_PERSON
of O O
17 O B_MEASURE
. O O
6 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
3 O B_MEASURE
. O O
7 O B_MEASURE
mmHg O I_MEASURE
. O O
delta O B_PROTEIN[GENE]/B_DISEASE
V O I_PROTEIN[GENE]/I_DISEASE
was O O
also O O
produced O O
by O O
changing O O
Pv O B_DISEASE/B_MEASURE
; O O
the O O
average O B_MEASURE/B_PROTEIN[GENE]
tau O B_MEASURE/I_PROTEIN[GENE]
v O O
( O O
1 O B_MEASURE
. O O
95 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_NUMBER[MEASURE]
. O O
37 O B_MEASURE
s O I_MEASURE
) O O
, O O
was O O
shorter O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
that O O
with O O
changes O B_MEASURE
in O O
flow O B_MEASURE/B_PROTEIN[GENE]
. O O

T1 O B_PROTEIN[GENE]/B_LOCATION
and O O
T2 O B_MEASURE
values O I_MEASURE
were O O
calculated O O
from O O
guinea O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
pig O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
brain O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
in O O
vivo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
at O O
0 O B_MEASURE
. O O
5 O B_MEASURE/B_LOCATION
T O I_MEASURE/I_LOCATION
. O O

Autophosphorylation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
the O O
major O B_GENE
phosphorylation O I_GENE
site O I_GENE
Y1235 O I_GENE
upregulates O O
the O O
kinase O B_MEASURE
activity O I_MEASURE
of O O
the O O
receptor O B_GENE
, O O
increasing O O
the O O
Vmax O B_MEASURE
of O O
the O O
phosphotransfer O B_ENZYME[GENE]
reaction O I_ENZYME[GENE]
. O O

Clinical O O
development O O
of O O
interleukin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
10 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

It O O
was O O
previously O O
shown O O
that O O
Vi B B_GENE/B_DISEASE
antigen I I_GENE/I_DISEASE
expression O O
was O O
regulated O O
by O O
a O O
system O O
similar O O
to O O
the O O
rcs B B_DISEASE_ADJECTIVE[DISEASE]
regulatory O O
system O O
involved O O
in O O
colanic O O
acid O O
synthesis O O
in O O
Escherichia O O
coli O O
. O O

This O O
effect O O
is O O
independent O O
of O O
the O O
Gal4 B B_GENE
protein I I_GENE
, O O
as O O
it O O
operates O O
in O O
a O O
gal4 B B_DISEASE_ADJECTIVE[DISEASE]
mutant I I_DISEASE_ADJECTIVE[DISEASE]
background O O
as O O
well O O
. O O

In O O
patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
which O O
these O O
criteria O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
not O O
met O O
only O O
the O O
reproducibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
VO2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O O
in O O
both O O
the O O
P O B_PROTEIN[GENE]/B_LOCATION
- O O
MET O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
the O O
C O B_OTHER/B_PROTEIN[GENE]
- O O
MET O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
indicated O O
that O O
the O O
maximal O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
VO2 O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
these O O
4 O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
had O O
been O O
reached O O
. O O

Critical O O
review O O
of O O
tests O O
for O O
the O O
HBs B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigen I B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
detection O O
of O O
infectious O O
blood O O

A O O
direct O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
statistically O O
reliable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
enzymes O B_PROTEIN[GENE]/B_MEASURE
with O O
the O O
initial O B_TIME[MEASURE]/B_LOCATION
state O I_TIME[MEASURE]/I_LOCATION
of O O
the O O
patients O B_PERSON/B_DISEASE
has O O
been O O
established O O
in O O
an O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
25 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
aged O O
from O O
18 O B_MEASURE
to O O
60 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
in O O
prosthesis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
+ O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O O
mitral O B_MEDICAL_DEVICE[OBJECT]/B_DISEASE_ADJECTIVE[DISEASE]
valve O I_MEDICAL_DEVICE[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
n O B_MEASURE
- O O
9 O B_MEASURE
) O O
and O O
closed O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
mitral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
commissurotomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
n O O
- O O
16 O B_MEASURE
) O O
. O O

The O O
vaccine O O
was O O
highly O O
immunogenic O O
, O O
since O O
111 O O
of O O
113 O O
patients O O
( O O
98 O O
% O O
) O O
produced O O
anti B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HBs I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
mIU O O
/ O O
ml O O
or O O
more O O
) O O
. O O

Vk8 B B_GENE
/ O O
Jk2 B B_MEASURE
and O O
Vk1 B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Jk5 B B_GENE/B_MEASURE
rearrangements O O
encoded O O
the O O
respective O O
L B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
V I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
total O B_MEASURE
of O O
114 O B_MEASURE
animals O I_MEASURE
were O O
infected O O
by O O
E O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
coli O B_BACTERIUM[BIO]
O2 O I_BACTERIUM[BIO]
: O O
K1 O B_PROTEIN[GENE]/B_MEASURE
: O O
H4 O B_MEASURE/B_LOCATION
by O O
the O O
hematogenic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
route O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
matrix O O
of O O
the O O
CBs O O
contains O O
the O O
diagnostic O O
protein O O
p80 B B_PROTEIN[GENE]/B_DISEASE
- O O
coilin B B_MEASURE/B_LOCATION
, O O
which O O
is O O
colocalized O O
with O O
the O O
U7 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
small I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ribonucleoprotein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
snRNP O O
) O O
, O O
whereas O O
the O O
attached O O
and O O
embedded O O
B O O
- O O
snurposomes O O
contain O O
splicing O O
snRNPs O O
. O O

These O O
data O O
, O O
taken O O
together O O
, O O
suggest O O
that O O
CRF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
produces O O
its O O
behavioral O O
activating O O
and O O
anxiogenic O O
effects O O
, O O
at O O
least O O
in O O
part O O
, O O
by O O
increasing O O
the O O
activity O O
of O O
LC O O
noradrenergic O O
neurons O O
. O O

Anti B B_PERSON/B_DISEASE
- I I_PERSON/I_DISEASE
Jo I I_PERSON/I_DISEASE
- I I_PERSON/I_DISEASE
1 I I_PERSON/I_DISEASE
antibody I I_PERSON/I_DISEASE
was O O
not O O
present O O
. O O

The O O
first O O
operon O O
, O O
orf1 O O
- O O
tolQRA B B_MEASURE
, O O
is O O
iron O O
regulated O O
throughout O O
growth O O
, O O
but O O
iron O O
- O O
regulated O O
expression O O
of O O
tolB B B_GENE/B_BACTERIUM[BIO]
and O O
oprL B B_DISEASE/B_GENE
fusions I B_DISEASE/I_GENE
occurs O O
only O O
in O O
late O O
log O O
phase O O
. O O

Using O O
green B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fluorescent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fusions O O
we O O
demonstrate O O
that O O
the O O
SYT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
SSX B B_LOCATION/B_GENE
and O O
the O O
SYT B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
SSX B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O O
are O O
nuclear O O
proteins O O
. O O

These O O
data O O
suggested O O
that O O
mutant B B_DISEASE
PS1 I I_DISEASE
may O O
cause O O
disease O O
as O O
a O O
result O O
of O O
reduction O O
in O O
PS1 B B_GENE
function O O
. O O

The O O
analysis O O
of O O
the O O
organization O O
of O O
the O O
sequence O O
of O O
the O O
human O O
ABP B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
DAO B B_LOCATION/B_PROTEIN[GENE]
gene O O
reveals O O
that O O
the O O
2 O O
. O O
4 O O
- O O
kilobase O O
messenger O O
RNA O O
is O O
transcribed O O
from O O
two O O
close O O
origins O O
identifying O O
the O O
proximal O O
promoter O O
. O O

Most O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
after O O
all O O
, O O
is O O
not O O
the O O
ionization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
technique O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
but O O
the O O
stage O B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
a O O
47 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
five O I_MEASURE
- O O
year O B_SEQUENCE[MEASURE]/B_LOCATION
survival O I_SEQUENCE[MEASURE]/I_LOCATION
rate O I_SEQUENCE[MEASURE]/I_LOCATION
in O O
T1N0 O B_PROTEIN[GENE]/B_MEASURE
as O O
compared O O
to O O
T2N0 O B_PROTEIN[GENE]/B_DISEASE
with O O
28 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
T1N1 O B_PROTEIN[GENE]/B_MEASURE
with O O
19 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
. O O

Recombinant B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MsERK1 I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
rMsERK1 B B_GENE
) O O
, O O
when O O
overexpressed O O
in O O
Escherichia O O
coli O O
, O O
is O O
recognized O O
by O O
antibodies O O
raised O O
against O O
MAP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
rat I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Xenopus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sea I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
star I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
by O O
anti B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphotyrosine I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antibodies I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
identification O O
of O O
SRP54sc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
SRP54sp B B_GENE
provides O O
the O O
first O O
evidence O O
for O O
SRP B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
related O O
proteins O O
in O O
yeast O O
. O O

The O O
prominent O B_DISEASE/B_MEASURE
fracture O I_DISEASE/I_MEASURE
of O O
women O B_PERSON/B_TIME[MEASURE]
older O B_PERSON/I_TIME[MEASURE]
than O O
75 O B_NUMBER[MEASURE]/B_ENT
years O I_NUMBER[MEASURE]/I_ENT
is O O
the O O
hip O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
fracture O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
type O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
II O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
osteoporosis O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
Pearson O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
s O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
correlation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
that O O
the O O
subjects O B_PERSON
who O O
had O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
SSMS O B_DISEASE
during O O
the O O
drum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rotation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generated O O
the O O
following O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
a O O
) O O
a O O
higher O B_MEASURE
rating O I_MEASURE
of O O
over O O
- O O
all O O
sickness O B_DISEASE/B_MEASURE
( O O
r O B_PROTEIN[GENE]/B_MEASURE
= O O
0 O B_NUMBER[MEASURE]
. O O
76 O B_MEASURE
) O O
; O O
b O O
) O O
a O O
higher O B_MEASURE/B_LOCATION
ratio O I_MEASURE/I_LOCATION
of O O
spectral O B_MEASURE/B_LOCATION
power O I_MEASURE/I_LOCATION
of O O
EGG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
4 O B_NUMBER[MEASURE]
- O O
9 O B_NUMBER[MEASURE]/B_LOCATION
cycles O I_NUMBER[MEASURE]/I_LOCATION
per O O
minute O B_TIME[MEASURE]
( O O
cpm O B_MEASURE/B_PROTEIN[GENE]
) O O
between O O
drum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
rotation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
and O O
baseline O B_MEASURE/B_ENT
periods O B_MEASURE/I_ENT
( O O
r O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_NUMBER[MEASURE]
. O O
63 O B_MEASURE
) O O
; O O
c O O
) O O
a O O
higher O B_MEASURE
net O I_MEASURE
percent O I_MEASURE
increase O I_MEASURE
of O O
spectral O B_MEASURE/B_LOCATION
power O I_MEASURE/I_LOCATION
in O O
the O O
EEG O B_MEASURE
frequency O I_MEASURE
band O I_MEASURE
0 O I_MEASURE
. O O
5 O B_MEASURE
- O O
4 O B_MEASURE
Hz O I_MEASURE
between O O
drum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
rotation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
and O O
baseline O B_TIME[MEASURE]/B_LOCATION
periods O I_TIME[MEASURE]/I_LOCATION
on O O
C3 O B_PROTEIN[GENE]
( O O
r O B_PROTEIN[GENE]
= O O
0 O B_NUMBER[MEASURE]
. O O
29 O B_MEASURE
) O O
and O O
C4 O B_PROTEIN[GENE]
( O O
r O B_PROTEIN[GENE]/B_MEASURE
= O O
0 O B_NUMBER[MEASURE]
. O O
31 O B_MEASURE
) O O
; O O
d O O
) O O
a O O
higher O B_MEASURE/B_LOCATION
ratio O I_MEASURE/I_LOCATION
of O O
spectral O B_MEASURE/B_LOCATION
power O I_MEASURE/I_LOCATION
of O O
EEG O B_MEASURE
frequency O I_MEASURE
band O I_MEASURE
0 O I_MEASURE
. O O
5 O B_MEASURE
- O O
4 O B_MEASURE
Hz O I_MEASURE
between O O
drum O B_MEASURE/B_ENT
rotation O I_MEASURE/I_ENT
and O O
baseline O B_TIME[MEASURE]/B_ENT
periods O I_TIME[MEASURE]/I_ENT
on O O
C3 O B_MEASURE/B_GENE
( O O
r O B_OTHER/B_GENE
= O O
0 O B_MEASURE/B_LOCATION
. O O
31 O B_MEASURE
) O O
; O O
and O O
e O O
) O O
a O O
higher O B_MEASURE
level O I_MEASURE
of O O
net O B_MEASURE
increase O I_MEASURE
in O O
skin O B_MEASURE/B_DISEASE
conductance O I_MEASURE/I_DISEASE
from O O
baseline O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
drum O B_MEASURE
rotation O I_MEASURE
( O O
r O B_MEASURE/B_GENE
= O O
0 O B_NUMBER[MEASURE]
. O O
30 O B_MEASURE
) O O
. O O

Fus3p B B_GENE
and O O
Kss1p B B_GENE/B_LOCATION
together O O
increase O O
the O O
expression O O
of O O
CLN3 B B_GENE/B_DISEASE
and O O
PCL2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
promote O O
budding O O
, O O
and O O
Kss1p B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
inhibits O O
the O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cascade O O
. O O

Like O O
the O O
DMA B B_SPECIES[BIO]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
but O O
unlike O O
all O O
other O O
mammalian B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
class I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
zebrafish O O
gene O O
codes O O
for O O
two O O
cysteine O O
residues O O
which O O
might O O
potentially O O
be O O
involved O O
in O O
the O O
formation O O
of O O
a O O
disulfide O O
bond O O
in O O
the O O
alpha O O
1 O O
domain O O
. O O

BK B B_GENE/B_BIO
- O O
induced O O
translocation O O
and O O
overexpression O O
of O O
PKC B B_GENE
isoforms I I_GENE
as O O
well O O
as O O
coexpression O O
of O O
inactive O O
or O O
constitutively O O
active O O
mutants O O
of O O
different O O
PKC B B_GENE
isozymes I I_GENE
provided O O
evidence O O
for O O
a O O
role O O
of O O
the O O
diacylglycerol O O
- O O
sensitive O O
PKCs B B_ENZYME[GENE]/B_LOCATION
alpha I I_ENZYME[GENE]/I_LOCATION
and I I_ENZYME[GENE]/I_LOCATION
epsilon I I_ENZYME[GENE]/I_LOCATION
in O O
BK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
signaling O O
toward O O
MAPK B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

A O O
lead O O
phthalocyanin O O
method O O
for O O
the O O
demonstration O O
of O O
acid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
hydrolases I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
in O O
plant O O
and O O
animal O O
tissues O O
. O O

Here O O
we O O
describe O O
the O O
characterization O O
of O O
cDNAs O O
encoding O O
two O O
unusual O O
E2Fs B B_GENE/B_BIO
, O O
E2F B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
E2F B B_MEASURE
- I I_MEASURE
5 I I_MEASURE
, O O
each O O
identified O O
by O O
the O O
ability O O
of O O
their O O
gene O O
product O O
to O O
interact O O
with O O
p130 B B_GENE/B_BIO
in O O
a O O
yeast O O
two O O
- O O
hybrid O O
system O O
. O O

Thus O O
, O O
CARP B B_GENE/B_BIO
is O O
a O O
YB B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
associated I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
and O O
represents O O
the O O
first O O
identified O O
cardiac O O
- O O
restricted O O
downstream O O
regulatory O O
gene O O
in O O
the O O
homeobox O O
gene O O
Nkx2 B B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
5 I I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pathway O O
and O O
may O O
serve O O
as O O
a O O
negative O O
regulator O O
of O O
HF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
dependent O O
pathways O O
for O O
ventricular O O
muscle O O
gene O O
expression O O
. O O

Each O O
receptor O O
must O O
therefore O O
engage O O
a O O
unique O O
subset O O
of O O
the O O
available O O
signaling O O
elements O O
- O O
- O O
at O O
least O O
partly O O
through O O
the O O
selection O O
of O O
proteins O O
with O O
src B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
homology I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
2 I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
domains I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
SH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

When O O
recombinant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gE I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
produced O O
in O O
HeLa O O
cells O O
was O O
probed O O
with O O
the O O
same O O
antiphosphotyrosine O O
antibody O O
, O O
a O O
dimeric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_COLOR
gE I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
form O O
at O O
130 O O
kDa O O
was O O
detected O O
on O O
the O O
cell O O
surface O O
. O O

Five O O
girls O O
with O O
Turner O O
' O O
s O O
syndrome O O
aged O O
12 O O
to O O
17 O O
years O O
showed O O
LH B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O O
( O O
5 O O
. O O
0 O O
- O O
14 O O
. O O
5 O O
IU O O
/ O O
12 O O
h O O
) O O
at O O
the O O
upper O O
end O O
of O O
or O O
slightly O O
above O O
the O O
normal O O
range O O
and O O
pathologically O O
high O O
values O O
( O O
22 O O
. O O
2 O O
- O O
43 O O
. O O
5 O O
IU O O
/ O O
12 O O
h O O
) O O
for O O
FSH B B_PERSON/B_GENE
. O O

In O O
vitro O O
death O O
assays O O
with O O
transient O O
overexpression O O
of O O
deletion O O
constructs O O
of O O
both O O
isoforms O O
using O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
reporter O O
gene O O
in O O
MCF7 O O
cells O O
suggest O O
the O O
following O O
: O O
1 O O
) O O
the O O
nucleotide O O
binding O O
domain O O
may O O
act O O
as O O
a O O
negative O O
regulator O O
of O O
the O O
killing O O
activity O O
of O O
DEFCAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
2 O O
) O O
the O O
LRR B B_DISEASE/B_PROTEIN[GENE]
/ O O
CARD B B_LOCATION/B_GENE
represents O O
a O O
putative O O
constitutively O O
active O O
inducer O O
of O O
apoptosis O O
; O O
3 O O
) O O
the O O
killing O O
activity O O
of O O
LRR B B_DISEASE/B_GENE
/ O O
CARD B B_LOCATION/B_GENE
is O O
inhibitable O O
by O O
benzyloxycarbonyl O O
- O O
Val O O
- O O
Ala O O
- O O
Asp O O
( O O
OMe O O
) O O
- O O
fluoromethyl O O
ketone O O
and O O
to O O
a O O
lesser O O
extent O O
by O O
Asp O O
- O O
Glu O O
- O O
Val O O
- O O
Asp O O
( O O
OMe O O
) O O
- O O
fluoromethyl O O
ketone O O
; O O
and O O
4 O O
) O O
the O O
CARD B B_PROTEIN[GENE]
is O O
critical O O
for O O
killing O O
activity O O
of O O
DEFCAP B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
parvovirus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B19 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
from O O
the O O
viral B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
p6 I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
promoter I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O O
B19p6 B B_GENE
) O O
is O O
restricted O O
to O O
primary O O
human O O
hematopoietic O O
cells O O
undergoing O O
erythroid O O
differentiation O O
. O O

This O O
fragment O O
contains O O
two O O
complete O O
endo B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glucanase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
designated O O
celCCC B B_DISEASE/B_GENE
and O O
celCCG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Analysis O O
of O O
the O O
5 O O
' O O
and O O
3 O O
' O O
termini O O
of O O
the O O
transcripts O O
produced O O
in O O
vivo O O
from O O
the O O
puf B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
operon I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
R I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
sphaeroides I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
PUF B B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
delta I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
348 I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
- I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
420 I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O O
three O O
transcripts O O
; O O
0 O O
. O O
59 O O
, O O
0 O O
. O O
64 O O
, O O
and O O
2 O O
. O O
63 O O
kilobases O O
) O O
lacking O O
the O O
puf O O
- O O
intercistronic O O
terminator O O
structure O O
were O O
identical O O
to O O
those O O
of O O
the O O
corresponding O O
puf B B_GENE/B_BIO
transcripts I I_GENE/I_BIO
derived O O
from O O
wild O O
- O O
type O O
R O O
. O O
sphaeroides O O
2 O O
. O O
4 O O
. O O
1 O O
( O O
four O O
transcripts O O
; O O
0 O O
. O O
50 O O
, O O
0 O O
. O O
66 O O
, O O
0 O O
. O O
71 O O
, O O
and O O
2 O O
. O O
7 O O
kilobases O O
) O O
showing O O
that O O
the O O
transcripts O O
begin O O
and O O
end O O
at O O
the O O
same O O
sites O O
. O O

The O O
optimum O B_MEASURE/B_DISEASE
cooling O I_MEASURE/I_DISEASE
rate O I_MEASURE/I_DISEASE
from O O
RT O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
5 O B_LOCATION/B_PROTEIN[GENE]
degrees O I_LOCATION/I_PROTEIN[GENE]
C O I_LOCATION/I_PROTEIN[GENE]
resulting O O
in O O
maximum O B_TIME[MEASURE]/B_DISEASE
survival O I_TIME[MEASURE]/I_DISEASE
of O O
human O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
spermatozoa O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
was O O
found O O
to O O
be O O
0 O B_MEASURE/B_LOCATION
. O O
5 O B_MEASURE
to O O
1 O B_MEASURE
degree O I_MEASURE
per O O
minute O B_TIME[MEASURE]
when O O
cooled O O
from O O
RT O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
5 O B_LOCATION/B_PROTEIN[GENE]
degrees O I_LOCATION/I_PROTEIN[GENE]
C O I_LOCATION/I_PROTEIN[GENE]
and O O
subsequently O O
frozen O O
- O O
thawed O O
in O O
liquid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrogen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LN2 O B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

In O O
summary O O
, O O
FGFR3 B B_GENE
signaling O O
pathway O O
utilizes O O
two O O
GRB2 B B_LOCATION/B_BIO
- I I_LOCATION/I_BIO
containing I I_LOCATION/I_BIO
complexes I I_LOCATION/I_BIO
; O O
Shc B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
GRB2 B B_MEASURE/B_GENE
. O O
Sos B B_LOCATION/B_DISEASE
and O O
80K B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
H I I_GENE/I_LOCATION
. O O
pp66 B B_PROTEIN[GENE]/B_LOCATION
. O O
GRB2 B B_MEASURE/B_PERSON
. O O
Sos B B_LOCATION/B_DISEASE
; O O
these O O
two O O
complexes O O
may O O
alternatively O O
link O O
FGFG3 B B_GENE
to O O
mitogen B B_GENE
- I I_GENE
activated I I_GENE
protein I I_GENE
kinase I I_GENE
. O O

Convergence O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
trigeminal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
input O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
with O O
visceral O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
phrenic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inputs O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
primate O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C1 O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
C2 O B_MEASURE/B_PROTEIN[GENE]
spinothalamic O I_MEASURE/I_PROTEIN[GENE]
tract O I_MEASURE/I_PROTEIN[GENE]
neurons O I_MEASURE/I_PROTEIN[GENE]
. O O

Phylogenetic O O
analysis O O
using O O
a O O
neighbor O O
- O O
joining O O
algorithm O O
showed O O
closest O O
similarity O O
of O O
the O O
horse B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
mu I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
encoding I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
constant I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
region I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
to O O
human O O
and O O
dog O O
sequences O O
. O O

However O O
, O O
and O O
in O O
contrast O O
to O O
other O O
MMP B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
genes I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
no O O
significative O O
synergistic O O
effect O O
on O O
CAT B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activity O O
between O O
the O O
AP B B_LOCATION/B_ORGANIZATION
- I I_LOCATION/I_ORGANIZATION
1 I I_LOCATION/I_ORGANIZATION
and O O
PEA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
found O O
in O O
the O O
collagenase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
found O O
. O O

The O O
equation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
mean O B_MEASURE
trabecular O I_MEASURE
number O I_MEASURE
passed O O
the O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
whereas O O
the O O
validity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
equations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
mean O B_MEASURE/B_LOCATION
trabecular O I_MEASURE/I_LOCATION
separation O I_MEASURE/I_LOCATION
and O O
Tb O B_PROTEIN[GENE]/B_LOCATION
. O O
Wi O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
appeared O O
limited O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
examine O O
the O O
effect O O
of O O
the O O
cAMP O O
signal O O
transduction O O
pathway O O
on O O
transcription O O
of O O
the O O
gene O O
encoding O O
the O O
catalytic O O
subunit O O
of O O
glucose B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
G6Pase B B_GENE/B_LOCATION
) O O
, O O
G6Pase B B_GENE
- O O
chloramphenicol B B_ENZYME[GENE]
acetyltransferase I I_ENZYME[GENE]
( O O
CAT B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
fusion O O
genes O O
were O O
transiently O O
transfected O O
into O O
either O O
the O O
liver O O
- O O
derived O O
HepG2 O O
or O O
kidney O O
- O O
derived O O
LLC O O
- O O
PK O O
cell O O
line O O
. O O

Several O O
reports O O
assert O O
that O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
affects O O
the O O
delta O O
5 O O
and O O
delta O O
4 O O
pathways O O
through O O
its O O
effect O O
on O O
the O O
activity O O
of O O
3beta B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydroxysteroid I B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dehydrogenase I B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3beta B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
OHSD I I_DISEASE/I_LOCATION
) O O
. O O

The O O
NrfC B B_GENE/B_LOCATION
polypeptide I I_GENE/I_LOCATION
, O O
M B B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
r I I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
24 I I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
567 I I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
contains O O
16 O O
cysteine O O
residues O O
arranged O O
in O O
four O O
clusters O O
typical O O
of O O
the O O
CooF B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
super I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
family I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
non O O
- O O
haem O O
iron O O
- O O
sulphur O O
proteins O O
. O O

Y1 B B_PROTEIN[GENE]
, O O
Y2 B B_PROTEIN[GENE]/B_BIO
, O O
and O O
Y4 B B_PROTEIN[GENE]/B_DISEASE
/ O O
PP1 B B_MEASURE
. O O

The O O
D O O
. O O
discoideum O O
proteins O O
were O O
entirely O O
conserved O O
over O O
the O O
four O O
regions O O
known O O
to O O
be O O
important O O
for O O
GTP O O
binding O O
and O O
all O O
contained O O
the O O
C O O
- O O
terminal O O
CAAX O O
aa O O
motifs O O
shared O O
by O O
other O O
Rho B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Co O O
- O O
operativity O O
of O O
functional O O
domains O O
in O O
the O O
muscle B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
specific I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
Myf I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Creatinine O O
and O O
creatine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phosphokinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CPK B B_MEASURE/B_DISEASE
) O O
. O O

In O O
our O O
initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
we O O
treated O O
MCF O B_PROTEIN[GENE]/B_BIO
- O O
7 O B_MEASURE
cells O I_MEASURE
with O O
paclitaxel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
which O O
results O O
in O O
the O O
arrest O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O O
G1 O B_MEASURE
with O O
4n O B_MEASURE/B_DISEASE
DNA O B_MEASURE/I_DISEASE
content O B_MEASURE/I_DISEASE
( O O
pseudo O B_PROTEIN[GENE]/B_MEASURE
G1 O I_PROTEIN[GENE]/I_MEASURE
) O O
. O O

The O O
glyoxysomal O O
and O O
plastid O O
molecular O O
chaperones O O
( O O
70 B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
kDa I I_DISEASE/I_LOCATION
heat I I_DISEASE/I_LOCATION
shock I I_DISEASE/I_LOCATION
protein I I_DISEASE/I_LOCATION
) O O
of O O
watermelon O O
cotyledons O O
are O O
encoded O O
by O O
a O O
single O O
gene O O
. O O

The O O
residual O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
small O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
rRNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
[ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
poky O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
] O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
appear O O
to O O
be O O
synthesized O O
via O O
the O O
upstream O B_GENE
promoter O I_GENE
( O O
s O B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
but O O
are O O
missing O O
37 O B_MEASURE
- O O
44 O B_TIME[MEASURE]/B_LOCATION
nucleotides O I_TIME[MEASURE]/I_LOCATION
from O O
their O O
5 O B_GENE/B_MEASURE
' O I_GENE/I_MEASURE
ends O I_GENE/I_MEASURE
, O O
indicating O O
either O O
that O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
rRNAs O B_GENE
are O O
processed O O
abnormally O O
or O O
that O O
abnormal O B_NUMBER[MEASURE]
5 O I_NUMBER[MEASURE]
' O O
RNA O B_GENE/B_LOCATION
ends O B_GENE/I_LOCATION
are O O
unstable O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
. O O

Studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
B O B_LOCATION/B_DISEASE
. O O
glabrata O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
B O B_LOCATION/B_DISEASE
. O O
straminea O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
and O O
B O B_PROTEIN[GENE]/B_LOCATION
. O O
tenagophila O B_SPECIES[BIO]/B_DISEASE
under O O
outdoor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Protein B B_NUMBER[MEASURE]/B_PERSON
kinase I I_NUMBER[MEASURE]/I_PERSON
C I I_NUMBER[MEASURE]/I_PERSON
transiently O O
activated O O
heteromeric B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
N I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
methyl I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
D I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
aspartate I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
channels I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
independent O O
of O O
the O O
phosphorylatable O O
C O O
- O O
terminal O O
splice O O
domain O O
and O O
of O O
consensus O O
phosphorylation O O
sites O O
. O O

They O O
are O O
found O O
to O O
have O O
several O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
advantages O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O O
the O O
conventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
indices O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
skewness O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
kurtosis O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
square O B_MEASURE
root O I_MEASURE
of O O
b1 O B_PROTEIN[GENE]
and O O
b2 O B_PROTEIN[GENE]
) O O
and O O
no O O
serious O B_DISEASE_ADJECTIVE[DISEASE]
drawbacks O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Siglec B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
predicted O O
to O O
contain O O
three O O
extracellular O O
immunoglobulin B B_GENE/B_LOCATION
- I B_GENE/I_LOCATION
like I B_GENE/I_LOCATION
domains I B_GENE/I_LOCATION
that O O
comprise O O
an O O
N B B_GENE
- I I_GENE
terminal I I_GENE
V I I_GENE
- I I_GENE
set I I_GENE
domain I I_GENE
and O O
two O O
C2 B B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
set I I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
domains I I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O O
a O O
transmembrane O O
region O O
and O O
a O O
cytoplasmic O O
tail O O
containing O O
two O O
putative O O
tyrosine O O
- O O
based O O
signaling O O
motifs O O
. O O

Determination O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
LD O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
30 O B_MEASURE/B_LOCATION
) O O
during O O
infant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
period O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
and O O
growth O B_TIME[MEASURE]/B_PERSON
period O B_TIME[MEASURE]/I_PERSON

The O O
COR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
biosynthetic O O
gene O O
cluster O O
in O O
P O O
. O O
syringae O O
pv O O
. O O
glycinea O O
PG4180 O O
is O O
encoded O O
by O O
a O O
32 O O
- O O
kb O O
region O O
which O O
contains O O
both O O
the O O
structural O O
and O O
regulatory O O
genes O O
needed O O
for O O
COR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
synthesis O O
. O O

Model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
pheasants O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
using O O
single O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
the O O
insecticide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Lindane O B_PERSON/B_PROTEIN[GENE]
) O O
the O O
herbicide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Terbutryn O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
a O O
mineral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fertilizer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
calcium O B_LOCATION/B_ORGANIZATION
ammonium O I_LOCATION/I_ORGANIZATION
nitrate O I_LOCATION/I_ORGANIZATION
) O O
and O O
the O O
fungicide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
HCB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

A O O
single O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
HD O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
session O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O O
cellulose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triacetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
polysulfone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
membrane O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O O
increased O O
water O B_MEASURE/B_DISEASE
content O B_MEASURE/I_DISEASE
both O O
at O O
forearm O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
and O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
leg O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

claR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
car B B_PRODUCT[OBJECT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
not O O
significantly O O
expressed O O
in O O
mutants O O
disrupted O O
in O O
the O O
ccaR B B_GENE
gene I I_GENE
, O O
a O O
regulatory O O
gene O O
that O O
controls O O
positively O O
clavulanic O O
acid O O
and O O
cephamycin O O
biosynthesis O O
. O O

Whereas O O
mutant B B_PERSON/B_LOCATION
6C4 I I_PERSON/I_LOCATION
specified O O
a O O
wild B B_GENE
- I I_GENE
type I I_GENE
- I I_GENE
size I I_GENE
Pol I I_GENE
protein I I_GENE
, O O
we O O
detected O O
no O O
full B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
length I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Pol I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
7E4 O O
- O O
infected O O
cell O O
extracts O O
. O O

Nuclear O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
extracts O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
Sertoli O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
found O O
to O O
cause O O
an O O
E O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
box O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
gel O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
shift O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
when O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
stimulated O O
to O O
differentiate O O
in O O
culture O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
under O O
basal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conditions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
binding O O
of O O
biotin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
the O O
protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
protection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
regions O B_LOCATION/B_PERSON
of O O
the O O
central O B_ENZYME[GENE]/B_LOCATION
domain O I_ENZYME[GENE]/I_LOCATION
in O O
the O O
vicinity O B_LOCATION/B_MEASURE
of O O
the O O
active O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
site O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O O
the O O
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
terminal O B_LOCATION/B_MEASURE
domain O I_LOCATION/I_MEASURE
from O O
chemical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cleavage O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
impairment O O
of O O
the O O
nocturnal O O
secretion O O
was O O
related O O
to O O
the O O
subjects O O
' O O
age O O
and O O
, O O
for O O
the O O
GH B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secretory O O
pattern O O
only O O
, O O
also O O
to O O
the O O
MMSE O O
score O O
. O O

Recombinant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Human I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Erythropoietin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Platinum O O
- O O
Based O O
Chemotherapy O O
In O O
Advanced O O
Ovarian O O
Cancer O O

A O O
wound O O
model O O
for O O
decubitus O O
and O O
leg O O
ulcers O O
consisting O O
of O O
human O O
dermal O O
fibroblasts O O
in O O
type B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
I I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
collagen I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
dermal O O
" O O
equivalent O O
" O O
matrix O O
( O O
DEM O O
) O O
was O O
exposed O O
in O O
vitro O O
to O O
electric O O
fields O O
similar O O
to O O
postulated O O
endogenous O O
fields O O
in O O
wounds O O
. O O

Hypocalcemia O O
is O O
usually O O
due O O
to O O
either O O
a O O
disturbance O O
in O O
the O O
parathyroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
adenylate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
cyclase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
system O O
or O O
a O O
disturbance O O
in O O
vitamin O O
D O O
metabolism O O
. O O

In O O
seven O O
patients O O
( O O
7 O O
. O O
8 O O
% O O
) O O
with O O
new O O
Q O O
- O O
waves O O
and O O
a O O
pathologic O O
CK B B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
MB I I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
profile O O
( O O
group O O
II O O
) O O
troponin B B_PERSON/B_LOCATION
T I I_PERSON/I_LOCATION
reached O O
median O O
levels O O
of O O
10 O O
. O O
47 O O
micrograms O O
/ O O
l O O
( O O
quartile O O
6 O O
. O O
34 O O
- O O
12 O O
. O O
50 O O
micrograms O O
/ O O
l O O
) O O
( O O
P O O
< O O
0 O O
. O O
001 O O
I O O
vs O O
II O O
) O O
. O O

The O O
132 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bp I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
PHO8p I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragment I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
connected O O
at O O
position O O
- O O
281 O O
of O O
the O O
5 O O
' O O
upstream O O
region O O
of O O
a O O
HIS5 B B_MEASURE
' I I_MEASURE
- O O
' B B_GENE/B_LOCATION
lacZ I I_GENE/I_LOCATION
fused O O
gene O O
, O O
could O O
sense O O
Pi O O
signals O O
in O O
vivo O O
, O O
but O O
a O O
20 O O
- O O
bp O O
synthetic O O
oligonucleotide O O
having O O
the O O
same O O
sequence O O
from O O
- O O
544 O O
to O O
- O O
525 O O
of O O
the O O
PHO8p B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
could O O
not O O
. O O

Plasmid O O
subclones O O
of O O
recombinant O O
phage O O
lambda O O
Asm152 O O
were O O
able O O
to O O
complement O O
both O O
Escherichia B B_BACTERIUM[BIO]/B_PERSON
coli I I_BACTERIUM[BIO]/I_PERSON
gltB I I_BACTERIUM[BIO]/I_PERSON
and O O
A O O
. O O
sesbaniae O O
Asm O O
- O O
Vi O O
mutants O O
; O O
NADPH B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glutamate I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthase I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
was O O
detected O O
in O O
all O O
such O O
strains O O
complemented O O
to O O
Asm O O
+ O O
. O O

The O O
sequence O O
of O O
LZ321 B B_GENE/B_PERSON
matched O O
that O O
of O O
RREB1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
transcription O O
factor O O
that O O
bound O O
to O O
a O O
Ras B B_GENE
responsive I I_GENE
element I I_GENE
( O O
RRE B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
very O O
different O O
from O O
the O O
sequence O O
with O O
which O O
we O O
isolated O O
LZ321 B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Basal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
reduced O O
to O O
20 O B_MEASURE
and O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
when O O
the O O
UGA O B_GENE
stop O I_GENE
codon O I_GENE
was O O
replaced O O
by O O
UAG O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
UAA O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
, O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
the O O
finding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
in O O
E O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
coli O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
translation O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
terminates O O
more O O
efficiently O O
at O O
UAG O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
UAA O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
at O O
UGA O B_PROTEIN[GENE]/B_LOCATION
. O O

Coronatine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
COR B B_LOCATION/B_ORGANIZATION
) O O
is O O
a O O
plasmid O O
- O O
encoded O O
phytotoxin O O
synthesized O O
by O O
several O O
pathovars O O
of O O
phytopathogenic O O
Pseudomonas O O
syringae O O
. O O

For O O
the O O
first O O
time O O
also O O
a O O
genomic O O
sequence O O
for O O
a O O
red B B_SPECIES[BIO]/B_PERSON
algal I I_SPECIES[BIO]/I_PERSON
lhc I I_SPECIES[BIO]/I_PERSON
gene I I_SPECIES[BIO]/I_PERSON
is O O
presented O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
The O O
effect O O
of O O
prolonged O O
nitrate O O
therapy O O
between O O
2 O O
days O O
and O O
6 O O
weeks O O
during O O
healing O O
after O O
infarction O O
on O O
serial O O
parameters O O
of O O
ventricular O O
remodeling O O
( O O
scar O O
expansion O O
, O O
scar O O
thinning O O
, O O
ventricular O O
dilation O O
, O O
and O O
hypertrophy O O
) O O
and O O
function O O
( O O
asynergy O O
or O O
akinesis O O
plus O O
dyskinesis O O
and O O
ejection O O
fraction O O
) O O
by O O
serial O O
two O O
- O O
dimensional O O
echocardiography O O
, O O
hemodynamics O O
, O O
postmortem O O
topography O O
( O O
computerized O O
planimetry O O
, O O
geometric O O
maps O O
, O O
and O O
radiographs O O
) O O
, O O
and O O
collagen B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
content O O
( O O
hydroxyproline O O
) O O
was O O
studied O O
in O O
64 O O
instrumented O O
dogs O O
randomized O O
2 O O
days O O
after O O
left O O
anterior O O
descending O O
coronary O O
artery O O
ligation O O
to O O
various O O
nitrate O O
regimens O O
( O O
n O O
= O O
32 O O
) O O
over O O
the O O
first O O
2 O O
weeks O O
( O O
subgroup O O
1 O O
: O O
2 O O
% O O
transdermal O O
nitroglycerin O O
at O O
8 O O
AM O O
and O O
4 O O
PM O O
, O O
n O O
= O O
6 O O
; O O
subgroup O O
2 O O
: O O
2 O O
% O O
transdermal O O
nitroglycerin O O
plus O O
2 O O
. O O
6 O O
mg O O
of O O
sustained O O
- O O
release O O
oral O O
nitroglycerin O O
at O O
8 O O
AM O O
, O O
3 O O
PM O O
, O O
and O O
10 O O
PM O O
, O O
n O O
= O O
5 O O
; O O
subgroup O O
3 O O
: O O
oral O O
isosorbide O O
dinitrate O O
, O O
30 O O
mg O O
at O O
8 O O
AM O O
and O O
4 O O
PM O O
, O O
n O O
= O O
11 O O
) O O
or O O
6 O O
weeks O O
( O O
subgroup O O
4 O O
: O O
isosorbide O O
dinitrate O O
, O O
n O O
= O O
10 O O
) O O
and O O
in O O
matching O O
controls O O
( O O
n O O
= O O
32 O O
) O O
. O O

Applying O O
the O O
experience O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
mentioned O O
above O O
, O O
4 O B_MEASURE/B_LOCATION
- O O
META O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
used O O
to O O
bond O O
a O O
proprietary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
photocuring O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
microfilled O O
composite O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
material O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
to O O
Class O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
V O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
cavities O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
freshly O O
extracted O O
human O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
teeth O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

We O O
report O O
five O O
of O O
13 O O
evaluable O O
patients O O
undergoing O O
allogeneic O O
sibling O O
BM O O
or O O
PBSC O O
transplantation O O
for O O
MM O O
between O O
1990 O O
and O O
1997 O O
who O O
met O O
the O O
criteria O O
for O O
adjuvant O O
alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
IFN I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
therapy O O
. O O

The O O
apparent O O
binding O O
constant O O
of O O
6 O O
to O O
calf O O
thymus O O
DNA O O
is O O
1 O O
. O O
68 O O
X O O
10 O O
( O O
5 O O
) O O
M O O
- O O
1 O O
whereas O O
netropsin B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
under O O
similar O O
conditions O O
gives O O
a O O
value O O
of O O
1 O O
. O O
85 O O
X O O
10 O O
( O O
7 O O
) O O
M O O
- O O
1 O O
. O O

TNF B B_PERSON
- I I_PERSON
alpha I I_PERSON
effect O O
was O O
eliminated O O
by O O
a O O
2 O O
- O O
bp O O
substitution O O
mutation O O
in O O
the O O
NF B B_GENE/B_LOCATION
- I B_GENE/I_LOCATION
kappa I B_GENE/I_LOCATION
B1 I B_GENE/I_LOCATION
binding I B_GENE/I_LOCATION
half I B_GENE/I_LOCATION
site I B_GENE/I_LOCATION
of O O
the O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
cis I I_GENE
element I I_GENE
. O O

As O O
already O O
available O O
for O O
the O O
other O O
known O O
mammalian O O
members O O
of O O
this O O
enzyme O O
family O O
, O O
we O O
here O O
define O O
structural O O
and O O
functional O O
features O O
of O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lymphoma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proprotein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
convertase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
LPC B B_DISEASE/B_LOCATION
) O O
. O O

Serum O O
levels O O
of O O
angiotensin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
converting I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
well O O
maintained O O
. O O

On O O
Western O O
blots O O
, O O
the O O
same O O
antibodies O O
recognized O O
the O O
recombinant O O
protein O O
migrating O O
slightly O O
slower O O
on O O
SDS O O
/ O O
PAGE O O
than O O
chicken B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
axonin I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
1 I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Also O O
, O O
PTx B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
no O O
effect O O
on O O
shear O O
- O O
dependent O O
activation O O
of O O
JNK B B_GENE
. O O

SETTING O B_MEASURE/B_LOCATION
: O O
Participants O B_PERSON
in O O
the O O
Physicians O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
a O O
randomized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
aspirin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
carotene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
U O B_OTHER/B_MEASURE
. O O
S O B_LOCATION/B_DISEASE
. O O
male O B_PERSON/B_LOCATION
physicians O I_PERSON/I_LOCATION
. O O

The O O
authors O O
suggest O O
that O O
alprazolam O O
may O O
have O O
enhanced O O
specificity O O
for O O
a O O
subpopulation O O
of O O
benzodiazepine B B_PERSON/B_BIO
receptors I I_PERSON/I_BIO
. O O

In O O
mouse O O
, O O
two O O
high O O
- O O
affinity O O
binding O O
sites O O
with O O
an O O
apparent O O
dissociation O O
constant O O
( O O
Kd O O
) O O
of O O
50 O O
to O O
100 O O
nM O O
have O O
been O O
mapped O O
in O O
the O O
5 O O
' O O
ETS B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
upstream O O
from O O
the O O
early O O
pre O O
- O O
rRNA O O
processing O O
site O O
. O O

Phytohemagglutinin B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PHA B B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
the O O
seed B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lectin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
common O O
bean O O
, O O
accumulates O O
in O O
protein O O
storage O O
vacuoles O O
of O O
storage O O
parenchyma O O
cells O O
in O O
cotyledons O O
. O O

Blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
samples O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
( O O
30 O B_TIME[MEASURE]/B_LOCATION
ml O B_TIME[MEASURE]/I_LOCATION
) O O
were O O
collected O O
via O O
an O O
indwelling O O
arm O B_PRODUCT[OBJECT]/B_LOCATION
catheter O B_PRODUCT[OBJECT]/I_LOCATION
at O O
rest O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
at O O
minutes O B_MEASURE/B_ENT
13 O I_MEASURE/I_ENT
and O O
28 O B_NUMBER[MEASURE]
of O O
exercise O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O O
determinations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
plasma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
EPI O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
serum O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fatty O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
FFA O B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glycerol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GLY O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GLU O B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
and O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lactate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
LA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Schottky O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
- O O
barrier O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
heights O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
Ti O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
TiSi2 O B_LOCATION/B_PERSON
on O O
n O B_PROTEIN[GENE]
- O O
type O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
p O B_MEASURE/B_PROTEIN[GENE]
- O O
type O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Si O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
100 O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

A O O
survey O O
of O O
children O O
with O O
HBsAg B B_DISEASE
markers I I_DISEASE
related O O
to O O
their O O
parents O O
HBV O O
markers O O
. O O

Immunological O O
studies O O
also O O
failed O O
to O O
demonstrate O O
any O O
significant O O
change O O
except O O
for O O
a O O
significant O O
increase O O
of O O
natural O O
killer O O
( O O
NK O O
) O O
cell O O
activity O O
after O O
IFN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
. O O

In O O
response O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
acoustical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
the O O
properties O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
response O B_MEASURE
latency O I_MEASURE
, O O
discharge O B_MEASURE
pattern O I_MEASURE
, O O
frequency O B_MEASURE/B_LOCATION
tuning O I_MEASURE/I_LOCATION
, O O
binaural O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
interaction O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
and O O
habituation O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
were O O
examined O O
to O O
allow O O
an O O
appraisal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
differentiation O B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
the O O
MGB O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
by O O
electrophysiological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
means O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Interferon B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
inducibility O O
of O O
IFI16 B B_GENE
may O O
be O O
regulated O O
by O O
an O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
/ I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
stimulated O O
response O O
consensus O O
element O O
in O O
the O O
5 O O
' O O
UT O O
exon O O
, O O
as O O
a O O
similar O O
motif O O
is O O
conserved O O
in O O
the O O
corresponding O O
position O O
in O O
the O O
related O O
myeloid B B_GENE
cell I I_GENE
nuclear I I_GENE
differentiation I I_GENE
antigen I I_GENE
gene O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O

The O O
quantification O B_MEASURE
limit O I_MEASURE
was O O
50 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
for O O
each O O
of O O
PHT O B_NUMBER[MEASURE]/B_PERSON
, O O
m O B_PROTEIN[GENE]/B_DISEASE
- O O
HPPH O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
p O O
- O O
HPPH O B_DISEASE/B_LOCATION
. O O

Individual O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intolerance O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
betaxolol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
continue O O
to O O
occur O O
and O O
care O O
is O O
always O O
required O O
when O O
patients O B_PERSON
with O O
cardiac O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
or O O
respiratory O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
dysfunction O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
are O O
exposed O O
to O O
any O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
antagonist O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Restriction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
isolated O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genomic O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
clones O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
indicated O O
that O O
the O O
endogenous O B_GENE/B_LOCATION
sequences O I_GENE/I_LOCATION
abutting O O
the O O
3 O B_LOCATION/B_GENE
' O I_LOCATION/I_GENE
ends O I_LOCATION/I_GENE
of O O
the O O
94 O B_MEASURE
- O O
A O B_OTHER/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
94 O B_MEASURE
- O O
K O B_PROTEIN[GENE]/B_LOCATION
transgenes O I_PROTEIN[GENE]/I_LOCATION
are O O
separated O O
by O O
less O B_MEASURE
than O O
20 O B_MEASURE/B_LOCATION
kb O I_MEASURE/I_LOCATION
, O O
providing O O
strong O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
support O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
single O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
integration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

In O O
serum O O
- O O
starved O O
NIH O O
3T3 O O
cells O O
, O O
v B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
raf I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
increased O O
mdr1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
approximately O O
10 O O
- O O
fold O O
compared O O
to O O
a O O
v B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
raf I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
frame O O
- O O
shift O O
control O O
. O O

The O O
effective O O
use O O
of O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dismutase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
human O O
erythrocytes O O
in O O
the O O
late O O
stages O O
of O O
experimental O O
influenza O O
infection O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
high O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
resolution O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
MF O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
ERG O B_LOCATION/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seems O O
more O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
than O O
low O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
resolution O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
MF O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
ERG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

On O O
days O B_TIME[MEASURE]
7 O I_TIME[MEASURE]
, O O
21 O B_MEASURE
, O O
and O O
35 O B_MEASURE
postinoculation O I_MEASURE
( O O
PI O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
all O O
birds O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
received O O
sheep O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
erythrocytes O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
intravenously O O
. O O

TNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stimulated O O
these O O
changes O O
in O O
part O O
by O O
increasing O O
transcription O O
and O O
stabilization O O
of O O
RNA O O
for O O
amphiregulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
an O O
EGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ligand O O
, O O
and O O
amphiregulin B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
directly O O
increased O O
HPV O O
- O O
16 O O
E6 B B_PROTEIN[GENE]/B_DISEASE
/ O O
E7 B B_MEASURE/B_PROTEIN[GENE]
and O O
cyclin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNAs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

BAG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
also O O
prevented O O
growth O O
arrest O O
following O O
UV O O
- O O
irradiation O O
- O O
induced O O
genotoxic O O
injury O O
without O O
interfering O O
with O O
accumulation O O
of O O
p53 B B_GENE
protein I I_GENE
or O O
p21 B B_GENE/B_DISEASE
( O O
waf B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
) O O
expression O O
. O O

N0 O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
more O O
favorable O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
than O O
N1 O B_PROTEIN[GENE]
or O O
N2 O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
disease O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O O

P53 B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
mutations I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
also O O
offer O O
new O O
approaches O O
to O O
the O O
study O O
of O O
the O O
origins O O
of O O
mutations O O
in O O
human O O
cancer O O
. O O

Desarrollo O B_MEASURE/B_ENT
de O I_MEASURE/I_ENT
un O I_MEASURE/I_ENT
modelo O I_MEASURE/I_ENT
matematico O I_MEASURE/I_ENT
general O I_MEASURE/I_ENT
para O I_MEASURE/I_ENT
los O I_MEASURE/I_ENT
procesos O I_MEASURE/I_ENT
fermentativos O I_MEASURE/I_ENT
, O O
Cinetica O B_MEASURE/B_ENT
de O I_MEASURE/I_ENT
la O I_MEASURE/I_ENT
degradacion O I_MEASURE/I_ENT
anaerobia O I_MEASURE/I_ENT
, O O
Ph O B_PROTEIN[GENE]/B_LOCATION
. O O
D O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_GENE/B_LOCATION
sequences O B_GENE/I_LOCATION
of O O
isoforms O B_PROTEIN[GENE]
beta O I_PROTEIN[GENE]
to O O
epsilon O O
contain O O
a O O
PEST O B_LOCATION/B_MEASURE
region O I_LOCATION/I_MEASURE
which O O
could O O
induce O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
intracellular O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
degradation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
isoforms O B_PROTEIN[GENE]
beta O I_PROTEIN[GENE]
and O O
delta O B_PROTEIN[GENE]
. O O

After O O
5 O O
days O O
stimulation O O
with O O
G B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CSF I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
micrograms O O
/ O O
kg O O
) O O
1l O O
of O O
blood O O
was O O
drawn O O
, O O
kept O O
unprocessed O O
for O O
3 O O
days O O
and O O
reinfused O O
24 O O
h O O
after O O
completion O O
of O O
chemotherapy O O
. O O

Directional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
growth O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
a O O
smectic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
smectic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
B O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
interface O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
lying O O
along O O
a O O
forbidden O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
orientation O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
centromeric O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dodeca O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
satellite O B_LOCATION/B_GENE
of O O
Drosophila O B_SPECIES[BIO]/B_GENE
forms O I_SPECIES[BIO]/I_GENE
altered O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
structures O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O O
which O O
its O O
purine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
rich O B_GENE/B_BACTERIUM[BIO]
strand O I_GENE/I_BACTERIUM[BIO]
( O O
G O B_PROTEIN[GENE]/B_LOCATION
- O O
strand O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
forms O O
stable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
fold O O
- O O
back O B_LOCATION/B_MEASURE
structures O I_LOCATION/I_MEASURE
, O O
while O O
the O O
complementary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
strand O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
remains O O
unstructured O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Mean O O
CD4 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
percentages O O
were O O
lower O O
postpartum O O
( O O
21 O O
. O O
9 O O
+ O O
/ O O
- O O
3 O O
. O O
4 O O
) O O
than O O
prepartum O O
( O O
45 O O
. O O
1 O O
+ O O
/ O O
- O O
6 O O
. O O
7 O O
) O O
in O O
all O O
five O O
patients O O
studied O O
, O O
although O O
proliferative O O
responses O O
to O O
the O O
mitogens B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phytohemagglutinin I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pokeweed I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
unchanged O O
during O O
the O O
study O O
period O O
. O O

Like O O
pimethixene O O
and O O
cyproheptadine O O
, O O
WA O O
335 O O
has O O
no O O
distinct O O
antagonistic O O
qualities O O
against O O
bradykinin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
. O O

This O O
clone O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
will O O
be O O
useful O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
identifying O O
the O O
genetic O B_LOCATION/B_PERSON
determinants O I_LOCATION/I_PERSON
of O O
FIV O B_GENE/B_DISEASE
- O O
Oma O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
s O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biological O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

There O O
was O O
91 O B_DISEASE_ADJECTIVE[DISEASE]
% O I_DISEASE_ADJECTIVE[DISEASE]
concordance O I_DISEASE_ADJECTIVE[DISEASE]
between O O
ST O B_PROTEIN[GENE]/B_DISEASE
- O O
RD O B_LOCATION/B_DISEASE
/ O O
RI O B_LOCATION/B_PROTEIN[GENE]
/ O O
LRD O B_LOCATION/B_PROTEIN[GENE]
201Tl O I_LOCATION/I_PROTEIN[GENE]
and O O
R O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
ST O B_PROTEIN[GENE]/B_DISEASE
/ O O
N O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
+ O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
Inf O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
99Tcm O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
tetrofosmin O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
regarding O O
reversibility O B_DISEASE
. O O

Both O O
residues O O
are O O
conserved O O
in O O
the O O
three O O
phosphorylated O O
paralogs O O
but O O
are O O
absent O O
in O O
the O O
ones O O
that O O
were O O
not O O
substrates O O
of O O
RsbT B B_GENE/B_NUMBER[MEASURE]
: O O
YetI B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
YezB B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O O
each O O
of O O
which O O
bears O O
only O O
one O O
of O O
the O O
conserved O O
residues O O
; O O
and O O
YtvA B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O O
which O O
lacks O O
both O O
residues O O
and O O
instead O O
possesses O O
an O O
N O O
- O O
terminal O O
PAS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
domain O O
. O O

Accordingly O O
, O O
constitutive O O
downregulation O O
of O O
expression O O
of O O
accessory O O
molecules O O
of O O
the O O
MHC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
reveal O O
differences O O
between O O
H2 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
class I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
I I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
alleles I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O O
antigen O O
presentation O O
not O O
encountered O O
when O O
the O O
expression O O
levels O O
are O O
augmented O O
. O O

Legionella B B_DISEASE/B_ORGANISM_FUNCTION
antibodies I I_DISEASE/I_ORGANISM_FUNCTION
in O O
domestic O O
animals O O

Using O O
the O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
electrical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analog O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
we O O
present O O
an O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O O
allows O O
calculation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
parameters O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
as O O
well O O
as O O
the O O
corner O B_MEASURE/B_LOCATION
frequency O I_MEASURE/I_LOCATION
of O O
the O O
network O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
f1 O B_PROTEIN[GENE]/B_MEASURE
) O O
, O O
without O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
for O O
similar O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assumptions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Thus O O
, O O
d O B_PROTEIN[GENE]/B_LOCATION
- O O
delta3 O B_GENE
- O O
carene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
about O O
four O B_SEQUENCE[MEASURE]/B_ENT
times O I_SEQUENCE[MEASURE]/I_ENT
more O O
potent O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
sensory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irritant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
I O O
- O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
pinene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
the O O
difference O B_MEASURE
with O O
I O O
- O O
alpha O B_PROTEIN[GENE]
- O O
pinene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
more O O
marked O O
; O O
as O O
a O O
sensory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
irritant O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
I O O
- O O
alpha O B_PROTEIN[GENE]
- O O
pinene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
almost O O
inactive O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
reconstituted O O
RNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
containing O O
the O O
mutant O O
alpha O O
subunits O O
were O O
examined O O
for O O
their O O
response O O
to O O
transcription O O
activation O O
by O O
cAMP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CRP I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
the O O
rrnBP1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
UP I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
element I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Non O O
- O O
dialyzable O O
transfer B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

Our O O
data O O
suggest O O
that O O
the O O
ZF B B_SEQUENCE[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
HD I I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
class O O
of O O
homeodomain B B_GENE/B_BIO
proteins I I_GENE/I_BIO
may O O
be O O
involved O O
in O O
the O O
establishment O O
of O O
the O O
characteristic O O
expression O O
pattern O O
of O O
the O O
C4 B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
PEPCase I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
gene I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
deduced O O
amino O O
acid O O
sequence O O
exhibits O O
95 O O
. O O
3 O O
and O O
76 O O
. O O
1 O O
% O O
identity O O
with O O
the O O
CAD B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hamster I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Squalus I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acanthias I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O O
: O O
There O O
were O O
no O O
significant O O
differences O O
in O O
the O O
mean O O
serum O O
vitamin O O
A O O
, O O
E O O
concentrations O O
and O O
vitamin O O
E O O
/ O O
cholesterol O O
ratio O O
between O O
pregnant O O
women O O
with O O
normal O O
hemoglobin B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
hemoglobinopathies O O
, O O
while O O
confounding O O
variables O O
that O O
might O O
affect O O
serum O O
vitamin O O
levels O O
i O O
. O O
e O O
. O O
maternal O O
age O O
, O O
gravida O O
, O O
BMI O O
, O O
gestational O O
age O O
, O O
hematocrit O O
, O O
hemoglobin B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
mean O O
corpuscular O O
hemoglobin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
concentration O O
and O O
blood O O
group O O
were O O
not O O
different O O
. O O

Fourteen O B_TIME[MEASURE]/B_LOCATION
samples O I_TIME[MEASURE]/I_LOCATION
, O O
seven O B_NUMBER[MEASURE]/B_LOCATION
each O O
of O O
IR64 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IR66 O B_MEASURE/B_PROTEIN[GENE]
were O O
studied O O
with O O
regard O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
moisture O B_MEASURE/B_COLOR
content O I_MEASURE/I_COLOR
, O O
germination O B_MEASURE/B_LOCATION
test O I_MEASURE/I_LOCATION
, O O
abnormal O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
seedlings O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
speed O B_MEASURE/B_SPORT[ENT]
of O O
germination O B_DISEASE/B_BIO
, O O
conductance O B_MEASURE/B_LOCATION
of O O
leachates O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
, O O
total O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dehydrogenase O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
total O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
free O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
amino O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
acids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
total O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
soluble O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sugar O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
fat O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
acidity O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
gelatinization O B_MEASURE/B_PERSON
temperature O I_MEASURE/I_PERSON
, O O
gel O B_MEASURE/B_DISEASE
consistency O I_MEASURE/I_DISEASE
, O O
amylose O B_MEASURE/B_ORGANIZATION
content O I_MEASURE/I_ORGANIZATION
, O O
translucency O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
per O O
cent O B_MEASURE
whiteness O I_MEASURE
. O O

The O O
gap B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein O O
knirps B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mediates O O
both O O
quenching O O
and O O
direct O O
repression O O
in O O
the O O
Drosophila O O
embryo O O
. O O

The O O
relationship O O
between O O
CSF B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
somatostatin I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
peripheral O O
thyroid O O
hormones O O
was O O
assessed O O
in O O
11 O O
affectively O O
ill O O
patients O O
before O O
and O O
during O O
carbamazepine O O
treatment O O
. O O

Treatments O O
were O O
two O O
adrenocorticotrophin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
ACTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
preparations O O
given O O
intramuscularly O O
at O O
2 O O
. O O
2 O O
U O O
/ O O
kg O O
, O O
one O O
of O O
the O O
ACTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparations O O
given O O
intramuscularly O O
at O O
1 O O
U O O
/ O O
kg O O
and O O
a O O
synthetic O O
polypeptide O O
with O O
ACTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
like I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activity O O
( O O
tetracosactrin O O
, O O
cosyntropin O O
) O O
given O O
intravenously O O
at O O
5 O O
micrograms O O
/ O O
kg O O
. O O

PRIP B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contains O O
two O O
LXXLL O O
signature O O
motifs O O
. O O

A O O
new O O
simple O O
identification O O
of O O
rheumatoid B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
nitrocellulose O O
was O O
developed O O
that O O
allows O O
quantitative O O
detection O O
. O O

Reversal O O
of O O
biliary O O
sphincter O O
spasm O O
with O O
low O O
dose O O
glucagon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
operative O O
cholangiography O O
. O O

Second O O
, O O
CGGA O O
- O O
containing O O
sequences O O
placed O O
at O O
- O O
88 O O
in O O
the O O
delta B B_GENE/B_PERSON
MTV I I_GENE/I_PERSON
- I I_GENE/I_PERSON
CAT I I_GENE/I_PERSON
reporter I I_GENE/I_PERSON
plasmid O O
conferred O O
insulin B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responsiveness O O
to O O
the O O
mammary B B_GENE/B_DISEASE
tumor I I_GENE/I_DISEASE
virus I I_GENE/I_DISEASE
promoter I I_GENE/I_DISEASE
. O O

Microenvironments O B_LOCATION/B_ORGANIZATION
dominated O O
by O O
cyanobacteria O B_BIO
( O O
BPC O B_PROTEIN[GENE]/B_LOCATION
) O O
had O O
a O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
pH O O
( O O
pH O O
7 O B_MEASURE
- O O
8 O B_MEASURE
) O O
than O O
those O O
dominated O O
by O O
lichen O B_SPECIES[BIO]/B_DISEASE
( O O
LTL O B_LOCATION/B_PROTEIN[GENE]
) O O
( O O
pH O B_MEASURE
4 O I_MEASURE
. O O
5 O B_MEASURE
- O O
5 O B_MEASURE
. O O
5 O B_MEASURE
) O O
. O O

A O O
drop O B_DISEASE/B_LOCATION
of O O
methylprednisolone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
vehicle O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constituent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
placed O O
on O O
the O O
dissected O O
plantar O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
nerve O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
proximal O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
to O O
the O O
stimulating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
electrodes O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
after O O
recording O O
control O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
responses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
fibre O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
volley O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
sciatic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nerve O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
C O B_PROTEIN[GENE]/B_MEASURE
- O O
fibre O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
evoked O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
reflex O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
discharge O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
flexor O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
motoneurons O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
) O O
. O O

Furthermore O O
, O O
Grap B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
associated O O
with O O
a O O
Ras B B_GENE
guanine I I_GENE
nucleotide I I_GENE
exchange I I_GENE
factor I I_GENE
mSos1 B I_GENE
, O O
primarily O O
through O O
its O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
terminal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
SH3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
domain I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
buthionine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfoximine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
BSO O B_LOCATION/B_DISEASE
) O O
and O O
disulfiram O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O O
DSF O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
on O O
the O O
urotoxicity O B_DISEASE
induced O O
by O O
cyclophosphamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CPA O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
was O O
examined O O
in O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

All O O
the O O
previously O O
mapped O O
structural O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
encoding O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
phage O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
LL O I_PROTEIN[GENE]/I_BACTERIUM[BIO]
- O O
H O B_MEASURE/B_OTHER
were O O
included O O
in O O
the O O
sequence O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
gene O O
encoding O O
the O O
cellulase B B_ENZYME[GENE]/B_BACTERIUM[BIO]
( O O
Avicelase B B_LOCATION/B_BIO
) O O
Cel1 B B_ENZYME[GENE]/B_LOCATION
from O O
Streptomyces O O
reticuli O O
and O O
analysis O O
of O O
protein O O
domains O O
. O O

We O O
found O O
that O O
secretion O O
of O O
chitinolytic O O
enzymes O O
by O O
cultured O O
L O O
. O O
major O O
parasites O O
is O O
inhibited O O
by O O
blood O O
or O O
hemoglobin B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
hence O O
these O O
enzymes O O
are O O
apparently O O
absent O O
from O O
the O O
blood O O
- O O
fed O O
infected O O
flies O O
, O O
where O O
the O O
cardiac O O
valve O O
appears O O
undamaged O O
. O O

Patients O O
in O O
the O O
mucinous O O
cyst O O
group O O
had O O
significantly O O
lower O O
CA B B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
125 I I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
cystic O O
fluid O O
levels O O
compared O O
with O O
women O O
with O O
endometriomas O O
and O O
dermoids O O
( O O
P O O
& O O
lt O O
; O O
0 O O
. O O
05 O O
) O O
. O O

SATB1 B B_GENE
interacted O O
with O O
CDP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
through O O
its O O
DNA O O
- O O
binding O O
domain O O
, O O
as O O
demonstrated O O
by O O
glutathione B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
S I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
transferase I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GST B B_LOCATION/B_GENE
) O O
pull O O
- O O
down O O
assays O O
. O O

The O O
predicted O O
5 O O
' O O
and O O
3 O O
' O O
ends O O
of O O
the O O
transcript O O
are O O
in O O
very O O
good O O
agreement O O
with O O
the O O
previously O O
determined O O
size O O
of O O
the O O
LEU3 B B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
message O O
. O O

This O O
cDNA O O
corresponded O O
to O O
FGF B B_GENE
- I I_GENE
binding I I_GENE
protein I I_GENE
( O O
FGF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BP I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
a O O
secreted O O
protein O O
previously O O
shown O O
to O O
bind O O
acidic O O
and O O
basic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
FGF I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
to O O
modulate O O
their O O
activities O O
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
replicative O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
intermediates O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
shows O O
that O O
plasmid O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
YRp7 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
contains O O
the O O
chromosomal O B_GENE/B_LOCATION
replicator O I_GENE/I_LOCATION
ARS1 O I_GENE/I_LOCATION
, O O
initiates O O
bidirectional O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
replication O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
a O O
100 O B_LOCATION
bp O I_LOCATION
region O I_LOCATION
within O O
the O O
sequence O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O O
for O O
autonomous O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
replication O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
. O O

Rewarding O O
properties O O
of O O
methylphenidate O O
: O O
sensitization O O
by O O
prior O O
exposure O O
to O O
the O O
drug O O
and O O
effects O O
of O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
D1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
D2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antagonists O O
. O O

psrA B B_PERSON/B_BIO
mutants I I_PERSON/I_BIO
of O O
both O O
Pseudomonas O O
species O O
lost O O
the O O
ability O O
to O O
induce O O
rpoS B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
at O O
stationary O O
phase O O
, O O
but O O
they O O
retained O O
the O O
ability O O
to O O
produce O O
quorum O O
- O O
sensing O O
autoinducer O O
molecules O O
. O O

Multivariable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
logistic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O O
that O O
mean O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
blood O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
glucose O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
level O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
for O O
the O O
first O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
2 O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
days O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
p O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
002 O B_MEASURE
) O O
, O O
obesity O B_TIME[MEASURE]/B_DISEASE
( O O
p O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
002 O B_MEASURE
) O O
, O O
and O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
internal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEDICAL_DEVICE[OBJECT]
mammary O B_DISEASE_ADJECTIVE[DISEASE]/I_MEDICAL_DEVICE[OBJECT]
artery O B_DISEASE_ADJECTIVE[DISEASE]/I_MEDICAL_DEVICE[OBJECT]
( O O
p O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
02 O B_MEASURE
) O O
were O O
all O O
independent O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predictors O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
deep O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
wound O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

This O O
new O O
receptor O O
, O O
TOR B B_GENE/B_DISEASE
( O O
thymus B B_PROTEIN[GENE]/B_MEASURE
orphan I I_PROTEIN[GENE]/I_MEASURE
receptor I I_PROTEIN[GENE]/I_MEASURE
) O O
, O O
is O O
most O O
closely O O
related O O
in O O
both O O
its O O
DNA O O
- O O
binding O O
domain O O
and O O
ligand O O
- O O
binding O O
domain O O
, O O
90 O O
% O O
and O O
53 O O
% O O
, O O
respectively O O
, O O
to O O
ROR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
RZR B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
clusters O O
with O O
these O O
two O O
receptors O O
and O O
RZR B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
beta I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
a O O
phylogenetic O O
tree O O
, O O
when O O
both O O
the O O
DNA O O
- O O
binding O O
domain O O
and O O
the O O
ligand O O
- O O
binding O O
domain O O
sequences O O
of O O
nuclear O O
receptors O O
are O O
compared O O
. O O

crt2 B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
mutants I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
show O O
a O O
defect O O
in O O
basal O O
level O O
expression O O
of O O
RNR1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
lacZ B B_GENE
reporter O O
constructs O O
. O O

We O O
prospectively O O
studied O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prolactin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PRL B B_PROTEIN[GENE]/B_LOCATION
) O O
elevation O O
after O O
different O O
types O O
of O O
documented O O
seizures O O
in O O
17 O O
patients O O
. O O

Values O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
K1 O B_PROTEIN[GENE]/B_LOCATION
and O O
Vd O B_DISEASE/B_PROTEIN[GENE]
were O O
significantly O O
increased O O
in O O
the O O
tumour O B_TIME[MEASURE]/B_DISEASE
tissue O I_TIME[MEASURE]/I_DISEASE
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
a O O
double O B_DISEASE_ADJECTIVE[DISEASE]
mutant O I_DISEASE_ADJECTIVE[DISEASE]
( O O
E482A O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
D489A O B_MEASURE/B_PROTEIN[GENE]
) O O
which O O
removed O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
charges O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
along O O
one O B_LOCATION/B_ENT
side O I_LOCATION/I_ENT
of O O
the O O
helix O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
negligible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
fusion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
gene O O
encoding O O
rat O O
peptidylglycine B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amidating I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monooxygenase I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PAM B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
contains O O
26 O O
protein O O
- O O
coding O O
exons O O
. O O

Free O O
protein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
S I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
deficiency O O
in O O
acute O O
ischemic O O
stroke O O
. O O

CONCLUSION O O
: O O
The O O
biodistribution O O
of O O
111In O O
IgG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
similar O O
to O O
that O O
of O O
99mTc O O
- O O
HMPAO O O
- O O
labeled O O
leukocytes O O
. O O

The O O
RsmA B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
mutant I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O O
like O O
its O O
parent O O
, O O
produces O O
N O O
- O O
( O O
3 O O
- O O
oxohexanoyl O O
) O O
- O O
L O O
- O O
homoserine O O
lactone O O
( O O
HSL O O
) O O
, O O
a O O
starvation O O
/ O O
cell O O
density O O
- O O
sensing O O
signal O O
required O O
for O O
extracellular O O
enzyme O O
production O O
. O O

RMR O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
positively O O
correlated O O
with O O
TEF O B_PROTEIN[GENE]/B_LOCATION
( O O
r O O
= O O
0 O B_MEASURE
. O O
613 O B_MEASURE
, O O
p O O
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
and O O
net O B_PROTEIN[GENE]/B_DISEASE
TEF O I_PROTEIN[GENE]/I_DISEASE
( O O
r O B_OTHER/B_GENE
= O O
0 O B_MEASURE
. O O
648 O B_MEASURE
, O O
p O O
< O O
0 O B_MEASURE
. O O
005 O B_MEASURE
) O O
in O O
the O O
luteal O B_BODY_PART_OR_ORGAN_COMPONENT
but O O
not O O
the O O
follicular O B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANISM_FUNCTION
phase O I_BODY_PART_OR_ORGAN_COMPONENT/I_ORGANISM_FUNCTION
. O O

The O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consisted O O
of O O
1 O B_NUMBER[MEASURE]/B_PERSON
) O O
fitting O O
first O B_SEQUENCE[MEASURE]
- O O
and O O
second O B_SEQUENCE[MEASURE]/B_LOCATION
- O O
order O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
autoregressive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
AR1 O B_PROTEIN[GENE]/B_DISEASE
and O O
AR2 O B_PROTEIN[GENE]/B_DISEASE
) O O
and O O
2 O B_SEQUENCE[MEASURE]
) O O
obtaining O O
the O O
power O B_MEASURE/B_PERSON
spectra O I_MEASURE/I_PERSON
of O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O O
fast O B_DISEASE/B_MEASURE
- O O
Fourier O B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transform O B_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Furthermore O O
, O O
the O O
data O O
suggest O O
an O O
immunological O O
non O O
- O O
responsiveness O O
to O O
enterotoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
in O O
a O O
considerable O O
portion O O
of O O
the O O
patients O O
. O O

The O O
longest O B_PROTEIN[GENE]/B_DISEASE
S1 O I_PROTEIN[GENE]/I_DISEASE
- O O
S2 O B_MEASURE/B_LOCATION
interval O I_MEASURE/I_LOCATION
at O O
which O O
S2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
failed O O
to O O
capture O O
( O O
effective O B_MEASURE/B_DISEASE
refractory O B_MEASURE/I_DISEASE
period O B_MEASURE/I_DISEASE
) O O
was O O
longer O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
by O O
5 O B_MEASURE
. O O
5 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
8 O B_NUMBER[MEASURE]
. O O
2 O B_MEASURE/B_PERSON
msec O I_MEASURE/I_PERSON
at O O
twice O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
threshold O I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
0 O B_MEASURE/B_LOCATION
. O O
05 O B_TIME[MEASURE]
less O I_TIME[MEASURE]
than O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
10 O B_MEASURE
) O O
and O O
5 O B_MEASURE
. O O
5 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
3 O B_MEASURE
. O O
5 O B_MEASURE/B_PERSON
msec O I_MEASURE/I_PERSON
at O O
5 O B_MEASURE/B_LOCATION
times O I_MEASURE/I_LOCATION
threshold O I_MEASURE/I_LOCATION
stimulation O I_MEASURE/I_LOCATION
( O O
p O B_MEASURE
less O I_MEASURE
than O O
0 O B_NUMBER[MEASURE]
. O O
01 O B_MEASURE
) O O
when O O
the O O
basic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drive O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
extrastimuli O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
delivered O O
to O O
separate O B_PERSON/B_PROTEIN[GENE]
sites O I_PERSON/I_PROTEIN[GENE]
. O O

The O O
T O B_PROTEIN[GENE]/B_MEASURE
( O O
CCO2 O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
was O O
related O O
to O O
the O O
PCO2 O B_MEASURE
by O O
a O O
Pearson O B_MEASURE
product O I_MEASURE
coefficient O I_MEASURE
of O O
0 O B_MEASURE
. O O
79 O B_MEASURE
( O O
p O B_MEASURE
< O I_MEASURE
. O O
0005 O B_MEASURE
) O O
, O O
with O O
a O O
mean O B_MEASURE/B_LOCATION
difference O I_MEASURE/I_LOCATION
of O O
1 O B_MEASURE
. O O
94 O B_MEASURE
( O O
T O B_PROTEIN[GENE]/B_OTHER
( O O
CCO2 O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
> O O
P O B_OTHER/B_PROTEIN[GENE]
( O O
CO2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
and O O
95 O B_MEASURE
% O I_MEASURE
confidence O I_MEASURE
interval O I_MEASURE
of O O
- O O
0 O B_MEASURE
. O O
12 O B_MEASURE
to O O
4 O B_NUMBER[MEASURE]
. O O
07 O B_MEASURE
. O O

Urease B B_BACTERIUM[BIO]/B_ENZYME[GENE]
activity O O
, O O
judged O O
as O O
the O O
amount O O
of O O
ammonia O O
production O O
from O O
urea O O
, O O
could O O
be O O
measured O O
at O O
25 O O
ng O O
per O O
tube O O
( O O
S O O
/ O O
N O O
= O O
1 O O
. O O
5 O O
) O O
with O O
Jack B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
bean I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
meal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
urease I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
. O O

Optical O O
rotation O O
of O O
the O O
second O O
harmonic O O
radiation O O
from O O
retinal O O
in O O
bacteriorhodopsin B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
monomers I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
Langmuir O O
- O O
Blodgett O O
film O O
: O O
evidence O O
for O O
nonplanar O O
retinal O O
structure O O
. O O

Structure O O
and O O
regulation O O
of O O
KGD2 B B_GENE
, O O
the O O
structural O O
gene O O
for O O
yeast B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dihydrolipoyl I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transsuccinylase I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
dehydrated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O O
Ta O B_MEASURE/B_LOCATION
38 O I_MEASURE/I_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
, O O
Tb O B_PROTEIN[GENE]/B_LOCATION
and O O
EWL O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
were O O
both O O
significantly O O
altered O O
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE/B_LOCATION
. O O
001 O B_MEASURE
) O O
from O O
the O O
normally O O
hydrated O O
state O B_LOCATION/B_PERSON
and O O
were O O
measured O O
at O O
39 O B_MEASURE
. O O
9 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
2 O B_MEASURE
degree O I_MEASURE
C O I_MEASURE
and O O
0 O B_MEASURE
. O O
84 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
09 O B_MEASURE/B_LOCATION
W O I_MEASURE/I_LOCATION
. O O

These O O
findings O O
suggest O O
that O O
the O O
proteolipids O O
of O O
the O O
vacuolar B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
H I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
+ I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
ATPases I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
evolved O O
in O O
parallel O O
with O O
the O O
eubacterial O O
proteolipid O O
, O O
from O O
a O O
common O O
ancestral O O
gene O O
that O O
underwent O O
gene O O
duplication O O
. O O

Homology O O
is O O
much O O
higher O O
( O O
64 O O
% O O
) O O
between O O
the O O
28 O O
- O O
kDa O O
protein O O
and O O
regions O O
that O O
are O O
strongly O O
conserved O O
among O O
the O O
members O O
of O O
the O O
serine B B_PERSON/B_BIO
protease I I_PERSON/I_BIO
family I I_PERSON/I_BIO
. O O

During O O
chronic O O
treatment O O
with O O
salmon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
calcitonin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
alkaline B B_GENE/B_DISEASE
phosphatase I I_GENE/I_DISEASE
activity O O
and O O
urinary O O
hydroxyproline O O
excretion O O
decrease O O
on O O
an O O
average O O
of O O
50 O O
% O O
in O O
patients O O
with O O
Paget O O
' O O
s O O
disease O O
. O O

Because O O
of O O
the O O
structural O O
similarities O O
the O O
new O O
gene O O
will O O
be O O
termed O O
scERV2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O O
now O O
on O O
. O O

Cortical O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
somatosensory O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
evoked O O
potentials O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
median O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
nerve O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
revealed O O
significantly O O
delayed O O
peak O B_MEASURE
latencies O I_MEASURE
of O O
N20 O B_PROTEIN[GENE]/B_MEASURE
, O O
P20 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
P25 O B_PROTEIN[GENE]/B_MEASURE
, O O
and O O
N26 O B_MEASURE/B_PROTEIN[GENE]
, O O
although O O
N16 O B_MEASURE/B_PERSON
latency O B_MEASURE/I_PERSON
was O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Stress O O
- O O
induced O O
suppression O O
of O O
the O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
afternoon O O
surge O O
in O O
ovariectomized O O
, O O
estrogen O O
- O O
treated O O
rats O O
and O O
the O O
nocturnal O O
surge O O
in O O
pseudopregnant O O
rats O O
are O O
accompanied O O
by O O
an O O
increase O O
in O O
median O O
eminence O O
dihydroxyphenylacetic O O
acid O O
concentrations O O
. O O

Children O B_PERSON/B_BIO
with O O
repeated O O
proteinuria O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O O
follow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
up O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tend O O
to O O
have O O
a O O
higher O B_MEASURE/B_LOCATION
incidence O I_MEASURE/I_LOCATION
of O O
pathologic O B_DISEASE
findings O I_DISEASE
on O O
the O O
i O O
. O O
v O B_PROTEIN[GENE]/B_LOCATION
. O O
- O O
pyelogram O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
carboxyl O B_PROTEIN[GENE]
globular O I_PROTEIN[GENE]
domain O I_PROTEIN[GENE]
was O O
found O O
to O O
be O O
encoded O O
by O O
six O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
exons O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
appear O O
to O O
delineate O O
its O O
structural O B_LOCATION/B_MEASURE
subdomains O I_LOCATION/I_MEASURE
. O O

Expression O O
of O O
the O O
Asp O O
but O O
not O O
the O O
Ala O O
gB B B_DISEASE/B_MEASURE
mutation O O
resulted O O
in O O
an O O
increase O O
in O O
the O O
steady O O
- O O
state O O
expression O O
of O O
gB B B_GENE/B_DISEASE
at O O
the O O
plasma O O
membrane O O
( O O
PM O O
) O O
in O O
U373 O O
cells O O
. O O

Thus O O
integration B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
host I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
required O O
for O O
normal O O
type B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
1 I I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
fimbriae I I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
phase O O
variation O O
in O O
E O O
. O O
coli O O
. O O

Insulin B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
has O O
been O O
expanded O O
by O O
development O O
of O O
human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
new O O
modes O O
of O O
injection O O
, O O
including O O
insulin B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
pumps O O
. O O

11 O O
: O O
5801 O O
- O O
5812 O O
, O O
1991 O O
) O O
present O O
evidence O O
that O O
the O O
Vps18 B B_GENE
/ O O
Pep3 B B_MEASURE/B_PERSON
protein O O
colocalizes O O
with O O
the O O
Vps11 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Pep5 B B_MEASURE/B_PERSON
protein O O
to O O
the O O
cytosolic O O
face O O
of O O
the O O
vacuolar O O
membrane O O
. O O

We O O
conclude O O
that O O
the O O
BR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
C I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
early I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gene I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
directly O O
activates O O
late B B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
gene I I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
transcription O O
by O O
interacting O O
with O O
late B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
gene I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
cis O O
- O O
acting O O
regulatory O O
elements O O
and O O
that O O
this O O
interaction O O
is O O
responsible O O
for O O
the O O
temporal O O
linkage O O
of O O
early O O
and O O
late O O
ecdysone O O
- O O
induced O O
gene O O
expression O O
. O O

These O O
patients O O
developed O O
severe O O
diabetic O O
symptoms O O
including O O
glucose O O
intolerance O O
, O O
weight O O
loss O O
, O O
impaired O O
energy O O
utilization O O
, O O
and O O
nerve O O
and O O
brain O O
disorders O O
that O O
were O O
refractory O O
to O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
corresponding O O
tetrapeptide O O
sequences O O
SSPD O O
and O O
SATD O O
for O O
human B B_GENE
and I I_GENE
mouse I I_GENE
PKC I I_GENE
- I I_GENE
epsilon I I_GENE
, O O
respectively O O
, O O
are O O
unusual O O
for O O
caspase B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
proteins O O
, O O
called O O
variant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
surface I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycoproteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
VSGs B B_LOCATION/B_ORGANIZATION
) O O
, O O
are O O
expressed O O
from O O
a O O
specific O O
locus O O
, O O
the O O
VSG B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ES I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

They O O
encode O O
proteins O O
whose O O
core O O
regions O O
display O O
great O O
similarity O O
to O O
Aspergillus B B_SPECIES[BIO]/B_GENE
HAPB I B_SPECIES[BIO]/I_GENE
, O O
HAPC B B_DISEASE/B_LOCATION
and O O
HAPE B B_DISEASE/B_PROTEIN[GENE]
and O O
to O O
known O O
HAP B B_GENE/B_BIO
homologs I I_GENE/I_BIO
from O O
other O O
organisms O O
. O O

Transcripts O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
initiating O O
at O O
the O O
CAGT O B_GENE/B_LOCATION
motif O I_GENE/I_LOCATION
( O O
proximal O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
transcripts O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
were O O
abolished O O
by O O
deletion O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
proximal O B_GENE/B_LOCATION
TATA O I_GENE/I_LOCATION
box O I_GENE/I_LOCATION
located O O
at O O
- O O
29 O B_TIME[MEASURE]/B_LOCATION
relative O I_TIME[MEASURE]/I_LOCATION
to O O
CAGT O B_MEASURE/B_GENE
. O O

Although O O
the O O
energy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
based O O
DFT O B_MEASURE
was O O
not O O
affected O O
by O O
isoproterenol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
from O O
6 O B_NUMBER[MEASURE]
. O O
1 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
1 O B_NUMBER[MEASURE]
. O O
5 O B_MEASURE
to O O
6 O B_MEASURE
. O O
0 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_NUMBER[MEASURE]
. O O
7 O B_MEASURE
J O I_MEASURE
) O O
, O O
it O O
was O O
decreased O O
to O O
3 O B_NUMBER[MEASURE]
. O O
7 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_NUMBER[MEASURE]
. O O
6 O B_MEASURE
J O I_MEASURE
in O O
the O O
third O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stage O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
infusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
E4031 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
isoproterenol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE/B_PERSON
vs O I_MEASURE/I_PERSON
. O O
baseline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
vs O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
isoproterenol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
. O O

The O O
dynamics O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
interaction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
retention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
3 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
hr O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
CPB O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O O
quantified O O
with O O
autologous O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
In O O
- O O
111 O B_TIME[MEASURE]/B_BIO
labeled O O
neutrophils O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
INN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
in O O
4 O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
20 O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Yorkshire O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pigs O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
28 O B_MEASURE
- O O
35 O B_MEASURE
kg O I_MEASURE
, O O
5 O B_PERSON/B_LOCATION
sham O I_PERSON/I_LOCATION
; O O
5 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
CPB O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hr O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
5 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
CPB O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
3 O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hr O I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
5 O B_MEASURE
CPB O I_MEASURE
with O O
heparinized O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
circuit O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
3 O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hr O B_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
; O O
anesthetized O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pigs O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
injected O O
with O O
INN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
500 O B_MEASURE
- O O
650 O B_MEASURE
microCi O I_MEASURE
) O O
, O O
30 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
before O O
CPB O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
heparinized O O
, O O
and O O
underwent O O
CPB O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
a O O
roller O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PRODUCT[OBJECT]
pump O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PRODUCT[OBJECT]
, O O
a O O
hollow O B_LOCATION/B_PROTEIN[GENE]
fiber O I_LOCATION/I_PROTEIN[GENE]
OX O I_LOCATION/I_PROTEIN[GENE]
( O O
Bentley O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CM O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5 O B_MEASURE
. O O
0 O B_MEASURE
m2 O I_MEASURE
) O O
and O O
AF O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Bentley O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AF O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
025 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
0 O B_MEASURE
. O O
25 O B_MEASURE
m2 O I_MEASURE
) O O
at O O
2 O B_NUMBER[MEASURE]/B_LOCATION
. O O
5 O B_MEASURE
- O O
3 O B_MEASURE
. O O
6 O B_MEASURE/B_LOCATION
l O I_MEASURE/I_LOCATION
/ O O
min O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
3 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hr O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Single O O
amino O O
acid O O
substitutions O O
were O O
shown O O
to O O
result O O
from O O
the O O
mutations O O
pdr1 B B_GENE
- I I_GENE
2 I I_GENE
( O O
M308I O O
) O O
, O O
pdr1 B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
3 I I_PROTEIN[GENE]/I_MEASURE
( O O
F815S O O
) O O
, O O
pdr1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
K302Q O O
) O O
, O O
pdr1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
P298A O O
) O O
and O O
pdr1 B B_MEASURE
- I I_MEASURE
8 I I_MEASURE
( O O
L1036 O O
W O O
) O O
, O O
whereas O O
the O O
intragenic O O
suppressor O O
mutant O O
pdr1 B B_GENE/B_BIO
- I I_GENE/I_BIO
100 I I_GENE/I_BIO
is O O
deleted O O
for O O
the O O
two O O
amino O O
acids O O
L537 O O
and O O
A538 O O
. O O

Amniotic O O
fluid O O
ionic O O
concentration O O
in O O
response O O
to O O
chronic O O
fetal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
vasopressin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
infusion O O
. O O

All O O
possessed O O
cutaneous O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
receptive O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fields O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O O
the O O
distal O B_LOCATION/B_BIO
segments O I_LOCATION/I_BIO
of O O
digits O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
2 O I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
3 O B_NUMBER[MEASURE]
, O O
or O O
4 O B_NUMBER[MEASURE]/B_LOCATION
. O O

Previous O O
data O O
suggested O O
a O O
subtle O O
increase O O
in O O
serum O O
P O O
at O O
the O O
time O O
of O O
hCG B B_GENE
injection O O
without O O
LH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surge O O
reduces O O
the O O
PR O O
of O O
women O O
having O O
oocyte O O
retrievals O O
for O O
IVF O O
; O O
this O O
study O O
compared O O
PRs O O
of O O
recipients O O
in O O
a O O
shared O O
oocyte O O
program O O
according O O
to O O
the O O
donors O O
' O O
pre B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
hCG I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
P O O
level O O
. O O

M O B_OTHER/B_MEASURE
. O O
, O O
Adrich O B_PERSON
, O O
Z O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Fournet O B_PERSON/B_LOCATION
, O O
B O B_PROTEIN[GENE]/B_DISEASE
. O O
, O O
Capon O B_PERSON
, O O
C O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Bonicel O B_PERSON
, O O
J O B_OTHER/B_PROTEIN[GENE]
. O O

80 O O
v B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ets I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
encoded O O
amino O O
- O O
acids O O
located O O
immediately O O
after O O
the O O
v B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myb I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
v B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ets I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
junction O O
are O O
not O O
found O O
in O O
P54 B B_GENE
/ O O
56c B B_MEASURE
- I I_MEASURE
ets I I_MEASURE
, O O
the O O
translation O O
product O O
of O O
the O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ets I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proto I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oncogene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
nor O O
in O O
a O O
set O O
of O O
cellular O O
proteins O O
of O O
64 O O
, O O
62 O O
, O O
and O O
60 O O
kDa O O
related O O
to O O
but O O
distinct O O
from O O
P54 B B_GENE
/ O O
56c B B_MEASURE
- I I_MEASURE
ets I I_MEASURE
. O O

Latex O O
products O O
( O O
gloves O O
, O O
balloons O O
, O O
and O O
condoms O O
) O O
directly O O
bound O O
IgE B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
from O O
all O O
four O O
patients O O
. O O

Previous O O
studies O O
have O O
shown O O
that O O
TGFbeta1 B B_GENE
expression O O
is O O
upregulated O O
in O O
mouse O O
keratinocytes O O
infected O O
with O O
a O O
v B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rasHa I I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
retrovirus O O
, O O
although O O
the O O
functional O O
significance O O
of O O
this O O
has O O
not O O
been O O
clear O O
. O O

The O O
overall O B_MEASURE
rate O I_MEASURE
of O O
biohydrogenation O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
C18 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
2 O B_NUMBER[MEASURE]
was O O
14 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
/ O O
h O O
, O O
but O O
declined O O
1 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
/ O O
h O B_OTHER/B_TIME[MEASURE]
for O O
each O O
percentage O B_TIME[MEASURE]/B_LOCATION
unit O I_TIME[MEASURE]/I_LOCATION
increase O I_TIME[MEASURE]/I_LOCATION
in O O
C18 O B_MEASURE/B_PROTEIN[GENE]
: O O
2 O B_NUMBER[MEASURE]
added O O
to O O
the O O
substrate O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
PRP4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Saccharomyces I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cerevisiae I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
an O O
essential O O
part O O
of O O
the O O
U4 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
U6 B B_MEASURE
snRNP O O
, O O
a O O
component O O
of O O
the O O
mRNA O O
splicing O O
apparatus O O
. O O

Peptide O O
competition O O
studies O O
have O O
localized O O
a O O
cyclin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interaction I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
site I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
a O O
Lys381Lys382Leu383Met384Phe385 O O
sequence O O
within O O
C O O
- O O
terminal O O
negative O O
regulatory O O
domain O O
of O O
human B B_GENE
p53 I I_GENE
. O O

Heterodimerization B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutant I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RXR I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failed O O
to O O
alter O O
GFP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
VDR B B_PROTEIN[GENE]/B_LOCATION
and O O
nlsGFP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
VDR B B_PROTEIN[GENE]/B_LOCATION
distribution O O
or O O
activity O O
. O O

The O O
cats O B_BIO/B_PERSON
with O O
stage O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
2 O B_DISEASE
lymphomas O I_DISEASE
that O O
were O O
FeLV O B_BIO/B_GENE
- O O
test O B_DISEASE_ADJECTIVE[DISEASE]
negative O I_DISEASE_ADJECTIVE[DISEASE]
had O O
the O O
best O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
response O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Where O O
the O O
resonator O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
has O O
two O B_MEASURE/B_LOCATION
holes O I_MEASURE/I_LOCATION
, O O
these O O
terms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
should O O
be O O
somewhat O O
modified O O
: O O
A O B_OTHER/B_PROTEIN[GENE]
is O O
the O O
combined O B_MEASURE/B_LOCATION
area O I_MEASURE/I_LOCATION
of O O
the O O
two O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
holes O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
L O B_PROTEIN[GENE]/B_LOCATION
is O O
16 O B_MEASURE
/ O O
3pi O B_MEASURE
r O I_MEASURE
( O O
~ O O
1 O B_MEASURE
. O O
7r O B_MEASURE
) O O
for O O
a O O
simple O B_LOCATION/B_MEASURE
hole O I_LOCATION/I_MEASURE
in O O
a O O
thin O B_MEASURE/B_DISEASE
- O O
walled O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
vessel O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
r O B_OTHER/B_PROTEIN[GENE]
is O O
the O O
radius O B_MEASURE/B_LOCATION
of O O
one O B_LOCATION/B_MEASURE
hole O B_LOCATION/I_MEASURE
( O O
Seto O B_PERSON/B_LOCATION
, O O
1971 O B_MEASURE
) O O
. O O

The O O
deviation O B_LOCATION/B_GENE
site O B_LOCATION/I_GENE
is O O
equivalent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
exon O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
exon O B_MEASURE
2 O I_MEASURE
splice O I_MEASURE
site O I_MEASURE
of O O
the O O
mouse O B_PROTEIN[GENE]/B_SPECIES[BIO]
C O I_PROTEIN[GENE]/I_SPECIES[BIO]
- O O
subunit O B_GENE/B_LOCATION
. O O

T O B_PROTEIN[GENE]/B_LOCATION
. O O
infestans O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
delpontei O B_SPECIES[BIO]/B_PERSON
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
rubrovaria O B_SPECIES[BIO]/B_LOCATION
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
sordida O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
guasayana O B_SPECIES[BIO]/B_LOCATION
and O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
vitticeps O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
from O O
infestans O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subgroup O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
pallidipennis O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
from O O
rubrofasciata O B_LOCATION
, O O
were O O
studied O O
. O O

The O O
N O O
- O O
terminal O O
sequence O O
of O O
the O O
extracellular B B_GENE
MEP20 I I_GENE
, O O
TKVAS B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
, O O
was O O
found O O
at O O
aa O O
194 O O
- O O
198 O O
within O O
the O O
ORF O O
. O O

Isolates O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
B O B_GENE/B_DISEASE
. O O
burgdorferi O B_BACTERIUM[BIO]/B_DISEASE
from O O
humans O B_PERSON/B_SPECIES[BIO]
, O O
rodents O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
I O O
. O O
dammini O B_SPECIES[BIO]/B_DISEASE
are O O
usually O O
indistinguishable O B_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
strains O B_BIO/B_PERSON
of O O
B O B_PROTEIN[GENE]/B_DISEASE
. O O
burgdorferi O B_BACTERIUM[BIO]/B_DISEASE
with O O
different O B_DISEASE_ADJECTIVE[DISEASE]
major O I_DISEASE_ADJECTIVE[DISEASE]
proteins O I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
identified O O
. O O

The O O
BHV B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
UL24 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
UL25 B B_MEASURE
, O O
UL26 B B_MEASURE
and O O
UL26 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
all O O
terminated O O
at O O
a O O
common O O
3 O O
' O O
- O O
polyadenylation O O
site O O
and O O
varied O O
significantly O O
in O O
their O O
relative O O
abundance O O
. O O

These O O
results O O
suggest O O
that O O
both O O
the O O
distinct O O
DNA O O
binding O O
properties O O
of O O
PMLRAR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homodimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
sequestration O O
of O O
RXR B B_GENE
by O O
PMLRARs B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
may O O
contribute O O
to O O
the O O
molecular O O
mechanisms O O
which O O
underlie O O
the O O
pathogenesis O O
of O O
APL O O
. O O

Deletion O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
were O O
constructed O O
, O O
removing O O
residues O B_MEASURE
2 O I_MEASURE
- O O
30 O B_MEASURE
, O O
31 O B_MEASURE
- O O
60 O B_MEASURE
, O O
61 O B_MEASURE
- O O
90 O B_MEASURE
, O O
and O O
49 O B_MEASURE
- O O
78 O B_MEASURE
of O O
the O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_PROTEIN[GENE]/B_LOCATION
cytoplasmic O I_PROTEIN[GENE]/I_LOCATION
domain O I_PROTEIN[GENE]/I_LOCATION
, O O
as O O
well O O
as O O
a O O
missense O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutation O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
a O O
dileucine O B_GENE
motif O I_GENE
. O O

Ureases B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
were O O
purified O O
from O O
the O O
recombinant O O
cells O O
and O O
shown O O
to O O
be O O
identical O O
to O O
control O O
enzyme O O
when O O
analyzed O O
by O O
gel O O
filtration O O
chromatography O O
and O O
sodium O O
dodecyl O O
sulfate O O
- O O
polyacrylamide O O
gel O O
electrophoresis O O
; O O
however O O
, O O
in O O
every O O
case O O
the O O
activity O O
levels O O
correlated O O
to O O
nickel O O
contents O O
as O O
analyzed O O
by O O
atomic O O
absorption O O
analysis O O
. O O

A O O
wide O O
conservation O O
of O O
iscSUA B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genes I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
nature O O
and O O
evidence O O
that O O
NifU B B_BACTERIUM[BIO]/B_GENE
and O O
NifS B B_LOCATION/B_GENE
participate O O
in O O
the O O
mobilization O O
of O O
iron O O
and O O
sulfur O O
for O O
nitrogenase B B_BIO/B_LOCATION
- O O
specific O O
iron O O
- O O
sulfur O O
cluster O O
formation O O
suggest O O
that O O
the O O
products O O
of O O
the O O
iscSUA B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genes I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
could O O
play O O
a O O
general O O
role O O
in O O
the O O
formation O O
or O O
repair O O
of O O
iron O O
- O O
sulfur O O
clusters O O
. O O

The O O
pattern O O
of O O
expression O O
of O O
this O O
and O O
other O O
Chi26 B B_PROTEIN[GENE]/B_SPECIES[BIO]
/ O O
Chi33 B B_MEASURE
chimeric O O
promoters O O
suggest O O
that O O
the O O
E B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
region I I_GENE/I_LOCATION
contains O O
cis O O
- O O
acting O O
sequences O O
which O O
activate O O
transcription O O
in O O
aleurone O O
and O O
silence O O
transcription O O
in O O
leaves O O
. O O

Four O O
newborns O O
in O O
this O O
group O O
became O O
HBsAg B B_DISEASE/B_PERSON
carriers O O
. O O

The O O
following O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
measured O O
: O O
onset O B_PROTEIN[GENE]/B_LOCATION
time O I_PROTEIN[GENE]/I_LOCATION
( O O
time O B_MEASURE/B_LOCATION
interval O I_MEASURE/I_LOCATION
from O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
maximal O B_MEASURE
or O O
total O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
block O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
T125 O B_MEASURE/B_PROTEIN[GENE]
/ O O
75 O B_MEASURE
( O O
time O B_TIME[MEASURE]/B_LOCATION
for O O
T1 O B_MEASURE
to O O
reach O O
25 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
or O O
75 O B_MEASURE
% O I_MEASURE
of O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
, O O
TOF70 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
time O B_TIME[MEASURE]/B_LOCATION
for O O
TOF O B_PROTEIN[GENE]
ratio O I_PROTEIN[GENE]
to O O
reach O O
70 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
, O O
heart O B_MEASURE/B_DISEASE
rate O I_MEASURE/I_DISEASE
and O O
blood O B_DISEASE/B_GENE
pressure O B_DISEASE/I_GENE
. O O

PC12 O O
cultures O O
that O O
had O O
been O O
" O O
primed O O
" O O
in O O
this O O
way O O
showed O O
an O O
accelerated O O
and O O
augmented O O
differentiation O O
response O O
to O O
nerve B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
growth I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
the O O
remaining O O
91 O O
patients O O
( O O
group O O
2 O O
) O O
, O O
Pseudomonas O O
( O O
18 O O
) O O
, O O
coagulase B B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
negative O O
Staphylococci O O
( O O
15 O O
) O O
, O O
Staphylococcus O O
epidermidis O O
( O O
23 O O
) O O
, O O
Staphylococcus O O
aureus O O
( O O
16 O O
) O O
, O O
Corynebacterium O O
species O O
( O O
12 O O
) O O
, O O
and O O
others O O
( O O
seven O O
) O O
were O O
isolated O O
. O O

Taken O O
together O O
, O O
these O O
results O O
demonstrate O O
that O O
the O O
BSMV B B_GENE/B_BIO
coat I I_GENE/I_BIO
protein I I_GENE/I_BIO
is O O
the O O
sole O O
translation O O
product O O
of O O
the O O
genomic B B_GENE
RNA I I_GENE
beta I I_GENE
, O O
whereas O O
sgRNA B B_GENE/B_BIO
beta I I_GENE/I_BIO
1 I I_GENE/I_BIO
serves O O
as O O
a O O
messenger O O
for O O
translation O O
of O O
the O O
beta B B_GENE
b I I_GENE
protein I I_GENE
, O O
and O O
sgRNA B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
beta I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
2 I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
functions O O
as O O
a O O
messenger O O
for O O
translation O O
of O O
beta B B_GENE
c I I_GENE
and O O
beta B B_GENE
d I I_GENE
and O O
the O O
newly O O
discovered O O
beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
d I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

At O O
the O O
start O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
performance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ride O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
plasma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glucose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
averaged O O
4 O B_MEASURE
. O O
2 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
0 O B_MEASURE
. O O
2 O B_MEASURE
, O O
5 O B_MEASURE
. O O
2 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
0 O B_MEASURE/B_LOCATION
. O O
1 O B_MEASURE
, O O
and O O
5 O B_MEASURE
. O O
7 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
2 O B_MEASURE/B_PERSON
mmol O I_MEASURE/I_PERSON
. O O
l O B_TIME[MEASURE]/B_DISEASE
- O O
1 O B_MEASURE
in O O
CON O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
CHO O B_PERSON/B_PROTEIN[GENE]
- O O
7 O B_MEASURE
, O O
and O O
CHO O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
0 O B_MEASURE
/ O O
21 O B_NUMBER[MEASURE]
, O O
respectively O O
( O O
all O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Therefore O O
prostaglandin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
characterized O O
in O O
relation O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
prostaglandin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
F2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
alpha O B_PROTEIN[GENE]
not O O
only O O
by O O
a O O
stronger O B_DISEASE_ADJECTIVE[DISEASE]
uterine O I_DISEASE_ADJECTIVE[DISEASE]
effectiveness O I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
also O O
at O O
the O O
same O B_TIME[MEASURE]/B_LOCATION
time O I_TIME[MEASURE]/I_LOCATION
a O O
pronounced O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
cardiovascular O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Its O O
prognostic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
impact O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
superior O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
the O O
T1 O B_PROTEIN[GENE]/B_MEASURE
/ O O
2 O B_PROTEIN[GENE]
one O I_PROTEIN[GENE]
( O O
RR O B_PROTEIN[GENE]/B_MEASURE
= O O
2 O B_MEASURE
. O O
9 O B_MEASURE
; O O
p O O
= O O
0 O B_MEASURE
. O O
0010 O B_MEASURE
) O O
. O O

Escherichia O O
coli O O
cells O O
expressing O O
a O O
mutant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glyV I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
glycine B B_PROTEIN[GENE]/B_LOCATION
tRNA I I_PROTEIN[GENE]/I_LOCATION
) O O
gene O O
have O O
a O O
UVM O O
- O O
constitutive O O
phenotype O O
: O O
implications O O
for O O
mechanisms O O
underlying O O
the O O
mutA B B_DISEASE/B_GENE
or O O
mutC B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
mutator I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
effect O O
. O O

The O O
atopic O O
disposition O O
, O O
indicated O O
by O O
positive O O
skin O O
reactions O O
and O O
IgE B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
antibody O O
titers O O
etc O O
. O O
, O O
and O O
the O O
bronchial O O
reactivity O O
to O O
inhaled O O
acetylcholine O O
were O O
examined O O
on O O
the O O
following O O
three O O
groups O O
: O O
( O O
1 O O
) O O
20 O O
young O O
adults O O
with O O
a O O
history O O
of O O
childhood O O
asthma O O
who O O
have O O
been O O
symptom O O
- O O
free O O
for O O
more O O
than O O
4 O O
yr O O
; O O
( O O
2 O O
) O O
20 O O
current O O
asthmatics O O
, O O
and O O
( O O
3 O O
) O O
20 O O
healthy O O
young O O
adults O O
. O O

sp O B_LOCATION/B_PROTEIN[GENE]
. O O
pisi O B_MEASURE/B_LOCATION
( O O
Nectria O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
haematococca O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mating O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
type O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
VI O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O O
by O O
the O O
hydroxy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
fatty O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
acids O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
plant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
cutin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O O
that O O
a O O
50 O B_MEASURE
- O O
kDa O B_MEASURE/B_LOCATION
nuclear O B_MEASURE/I_LOCATION
protein O B_MEASURE/I_LOCATION
binds O O
to O O
a O O
promoter O B_GENE
that O O
contains O O
this O O
element O B_PROTEIN[GENE]
. O O

We O O
conclude O O
that O O
these O O
cDNAs O O
belong O O
to O O
a O O
novel O O
GST B B_GENE/B_BIO
class O O
hereby O O
designated O O
Kappa O O
, O O
with O O
the O O
rat B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
GST I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
subunit I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
13 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
designated O O
rGSTK1 B B_PROTEIN[GENE]
and O O
the O O
human O O
gene O O
being O O
called O O
hGSTK1 B B_GENE
. O O

Previous O O
studies O O
using O O
partial O O
sequences O O
have O O
suggested O O
the O O
potential O O
of O O
26S B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
large B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
subunit I I_MEASURE/I_GENE
( O O
LSU B B_LOCATION/B_MEASURE
) O O
rDNA O O
for O O
phylogeny O O
retrieval O O
at O O
taxonomic O O
levels O O
comparable O O
to O O
those O O
investigated O O
with O O
18S B B_GENE/B_MEASURE
rDNA I I_GENE/I_MEASURE
. O O

The O O
prevalence O O
of O O
antibodies O O
to O O
HRES B B_DISEASE
- I I_DISEASE
1 I I_DISEASE
peptides I I_DISEASE
pep14 I I_DISEASE
- I I_DISEASE
24 I I_DISEASE
and I I_DISEASE
pep117 I I_DISEASE
- I I_DISEASE
127 I I_DISEASE
was O O
determined O O
in O O
65 O O
normal O O
blood O O
donors O O
and O O
146 O O
patients O O
with O O
immunological O O
disorders O O
. O O

The O O
contractile O O
effects O O
of O O
oxytocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
prostaglandin O O
F2 O O
alpha O O
and O O
their O O
combined O O
use O O
on O O
human O O
pregnant O O
myometrium O O
were O O
studied O O
in O O
vitro O O
. O O

These O O
involve O O
( O O
1 O O
) O O
subcloning O O
a O O
promoterless O O
sucCD B B_LOCATION/B_GENE
fragment I B_LOCATION/I_GENE
downstream O O
of O O
the O O
lac B B_GENE/B_BIO
promoter I I_GENE/I_BIO
in O O
M13mp10 O O
, O O
and O O
( O O
2 O O
) O O
precise O O
splicing O O
of O O
the O O
suc B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
coding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
efficient O O
atpE B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
ribosome I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
- I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
binding I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
site I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
and O O
expression O O
from O O
the O O
thermoinducible O O
lambda O O
promoters O O
in O O
the O O
pJLA503 O O
vector O O
. O O

Transcription O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
eukaryotic O B_GENE
tRNA O I_GENE
genes O I_GENE
is O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
on O O
the O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
and O O
B O B_PROTEIN[GENE]/B_DISEASE
- O O
Box O B_LOCATION/B_BIO
internal O I_LOCATION/I_BIO
control O I_LOCATION/I_BIO
regions O I_LOCATION/I_BIO
( O O
ICRs O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
the O O
upstream O B_GENE/B_LOCATION
transcription O I_GENE/I_LOCATION
modulatory O I_GENE/I_LOCATION
region O I_GENE/I_LOCATION
. O O

Retroviral O O
vector O O
producer O O
cell O O
populations O O
and O O
cell O O
clones O O
were O O
established O O
for O O
each O O
chLTR B B_PERSON/B_GENE
vector O O
, O O
and O O
all O O
were O O
capable O O
of O O
yielding O O
high O O
vector O O
titers O O
( O O
> O O
10 O O
( O O
5 O O
) O O
G418R B B_MEASURE
cfu O O
/ O O
ml O O
on O O
NIH O O
- O O
3T3 O O
) O O
. O O

The O O
addition O O
of O O
novel O O
techniques O O
, O O
such O O
as O O
histopathologic O O
ultrastaging O O
, O O
immunohistochemistry O O
staining O O
, O O
and O O
reverse B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcriptase I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymerase O O
chain O O
reaction O O
assays O O
, O O
will O O
help O O
increase O O
the O O
accuracy O O
and O O
rate O O
of O O
detection O O
of O O
disease O O
. O O

Methylprednisolone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
U O B_PROTEIN[GENE]/B_LOCATION
- O O
74006F O B_MEASURE/B_LOCATION
were O O
equally O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O O
preventing O O
neurological O B_DISEASE
dysfunction O I_DISEASE
compared O O
to O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
; O O
U O B_PROTEIN[GENE]/B_LOCATION
- O O
78517F O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
slightly O O
less O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
U O B_PROTEIN[GENE]/B_LOCATION
- O O
74006F O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
methylprednisolone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
was O O
significantly O O
better O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
vehicle O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
preventing O O
neurological O B_DISEASE
dysfunction O I_DISEASE
. O O

The O O
TaqI B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
HaeIII B B_GENE/B_DISEASE
RFLPs O O
will O O
provide O O
tools O O
for O O
the O O
genetic O O
analysis O O
of O O
CR2 B B_DISEASE/B_BIO
. O O

Ptx1 B B_GENE/B_PERSON
belongs O O
to O O
an O O
expanding O O
family O O
of O O
bicoid B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
related I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
vertebrate O O
homeobox O O
genes O O
. O O

Differential O O
transcription O O
of O O
plastome O O
- O O
encoded O O
genes O O
in O O
the O O
mesophyll O O
and O O
bundle O O
- O O
sheath O O
chloroplasts O O
of O O
the O O
monocotyledonous O O
NADP O O
- O O
malic B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
type O O
C4 O O
plants O O
maize O O
and O O
Sorghum O O
. O O

The O O
MEE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
was O O
significantly O O
greater O B_MEASURE
than O O
the O O
BEE O B_PROTEIN[GENE]/B_LOCATION
and O O
significantly O O
less O B_MEASURE
than O O
the O O
calculated O B_MEASURE/B_LOCATION
energy O I_MEASURE/I_LOCATION
expenditure O I_MEASURE/I_LOCATION
. O O

These O O
results O O
suggest O O
that O O
E6010 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
of O O
clinical O O
value O O
in O O
the O O
treatment O O
of O O
coronary O O
occlusion O O
. O O

To O O
better O O
understand O O
the O O
relationship O O
between O O
expression O O
of O O
an O O
oncogene O O
and O O
genetic O O
instability O O
, O O
we O O
have O O
studied O O
a O O
cell O O
line O O
expressing O O
an O O
activated B B_GENE
human I I_GENE
Ha I I_GENE
- I I_GENE
ras I I_GENE
under O O
the O O
control O O
of O O
bacterial B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
lactose I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
operon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
regulatory I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
elements I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
changes O O
in O O
methotrexate O O
resistance O O
and O O
dihydrofolate B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reductase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
dhfr B B_LOCATION/B_PROTEIN[GENE]
) O O
gene O O
amplification O O
following O O
mutant B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ha I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ras I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induction O O
. O O

The O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
work O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
represents O O
an O O
attempt O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
develop O O
a O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
measuring O O
relative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
blood O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
flow O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
intestinal O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
capillaries O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
by O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorescein O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Na O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
F O B_PROTEIN[GENE]/B_DISEASE
) O O
as O O
an O O
indicator O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substance O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

25 O B_PERSON
patients O I_PERSON
received O O
20 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
mgs O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
hyoscine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
N O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
butyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
bromide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
rest O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mgs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
propinoxate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
i O O
. O O
v O B_PROTEIN[GENE]/B_LOCATION
. O O
plus O O
diazepam O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
expression O O
of O O
Scmh1 B B_GENE
and O O
rae28 B B_LOCATION/B_GENE
/ O O
mph1 B B_MEASURE
is O O
well O O
correlated O O
in O O
most O O
tissues O O
of O O
embryos O O
. O O

CERIP B B_ORGANIZATION/B_PERSON
interaction O O
. O O

Dmyd B B_PERSON
clone O O
encodes O O
a O O
polypeptide O O
of O O
332 O O
amino O O
acids O O
with O O
82 O O
% O O
identity O O
to O O
MyoD B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
in O O
the O O
41 O O
amino O O
acids O O
of O O
the O O
putative O O
helix O O
- O O
loop O O
- O O
helix O O
region O O
and O O
100 O O
% O O
identity O O
in O O
the O O
13 O O
amino O O
acids O O
of O O
the O O
basic O O
domain O O
proposed O O
to O O
contain O O
the O O
essential O O
recognition O O
code O O
for O O
muscle O O
- O O
specific O O
gene O O
activation O O
. O O

Triaxiality O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
proton O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
neutron O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interacting O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boson O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Perturbed O O
O O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
6 O B_NUMBER[MEASURE]
) O O
symmetry O B_MEASURE/B_LOCATION
with O O
application O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
mass O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

The O O
two O B_LOCATION/B_BIO
redox O B_LOCATION/I_BIO
centers O B_LOCATION/I_BIO
in O O
the O O
protein O B_ENZYME[GENE]/B_BACTERIUM[BIO]
, O O
FAD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
a O O
[ O B_LOCATION/B_BIO
4Fe4S O B_LOCATION/I_BIO
] O O
+ O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
, O O
+ O O
1 O B_MEASURE/B_LOCATION
cluster O I_MEASURE/I_LOCATION
, O O
are O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
64 O B_MEASURE
- O O
kDa O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monomer O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
pra2 B B_GENE/B_BIO
gene I I_GENE/I_BIO
encodes O O
a O O
pea B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Pisum I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sativum I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
small I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
GTPase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
belonging O O
to O O
the O O
YPT B B_GENE/B_DISEASE
/ O O
rab B B_PERSON/B_PROTEIN[GENE]
family O O
, O O
and O O
its O O
expression O O
is O O
down O O
- O O
regulated O O
by O O
light O O
, O O
mediated O O
by O O
phytochrome B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Human B B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
murine I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytotoxic I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lymphocyte I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serine I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteases I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
subsite O O
mapping O O
with O O
peptide O O
thioester O O
substrates O O
and O O
inhibition O O
of O O
enzyme O O
activity O O
and O O
cytolysis O O
by O O
isocoumarins O O
. O O

In O O
addition O B_MEASURE/B_LOCATION
, O O
WR O B_PROTEIN[GENE]/B_DISEASE
- O O
3689 O B_MEASURE
, O O
WR O B_PROTEIN[GENE]/B_DISEASE
- O O
109342 O B_MEASURE
, O O
and O O
WR O B_PROTEIN[GENE]/B_DISEASE
- O O
168643 O B_MEASURE
were O O
used O O
with O O
per O O
os O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
determine O O
hematopoietic O B_DISEASE/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lethality O B_DISEASE/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
contrast O O
, O O
corticotropin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
releasing I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CRF B B_GENE/B_DISEASE
) O O
, O O
injected O O
centrally O O
produces O O
a O O
suppression O O
of O O
punished O O
and O O
non O O
- O O
punished O O
responding O O
in O O
the O O
conflict O O
test O O
consistent O O
with O O
its O O
hypothesized O O
role O O
in O O
mediating O O
behavioral O O
responses O O
to O O
stress O O
. O O

We O O
identified O O
clones O O
of O O
Chlamydomonas O O
genomic O O
DNA O O
that O O
rescued O O
the O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
dependent O O
axonemal O O
microtubule O O
severing O O
defect O O
of O O
fa1 B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

Plasma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hemopexin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
homeostasis O O
during O O
the O O
acute O O
phase O O
response O O
. O O

This O O
is O O
similar O O
to O O
previous O O
reports O O
of O O
muscle B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
creatine I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphokinase I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release O O
in O O
psychiatric O O
patients O O
. O O

Deletion O O
analysis O O
defines O O
distinct O O
functional O O
domains O O
for O O
protein O O
- O O
protein O O
and O O
nucleic O O
acid O O
interactions O O
in O O
the O O
ORF1 B B_GENE/B_BIO
protein I I_GENE/I_BIO
of O O
mouse O O
LINE B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_VIRUS[BIO]
- I B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_VIRUS[BIO]
1 I B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_VIRUS[BIO]
. O O

As O O
a O O
test O O
of O O
this O O
hypothesis O O
, O O
we O O
predicted O O
that O O
mice O O
which O O
have O O
altered O O
expression O O
of O O
class O O
I O O
gene O O
products O O
, O O
the O O
beta2 B B_GENE
- I I_GENE
microglobulin I I_GENE
knockout O O
mice O O
, O O
[ B B_TIME[MEASURE]/B_LOCATION
beta2m I I_TIME[MEASURE]/I_LOCATION
( I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
/ I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
) I I_TIME[MEASURE]/I_LOCATION
] I I_TIME[MEASURE]/I_LOCATION
, O O
would O O
develop O O
Fe O O
overload O O
. O O

Though O O
it O O
has O O
been O O
established O O
that O O
skinfold O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anthropometry O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
has O O
severe O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
limitations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
as O O
a O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
deriving O O
total O B_MEASURE/B_PROTEIN[GENE]
body O B_MEASURE/I_PROTEIN[GENE]
fat O B_MEASURE/I_PROTEIN[GENE]
( O O
TBF O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
the O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
the O O
problem O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
might O O
be O O
related O O
more O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O O
the O O
assumptions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
implicit O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
densitometry O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
has O O
to O O
be O O
addressed O O
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
In O O
lung O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protective O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strategy O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
expiratory O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
pressure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
( O O
PEEP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
slightly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
Pflex O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
the O O
airway O B_MEASURE/B_LOCATION
pressure O I_MEASURE/I_LOCATION
corresponding O I_MEASURE/I_LOCATION
to O O
the O O
lower O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inflection O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
point O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LIP O B_LOCATION/B_PROTEIN[GENE]
) O O
on O O
the O O
inspiratory O B_MEASURE/B_LOCATION
pressure O I_MEASURE/I_LOCATION
- O O
volume O B_MEASURE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
- O O
V O B_OTHER/B_PROTEIN[GENE]
) O O
curve O B_MEASURE
measured O O
with O O
ZEEP O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
is O O
generally O O
recommended O O
. O O

These O O
results O O
indicate O O
that O O
patients O O
with O O
SS O O
and O O
evidence O O
of O O
exercise O O
- O O
induced O O
ST O O
- O O
segment O O
depression O O
may O O
have O O
decreased O O
myocardial O O
oxygen O O
supply O O
due O O
to O O
low O O
hemoglobin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels O O
and O O
increased O O
myocardial O O
oxygen O O
demand O O
( O O
elevated O O
double O O
products O O
) O O
when O O
compared O O
to O O
subjects O O
with O O
SS O O
who O O
do O O
not O O
have O O
exercise O O
- O O
induced O O
ST O O
- O O
segment O O
depression O O
. O O

Using O O
this O O
oligonucleotide O O
as O O
a O O
probe O O
, O O
an O O
8 O O
- O O
kilobase O O
HindIII B B_MEASURE/B_LOCATION
fragment O O
of O O
genomic O O
DNA O O
was O O
isolated O O
and O O
subjected O O
to O O
Sanger O O
dideoxy O O
DNA O O
sequencing O O
. O O

Four O O
cDNAs O O
( O O
Kox4 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Kox7 B B_MEASURE/B_GENE
, O O
Kox12 B B_MEASURE/B_GENE
, O O
and O O
Kox15 B B_MEASURE
) O O
were O O
identified O O
that O O
match O O
one O O
or O O
more O O
genomic O O
clones O O
; O O
these O O
matches O O
were O O
confirmed O O
by O O
nucleotide O O
sequence O O
analysis O O
. O O

Relaxant O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
prostaglandin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PGE1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
and O O
papaverine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PAP O B_PROTEIN[GENE]/B_DISEASE
) O O
were O O
measured O O
in O O
strips O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
corpus O B_BODY_PART_OR_ORGAN_COMPONENT
cavernosum O I_BODY_PART_OR_ORGAN_COMPONENT
smooth O I_BODY_PART_OR_ORGAN_COMPONENT
muscle O I_BODY_PART_OR_ORGAN_COMPONENT
taken O O
from O O
a O O
healthy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
men O B_PERSON/B_BIO
( O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
; O O
n O B_MEASURE/B_PROTEIN[GENE]
= O O
5 O B_MEASURE
) O O
, O O
from O O
arteriogenically O O
impotent O B_DISEASE_ADJECTIVE[DISEASE]
men O I_DISEASE_ADJECTIVE[DISEASE]
( O O
B O B_LOCATION/B_DISEASE
; O O
n O O
= O O
6 O B_MEASURE
) O O
and O O
from O O
additionally O O
diabetic O B_PERSON/B_BIO
impotent O I_PERSON/I_BIO
men O I_PERSON/I_BIO
( O O
C O B_PROTEIN[GENE]/B_LOCATION
; O O
n O B_MEASURE/B_PROTEIN[GENE]
= O O
5 O B_MEASURE
) O O
with O O
venous O B_DISEASE
leakage O I_DISEASE
. O O

Sequence O O
analysis O O
and O O
electrophoretic O O
mobility O O
shift O O
experiments O O
suggest O O
that O O
GnSE B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
response I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
elements I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
interact O O
, O O
in O O
these O O
two O O
regions O O
, O O
with O O
GATA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LIM I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
. O O

The O O
transfer O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
by O O
conjugation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
E O B_BACTERIUM[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
coli O B_BACTERIUM[BIO]/B_PERSON
K12 O I_BACTERIUM[BIO]/I_PERSON
of O O
ampicillin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
carbenicillin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resistance O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
obtained O O
with O O
14 O B_BACTERIUM[BIO]/B_NUMBER[MEASURE]
strains O B_BACTERIUM[BIO]/I_NUMBER[MEASURE]
: O O
( O O
E O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
coli O B_BACTERIUM[BIO]
: O O
9 O B_NUMBER[MEASURE]
, O O
C O B_OTHER/B_GENE
. O O
freundii O B_BACTERIUM[BIO]/B_DISEASE
: O O
1 O B_NUMBER[MEASURE]
, O O
K O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
pneumoniae O B_BACTERIUM[BIO]/B_MEASURE
: O O
1 O B_NUMBER[MEASURE]
, O O
E O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
cloacae O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
: O O
2 O B_NUMBER[MEASURE]
, O O
P O B_OTHER/B_LOCATION
. O O
stuartii O B_BACTERIUM[BIO]/B_MEASURE
: O O
1 O B_MEASURE
) O O
. O O

Using O O
the O O
conflict O O
drinking O O
test O O
as O O
a O O
model O O
, O O
we O O
studied O O
in O O
rats O O
the O O
effect O O
of O O
the O O
nonselective O O
beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
adrenoceptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers O O
pindolol O O
and O O
cyanopindolol O O
which O O
bind O O
to O O
5 B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HT1A I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HT1B I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
of O O
the O O
selective O O
beta B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adrenoceptor I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonists O O
betaxolol O O
and O O
ICI O O
118 O O
, O O
551 O O
, O O
respectively O O
, O O
which O O
have O O
a O O
negligible O O
affinity O O
for O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
HT I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Glycoprotein O O
biosynthesis O O
in O O
Saccharomyces O O
cerevisiae O O
: O O
ngd29 B B_LOCATION/B_GENE
, O O
an O O
N O O
- O O
glycosylation O O
mutant O O
allelic O O
to O O
och1 B B_SPECIES[BIO]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O O
a O O
defect O O
in O O
the O O
initiation O O
of O O
outer O O
chain O O
formation O O
. O O

These O O
motions O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
were O O
found O O
in O O
the O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
and O O
C O B_PROTEIN[GENE]/B_LOCATION
- O O
terminal O B_LOCATION/B_MEASURE
tails O I_LOCATION/I_MEASURE
, O O
in O O
segment O B_MEASURE/B_LOCATION
33 O I_MEASURE/I_LOCATION
- O O
35 O B_MEASURE
which O O
forms O O
the O O
turn O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
strands O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
S1 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
S2 O B_MEASURE/B_PROTEIN[GENE]
, O O
and O O
residues O B_MEASURE
47 O I_MEASURE
- O O
52 O B_MEASURE
located O O
in O O
a O O
long O B_LOCATION/B_MEASURE
loop O I_LOCATION/I_MEASURE
preceding O O
strand O B_PROTEIN[GENE]/B_NUMBER[MEASURE]
S3 O I_PROTEIN[GENE]/I_NUMBER[MEASURE]
. O O

The O O
uap100 B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
cis O O
- O O
acting O O
, O O
up O O
- O O
promoter O O
, O O
constitutive O O
mutation O O
is O O
a O O
duplication O O
that O O
comprises O O
two O O
GATA O O
sites O O
and O O
suppresses O O
weakly O O
the O O
AREA B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
zinc I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
finger I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
but O O
does O O
not O O
alleviate O O
the O O
need O O
for O O
functional O O
UAY B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
AREA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

CHIEF O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OUTCOME O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MEASURES O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Endoluminal O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
release O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
prostacyclin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
6 O B_MEASURE
- O O
Keto O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
PGF1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
thromboxane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
TxB2 O B_PROTEIN[GENE]
) O O
, O O
patency O B_DISEASE
, O O
EC O B_DISEASE_ADJECTIVE[DISEASE]
coverage O I_DISEASE_ADJECTIVE[DISEASE]
and O O
cell O B_DISEASE_ADJECTIVE[DISEASE]
identity O I_DISEASE_ADJECTIVE[DISEASE]
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Children O B_PERSON
with O O
attention O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
deficit O B_DISEASE
/ O O
hyperactivity O B_DISEASE
disorder O I_DISEASE
( O O
ADHD O B_DISEASE
; O O
n O O
= O O
282 O B_MEASURE
) O O
, O O
all O O
subtypes O B_PERSON
, O O
ages O B_NUMBER[MEASURE]/B_LOCATION
6 O I_NUMBER[MEASURE]/I_LOCATION
to O O
12 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
, O O
were O O
randomized O O
to O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
n O B_MEASURE/B_LOCATION
= O O
90 O B_MEASURE
) O O
, O O
immediate O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
release O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
methylphenidate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
IR O B_DISEASE/B_PROTEIN[GENE]
MPH O B_DISEASE/I_PROTEIN[GENE]
) O O
3 O B_NUMBER[MEASURE]/B_LOCATION
times O I_NUMBER[MEASURE]/I_LOCATION
a O O
day O B_TIME[MEASURE]
( O O
tid O B_PROTEIN[GENE]/B_LOCATION
; O O
dosed O O
every O O
4 O B_TIME[MEASURE]/B_ENT
hours O I_TIME[MEASURE]/I_ENT
; O O
n O B_MEASURE/B_LOCATION
= O O
97 O B_MEASURE
) O O
, O O
or O O
OROS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MPH O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
once O O
a O O
day O B_TIME[MEASURE]
( O O
qd O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
; O O
n O B_OTHER/B_LOCATION
= O O
95 O B_MEASURE
) O O
in O O
a O O
double O B_MEASURE
- O O
blind O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
28 O B_NUMBER[MEASURE]
- O O
day O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
trial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Cloning O O
and O O
sequence O O
analysis O O
of O O
a O O
chymotrypsinlike B B_DISEASE_ADJECTIVE[DISEASE]
protease I I_DISEASE_ADJECTIVE[DISEASE]
from I I_DISEASE_ADJECTIVE[DISEASE]
Treponema I I_DISEASE_ADJECTIVE[DISEASE]
denticola O O
. O O

V B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
ErbB I I_DISEASE/I_LOCATION
- I I_DISEASE/I_LOCATION
mediated I I_DISEASE/I_LOCATION
complex I I_DISEASE/I_LOCATION
formation O O
and O O
transformation O O
have O O
been O O
shown O O
to O O
occur O O
independently O O
of O O
Ras B B_GENE/B_DISEASE
activation O O
. O O

The O O
sequence O B_LOCATION/B_PROTEIN[GENE]
contained O O
five O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
repeats O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
hypothetical O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
leucine O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
zipper O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
motif O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
one O B_NUMBER[MEASURE]
is O O
in O O
the O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
globular O B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
domain O B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
four O B_NUMBER[MEASURE]/B_PERSON
are O O
in O O
the O O
central O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
helical O B_LOCATION/B_GENE
stalk O I_LOCATION/I_GENE
. O O

Genomic O O
organization O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
multidrug I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resistance I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MDR1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
origin O O
of O O
P B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
glycoproteins I I_DISEASE_ADJECTIVE[DISEASE]
. O O

Since O O
nearly O O
all O O
transformants O O
involving O O
homeologous O O
DNAs O O
carried O O
a O O
single O O
recombinant O O
plasmid O O
in O O
both O O
Pms B B_LOCATION/B_DISEASE
+ I I_LOCATION/I_DISEASE
and O O
Pms B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
strains O O
, O O
stable O O
heteroduplex O O
DNA O O
appears O O
less O O
likely O O
than O O
for O O
homologous O O
DNAs O O
. O O

A O O
sequence O O
- O O
ready O O
3 O O
- O O
Mb O O
PAC O O
contig O O
covering O O
16 O O
breakpoints O O
of O O
the O O
Wilms B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
tumor I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
/ I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
anirida I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
region I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
human O O
chromosome O O
11p13 O O
. O O

The O O
MAP B B_ENZYME[GENE]/B_MEASURE
kinase I I_ENZYME[GENE]/I_MEASURE
kinase I I_ENZYME[GENE]/I_MEASURE
kinase I I_ENZYME[GENE]/I_MEASURE
MLK2 B I_ENZYME[GENE]/I_MEASURE
co O O
- O O
localizes O O
with O O
activated O O
JNK B B_GENE
along O O
microtubules O O
and O O
associates O O
with O O
kinesin B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
superfamily I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
motor O O
KIF3 B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
the O O
quasiparticle O B_PROTEIN[GENE]/B_MEASURE
scattering O I_PROTEIN[GENE]/I_MEASURE
rate O I_PROTEIN[GENE]/I_MEASURE
tau O I_PROTEIN[GENE]/I_MEASURE
( O O
- O O
1 O B_NUMBER[MEASURE]
) O O
is O O
such O B_MEASURE/B_LOCATION
that O O
Planck O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
' O O
s O O
over O O
2pi O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
tau O B_PROTEIN[GENE]/B_DISEASE
approximately O O
6t O B_MEASURE/B_LOCATION
( O O
perpendicular O B_TIME[MEASURE]
) O O
, O O
implying O O
that O O
kappa O B_PROTEIN[GENE]/B_LOCATION
- O O
( O O
BEDT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
TTF O B_PROTEIN[GENE]/B_LOCATION
) O O
2Cu O B_LOCATION
( O O
NCS O B_DISEASE/B_LOCATION
) O O
( O O
2 O B_TIME[MEASURE]/B_LOCATION
) O O
meets O O
the O O
criterion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
used O O
to O O
identify O O
interlayer O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
incoherence O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Although O O
polyubiquitin B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chains I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
linked O O
through O O
Lys O O
( O O
29 O O
) O O
of O O
ubiquitin B B_GENE
have O O
been O O
implicated O O
in O O
the O O
targeting O O
of O O
certain O O
substrates O O
to O O
proteasomes O O
, O O
the O O
signaling O O
properties O O
of O O
these O O
chains O O
are O O
poorly O O
understood O O
. O O

Two O O
methods O O
for O O
the O O
routine O O
determination O O
of O O
blood O O
hemoglobin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
oxygen O O
affinity O O
are O O
described O O
. O O

Thirty O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
after O O
reperfusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
lung O B_MEASURE/B_PROTEIN[GENE]
lymph O B_MEASURE/I_PROTEIN[GENE]
flow O B_MEASURE/I_PROTEIN[GENE]
( O O
QL O B_PROTEIN[GENE]/B_LOCATION
) O O
increased O O
from O O
4 O B_MEASURE
. O O
3 O B_MEASURE
to O O
8 O B_MEASURE
. O O
3 O B_MEASURE
ml O I_MEASURE
/ O O
30 O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_NUMBER[MEASURE]
. O O
05 O B_MEASURE
) O O
, O O
lymph O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
/ O O
plasma O B_MEASURE/B_BIO
protein O B_MEASURE/I_BIO
ratio O B_MEASURE/I_BIO
was O O
unchanged O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O O
0 O B_MEASURE
. O O
6 O B_MEASURE
, O O
and O O
the O O
lymph O B_MEASURE
protein O I_MEASURE
clearance O I_MEASURE
increased O O
from O O
2 O B_MEASURE
. O O
6 O B_MEASURE
to O O
4 O B_MEASURE
. O O
6 O B_MEASURE
ml O I_MEASURE
/ O O
30 O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_NUMBER[MEASURE]
. O O
05 O B_MEASURE
) O O
, O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
consistent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
increased O O
microvascular O B_DISEASE
permeability O I_DISEASE
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
we O O
show O O
that O O
the O O
activating O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
mutation O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
not O O
the O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
creating O O
an O O
exonic O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
enhancer O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ESE O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
or O O
disrupting O O
a O O
putative O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
secondary O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
structure O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
kinase O B_GENE
domains O I_GENE
encoded O O
in O O
the O O
COOH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
moiety O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O O
94 O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
% O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
conserved O O
; O O
the O O
NH2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
moieties O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
are O O
approximately O O
65 O B_TIME[MEASURE]/B_PERSON
% O I_TIME[MEASURE]/I_PERSON
homologous O I_TIME[MEASURE]/I_PERSON
, O O
suggesting O O
this O O
region O B_LOCATION/B_BIO
may O O
encode O O
sequences O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
conferring O O
differential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
regulation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
two O B_ENZYME[GENE]
kinases O I_ENZYME[GENE]
. O O

In O O
rats O O
exposed O O
to O O
Cd O O
for O O
30 O O
d O O
, O O
the O O
levels O O
of O O
urinary O O
excretion O O
of O O
cAMP O O
after O O
treatment O O
with O O
parathyroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
PTH B B_GENE/B_LOCATION
) O O
, O O
parathyroidectomy O O
( O O
PTX O O
) O O
, O O
or O O
1 O O
alpha O O
- O O
hydroxycholecalciferol O O
( O O
1 O O
alpha O O
- O O
OH O O
- O O
D3 O O
) O O
showed O O
almost O O
the O O
same O O
patterns O O
as O O
those O O
of O O
control O O
rats O O
: O O
the O O
response O O
of O O
urinary O O
cAMP O O
to O O
treatment O O
with O O
PTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
not O O
influenced O O
by O O
continuous O O
oral O O
administration O O
of O O
Cd O O
. O O

In O O
the O O
absence O O
of O O
shock O O
, O O
sepsis O O
, O O
or O O
other O O
identifiable O O
causes O O
of O O
lactic O O
acidosis O O
, O O
the O O
severe O O
anemia O O
( O O
hemoglobin B B_MEASURE/B_LOCATION
1 O O
. O O
2 O O
g O O
/ O O
dl O O
) O O
appeared O O
to O O
be O O
the O O
primary O O
etiologic O O
factor O O
. O O

The O O
time O O
- O O
dependent O O
changes O O
in O O
measured O O
facility O O
of O O
outflow O O
or O O
" O O
washout O O
phenomenon O O
" O O
appeared O O
to O O
result O O
from O O
the O O
gradual O O
dissolution O O
of O O
the O O
hyaluronidase B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
sensitive O O
component O O
of O O
the O O
barriers O O
to O O
aqueous O O
outflow O O
in O O
the O O
canine O O
eye O O
. O O

Further O O
comparative O O
analysis O O
identified O O
an O O
ADNP B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
paralog O O
( O O
33 O O
% O O
identity O O
and O O
46 O O
% O O
similarity O O
) O O
, O O
indicating O O
that O O
these O O
genes O O
belong O O
to O O
a O O
novel O O
protein O O
family O O
with O O
a O O
nine O O
- O O
zinc O O
finger O O
motif O O
followed O O
by O O
a O O
homeobox O O
domain O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Two O B_PERSON
patients O I_PERSON
developed O O
cervical O B_DISEASE
myelopathy O I_DISEASE
or O O
radiculopathy O B_DISEASE
after O O
spinal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
manipulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
and O O
magnetic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
resonance O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
showed O O
herniated O O
cervical O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
discs O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
at O O
C4 O B_PROTEIN[GENE]
- O O
C5 O B_MEASURE/B_PROTEIN[GENE]
and O O
C6 O B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
C7 O B_MEASURE/B_PROTEIN[GENE]
, O O
respectively O O
. O O

IRIS B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
/ O O
GAS B B_VIRUS[BIO]/B_GENE
DNA O O
also O O
formed O O
a O O
number O O
of O O
specific O O
complexes O O
with O O
constitutively O O
expressed O O
factors O O
, O O
none O O
of O O
which O O
were O O
affected O O
by O O
the O O
above O O
Abs O O
. O O

Tre O B_GENE/B_LOCATION
during O O
exercise O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
35 O B_MEASURE/B_LOCATION
W O I_MEASURE/I_LOCATION
at O O
23 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
correlated O O
r O O
= O O
- O O
70 O B_MEASURE
with O O
Vo2max O B_MEASURE/B_LOCATION
and O O
r O B_PROTEIN[GENE]/B_MEASURE
= O O
0 O B_MEASURE
. O O
80 O B_MEASURE
with O O
Tre O B_PROTEIN[GENE]/B_LOCATION
during O O
exercise O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O O
heat O B_LOCATION
. O O

Our O O
results O O
showed O O
that O O
the O O
5 O O
- O O
hydroxytryptamine O O
( O O
5 O O
- O O
HT O O
) O O
content O O
in O O
platelets O O
was O O
: O O
( O O
1 O O
) O O
increased O O
in O O
the O O
subgroup O O
of O O
anti O O
- O O
social O O
alcoholics O O
; O O
( O O
2 O O
) O O
transiently O O
and O O
differently O O
altered O O
in O O
alcoholics O O
compared O O
to O O
opiate O O
addicts O O
; O O
and O O
( O O
3 O O
) O O
lowered O O
in O O
drinking O O
alcoholics O O
and O O
normal O O
in O O
alcoholics O O
who O O
were O O
drinking O O
as O O
well O O
as O O
smoking O O
( O O
that O O
may O O
occur O O
via O O
MAO B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition O O
by O O
smoke O O
) O O
. O O

As O O
much O O
thrombin B B_GENE
was O O
formed O O
during O O
cardiopulmonary O O
bypass O O
( O O
measured O O
by O O
the O O
prothrombin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragment I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
thrombin B B_GENE
- O O
antithrombin B B_GENE
complexes O O
) O O
as O O
in O O
normal O O
patients O O
, O O
showing O O
that O O
factor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
XII I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
not O O
necessary O O
for O O
thrombin B B_PROTEIN[GENE]
generation O O
. O O

In O O
vitro O O
binding O O
studies O O
previously O O
showed O O
that O O
NF B B_GENE/B_PERSON
- I I_GENE/I_PERSON
kappa I I_GENE/I_PERSON
B I I_GENE/I_PERSON
p50 B I_GENE/I_PERSON
homodimer O O
binds O O
the O O
switch B B_LOCATION
nuclear I I_LOCATION
B I I_LOCATION
- I I_LOCATION
site I I_LOCATION
protein I I_LOCATION
( O O
SNIP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
of O O
the O O
S B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gamma I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
3 I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
tandem I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
repeat I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

These O O
results O O
indicate O O
that O O
( O O
1 O O
) O O
RXR B B_PROTEIN[GENE]/B_LOCATION
- O O
TR B B_PROTEIN[GENE]/B_DISEASE
heterodimers O O
play O O
a O O
role O O
in O O
basal O O
transactivation O O
and O O
T3 O O
suppression O O
of O O
negatively O O
regulated O O
genes O O
, O O
and O O
( O O
2 O O
) O O
RXRs B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
increase O O
the O O
dominant O O
negative O O
effect O O
of O O
some O O
mutant O O
TRs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
on O O
specific O O
negative O O
TREs O O
. O O

5 O O
. O O
3 O B_MEASURE
+ O O
/ O O
- O O
6 O B_MEASURE
. O O
6 O B_MEASURE
for O O
risperidone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
09 O B_MEASURE
) O O
. O O

273 O B_MEASURE/B_LOCATION
, O O
27420 O B_TIME[MEASURE]/B_LOCATION
- O O
27429 O B_NUMBER[MEASURE]/B_LOCATION
) O O
a O O
putative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
peroxisome O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
proliferator O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
activated O O
receptor O B_PROTEIN[GENE]/B_LOCATION
response O I_PROTEIN[GENE]/I_LOCATION
element O I_PROTEIN[GENE]/I_LOCATION
( O O
PPRE O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O O
- O O
458 O B_MEASURE
to O O
- O O
474 O B_MEASURE
. O O

When O O
the O O
opioid O O
antagonist O O
was O O
administered O O
to O O
animals O O
24 O O
hr O O
after O O
termination O O
of O O
single O O
or O O
multiple O O
exposures O O
to O O
restraint O O
, O O
NALT O O
- O O
induced O O
increases O O
in O O
basal O O
plasma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
LH I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
significantly O O
attenuated O O
in O O
the O O
chronically O O
stressed O O
rats O O
compared O O
to O O
animals O O
subjected O O
to O O
stress O O
only O O
once O O
or O O
not O O
at O O
all O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Plasma B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
colony I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
stimulating I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
analysis O O
and O O
the O O
clinical O O
significance O O

Sequence O O
analysis O O
identifies O O
a O O
ras B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
associating I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
RA B B_DISEASE/B_PROTEIN[GENE]
) O O
- O O
like O O
domain O O
in O O
the O O
N O O
- O O
termini O O
of O O
band B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
JEF I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
the O O
Grb7 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
10 I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
/ I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
14 I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
adapter I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
family I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Patients O O
received O O
BPB O O
using O O
bupivacaine O O
2 O O
mg O O
kg O O
- O O
1 O O
with O O
adrenaline O O
1 O O
in O O
200 O O
, O O
000 O O
, O O
either O O
with O O
or O O
without O O
hyaluronidase B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
3000 O O
iu O O
, O O
in O O
a O O
volume O O
of O O
0 O O
. O O
5 O O
ml O O
per O O
2 O O
. O O
54 O O
cm O O
of O O
the O O
patient O O
' O O
s O O
height O O
. O O

Rhinovirus B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
2A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protease I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
foot B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mouth I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
disease I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
L I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protease I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
used O O
to O O
analyze O O
the O O
association O O
of O O
eIF4G B B_GENE/B_DISEASE
with O O
eIF4A B B_GENE
, O O
eIF4E B B_GENE
, O O
and O O
eIF3 B B_GENE
. O O

We O O
suggest O O
that O O
this O O
effect O O
of O O
Myc B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
is O O
mediated O O
by O O
its O O
action O O
upstream O O
of O O
cyclin B B_GENE
E I I_GENE
- O O
CDK2 B B_GENE/B_DISEASE
, O O
and O O
occurs O O
via O O
the O O
neutralization O O
of O O
p27 B B_GENE
( O O
Kip1 B B_PROTEIN[GENE]/B_LOCATION
) O O
family O O
proteins O O
, O O
rather O O
than O O
induction O O
of O O
Cdc25A B B_GENE
. O O

Although O O
FKH2 B B_GENE
is O O
redundant O O
with O O
FKH1 B B_GENE
in O O
controlling O O
pseudohyphal O O
growth O O
, O O
the O O
two O O
genes O O
have O O
different O O
functions O O
in O O
silencing O O
HMRa B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

The O O
aromatic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hydrocarbon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AHR B B_GENE/B_LOCATION
) O O
is O O
a O O
ligand O O
- O O
activated O O
transcription O O
factor O O
that O O
regulates O O
the O O
expression O O
of O O
several O O
drug O O
- O O
metabolizing O O
enzymes O O
and O O
has O O
been O O
implicated O O
in O O
immunosuppression O O
, O O
teratogenesis O O
, O O
cell O O
- O O
specific O O
hyperplasia O O
, O O
and O O
certain O O
types O O
of O O
malignancies O O
and O O
toxicities O O
. O O

Positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
linear O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
correlations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
found O O
when O O
the O O
AUC O B_MEASURE
( O O
0 O B_MEASURE
- O O
12 O B_MEASURE
) O O
( O O
r O B_OTHER/B_GENE
= O O
0 O B_NUMBER[MEASURE]
. O O
68 O B_MEASURE
; O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_NUMBER[MEASURE]
. O O
01 O B_MEASURE
) O O
, O O
the O O
maximum O B_MEASURE
plasma O I_MEASURE
concentration O I_MEASURE
( O O
r O B_OTHER/B_GENE
= O O
0 O B_MEASURE
. O O
34 O B_MEASURE
; O O
P O B_MEASURE/B_PERSON
less O I_MEASURE/I_PERSON
than O O
0 O B_NUMBER[MEASURE]
. O O
01 O B_MEASURE
) O O
, O O
the O O
minimum O B_MEASURE/B_DISEASE
plasma O I_MEASURE/I_DISEASE
concentration O I_MEASURE/I_DISEASE
( O O
r O B_OTHER/B_GENE
= O O
0 O B_NUMBER[MEASURE]
. O O
55 O B_MEASURE
; O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_NUMBER[MEASURE]
. O O
01 O B_MEASURE
) O O
, O O
and O O
the O O
elimination O B_PROTEIN[GENE]/B_LOCATION
t1 O I_PROTEIN[GENE]/I_LOCATION
/ O O
2 O B_MEASURE
( O O
r O B_OTHER/B_GENE
= O O
0 O B_MEASURE
. O O
46 O B_MEASURE
; O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_NUMBER[MEASURE]
. O O
01 O B_MEASURE
) O O
were O O
regressed O O
with O O
age O B_MEASURE
. O O

Mutation O O
of O O
the O O
distal O O
E2F B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
in O O
the O O
cdc25A B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
abolished O O
E2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
repression O O
, O O
whereas O O
mutation O O
of O O
the O O
proximal O O
E2F B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O O
the O O
E2 B B_MEASURE/B_LOCATION
site I I_MEASURE/I_LOCATION
had O O
no O O
effect O O
. O O

These O O
results O O
demonstrate O O
a O O
specific O O
association O O
of O O
SIV O O
and O O
HIV B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
2 I I_GENE/I_DISEASE
nef I I_GENE/I_DISEASE
, O O
but O O
not O O
HIV B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
nef I I_GENE/I_DISEASE
, O O
with O O
TCRzeta B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Multiple O O
aortic O O
thrombi O O
associated O O
with O O
protein B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
deficiency O O
. O O

Platelet B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
in O O
patients O O
with O O
coronary O O
artery O O
disease O O
. O O

There O O
was O O
no O O
difference O B_MEASURE
in O O
the O O
day O B_MEASURE/B_LOCATION
- O O
42 O B_MEASURE
cure O I_MEASURE
rates O I_MEASURE
between O O
the O O
QC7 O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
n O B_OTHER/B_MEASURE
= O O
65 O B_MEASURE
) O O
and O O
A7 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
n O B_OTHER/B_LOCATION
= O O
64 O B_MEASURE
) O O
regimens O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
an O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
100 O B_MEASURE
% O I_MEASURE
in O O
both O O
, O O
confirmed O O
by O O
parasite O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
genotyping O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

In O O
addition O O
, O O
the O O
results O O
suggest O O
that O O
N O O
region O O
diversity O O
at O O
V B B_OTHER/B_NUMBER[MEASURE]
( O O
D B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
J B B_OTHER/B_PERSON
junctions O O
within O O
rearranged O O
immunoglobulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
T B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loci I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
only O O
be O O
introduced O O
after O O
the O O
generation O O
of O O
RAG B B_ENZYME[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
catalyzed O O
DNA O O
double O O
- O O
strand O O
breaks O O
, O O
i O O
. O O
e O O
. O O
during O O
the O O
DNA O O
end O O
joining O O
phase O O
of O O
the O O
V B B_OTHER/B_DISEASE_ADJECTIVE[DISEASE]
( O O
D B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
J B B_OTHER/B_GENE
recombination O O
reaction O O
. O O

Exhaled O O
NO O O
was O O
assessed O O
by O O
controlled O O
- O O
flow O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chemoluminescence O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O O
adjusting O O
for O O
trapped O B_MEASURE/B_DISEASE
air O I_MEASURE/I_DISEASE
and O O
after O O
generating O O
pressure O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
oral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cavity O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O O
was O O
sufficient O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
close O O
the O O
soft O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
palate O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Eco O B_PROTEIN[GENE]/B_LOCATION
Physics O I_PROTEIN[GENE]/I_LOCATION
CLD O I_PROTEIN[GENE]/I_LOCATION
77 O I_PROTEIN[GENE]/I_LOCATION
AM O I_PROTEIN[GENE]/I_LOCATION
analyzer O I_PROTEIN[GENE]/I_LOCATION
) O O
. O O

CAT B B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assays O O
demonstrated O O
that O O
overexpression O O
of O O
RXRalpha B B_GENE/B_DISEASE
conferred O O
the O O
best O O
RA O O
response O O
, O O
consistent O O
with O O
our O O
previous O O
observation O O
that O O
9 O O
- O O
cis O O
- O O
RA O O
is O O
more O O
potent O O
than O O
all O O
- O O
trans O O
- O O
RA O O
for O O
inducing O O
the O O
expression O O
of O O
the O O
AFP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

DRAP27 B B_GENE/B_DISEASE
is O O
recognized O O
by O O
CD9 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Furthermore O O
we O O
elucidate O O
the O O
subtle O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
highly O O
anisotropic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interchain O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
reveal O O
the O O
detailed O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
atomic O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
temperature O B_MEASURE
( O O
8x2 O B_PROTEIN[GENE]/B_LOCATION
) O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

To O O
quantify O O
the O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coupling O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
fresh O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
cadaveric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
human O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
lumbar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
spine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
specimens O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
L1 O B_PROTEIN[GENE]
- O O
S1 O B_MEASURE/B_PROTEIN[GENE]
) O O
were O O
used O O
. O O

One O O
cytoplasmic O O
target O O
which O O
reflects O O
the O O
functional O O
state O O
of O O
the O O
plastids O O
is O O
protein B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
three O O
chromosomes O O
share O O
the O O
transferrin B B_GENE
gene I I_GENE
( O O
TF B B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
the O O
myosin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
light I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polypeptide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MYL3 B B_GENE/B_LOCATION
) O O
, O O
and O O
the O O
acylpeptide B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hydrolase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
APEH B B_LOCATION/B_DISEASE
) O O
. O O

Based O O
on O O
our O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ORF2 O B_GENE/B_BIO
from O O
most O B_BIO/B_PROTEIN[GENE]
isolates O B_BIO/I_PROTEIN[GENE]
excluding O O
G1 O B_GENE/B_LOCATION
encode O I_GENE/I_LOCATION
truncated O O
49 O B_GENE
aa O I_GENE
( O O
pORF2a O B_PROTEIN[GENE]/B_LOCATION
) O O
because O O
of O O
an O O
in O O
- O O
frame O B_GENE/B_LOCATION
stop O B_GENE/I_LOCATION
codon O B_GENE/I_LOCATION
, O O
although O O
ORF2s O B_GENE/B_BIO
from O O
most O B_PROTEIN[GENE]/B_MEASURE
G1 O I_PROTEIN[GENE]/I_MEASURE
isolates O I_PROTEIN[GENE]/I_MEASURE
encode O O
202 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
aa O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
pORF2ab O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

We O O
conclude O O
that O O
although O O
the O O
G3 O B_GENE/B_LOCATION
sequence O I_GENE/I_LOCATION
contains O O
two O B_GENE
protein O I_GENE
- O O
binding O O
motifs O B_PERSON/B_LOCATION
, O O
the O O
organization O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
G3 O B_PROTEIN[GENE]
enhancer O I_PROTEIN[GENE]
- O O
like O B_LOCATION/B_PERSON
element O I_LOCATION/I_PERSON
is O O
not O O
bipartite O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
. O O

When O O
severe O O
hypoxia O O
was O O
acutely O O
produced O O
by O O
ventilation O O
with O O
low O O
- O O
oxygen O O
mixtures O O
in O O
experimental O O
( O O
PaO2 O O
, O O
23 O O
. O O
7 O O
+ O O
/ O O
- O O
1 O O
. O O
7 O O
torr O O
) O O
and O O
control O O
animals O O
( O O
PaO2 O O
, O O
26 O O
. O O
3 O O
+ O O
/ O O
- O O
1 O O
. O O
0 O O
torr O O
) O O
, O O
plasma B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
insulin I B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
responses O O
were O O
markedly O O
inhibited O O
in O O
both O O
. O O

Uptake O O
of O O
colicins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
required O O
different O O
domains O O
in O O
TonB B B_BACTERIUM[BIO]/B_PROTEIN[GENE]
, O O
for O O
colicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
M I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
around O O
residue O O
160 O O
and O O
for O O
colicin B B_PROTEIN[GENE]/B_BIO
Ia I I_PROTEIN[GENE]/I_BIO
, O O
a O O
domain O O
closer O O
to O O
the O O
C O O
- O O
terminal O O
end O O
. O O

It O O
is O O
dangerous O O
to O O
label O O
such O O
conditions O O
as O O
' O O
inappropriate O O
' O O
secretion O O
of O O
ADH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
since O O
the O O
maintenance O O
of O O
circulating O O
volume O O
is O O
at O O
least O O
as O O
important O O
a O O
physiological O O
requirement O O
as O O
the O O
defence O O
of O O
tonicity O O
. O O

The O O
complete O B_GENE/B_MEASURE
nucleotide O I_GENE/I_MEASURE
sequence O I_GENE/I_MEASURE
of O O
odontoglossum O B_SPECIES[BIO]
ringspot O I_SPECIES[BIO]
virus O I_SPECIES[BIO]
( O O
Cy O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_VIRUS[BIO]/B_PROTEIN[GENE]
strain O B_VIRUS[BIO]/I_PROTEIN[GENE]
) O O
genomic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cells O O
were O O
cotransfected O O
with O O
this O O
plasmid O O
, O O
and O O
the O O
appropriate O O
responder O O
plasmids O O
and O O
clonies O O
were O O
selected O O
on O O
the O O
basis O O
of O O
their O O
resistance O O
to O O
Geneticin O O
( O O
via O O
the O O
neomycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aminoglycoside I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphotransferase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

SCAN B B_DISEASE
boxes O O
are O O
found O O
in O O
eight O O
other O O
genes O O
in O O
the O O
GenBank O O
database O O
, O O
five O O
of O O
which O O
are O O
also O O
in O O
the O O
Kruppel B B_PERSON/B_LOCATION
family I B_PERSON/I_LOCATION
of O O
zinc B B_PROTEIN[GENE]/B_BIO
finger I I_PROTEIN[GENE]/I_BIO
proteins I I_PROTEIN[GENE]/I_BIO
lacking O O
KRAB B B_GENE/B_MEASURE
A I I_GENE/I_MEASURE
and I I_GENE/I_MEASURE
B I I_GENE/I_MEASURE
domains O O
and O O
thereby O O
define O O
a O O
new O O
subclass O O
of O O
zinc B B_GENE/B_BIO
finger I I_GENE/I_BIO
proteins I I_GENE/I_BIO
. O O

In O O
the O O
plant B B_BODY_PART_OR_ORGAN_COMPONENT
malate I I_BODY_PART_OR_ORGAN_COMPONENT
synthases I I_BODY_PART_OR_ORGAN_COMPONENT
, O O
the O O
extension O O
is O O
probably O O
involved O O
in O O
routing O O
to O O
the O O
microbodies O O
, O O
since O O
it O O
contains O O
the O O
potential O O
peroxisomal O O
targeting O O
signal O O
, O O
Ser O O
- O O
Arg O O
/ O O
Lys O O
- O O
Leu O O
, O O
at O O
the O O
carboxy O O
terminus O O
. O O

A O O
regulatory O O
element O O
of O O
the O O
empty B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spiracles I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homeobox O O
gene O O
is O O
composed O O
of O O
three O O
distinct O O
conserved O O
regions O O
that O O
bind O O
regulatory O O
proteins O O
. O O

To O O
investigate O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hyperthyroidism O B_DISEASE
on O O
the O O
pattern O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
time O B_MEASURE
course O I_MEASURE
of O O
O2 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
uptake O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
VO2 O B_PROTEIN[GENE]
) O O
following O O
the O O
transition O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
rest O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
exercise O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
six O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
and O O
six O B_PERSON
healthy O I_PERSON
subjects O I_PERSON
performed O O
cycle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exercise O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
at O O
an O O
average O B_MEASURE/B_LOCATION
work O I_MEASURE/I_LOCATION
rate O I_MEASURE/I_LOCATION
( O O
WR O B_PROTEIN[GENE]/B_DISEASE
) O O
of O O
18 O B_MEASURE
and O O
20 O B_MEASURE/B_LOCATION
W O I_MEASURE/I_LOCATION
respectively O O
. O O

This O O
raises O O
the O O
possibility O O
that O O
recombination O O
occurred O O
between O O
corresponding O O
LTR O O
and O O
vif B B_PERSON/B_NUMBER[MEASURE]
loci I B_PERSON/I_NUMBER[MEASURE]
of O O
the O O
quasi O O
- O O
species O O
present O O
in O O
the O O
isolates O O
described O O
here O O
. O O

The O O
gene B B_GENE
atp6 I I_GENE
, O O
encoding O O
subunit O O
6 O O
of O O
the O O
mitochondrial O O
F0 B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
ATPase B B_PROTEIN[GENE]/B_MEASURE
complex O O
, O O
has O O
been O O
characterized O O
from O O
both O O
the O O
normal O O
( O O
fertile O O
) O O
and O O
Ogura O O
( O O
male O O
- O O
sterile O O
) O O
radish O O
cytoplasms O O
in O O
order O O
to O O
determine O O
if O O
previously O O
identified O O
atp6 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
transcriptional O O
differences O O
could O O
play O O
a O O
role O O
in O O
cytoplasmic O O
male O O
sterility O O
. O O

When O O
the O O
same O B_MEASURE
single O I_MEASURE
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
acid O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
directly O O
introduced O O
into O O
the O O
parental O B_PROTEIN[GENE]/B_DISEASE
PV O I_PROTEIN[GENE]/I_DISEASE
/ O O
CBV4 O B_PROTEIN[GENE]/B_LOCATION
- O O
2A O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genome O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
chimeric O B_BIO/B_DISEASE
viruses O I_BIO/I_DISEASE
with O O
a O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
plaque O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
phenotype O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
a O O
wild O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_VIRUS[BIO]
PV O B_DISEASE_ADJECTIVE[DISEASE]/I_VIRUS[BIO]
- O O
like O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pattern O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
obtained O O
upon O O
transfection O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
an O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrating O O
that O O
these O O
point O B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
alone O O
had O O
a O O
drastic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
growth O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
PV O B_DISEASE/B_PROTEIN[GENE]
/ O O
CBV4 O B_LOCATION/B_DISEASE
chimeric O I_LOCATION/I_DISEASE
virus O I_LOCATION/I_DISEASE
. O O

Hpr1 B B_PERSON/B_LOCATION
forms O O
, O O
together O O
with O O
Tho2 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Mft1 B B_GENE/B_LOCATION
, O O
and O O
Thp2 B B_GENE/B_PERSON
, O O
the O O
THO B B_LOCATION
complex I I_LOCATION
, O O
which O O
controls O O
transcription O O
elongation O O
and O O
genome O O
stability O O
in O O
Saccharomyces O O
cerevisiae O O
. O O

Transfection O O
of O O
H B B_NUMBER[MEASURE]/B_PERSON
chain I I_NUMBER[MEASURE]/I_PERSON
loss I I_NUMBER[MEASURE]/I_PERSON
variant I I_NUMBER[MEASURE]/I_PERSON
myeloma O O
with O O
the O O
complete O O
12 O O
kb O O
construct O O
, O O
termed O O
238H B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Cmicro I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
resulted O O
in O O
secretion O O
of O O
intact O O
Ig O O
pairing O O
238H B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Cmicro I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
with O O
a O O
lambda B B_GENE
L I I_GENE
chain I I_GENE
; O O
however O O
, O O
transfectant B B_GENE/B_BIO
Ig I I_GENE/I_BIO
lacked O O
autoreactivity O O
and O O
pathogenicity O O
. O O

Here O O
we O O
show O O
that O O
one O O
nudF B B_GENE
suppressor I I_GENE
also O O
suppresses O O
hs O O
- O O
mutations O O
in O O
nudA B B_GENE/B_DISEASE
, O O
nudC B B_DISEASE/B_PROTEIN[GENE]
, O O
and O O
nudG B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
deletions O O
in O O
nudA B B_LOCATION/B_ORGANIZATION
and O O
nudF B B_PROTEIN[GENE]/B_LOCATION
. O O

Treatment O O
of O O
cells O O
for O O
10 O O
min O O
with O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
resulted O O
in O O
activation O O
of O O
p44 B B_GENE
/ I I_GENE
42 I I_GENE
MAPK O O
, O O
p38 B B_GENE/B_LOCATION
, O O
and O O
JNK B B_GENE
. O O

Sixtieth O O
anniversary O O
of O O
Angiotensin B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

The O O
rate O O
of O O
collagen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
synthesis O O
in O O
normal O O
scar O O
was O O
approximately O O
constant O O
between O O
6 O O
months O O
and O O
20 O O
years O O
after O O
the O O
initial O O
wounding O O
, O O
but O O
in O O
both O O
hypertrophic O O
scar O O
and O O
keloid O O
the O O
rate O O
was O O
initially O O
approximately O O
twice O O
that O O
in O O
normal O O
scar O O
, O O
and O O
2 O O
- O O
3 O O
years O O
after O O
wounding O O
it O O
fell O O
to O O
approximately O O
the O O
same O O
level O O
as O O
in O O
normal O O
scar O O
. O O

The O O
LIF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O O
to O O
be O O
released O O
by O O
the O O
patient O O
' O O
s O O
peripheral O O
blood O O
lymphocytes O O
when O O
cultured O O
with O O
optimal O O
doses O O
of O O
propranolol O O
. O O

Collectively O O
, O O
these O O
studies O O
suggest O O
that O O
the O O
major O O
EGF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
stimulated O O
mitotic O O
growth O O
pathways O O
may O O
not O O
be O O
absolutely O O
linked O O
to O O
the O O
stat91 B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
pathways O O
and O O
that O O
such O O
transcription O O
complexes O O
are O O
more O O
complex O O
than O O
previously O O
reported O O
. O O

The O O
oxalate B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxidase I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O O
results O O
in O O
a O O
mean O O
and O O
reference O O
interval O O
for O O
oxalate O O
excretion O O
that O O
are O O
comparable O O
with O O
those O O
by O O
isotope O O
dilution O O
, O O
gas O O
- O O
chromatographic O O
, O O
colorimetric O O
, O O
and O O
other O O
enzymic O O
procedures O O
. O O

Amplitude O B_TIME[MEASURE]
of O O
late O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
surface O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
P2 O B_PROTEIN[GENE]
and O O
N2 O B_PROTEIN[GENE]
) O O
and O O
depth O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
B O B_PROTEIN[GENE]/B_DISEASE
and O O
C O B_PROTEIN[GENE]
) O O
components O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significantly O O
decreased O O
when O O
patients O B_PERSON/B_MEASURE
shifted O O
from O O
SWS O B_LOCATION/B_PROTEIN[GENE]
IV O I_LOCATION/I_PROTEIN[GENE]
to O O
PS O B_PROTEIN[GENE]/B_LOCATION
and O O
increased O O
from O O
PS O B_PROTEIN[GENE]/B_LOCATION
to O O
W2 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Blood O O
samples O O
for O O
determination O O
of O O
fibrinolytic O O
activity O O
and O O
factor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
VIII I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
plasma O O
were O O
obtained O O
before O O
and O O
immediately O O
after O O
the O O
end O O
of O O
compression O O
and O O
application O O
of O O
a O O
stocking O O
, O O
respectively O O
. O O

The O O
ossification O B_LOCATION
was O O
located O O
on O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
side O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O O
C3 O B_PROTEIN[GENE]/B_LOCATION
- O O
4 O B_NUMBER[MEASURE]
. O O

The O O
DFGF B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
R I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
thus O O
participate O O
in O O
receiving O O
spatial O O
cues O O
that O O
guide O O
tracheal O O
cell O O
outgrowth O O
. O O

A O O
. O O
nidulans O O
transformants O O
secreted O O
high O O
amounts O O
of O O
PGI B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
PGII B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
comparison O O
to O O
the O O
previously O O
characterized O O
A O O
. O O
niger O O
transformants O O
and O O
a O O
novel O O
polygalacturonase B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O O
PGC B B_LOCATION/B_GENE
) O O
was O O
produced O O
at O O
high O O
levels O O
by O O
A O O
. O O
nidulans O O
transformed O O
with O O
the O O
subcloned O O
pgaC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

KatA B B_LOCATION/B_TIME[MEASURE]
, O O
AhpCF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
heme O O
biosynthesis O O
enzymes O O
, O O
and O O
MrgA B B_ENZYME[GENE]/B_BACTERIUM[BIO]
are O O
also O O
induced O O
upon O O
entry O O
into O O
stationary O O
phase O O
under O O
conditions O O
of O O
iron O O
and O O
manganese O O
limitation O O
. O O

As O O
usual O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tests O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
as O O
" O O
time O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
of O O
cephalin O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
are O O
slightly O O
sensible O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
LMW O B_DISEASE/B_PROTEIN[GENE]
- O O
Hep O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
only O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
Xa O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
used O O
. O O

Over O O
9 O B_MEASURE
kb O I_MEASURE
of O O
DNA O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
obtained O O
for O O
one O B_DISEASE/B_GENE
clone O B_DISEASE/I_GENE
( O O
A1 O B_PROTEIN[GENE]/B_MEASURE
) O O
with O O
a O O
total O B_MEASURE
IGS O I_MEASURE
length O I_MEASURE
of O O
approximately O O
12 O B_MEASURE
. O O
4 O B_MEASURE
kb O I_MEASURE
. O O

Eight O O
of O O
the O O
17 O O
seropositive O O
patients O O
failed O O
to O O
develop O O
detectable O O
hepatitis B B_DISEASE
B I I_DISEASE
surface I I_DISEASE
antibody I I_DISEASE
within O O
three O O
months O O
of O O
the O O
third O O
injection O O
compared O O
with O O
only O O
one O O
of O O
the O O
18 O O
seronegative O O
patients O O
( O O
p O O
less O O
than O O
0 O O
. O O
01 O O
) O O
. O O

Relation O O
between O O
circulating O O
immune O O
complexes O O
and O O
serum B B_DISEASE
ferritin I I_DISEASE
in O O
hemosiderosis O O
of O O
different O O
etiologies O O

Treatment O O
of O O
excessive O O
bleeding O O
after O O
cardiopulmonary O O
bypass O O
was O O
based O O
on O O
an O O
algorithm O O
using O O
point O O
- O O
of O O
- O O
care O O
testing O O
with O O
whole O O
blood B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prothrombin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
time O O
, O O
activated O O
partial O O
thromboplastin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
time O O
, O O
heparinase B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
activated O O
clotting O O
time O O
, O O
and O O
platelet O O
count O O
. O O

We O O
have O O
previously O O
reported O O
the O O
first O O
isolation O O
of O O
a O O
c B B_DISEASE
- I I_DISEASE
myc I I_DISEASE
- I I_DISEASE
null I I_DISEASE
cell O O
line O O
. O O

In O O
both O O
study O O
stages O O
. O O
post O O
- O O
exposure O O
treatment O O
consisted O O
of O O
five O O
injections O O
of O O
vaccine O O
[ O O
( O O
D O O
) O O
ays O O
0 O O
, O O
3 O O
, O O
7 O O
, O O
14 O O
, O O
28 O O
] O O
, O O
together O O
with O O
a O O
dose O O
of O O
rabies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoglobulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
RIG B B_LOCATION/B_MEASURE
) O O
of O O
equine O O
or O O
human O O
origin O O
on O O
D0 O O
. O O

Our O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
investigated O O
the O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
the O O
combination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
a O O
high O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
NaCl O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
diet O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
social O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
isolation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stress O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
would O O
increase O O
systolic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
blood O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
pressure O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
SBP O B_LOCATION/B_DISEASE
) O O
and O O
endogenous O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pump O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ligands O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SPL O B_LOCATION/B_ORGANIZATION
) O O
, O O
ouabainlike O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compound O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
OLC O B_LOCATION/B_DISEASE
) O O
, O O
and O O
marinobufagenin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MBG O B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

It O O
is O O
suggested O O
that O O
the O O
loss O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
weight O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]
in O O
food O B_DISEASE/B_GENE
intake O I_DISEASE/I_GENE
and O O
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]
in O O
brain O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
MOPEG O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
SO4 O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
induced O O
by O O
cyanamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reflect O O
possible O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
anorectic O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
properties O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
CYP7A1 B B_GENE/B_PERSON
transgenic O O
mice O O
, O O
livers O O
contained O O
approximately O O
3 O O
- O O
fold O O
more O O
sterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
response I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
element I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Adenocarcinoma O B_DISEASE/B_PERSON
and O O
large O B_DISEASE/B_LOCATION
cell O I_DISEASE/I_LOCATION
carcinoma O I_DISEASE/I_LOCATION
have O O
a O O
worse O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prognosis O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
squamous O B_DISEASE/B_PERSON
cell O I_DISEASE/I_PERSON
carcinoma O I_DISEASE/I_PERSON
in O O
the O O
T1N1 O B_PROTEIN[GENE]/B_DISEASE
and O O
T2N1 O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
subsets O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O O

This O O
is O O
a O O
consensus O O
casein B B_ENZYME[GENE]
kinase I I_ENZYME[GENE]
II I I_ENZYME[GENE]
( O O
CKII B B_GENE/B_MEASURE
) O O
site O O
and O O
, O O
using O O
purified O O
wild O O
- O O
type O O
and O O
mutant O O
proteins O O
, O O
we O O
show O O
that O O
it O O
is O O
the O O
main O O
CKII B B_LOCATION/B_PERSON
site I I_LOCATION/I_PERSON
in O O
the O O
body O O
of O O
the O O
N O O
- O O
terminal O O
complex O O
- O O
forming O O
region O O
. O O

Interaction O O
between O O
the O O
tobacco O O
DNA O O
- O O
binding O O
activity O O
CBF B B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
the O O
cyt B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
Agrobacterium O O
tumefaciens O O
T O O
- O O
DNA O O
gene O O
T B B_LOCATION/B_PERSON
- I I_LOCATION/I_PERSON
CYT I I_LOCATION/I_PERSON
correlates O O
with O O
cyt B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
directed O O
gene O O
expression O O
in O O
multiple O O
tobacco O O
tissue O O
types O O
. O O

The O O
N1 O B_PROTEIN[GENE]/B_DISEASE
- O O
P2 O B_MEASURE
amplitudes O I_MEASURE
of O O
the O O
AEP O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
decreased O O
with O O
increasing O O
strength O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
muscular O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
innervation O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

SN O B_MEASURE/B_PROTEIN[GENE]
- O O
38 O B_MEASURE/B_BIO
rebound O B_MEASURE/I_BIO
concentrations O B_MEASURE/I_BIO
were O O
observed O O
in O O
many O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
courses O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
at O O
about O O
0 O B_MEASURE/B_LOCATION
. O O
5 O B_MEASURE
to O O
1 O B_MEASURE/B_ENT
hour O I_MEASURE/I_ENT
following O O
the O O
end O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
i O O
. O O
v O B_PROTEIN[GENE]/B_MEASURE
. O O
infusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
which O O
is O O
suggestive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
enterohepatic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recycling O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Sequence O O
analysis O O
of O O
AEBP2 B B_GENE
cDNA I I_GENE
revealed O O
that O O
it O O
encodes O O
a O O
protein O O
containing O O
three O O
Gli B B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
- O O
Kruppel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
Cys2 O O
- O O
His2 O O
) O O
- O O
type O O
zinc O O
fingers O O
. O O

The O O
regulatory O O
genes O O
cnrYXH B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
cloned O O
, O O
overexpressed O O
, O O
and O O
purified O O
in O O
Escherichia O O
coli O O
. O O

Examination O O
of O O
the O O
Coomassie O O
- O O
stained O O
gels O O
revealed O O
that O O
the O O
capsid O O
- O O
like O O
particles O O
composed O O
of O O
the O O
N11 B B_PERSON/B_VIRUS[BIO]
- I I_PERSON/I_VIRUS[BIO]
VP1 I I_PERSON/I_VIRUS[BIO]
protein O O
did O O
not O O
contain O O
any O O
host O O
- O O
derived O O
histones B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
increments O O
in O O
median O O
plasma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
secretin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concentration O O
were O O
1 O O
. O O
6 O O
, O O
3 O O
. O O
0 O O
, O O
and O O
6 O O
. O O
4 O O
pmol O O
x O O
1 O O
( O O
- O O
1 O O
) O O
after O O
secretin B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
125 O O
, O O
250 O O
and O O
500 O O
fmol O O
x O O
kg O O
- O O
1 O O
, O O
and O O
the O O
corresponding O O
15 O O
- O O
min O O
bicarbonate O O
output O O
283 O O
, O O
442 O O
, O O
and O O
1435 O O
micromol O O
, O O
respectively O O
. O O

A O O
search O O
was O O
conducted O O
for O O
suppressors O O
of O O
the O O
inositol O O
auxotrophic O O
phenotype O O
of O O
the O O
ino4 B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
mutant I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
of O O
yeast O O
. O O

Paradoxically O O
, O O
loop O O
3i O O
from O O
the O O
M1Ach B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
muscarinic I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
also O O
maximally O O
inhibited O O
GnRH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O O
- O O
stimulated O O
cAMP O O
accumulation O O
and O O
PRL B B_GENE
release O O
by O O
40 O O
% O O
( O O
both O O
effects O O
mediated O O
through O O
activation O O
of O O
the O O
Gs B B_PROTEIN[GENE]/B_LOCATION
protein I I_PROTEIN[GENE]/I_LOCATION
) O O
. O O

Three O O
high O O
- O O
amylose O O
rice O O
varieties O O
, O O
IR42 O O
, O O
IR36 O O
, O O
and O O
IR62 O O
, O O
with O O
similar O O
chemical O O
composition O O
including O O
amylose O O
content O O
( O O
26 O O
. O O
7 O O
- O O
27 O O
. O O
0 O O
% O O
) O O
, O O
were O O
cooked O O
under O O
the O O
same O O
conditions O O
and O O
tested O O
for O O
in O O
vitro O O
digestibility O O
as O O
well O O
as O O
blood O O
glucose O O
and O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
responses O O
in O O
healthy O O
human O O
volunteers O O
. O O

Using O O
beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AR I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
luciferase B B_GENE
reporter O O
recombinants O O
, O O
we O O
have O O
previously O O
determined O O
that O O
important O O
beta B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AR I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genetic O O
elements O O
controlling O O
expression O O
within O O
the O O
C6 O O
glioma O O
cell O O
line O O
are O O
contained O O
within O O
the O O
region O O
- O O
396 O O
to O O
- O O
299 O O
, O O
relative O O
to O O
the O O
translational O O
start O O
site O O
. O O

Our O O
case O O
, O O
however O O
, O O
had O O
no O O
histologic O O
evidence O O
of O O
malignancy O O
, O O
no O O
serum B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fetoprotein I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
7 O O
months O O
of O O
age O O
, O O
and O O
no O O
recurrence O O
at O O
1 O O
years O O
. O O

METHOD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
After O O
eligibility O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
patients O B_PERSON
were O O
randomly O O
allocated O O
in O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
the O O
following O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
M O B_OTHER/B_LOCATION
= O O
methylprednisolone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
30 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O
kg O B_MEASURE/B_LOCATION
- O O
1 O B_NUMBER[MEASURE]/B_LOCATION
over O O
1 O B_NUMBER[MEASURE]/B_ENT
hour O I_NUMBER[MEASURE]/I_ENT
, O O
followed O O
by O O
5 O B_MEASURE
. O O
4 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
kg O B_MEASURE/B_LOCATION
- O O
1 O B_NUMBER[MEASURE]
. O O
h O O
- O O
1 O B_NUMBER[MEASURE]
for O O
23 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
hours O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O O
N O B_OTHER/B_LOCATION
= O O
nimodipine O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
015 O B_MEASURE
mg O I_MEASURE
. O O
kg O B_MEASURE/B_LOCATION
- O O
1 O B_NUMBER[MEASURE]
. O O
h O O
- O O
1 O B_NUMBER[MEASURE]
over O O
2 O B_MEASURE/B_ENT
hours O I_MEASURE/I_ENT
followed O O
by O O
0 O B_MEASURE
. O O
03 O B_MEASURE/B_PERSON
mg O I_MEASURE/I_PERSON
. O O
kg O B_MEASURE/B_LOCATION
- O O
1 O B_NUMBER[MEASURE]
. O O
h O O
- O O
1 O B_NUMBER[MEASURE]
for O O
7 O B_ENT/B_LOCATION
days O I_ENT/I_LOCATION
, O O
MN O B_LOCATION/B_DISEASE
or O O
P O B_PROTEIN[GENE]/B_LOCATION
. O O

RNA O O
unwinding O O
in O O
U4 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
U6 B B_MEASURE
snRNPs O O
requires O O
ATP O O
hydrolysis O O
and O O
the O O
DEIH O O
- O O
box O O
splicing O O
factor O O
Brr2 B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Similarly O O
, O O
beta B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
adrenoceptors I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
blockade O O
has O O
been O O
shown O O
to O O
be O O
of O O
value O O
in O O
achieving O O
continence O O
in O O
a O O
small O O
group O O
of O O
patients O O
. O O

Brainstem O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
auditory O I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evoked O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
responses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
BAEPs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
were O O
recorded O O
from O O
CZ O B_LOCATION/B_PROTEIN[GENE]
- O O
A1 O B_PROTEIN[GENE]
and O O
CZ O B_LOCATION/B_PROTEIN[GENE]
- O O
A2 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
scalp O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
regions O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
23 O B_NUMBER[MEASURE]
hypertensive O I_NUMBER[MEASURE]
and O O
14 O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
normotensive O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
subjects O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

SM B B_LOCATION/B_PERSON
binds O O
RNA O O
in O O
vitro O O
, O O
suggesting O O
that O O
sequence O O
- O O
or O O
structure O O
- O O
specific O O
mRNA O O
interactions O O
might O O
mediate O O
SM B B_PROTEIN[GENE]/B_DISEASE
specificity O O
. O O

Ras B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
involvement O O
in O O
signal O O
transduction O O
by O O
the O O
serotonin B B_GENE
5 I I_GENE
- I I_GENE
HT2B I I_GENE
receptor I I_GENE
. O O

Three O O
putative O O
ORFs O O
have O O
significant O O
homology O O
with O O
known O O
proteins O O
: O O
L0968 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
new O O
member O O
of O O
the O O
very O O
large O O
' B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seripauperins I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family O O
, O O
comprising O O
at O O
least O O
20 O O
yeast O O
members O O
; O O
L1313 B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
new O O
ABC B B_GENE/B_LOCATION
transporter I I_GENE/I_LOCATION
highly O O
homologous O O
to O O
the O O
yeast O O
cadmium O O
resistance O O
protein O O
Ycf1p B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
to O O
the O O
human B B_GENE/B_BIO
multidrug I I_GENE/I_BIO
resistance I I_GENE/I_BIO
protein I I_GENE/I_BIO
hMRP1 B I_GENE/I_BIO
; O O
the O O
C O O
- O O
terminal O O
part O O
of O O
L1325 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
present O O
in O O
our O O
sequence O O
is O O
very O O
homologous O O
to O O
the O O
fruit O O
fly O O
abdominal O O
segment O O
formation O O
protein O O
Pumilio B B_PERSON/B_PROTEIN[GENE]
. O O

Elevated O O
systolic O O
blood O O
pressure O O
and O O
high O O
postglucose O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
showed O O
an O O
independent O O
, O O
significant O O
association O O
with O O
left O O
ventricular O O
mass O O
in O O
female O O
diabetic O O
subjects O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
investigated O O
if O O
signal O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
- O O
averaged O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amplitude O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
atrial O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentials O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predict O O
atrial O B_DISEASE
fibrillation O I_DISEASE
or O O
flutter O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
AFF O B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

Effect O O
of O O
age O O
on O O
glucose O O
, O O
reducing O O
sugars O O
and O O
plasma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
blood O O
of O O
milk O O
- O O
fed O O
calves O O
. O O

With O O
this O O
study O O
, O O
a O O
total O O
of O O
13 O O
operators O O
for O O
the O O
glp B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
regulon I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
been O O
characterized O O
. O O

A O O
case O B_PERSON/B_LOCATION
of O O
heterotopic O B_DISEASE
gastric O I_DISEASE
mucosa O I_DISEASE
( O O
pyloric O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
gland O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
the O O
wall O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O O
the O O
gallbladder O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O O
reported O O
. O O

This O O
communication O O
presents O O
two O O
patients O O
with O O
clinically O O
massive O O
PE O O
of O O
recent O O
onset O O
( O O
confirmed O O
by O O
lung O O
perfusion O O
scans O O
) O O
who O O
were O O
successfully O O
treated O O
with O O
a O O
single O O
i O O
. O O
v O O
. O O
dose O O
of O O
30 O O
mg O O
of O O
anisoylated B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
lys I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
plasminogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
streptokinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activator I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
complex I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
APSAC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
comparable O O
to O O
1 O O
, O O
500 O O
, O O
000 O O
U O O
of O O
streptokinase B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
followed O O
by O O
systemic O O
heparinization O O
for O O
7 O O
days O O
. O O

Engineering O O
temperature O O
- O O
sensitive O O
SH3 B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
domains I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

At O O
1 O B_TIME[MEASURE]/B_PERSON
min O I_TIME[MEASURE]/I_PERSON
postalfentanil O I_TIME[MEASURE]/I_PERSON
, O O
N2O O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
caused O O
significantly O O
more O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
rigidity O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
100 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
O2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

Comparative O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ultrafiltration O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
UF O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
BiGG O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
standard O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lactate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
La O B_LOCATION/B_MEASURE
) O O
solutions O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rabbits O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
net O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
UF O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
La O B_LOCATION
solution O I_LOCATION
peaked O O
at O O
2 O B_MEASURE
h O O
and O O
decreased O O
significantly O O
at O O
4 O B_MEASURE
h O O
and O O
6 O B_MEASURE
h O O
. O O

p107 B B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
induction O O
of O O
E2F B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O O
binding O O
was O O
observed O O
primarily O O
in O O
S O O
phase O O
cells O O
coincident O O
with O O
the O O
increase O O
in O O
p107 B B_GENE
protein I I_GENE
levels O O
. O O

Both O O
flavoproteins O O
are O O
active O O
as O O
AhpC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
reductases I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O O
mediate O O
electron O O
transfer O O
, O O
resulting O O
in O O
the O O
NADH O O
- O O
dependent O O
reduction O O
of O O
hydrogen O O
peroxide O O
and O O
cumene O O
hydroperoxide O O
. O O

DNMT2 B B_GENE
binds O O
AdoHcy O O
in O O
the O O
same O O
conformation O O
as O O
confirmed O O
m B B_GENE
( I I_GENE
5 I I_GENE
) I I_GENE
C I I_GENE
MTases I I_GENE
and O O
, O O
while O O
DNMT2 B B_TIME[MEASURE]/B_LOCATION
shares O O
all O O
sequence O O
and O O
structural O O
features O O
with O O
m B B_GENE/B_DISEASE
( I I_GENE/I_DISEASE
5 I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
C I I_GENE/I_DISEASE
MTases I I_GENE/I_DISEASE
, O O
it O O
has O O
failed O O
to O O
demonstrate O O
detectable O O
transmethylase O O
activity O O
. O O

Ten O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
( O O
aged O B_MEASURE/B_PERSON
28 O I_MEASURE/I_PERSON
- O O
76 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
) O O
with O O
a O O
terminal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
jejunostomy O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
located O O
within O O
the O O
first O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
meter O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
jejunum O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
treated O O
by O O
infusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
an O O
elemental O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
diet O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
into O O
the O O
distal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
small O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
bowel O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
( O O
IEDDSB O B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

We O O
have O O
earlier O O
proposed O O
that O O
CG O B_GENE/B_DISEASE
rich O I_GENE/I_DISEASE
sequences O I_GENE/I_DISEASE
resembling O O
CpG O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
islands O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
are O O
associated O O
with O O
many O B_DISEASE/B_GENE
imprinted O B_DISEASE/I_GENE
genes O B_DISEASE/I_GENE
and O O
often O O
subject O B_PERSON/B_TIME[MEASURE]
to O O
parental O B_PERSON/B_LOCATION
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methylation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
could O O
act O O
as O O
a O O
common O B_GENE/B_PERSON
imprinting O I_GENE/I_PERSON
element O I_GENE/I_PERSON
. O O

The O O
atpA B B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
reading O O
frame O O
ends O O
with O O
four O O
tandem O O
UGA O O
codons O O
which O O
overlap O O
four O O
tandem O O
AUG O O
codons O O
initiating O O
an O O
unidentified O O
reading O O
frame O O
, O O
orf214 O O
. O O

Vasodilator O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
hypotensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
optical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
isomers O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
nicardipine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
YC O B_LOCATION/B_PROTEIN[GENE]
- O O
93 O B_NUMBER[MEASURE]
) O O
, O O
a O O
new O B_PROTEIN[GENE]
Ca2 O I_PROTEIN[GENE]
+ O I_PROTEIN[GENE]
- O O
antagonist O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Nicotinic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
antagonists O O
mecamylamine O O
( O O
0 O O
. O O
5 O O
and O O
1 O O
mg O O
/ O O
kg O O
) O O
and O O
hexamethonium O O
( O O
5 O O
and O O
10 O O
mg O O
/ O O
kg O O
) O O
reduced O O
the O O
response O O
induced O O
by O O
nicotine O O
( O O
0 O O
. O O
25 O O
mg O O
/ O O
kg O O
) O O
. O O

The O O
gene O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predicts O O
a O O
150 O B_MEASURE
, O O
825 O B_MEASURE/B_LOCATION
mol O I_MEASURE/I_LOCATION
wt O I_MEASURE/I_LOCATION
apoprotein O I_MEASURE/I_LOCATION
of O O
1363 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O O
an O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_LOCATION/B_PROTEIN[GENE]
hydrophobic O I_LOCATION/I_PROTEIN[GENE]
signal O I_LOCATION/I_PROTEIN[GENE]
sequence O I_LOCATION/I_PROTEIN[GENE]
of O O
17 O B_MEASURE
amino O I_MEASURE
acids O I_MEASURE
, O O
19 O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential O B_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N O B_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
linked O O
glycosylation O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
hydrophobic O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anchor O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
approximately O O
17 O B_MEASURE
amino O I_MEASURE
acids O I_MEASURE
near O O
the O O
C O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
terminus O B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
a O O
hydrophilic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
rich O B_LOCATION
C O I_LOCATION
terminus O I_LOCATION
of O O
35 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
amino O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
acids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Samples O O
( O O
1 O O
g O O
) O O
were O O
extracted O O
with O O
0 O O
. O O
5 O O
% O O
potassium O O
chloride O O
( O O
KCl O O
) O O
in O O
70 O O
% O O
methanol O O
( O O
5 O O
ml O O
) O O
and O O
diluted O O
subsequently O O
to O O
give O O
two O O
- O O
fold O O
to O O
ten O O
- O O
fold O O
step O O
- O O
wise O O
dilutions O O
in O O
phosphate O O
- O O
buffered O O
saline O O
containing O O
0 O O
. O O
05 O O
% O O
Tween O O
20 O O
and O O
0 O O
. O O
2 O O
% O O
bovine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
serum I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
albumin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PBS O O
- O O
T O O
BSA B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Possible O O
or O O
definite O O
neglect O O
or O O
abuse O O
before O O
36 O O
months O O
of O O
age O O
was O O
correlated O O
with O O
low O O
DBH B B_PERSON/B_DISEASE
activity O O
. O O

Previously O O
, O O
we O O
identified O O
two O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
SMC I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
hCAP B B_LOCATION/B_DISEASE
- I I_LOCATION/I_DISEASE
C I I_LOCATION/I_DISEASE
and O O
hCAP B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
E I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
form O O
a O O
heterodimeric O O
complex O O
( O O
hCAP B B_DISEASE/B_LOCATION
- I B_DISEASE/I_LOCATION
C I B_DISEASE/I_LOCATION
- O O
hCAP B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
E I I_PROTEIN[GENE]/I_LOCATION
) O O
in O O
the O O
cell O O
. O O

Both O O
the O O
inactive O O
domain B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
II I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
P68 I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mutant I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
the O O
deletion O O
mutant O O
lacking O O
aa O O
91 O O
- O O
243 O O
were O O
less O O
inhibitory O O
to O O
growth O O
in O O
yeast O O
due O O
to O O
the O O
reduced O O
ability O O
to O O
phosphorylate O O
initiation B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O O
. O O

PKCI B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
is O O
a O O
member O O
of O O
the O O
HIT B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
family I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
of O O
proteins O O
, O O
shown O O
by O O
sequence O O
identity O O
to O O
be O O
conserved O O
in O O
a O O
broad O O
range O O
of O O
organisms O O
including O O
mycoplasma O O
, O O
plants O O
, O O
and O O
humans O O
. O O

It O O
was O O
found O O
that O O
on O O
the O O
14th O O
and O O
21st O O
day O O
after O O
cimetidine O O
administration O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gastrin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
were O O
significantly O O
elevated O O
. O O

Electronic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
Si O B_LOCATION/B_NUMBER[MEASURE]
( O O
111 O B_MEASURE
) O O
- O O
NiSi2 O B_LOCATION/B_PERSON
( O O
111 O B_MEASURE
) O O
A O O
- O O
type O B_LOCATION/B_DISEASE
and O O
B O B_PROTEIN[GENE]/B_DISEASE
- O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
interfaces O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Inhibitory O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
characterized O O
by O O
the O O
presence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
a O O
characteristic O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
sequence O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
known O O
as O O
an O O
immunoreceptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tyrosine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
based O O
inhibitory O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motif O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ITIM O B_ORGANIZATION/B_GENE
) O O
in O O
their O O
cytoplasmic O B_LOCATION/B_BIO
tail O B_LOCATION/I_BIO
. O O

The O O
nucleotide O B_LOCATION
sequence O I_LOCATION
of O O
the O O
gene O B_GENE/B_LOCATION
encoding O O
this O O
product O B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
determined O O
and O O
the O O
amino O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deduced O O
. O O

Molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
the O O
mannitol O B_GENE/B_BIO
operon O I_GENE/I_BIO
of O O
Clostridium O B_BIO/B_GENE
acetobutylicum O I_BIO/I_GENE
encoding O O
a O O
phosphotransferase O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
system O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
putative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PTS O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
modulated O O
regulator O B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
sequence O O
of O O
the O O
gene O O
upstream O O
to O O
the O O
cap O O
site O O
contains O O
characteristic O O
RNA B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
polymerase I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
II I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
promoter I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
binding I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
sites I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
: O O
a O O
putative O O
TATA O O
box O O
at O O
position O O
- O O
29 O O
and O O
a O O
Sp B B_GENE
1 I I_GENE
binding I I_GENE
site I I_GENE
( O O
GGGGCGGAGA O O
) O O
at O O
position O O
- O O
48 O O
. O O

Promoter O O
constructs O O
containing O O
mutations O O
in O O
the O O
PTRE B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sequence I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
selectively O O
abolished O O
the O O
binding O O
of O O
either O O
one O O
or O O
both O O
complexes O O
exerted O O
opposite O O
effects O O
on O O
the O O
transcriptional O O
activity O O
of O O
trypsin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
A O O
. O O
gambiae O O
and O O
Aedes O O
aegypti O O
cell O O
lines O O
. O O

The O O
Rep78 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
adeno O O
- O O
associated O O
virus O O
( O O
AAV O O
) O O
contains O O
amino O O
acid O O
sequence O O
motifs O O
common O O
to O O
rolling B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
circle I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
replication I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
RCR I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
) I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
initiator I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Reality O O
and O O
clinical O O
application O O
of O O
immunoglobulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
preparations O O

Nuclear O O
transcription O O
assays O O
confirmed O O
that O O
cys B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
under O O
sulfur O O
- O O
regulated O O
transcriptional O O
control O O
and O O
that O O
cys B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
3 I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
+ I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
transcription O O
was O O
constitutive O O
in O O
sulfur B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
controller I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
scon B B_LOCATION/B_DISEASE
) O O
- O O
negative O O
regulator O O
mutants O O
. O O

Two O O
adjacent O O
, O O
highly O O
homologous B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
endoglucanase I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
genes I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
celD B B_LOCATION/B_GENE
and O O
celE B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
Fibrobacter O O
succinogenes O O
S85 O O
, O O
which O O
were O O
separated O O
by O O
an O O
AT O O
- O O
rich O O
223 O O
- O O
nucleotide O O
intergenic O O
region O O
were O O
characterized O O
. O O

It O O
is O O
concluded O O
that O O
the O O
new O O
class O O
of O O
competitive O O
NMDA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antagonists O O
, O O
exemplified O O
by O O
CGP O O
37849 O O
, O O
is O O
the O O
most O O
promising O O
candidate O O
for O O
clinical O O
trials O O
in O O
anxiety O O
disorders O O
. O O

METHODS O O
: O O
The O O
prevalence O O
of O O
haemagglutination B B_DISEASE
inhibiting I I_DISEASE
( I I_DISEASE
HI I I_DISEASE
) I I_DISEASE
antibodies I I_DISEASE
to O O
JE O O
virus O O
( O O
JEV O O
) O O
, O O
West O O
Nile O O
virus O O
( O O
WNV O O
) O O
and O O
dengue O O
- O O
2 O O
virus O O
( O O
DEN O O
- O O
2 O O
) O O
was O O
detected O O
by O O
HI O O
test O O
and O O
IgM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
capture O O
ELISA O O
( O O
MAC O O
ELISA O O
) O O
was O O
performed O O
to O O
determine O O
recent O O
infections O O
with O O
JE O O
virus O O
. O O

The O O
crystal O O
structure O O
of O O
the O O
yeast O O
Phe B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tRNAPhe I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ternary I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
Thermus O O
aquaticus O O
EF B B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- I B_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
Tu I B_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O O
GDPNP O O
( O O
Phe B B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- I B_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
TC I B_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O O
has O O
previously O O
been O O
determined O O
as O O
one O O
representative O O
of O O
this O O
general O O
yet O O
highly O O
discriminating O O
complex O O
formation O O
. O O

Quantitative O O
measurement O O
of O O
antigamma B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
globulin I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
factors I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
rheumatoid B B_DISEASE/B_LOCATION
factors I I_DISEASE/I_LOCATION
) O O
using O O
laser O O
- O O
nephelometry O O
in O O
comparison O O
with O O
the O O
latex O O
agglutination O O
test O O
and O O
the O O
Waaler O O
- O O
Rose O O
test O O

Base O O
substitutions O O
within O O
this O O
NFIL B B_LOCATION/B_BIO
- I I_LOCATION/I_BIO
6 I I_LOCATION/I_BIO
site I I_LOCATION/I_BIO
resulted O O
in O O
virtual O O
elimination O O
of O O
LPS O O
- O O
induced O O
IL B B_GENE
- I I_GENE
1 I I_GENE
beta I I_GENE
gene I I_GENE
transcription O O
. O O

Mortality O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
not O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
chi2 O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
0 O B_MEASURE
. O O
0298 O B_MEASURE
, O O
p O O
> O O
0 O B_MEASURE
. O O
5 O B_MEASURE
) O O
. O O

The O O
sensitivity O O
of O O
central B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dopamine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
assessed O O
with O O
the O O
growth B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
hormone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
response O O
to O O
apomorphine O O
application O O
. O O

Oral O O
basal O O
body O O
temperature O O
( O O
BBT O O
) O O
recordings O O
of O O
46 O O
women O O
that O O
conceived O O
by O O
donor O O
insemination O O
and O O
who O O
had O O
midcycle O O
monitoring O O
of O O
luteinising B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hormone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
LH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
were O O
analysed O O
to O O
establish O O
features O O
associated O O
with O O
an O O
optimal O O
cycle O O
. O O

A O O
DNA O O
fragment O O
that O O
complements O O
the O O
uvs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
mutation O O
was O O
subcloned O O
by O O
monitoring O O
its O O
ability O O
to O O
transform O O
the O O
uvs B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
mutant I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
to O O
MMS O O
resistance O O
. O O

The O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lbc I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oncogene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
product I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
guanine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
exchange I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
specifically O O
activates O O
the O O
Rho B B_GENE
small I I_GENE
GTP I I_GENE
binding I I_GENE
protein I I_GENE
, O O
thus O O
resulting O O
in O O
biologically O O
active O O
, O O
GTP O O
- O O
bound O O
Rho B B_GENE
, O O
which O O
in O O
turn O O
mediates O O
actin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cytoskeletal O O
reorganization O O
, O O
gene O O
transcription O O
, O O
and O O
entry O O
into O O
the O O
mitotic O O
S O O
phase O O
. O O

Insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
stimulated O O
autophosphorylation O O
at O O
specific O O
sites O O
in O O
the O O
tyrosine B B_LOCATION/B_PERSON
kinase I I_LOCATION/I_PERSON
domain I I_LOCATION/I_PERSON
of O O
the O O
receptor O O
' O O
s O O
beta O O
- O O
subunit O O
is O O
correlated O O
kinetically O O
with O O
activation O O
of O O
kinase O O
- O O
catalyzed O O
phosphorylation O O
of O O
a O O
model O O
substrate O O
( O O
reduced O O
and O O
carboxyamidomethylated O O
lysozyme B B_GENE
; O O
RCAM B B_GENE
- I I_GENE
lysozyme I I_GENE
) O O
. O O

Interestingly O O
, O O
the O O
NES B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
mutant I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
proteins I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
appeared O O
to O O
have O O
altered O O
interactions O O
with O O
the O O
splicing O O
complex O O
, O O
binding O O
more O O
tightly O O
to O O
SC35 B B_GENE/B_BIO
in O O
co O O
- O O
immunoprecipitation O O
assays O O
. O O

sae1 B B_PERSON/B_GENE
- I I_PERSON/I_GENE
1 I I_PERSON/I_GENE
produces O O
recombinants O O
but O O
very O O
slowly O O
and O O
ultimately O O
to O O
less O O
than O O
half O O
the O O
wild O O
- O O
type O O
level O O
; O O
sae3 B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
- I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
1 I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
makes O O
persistent O O
hyper O O
- O O
resected O O
meiotic O O
double O O
- O O
strand O O
breaks O O
and O O
has O O
a O O
severe O O
defect O O
in O O
formation O O
of O O
recombinants O O
. O O

Therefore O O
the O O
effect O O
of O O
GAL11 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
on O O
PGK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription O O
must O O
be O O
mediated O O
at O O
the O O
PGK B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
UAS I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
presumably O O
as O O
part O O
of O O
the O O
activation O O
complex O O
. O O

Meq B B_GENE/B_PERSON
/ O O
c B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
Jun I I_GENE/I_LOCATION
heterodimers O O
bind O O
to O O
an O O
AP1 B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
like I I_GENE/I_LOCATION
sequence I I_GENE/I_LOCATION
in O O
the O O
meq B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
region I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
an O O
affinity O O
much O O
greater O O
than O O
that O O
of O O
Meq B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Meq B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
c B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
Jun I I_GENE/I_LOCATION
/ O O
c B B_GENE/B_PERSON
- I I_GENE/I_PERSON
Jun I I_GENE/I_PERSON
homodimers O O
. O O

Moreover O O
, O O
the O O
noncoordinate O O
effects O O
of O O
FSK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
PMA O O
- O O
stimulated O O
MKK B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
MAPK B B_GENE
activities O O
indicates O O
the O O
presence O O
of O O
a O O
additional O O
distal O O
cAMP O O
- O O
dependent O O
inhibitory O O
mechanisms O O
. O O

Mean O B_MEASURE/B_PERSON
total O I_MEASURE/I_PERSON
homocysteine O I_MEASURE/I_PERSON
( O O
tHcy O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
was O O
21 O B_MEASURE
. O O
1 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
9 O B_MEASURE
. O O
5 O B_MEASURE
micromol O I_MEASURE
/ O O
L O B_OTHER/B_MEASURE
and O O
median O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
19 O B_MEASURE/B_PERSON
micromol O I_MEASURE/I_PERSON
/ O O
L O B_OTHER/B_MEASURE
. O O

Nonlethal O O
sec71 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
sec72 B B_DISEASE/B_LOCATION
- I B_DISEASE/I_LOCATION
1 I B_DISEASE/I_LOCATION
mutations I B_DISEASE/I_LOCATION
eliminate O O
proteins O O
associated O O
with O O
the O O
Sec63p B B_GENE/B_LOCATION
- O O
BiP B B_GENE/B_MEASURE
complex O O
from O O
S O O
. O O
cerevisiae O O
. O O

Similarly O O
, O O
TAM B B_PERSON/B_ORGANIZATION
- I I_PERSON/I_ORGANIZATION
67 I I_PERSON/I_ORGANIZATION
reverted O O
the O O
morphology O O
of O O
the O O
AdoMetDC B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antisense I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expressors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
cdc42W97R B B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
temperature I I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
- I I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
sensitive I I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
allele I I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O O
S O O
. O O
cerevisiae O O
displayed O O
the O O
same O O
cell O O
- O O
division O O
- O O
cycle O O
arrest O O
phenotype O O
( O O
large O O
, O O
round O O
unbudded O O
cells O O
) O O
as O O
the O O
cdc42 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
1ts I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mutant I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

Sequence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analyses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O O
a O O
partial O B_GENE/B_LOCATION
941 O I_GENE/I_LOCATION
bp O I_GENE/I_LOCATION
cDNA O I_GENE/I_LOCATION
that O O
encoded O O
a O O
313 O B_MEASURE
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
acid O B_PROTEIN[GENE]
polypeptide O I_PROTEIN[GENE]
. O O

Sequence O O
analysis O O
revealed O O
100 O O
% O O
homology O O
of O O
all O O
RA O O
- O O
derived O O
PTEN B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fragments I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
those O O
from O O
normal O O
SF O O
as O O
well O O
as O O
to O O
the O O
published O O
GenBank O O
sequence O O
( O O
accession O O
number O O
U93051 B B_MEASURE/B_PERSON
) O O
. O O

174 O B_MEASURE
, O O
233 O B_MEASURE
- O O
247 O B_MEASURE
) O O
and O O
Serrate O B_NUMBER[MEASURE]/B_LOCATION
( O O
Serrate1 O B_TIME[MEASURE]/B_PROTEIN[GENE]
and O O
2 O B_NUMBER[MEASURE]
; O O
Myat O B_PERSON/B_LOCATION
, O O
A O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O
, O O
Henrique O B_PERSON
, O O
D O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Ish O B_PERSON/B_LOCATION
- O O
Horowicz O B_PERSON/B_LOCATION
, O O
D O B_OTHER/B_LOCATION
. O O
and O O
Lewis O B_PERSON
, O O
J O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
1996 O B_MEASURE/B_PERSON
. O O

Many O B_SPECIES[BIO]/B_MEASURE
retroviruses O I_SPECIES[BIO]/I_MEASURE
, O O
including O O
the O O
human O B_SPECIES[BIO]
and O O
simian O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
viruses O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
contain O O
a O O
leucine O B_GENE
zipper O I_GENE
- O O
like O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
highly O O
conserved O B_LOCATION/B_TIME[MEASURE]
region O B_LOCATION/I_TIME[MEASURE]
of O O
the O O
external O B_LOCATION/B_ORGANIZATION
domain O I_LOCATION/I_ORGANIZATION
of O O
the O O
transmembrane O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
( O O
TM O B_LOCATION/B_DISEASE
) O O
glycoprotein O B_PROTEIN[GENE]/B_LOCATION
. O O

Internal O O
controls O O
over O O
the O O
volume O O
of O O
milk O O
suckled O O
do O O
not O O
appear O O
until O O
infant O O
rats O O
are O O
about O O
2 O O
weeks O O
of O O
age O O
at O O
which O O
time O O
gastric O O
distension O O
, O O
milk O O
, O O
systemic O O
dehydration O O
, O O
and O O
intestinal B B_DISEASE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I I_DISEASE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cholecystokinin I I_DISEASE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suppress O O
milk O O
intake O O
derived O O
through O O
suckling O O
. O O

Concerning O O
the O O
practical O O
approach O O
in O O
a O O
clinical O O
setting O O
, O O
it O O
has O O
to O O
be O O
pointed O O
out O O
that O O
with O O
these O O
diseases O O
a O O
hepatitis O O
C O O
infection O O
has O O
to O O
be O O
considered O O
and O O
testing O O
for O O
hepatitis B B_DISEASE
C I I_DISEASE
antibodies I I_DISEASE
and O O
, O O
if O O
positive O O
, O O
hepatitis B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RNA I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
indicated O O
. O O

Detailed O O
comparison O O
of O O
the O O
sequences O O
of O O
cp35 B B_SPECIES[BIO]
and O O
human B B_MEASURE/B_GENE
calpactin I I_MEASURE/I_GENE
II I I_MEASURE/I_GENE
shows O O
that O O
the O O
only O O
substantial O O
sequence O O
dissimilarity O O
is O O
a O O
domain O O
encoding O O
amino O O
acids O O
between O O
residues O O
20 O O
and O O
40 O O
which O O
includes O O
a O O
tyrosine O O
phosphorylation O O
site O O
in O O
the O O
human O O
molecule O O
, O O
along O O
with O O
other O O
residues O O
of O O
possible O O
physiological O O
significance O O
. O O

Alternative O O
immune B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparation O O
when O O
standard O O
immune B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
available O O
. O O

Plasma B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
insulin I B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
responses O O
to O O
glucose O O
in O O
femoral O O
, O O
hepatic O O
, O O
and O O
pancreatic O O
veins O O
in O O
dogs O O
. O O

In O O
lyzozyme B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
activity O O
there O O
was O O
periodicity O O
in O O
three O O
groups O O
but O O
not O O
in O O
the O O
youngest O O
foals O O
. O O

The O O
isomerization O O
of O O
the O O
pre O O
- O O
existing O O
closed O O
complex O O
to O O
an O O
open O O
promoter O O
form O O
, O O
as O O
judged O O
by O O
the O O
local O O
denaturation O O
of O O
promoter O O
DNA O O
which O O
rendered O O
sequences O O
from O O
+ O O
5 O O
to O O
- O O
10 O O
reactive O O
towards O O
KMnO4 O O
, O O
was O O
shown O O
to O O
be O O
fully O O
dependent O O
on O O
NifA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O O

The O O
maternal B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
par I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
segregation O O
of O O
cell O O
fate O O
specification O O
activities O O
in O O
early O O
Caenorhabditis O O
elegans O O
embryos O O
. O O

Detailed O O
analysis O O
of O O
the O O
predicted O O
amino O O
acid O O
sequence O O
revealed O O
sequence O O
elements O O
which O O
are O O
conserved O O
in O O
many O O
DNA B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
and I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
polymerases I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Gel O O
shift O O
and O O
southwestern O O
experiments O O
revealed O O
nuclear O O
proteins O O
of O O
43 O O
kDa O O
and O O
30 O O
kDa O O
in O O
GC O O
and O O
fish O O
cells O O
, O O
respectively O O
, O O
that O O
bind O O
specifically O O
to O O
the O O
tGH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
CRE O O
, O O
suggesting O O
the O O
involvement O O
of O O
CRE B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
activating B B_GENE
- I I_GENE
transcription I I_GENE
- I I_GENE
factor I I_GENE
- I I_GENE
l I I_GENE
- O O
related O O
peptides O O
in O O
cAMP O O
response O O
. O O

Restriction O O
mapping O O
showed O O
that O O
the O O
two O O
recombinant O O
plasmids O O
shared O O
an O O
EcoRI B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
fragment I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
8 O O
. O O
9 O O
kb O O
. O O

After O O
first O O
strand O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cDNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
synthesis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
fetal O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
brain O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
mRNAs O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
short O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fragment O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cDNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
sf O B_PROTEIN[GENE]/B_LOCATION
- O O
cDNAs O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
were O O
synthesized O O
with O O
a O O
two O B_NUMBER[MEASURE]
- O O
step O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amplification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
our O O
modified O O
Degenerate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Oligonucleotide O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Primed O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Shuttle O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Polymerase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DOP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
Shuttle O B_PERSON/B_PROTEIN[GENE]
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Profilins B B_NUMBER[MEASURE]/B_PERSON
IIa I I_NUMBER[MEASURE]/I_PERSON
and I I_NUMBER[MEASURE]/I_PERSON
IIb I I_NUMBER[MEASURE]/I_PERSON
are O O
also O O
present O O
in O O
humans O O
, O O
suggesting O O
that O O
all O O
mammals O O
have O O
three O O
profilin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Using O O
the O O
yeast O O
two O O
- O O
hybrid O O
system O O
, O O
we O O
have O O
isolated O O
an O O
835 O O
amino O O
acid O O
RING O O
finger O O
( O O
C3HC4 O O
zinc O O
finger O O
) O O
protein O O
, O O
TIF1 B B_GENE
beta I I_GENE
( O O
also O O
named O O
KAP B B_GENE
- I I_GENE
1 I I_GENE
) O O
, O O
that O O
specifically O O
interacts O O
with O O
the O O
KRAB B B_GENE/B_LOCATION
domain I I_GENE/I_LOCATION
of O O
the O O
human O O
zinc O O
finger O O
factor O O
KOX1 B B_PROTEIN[GENE]/B_MEASURE
/ O O
ZNF10 B B_MEASURE
. O O

The O O
reduced O O
expression O O
caused O O
by O O
multimerization O O
of O O
UAS2 O O
in O O
the O O
native O O
promoter O O
was O O
observed O O
only O O
in O O
the O O
presence O O
of O O
ADR1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Mean O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
disposition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
constants O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
+ O B_MEASURE/B_DISEASE
/ O O
- O O
SD O B_DISEASE/B_PROTEIN[GENE]
) O O
were O O
obtained O O
from O O
individualized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fits O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
V1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
: O O
0 O B_MEASURE
. O O
398 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
336 O B_MEASURE
LITER O I_MEASURE
/ O O
KG O B_MEASURE
, O O
Vdarea O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
: O O
2 O B_MEASURE
. O O
53 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
72 O B_TIME[MEASURE]
liter O I_TIME[MEASURE]
/ O O
kg O B_MEASURE
, O O
alpha O B_PROTEIN[GENE]/B_MEASURE
: O O
0 O B_NUMBER[MEASURE]
. O O
316 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_NUMBER[MEASURE]
. O O
294 O B_MEASURE/B_PERSON
min O I_MEASURE/I_PERSON
- O O
1 O B_NUMBER[MEASURE]
, O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
0 O B_NUMBER[MEASURE]
. O O
00204 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_NUMBER[MEASURE]
. O O
00262 O B_MEASURE/B_PERSON
min O I_MEASURE/I_PERSON
- O O
1 O B_NUMBER[MEASURE]
, O O
k2 O O
: O O
0 O B_NUMBER[MEASURE]
. O O
0305 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_NUMBER[MEASURE]
. O O
0101 O B_MEASURE/B_PERSON
min O I_MEASURE/I_PERSON
- O O
1 O B_NUMBER[MEASURE]
) O O
. O O

The O O
model O O
therefore O O
predicts O O
that O O
1 O O
) O O
on O O
- O O
line O O
calculation O O
of O O
airway O O
dead O O
space O O
and O O
end O O
- O O
expired O O
lung O O
volume O O
can O O
be O O
made O O
by O O
the O O
addition O O
of O O
an O O
oxygen O O
sine O O
- O O
wave O O
perturbation O O
component O O
to O O
the O O
mean O O
FIO2 O O
; O O
and O O
( O O
2 O O
) O O
QS O O
/ O O
QT O O
can O O
be O O
measured O O
from O O
the O O
resultant O O
oxygen O O
perturbation O O
sine O O
- O O
wave O O
amplitudes O O
in O O
the O O
expired O O
gas O O
and O O
in O O
arterial O O
and O O
mixed O O
- O O
venous O O
blood O O
and O O
is O O
independent O O
of O O
the O O
mean O O
blood O O
oxygen O O
partial O O
pressure O O
and O O
oxyhemoglobin B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
saturation O O
values O O
. O O

Consistent O O
with O O
this O O
, O O
rh5 B B_GENE/B_SPECIES[BIO]
expression O O
in O O
R8 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disappears O O
when O O
R7 O O
cells O O
are O O
absent O O
( O O
in O O
sevenless B B_PERSON/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutant I I_PERSON/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Fulminant O O
hepatic O O
failure O O
in O O
these O O
cases O O
could O O
be O O
characterized O O
by O O
: O O
( O O
1 O O
) O O
rapid O O
decrease O O
in O O
serum B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
alanine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transaminase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ALT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
level O O
after O O
discontinuation O O
of O O
ecarazine O O
, O O
( O O
2 O O
) O O
prolonged O O
jaundice O O
despite O O
discontinuation O O
of O O
ecarazine O O
, O O
( O O
3 O O
) O O
high O O
incidence O O
of O O
anti B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
nuclear I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
antibody I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
ANA B B_DISEASE/B_GENE
) O O
( O O
57 O O
% O O
) O O
, O O
and O O
( O O
4 O O
) O O
histological O O
findings O O
of O O
extensive O O
hepatocellular O O
necrosis O O
ranging O O
from O O
bridging O O
necrosis O O
to O O
massive O O
necrosis O O
. O O

Localization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
porcine O B_PROTEIN[GENE]
enzyme O I_PROTEIN[GENE]
in O O
the O O
endoplasmic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
reticulum O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
immuno O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
- O O
electron O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
microscopic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
pig O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hepatocytes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Monoclonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
the O O
hapten O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenyloxazolone O I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
raised O O
7 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
after O O
immunization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O O
mice O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
six O B_NUMBER[MEASURE]/B_BIO
strains O I_NUMBER[MEASURE]/I_BIO
( O O
BALB O B_SPECIES[BIO]/B_PROTEIN[GENE]
/ O O
c O B_DISEASE/B_LOCATION
, O O
C57BL O B_BIO/B_PROTEIN[GENE]
- O O
Igha O B_MEASURE/B_DISEASE
, O O
DBA2 O B_LOCATION/B_PROTEIN[GENE]
, O O
RF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O O
J O B_OTHER/B_PROTEIN[GENE]
, O O
and O O
CE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
. O O

Six O O
cDNAs O O
represent O O
human O O
homologs O O
of O O
genes O O
known O O
in O O
other O O
species O O
, O O
namely O O
, O O
mouse B B_GENE/B_SPECIES[BIO]
HSPE71 I B_GENE/I_SPECIES[BIO]
, O O
Rat B B_GENE
RhoGAP I I_GENE
protein I I_GENE
, O O
S B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
cerevisiae I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
leucyl I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
tRNA I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
synthetase I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
S B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cerevisiae I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chromosome I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ORF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
YBLO44W I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
determine O O
the O O
role O O
of O O
elevated O O
FAK B B_GENE
expression O O
in O O
facilitating O O
epidermal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
growth I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
EGF B B_GENE
) O O
- O O
stimulated O O
human O O
adenocarcinoma O O
( O O
A549 O O
) O O
cell O O
motility O O
, O O
antisense O O
oligonucleotides O O
were O O
used O O
to O O
reduce O O
FAK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
> O O
75 O O
% O O
. O O

To O O
further O O
study O O
the O O
role O O
of O O
tTG B B_GENE
in O O
liver O O
disease O O
, O O
we O O
initiated O O
investigations O O
into O O
the O O
effect O O
of O O
a O O
proinflammatory O O
mediator O O
, O O
tumor B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
necrosis I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TNF I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
on O O
tTG B B_GENE
activity O O
in O O
cultured O O
liver O O
cells O O
. O O

By O O
contrast O O
, O O
CIS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
failed O O
to O O
affect O O
the O O
IL B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
9 I I_DISEASE_ADJECTIVE[DISEASE]
response O O
. O O

In O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
phosphorus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
limitation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
fungus O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
Neurospora O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
crassa O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
synthesizes O O
a O O
number O B_MEASURE/B_LOCATION
of O O
enzymes O B_ENZYME[GENE]
that O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
bring O O
more O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
the O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O O

Blood O O
pressure O O
was O O
controlled O O
long O O
term O O
( O O
with O O
/ O O
without O O
diuretics O O
/ O O
beta B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
adrenoreceptor I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
blocking O O
drugs O O
) O O
in O O
sixteen O O
out O O
of O O
nineteen O O
patients O O
with O O
mild O O
- O O
moderate O O
hypertension O O
. O O

Disruption O O
of O O
INP53 B B_GENE/B_BIO
, O O
but O O
not O O
the O O
related O O
INP51 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
INP52 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
resulted O O
in O O
alpha B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DISEASE_ADJECTIVE[DISEASE]
maturation O O
defects O O
and O O
exacerbated O O
alpha B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factor I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
maturation O O
defects O O
when O O
combined O O
with O O
chc1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
521 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Regardless O O
of O O
muscle O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
tensioning O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
or O O
marination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatments O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
aging O O
of O O
the O O
carcass O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
for O O
24 O B_MEASURE
h O O
( O O
T1 O B_PROTEIN[GENE]
, O O
T2 O B_PROTEIN[GENE]
, O O
and O O
T3 O B_PROTEIN[GENE]
) O O
produced O O
meats O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O O
lower O B_MEASURE
shear O I_MEASURE
values O I_MEASURE
than O O
those O O
from O O
hot O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- O O
boned O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
carcasses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
T4 O B_PROTEIN[GENE]
and O O
T5 O B_PROTEIN[GENE]
) O O
. O O

Furthermore O O
, O O
rubella B B_DISEASE
IgM I I_DISEASE
antibody I I_DISEASE
was O O
never O O
detected O O
after O O
immunization O O
in O O
women O O
who O O
were O O
HAI O O
- O O
negative O O
and O O
LA O O
- O O
positive O O
during O O
pregnancy O O
. O O

Disease O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
free O B_MEASURE/B_LOCATION
interval O I_MEASURE/I_LOCATION
was O O
greater O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
node O B_DISEASE/B_GENE
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
Lx O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
patients O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O O
both O O
T1 O B_PROTEIN[GENE]
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
007 O B_MEASURE
) O O
and O O
T2 O B_PROTEIN[GENE]
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
presentations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

A O O
review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
156 O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
younger O I_PERSON/I_TIME[MEASURE]
than O O
40 O B_NUMBER[MEASURE]
treated O O
at O O
our O O
Department O B_LOCATION/B_ORGANIZATION
between O O
1960 O B_MEASURE
and O O
1991 O B_MEASURE
with O O
transitional O B_DISEASE
cell O I_DISEASE
carcinoma O I_DISEASE
of O O
the O O
bladder O B_BODY_PART_OR_ORGAN_COMPONENT
revealed O O
that O O
89 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
had O O
superficial O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
Ta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
T1 O B_PROTEIN[GENE]/B_LOCATION
) O O
disease O B_DISEASE
and O O
the O O
remaining O O
10 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
presented O O
with O O
invasive O B_DISEASE
disease O I_DISEASE
. O O

The O O
Gastrointestinal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Tumor O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
GITSG O B_DISEASE/B_ORGANIZATION
) O O
protocol O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GI O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
7175 O B_NUMBER[MEASURE]/B_LOCATION
randomized O O
227 O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
1975 O B_MEASURE
and O O
1980 O B_MEASURE
following O O
complete O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgical O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
stages O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
B2 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
C O B_PROTEIN[GENE]
rectal O O
adenocarcinoma O B_DISEASE
to O O
four O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arms O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
( O O
1 O B_SEQUENCE[MEASURE]/B_LOCATION
) O O
no O O
adjuvant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
( O O
2 O B_NUMBER[MEASURE]/B_PERSON
) O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
only O O
, O O
( O O
3 O B_NUMBER[MEASURE]/B_LOCATION
) O O
radiotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
only O O
, O O
and O O
( O O
4 O B_NUMBER[MEASURE]
) O O
radiotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
combined O O
modality O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
. O O

The O O
DNA O O
element O O
through O O
which O O
EBNA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
3C I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activates O O
the O O
LMP B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
includes O O
a O O
Spi B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
/ O O
Spi B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O O
site O O
, O O
previously O O
characterized O O
as O O
an O O
important O O
EBNA B B_MEASURE/B_LOCATION
- I B_MEASURE/I_LOCATION
2 I B_MEASURE/I_LOCATION
response I B_MEASURE/I_LOCATION
element I B_MEASURE/I_LOCATION
. O O

Furthermore O O
, O O
deletion O O
of O O
two O O
potential O O
Ste11 B B_GENE/B_LOCATION
recognition I I_GENE/I_LOCATION
sites I I_GENE/I_LOCATION
in O O
the O O
fus1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region O O
abolished O O
transcription O O
, O O
and O O
expression O O
could O O
be O O
restored O O
when O O
we O O
inserted O O
a O O
different O O
Ste11 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
the O O
mat1 B B_TIME[MEASURE]/B_PERSON
- I I_TIME[MEASURE]/I_PERSON
P I I_TIME[MEASURE]/I_PERSON
promoter I I_TIME[MEASURE]/I_PERSON
. O O

Finally O O
, O O
we O O
demonstrate O O
that O O
animals O O
carrying O O
a O O
snf B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutation O O
that O O
converts O O
SNF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
a O O
bifunctional O O
protein O O
to O O
a O O
U1 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
snRNP I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
specific I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
viable O O
. O O

METHODS O B_MEASURE
: O O
Autocapture O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
devices O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
( O O
Pacesetter O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Microny O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SR O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
- O O
and O O
Regency O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SR O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
- O O
; O O
Pacesetter O B_PERSON/B_TIME[MEASURE]
, O O
Solna O B_PERSON/B_LOCATION
, O O
Sweden O B_LOCATION
) O O
and O O
steroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
eluting O O
epicardial O B_MEDICAL_DEVICE[OBJECT]/B_DISEASE_ADJECTIVE[DISEASE]
pacing O I_MEDICAL_DEVICE[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
leads O I_MEDICAL_DEVICE[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Medtronic O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CapSure O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epi O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10366 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
Medtronic O B_PERSON/B_LOCATION
, O O
Inc O B_ORGANIZATION/B_MEASURE
, O O
Minneapolis O B_LOCATION/B_PERSON
, O O
MN O B_LOCATION
) O O
were O O
implanted O O
in O O
14 O B_PERSON/B_ENT
children O I_PERSON/I_ENT
. O O

Pyridostigmine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
pretreatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
supplemented O O
by O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
two O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
an O O
antidotal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combination O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
A O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
TM O B_PROTEIN[GENE]/B_DISEASE
, O O
B O B_OTHER/B_LOCATION
) O O
consisting O O
of O O
0 O B_MEASURE
. O O
05 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
atropine O I_MEASURE
, O O
2 O B_MEASURE
. O O
24 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE/B_LOCATION
TMB O I_MEASURE/I_LOCATION
- O O
4 O B_NUMBER[MEASURE]
, O O
and O O
0 O B_MEASURE
. O O
4 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benactyzine O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
assured O O
survival O B_DISEASE_ADJECTIVE[DISEASE]
in O O
five O B_NUMBER[MEASURE]/B_BIO
of O O
six O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals O I_ENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O O
three O B_NUMBER[MEASURE]/B_LOCATION
separate O I_NUMBER[MEASURE]/I_LOCATION
exposures O I_NUMBER[MEASURE]/I_LOCATION
to O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
LD50 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
soman O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
induction O O
of O O
the O O
composite O O
H B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
PK I I_PROTEIN[GENE]/I_LOCATION
/ O O
Tag B B_GENE/B_MEASURE
and O O
SV B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
PK I I_GENE/I_LOCATION
/ O O
Tag B B_GENE/B_LOCATION
transgenes O O
by O O
a O O
carbohydrate O O
- O O
rich O O
diet O O
in O O
the O O
liver O O
was O O
similar O O
to O O
that O O
of O O
the O O
endogenous B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
L I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
PK I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Patients O B_PERSON/B_BIO
with O O
advanced O B_DISEASE/B_LOCATION
ovarian O I_DISEASE/I_LOCATION
carcinoma O I_DISEASE/I_LOCATION
, O O
Stage O B_PROTEIN[GENE]/B_TIME[MEASURE]
III O I_PROTEIN[GENE]/I_TIME[MEASURE]
or O O
IV O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
International O B_ORGANIZATION/B_LOCATION
Federation O I_ORGANIZATION/I_LOCATION
of O O
Gynaecology O B_PERSON/B_DISEASE
and O O
Obstetrics O B_DISEASE/B_LOCATION
) O O
, O O
were O O
randomized O O
to O O
primary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chemotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
doxorubicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Adriamycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
and O O
cisplatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
or O O
minus O B_MEASURE
hexamethylmelamine O I_MEASURE
, O O
and O O
cyclophosphamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CHAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

To O O
understand O O
this O O
dramatic O O
effect O O
, O O
we O O
examined O O
the O O
localization O O
of O O
SR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
found O O
that O O
SC35 B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
shifted O O
to O O
the O O
cytoplasm O O
in O O
sky1Delta B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
yeast O O
, O O
although O O
this O O
phenomenon O O
was O O
not O O
obvious O O
with O O
ASF B B_LOCATION/B_GENE
/ O O
SF2 B B_GENE/B_LOCATION
, O O
indicating O O
that O O
nuclear O O
import O O
of O O
SR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
differentially O O
regulated O O
by O O
phosphorylation O O
. O O

On O O
the O O
contrary O O
i O O
. O O
v O O
. O O
administration O O
of O O
calcitonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O O
intrapyloric O O
pressure O O
via O O
vagal O O
nerves O O
in O O
atropinized O O
or O O
gallaminized O O
animals O O
. O O

We O O
conclude O O
that O O
in O O
the O O
presence O O
of O O
fatty O O
acids O O
in O O
the O O
medium O O
transcription O O
of O O
SPS19 B B_GENE
is O O
directly O O
regulated O O
by O O
both O O
Pip2p B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
Oaf1p B B_MEASURE
and O O
Adr1p B B_GENE
. O O

We O O
found O O
that O O
in O O
premature O O
infants O O
plasminogen B B_GENE
levels O O
are O O
low O O
; O O
thus O O
, O O
defense O O
against O O
intra O O
- O O
alveolar O O
fibrin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deposition O O
during O O
birth O O
trauma O O
is O O
reduced O O
. O O

Studies O O
on O O
the O O
reaction O O
of O O
cytochrome B B_BIO/B_DISEASE
c I I_BIO/I_DISEASE
with O O
corticosteroids O O
. O O

Selective O O
upper O O
abdominal O O
sympathectomy O O
increased O O
basal O O
acid O O
output O O
in O O
rats O O
but O O
was O O
without O O
effect O O
on O O
stimulated O O
acid O O
output O O
, O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gastrin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concentration O O
, O O
and O O
gastric B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mucosal I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
histidine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
decarboxylase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
. O O

Here O O
we O O
describe O O
the O O
cloning O O
and O O
initial O O
characterization O O
of O O
IPP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
novel O O
human O O
gene O O
that O O
predicts O O
a O O
kelch B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
homologous O O
to O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Ipp I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
previously O O
described O O
kelch B B_PERSON/B_BIO
family I B_PERSON/I_BIO
member I B_PERSON/I_BIO
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
erythrosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Red O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
rose O O
bengal O B_LOCATION/B_COLOR
B O I_LOCATION/I_COLOR
( O O
Red O B_MEASURE/B_PROTEIN[GENE]
105 O I_MEASURE/I_PROTEIN[GENE]
) O O
and O O
thyroidectomy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
thyroid O B_DISEASE
tumor O I_DISEASE
were O O
examined O O
in O O
male O B_SPECIES[BIO]/B_GENE
Wistar O I_SPECIES[BIO]/I_GENE
rats O I_SPECIES[BIO]/I_GENE
treated O O
with O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_OTHER
- O O
bis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
2 O B_MEASURE
- O O
hydroxypropyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
nitrosamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DHPN O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
AmyI B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
specific O O
3 O O
' O O
- O O
UTR O O
is O O
characterized O O
by O O
the O O
absence O O
of O O
IR O O
sequences O O
and O O
the O O
presence O O
of O O
a O O
putative O O
' O O
AATAAA O O
' O O
polyadenylation O O
signal O O
. O O

Effect O O
of O O
bromocriptine O O
and O O
metoclopramide O O
on O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prolactin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
in O O
patients O O
with O O
amyotrophic O O
lateral O O
sclerosis O O
. O O

To O O
evaluate O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
selective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
thromboxane O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
A2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockade O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
platelet O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reactivity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
refractory O B_DISEASE
unstable O I_DISEASE
angina O I_DISEASE
, O O
OKY O B_PROTEIN[GENE]/B_LOCATION
- O O
046 O B_NUMBER[MEASURE]
( O O
600 O B_TIME[MEASURE]
mg O I_TIME[MEASURE]
/ O O
day O B_TIME[MEASURE]
, O O
p O B_TIME[MEASURE]/B_DISEASE
. O O
o O O
. O O
) O O
was O O
administered O O
to O O
another O O
14 O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
with O O
refractory O B_DISEASE
unstable O I_DISEASE
angina O I_DISEASE
in O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
conventional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

mCgA B B_MEASURE/B_GENE
- O O
92 O O
to O O
- O O
64 O O
bp O O
, O O
comprising O O
the O O
Sp1 B B_GENE/B_LOCATION
/ O O
Egr B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
site O O
and O O
the O O
CRE O O
motif O O
, O O
conferred O O
gastrin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
responsiveness O O
to O O
a O O
heterologous B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thymidine I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoter I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O O
, O O
and O O
therefore O O
functions O O
as O O
a O O
" O O
true O O
" O O
enhancer O O
element O O
. O O

Together O O
with O O
the O O
up O O
- O O
regulation O O
of O O
the O O
cAMP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
modulator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CREM B B_GENE/B_LOCATION
) O O
mRNA O O
and O O
protein O O
levels O O
demonstrated O O
previously O O
in O O
CREB B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutant I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mice O O
, O O
we O O
suggest O O
that O O
the O O
up O O
- O O
regulation O O
of O O
CREB B B_GENE
beta I I_GENE
may O O
also O O
contribute O O
to O O
compensation O O
within O O
the O O
CREB B B_GENE/B_LOCATION
/ O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family O O
of O O
transcription O O
factors O O
, O O
when O O
CREB B B_GENE
delta I I_GENE
and O O
CREB B B_GENE
alpha I I_GENE
are O O
absent O O
. O O

Individual O O
and O O
combined O O
effects O O
of O O
fumonisin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
B1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
present O O
in O O
Fusarium O O
moniliforme O O
culture O O
material O O
and O O
diacetoxyscirpenol O O
or O O
ochratoxin O O
A O O
in O O
turkey O O
poults O O
. O O

The O O
Grb2 B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
SH3 B B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
C I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
) I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
binding I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
region I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
Gab1 B B_GENE
has O O
significant O O
homology O O
to O O
a O O
region O O
of O O
the O O
adapter B B_BIO/B_GENE
protein I I_BIO/I_GENE
SLP I I_BIO/I_GENE
- I I_BIO/I_GENE
76 I I_BIO/I_GENE
. O O

A O O
phase O O
II O O
study O O
of O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
5 O O
- O O
fluorouracil O O
in O O
advanced O O
renal O O
carcinoma O O
: O O
clinical O O
data O O
and O O
laboratory O O
evidence O O
of O O
protease O O
activation O O
. O O

The O O
collicular O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
labels O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
found O O
after O O
injections O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
within O O
the O O
MST O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
area O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exhibited O O
their O O
distribution O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O O
the O O
deep O B_DISEASE/B_PROTEIN[GENE]
SC O B_DISEASE/I_PROTEIN[GENE]
subdivision O B_DISEASE/I_PROTEIN[GENE]
, O O
whereas O O
they O O
spared O O
all O O
the O O
superficial O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
layers O B_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
but O O
the O O
deep O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
part O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
SO O B_LOCATION/B_PROTEIN[GENE]
. O O

When O O
furA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
alone O O
was O O
introduced O O
into O O
the O O
Delta O O
( O O
furA B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
- O O
katG B B_GENE
) O O
mutant O O
, O O
survival O O
in O O
mouse O O
lungs O O
was O O
moderately O O
increased O O
, O O
suggesting O O
that O O
FurA B B_BACTERIUM[BIO]/B_GENE
could O O
regulate O O
genes O O
, O O
other O O
than O O
katG B B_GENE
, O O
that O O
are O O
involved O O
in O O
pathogenesis O O
. O O

The O O
authors O O
recommend O O
in O O
cases O O
with O O
an O O
elevated O O
transaminase O O
serum O O
activity O O
more O O
frequent O O
check O O
- O O
up O O
examinations O O
to O O
avoid O O
missing O O
of O O
a O O
relapse O O
, O O
and O O
to O O
examine O O
repeatedly O O
IgM B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
anti B I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
HAV I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
as O O
in O O
protracted O O
forms O O
of O O
hepatitis O O
IgM B B_DISEASE/B_PERSON
anti B I_DISEASE/I_PERSON
- I I_DISEASE/I_PERSON
HAV I I_DISEASE/I_PERSON
may O O
persist O O
even O O
when O O
the O O
transaminase O O
activity O O
is O O
normal O O
. O O

On O O
day O B_TIME[MEASURE]/B_LOCATION
1 O I_TIME[MEASURE]/I_LOCATION
at O O
3500 O B_MEASURE/B_ORGANISM_FUNCTION
m O B_MEASURE/I_ORGANISM_FUNCTION
, O O
RI O B_PROTEIN[GENE]/B_LOCATION
showed O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
fall O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
body O B_MEASURE/B_LOCATION
weight O I_MEASURE/I_LOCATION
( O O
BW O B_LOCATION/B_MEASURE
) O O
with O O
respect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
SL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
but O O
AI O B_LOCATION/B_PROTEIN[GENE]
maintained O O
it O O
. O O

Transcriptional O O
activation O O
of O O
the O O
proopiomelanocortin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
cyclic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
AMP I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
responsive I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
element I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
NF1 B B_PERSON/B_LOCATION
family I B_PERSON/I_LOCATION
members O O
and O O
HNF4 B B_GENE/B_PERSON
interacted O O
with O O
overlapping O O
sequences O O
of O O
the O O
L O O
- O O
II O O
element O O
, O O
wherein O O
the O O
5 O O
' O O
half O O
- O O
site O O
was O O
more O O
critical O O
for O O
NF1 B B_GENE/B_DISEASE
binding O O
, O O
and O O
the O O
3 O O
' O O
site O O
was O O
more O O
important O O
for O O
HNF4 B B_GENE/B_LOCATION
binding O O
. O O

RAP B B_GENE/B_DISEASE
has O O
been O O
shown O O
to O O
be O O
a O O
useful O O
vaccine O O
target O O
site O O
, O O
and O O
RIP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
inhibitory O O
AIPs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
therapeutic O O
molecules O O
to O O
prevent O O
and O O
suppress O O
S O O
. O O
aureus O O
infections O O
. O O

After O O
institution O O
of O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
, O O
diabetic O O
control O O
was O O
improved O O
as O O
demonstrated O O
by O O
decreasing O O
levels O O
of O O
HbA1 B B_DISEASE/B_GENE
. O O

Measurement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
spectral O B_PROTEIN[GENE]/B_LOCATION
sensitivity O I_PROTEIN[GENE]/I_LOCATION
and O O
the O O
ERG O B_MEASURE
can O O
thus O O
help O O
in O O
the O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
three O B_DISEASE_ADJECTIVE[DISEASE]
hereditary O I_DISEASE_ADJECTIVE[DISEASE]
diseases O I_DISEASE_ADJECTIVE[DISEASE]
. O O

As O O
a O O
quantitative O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
index O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cochlear O B_MEASURE/B_DISEASE
function O I_MEASURE/I_DISEASE
, O O
2f1 O B_PROTEIN[GENE]/B_MEASURE
- O O
f2 O B_MEASURE
distortion O I_MEASURE
- O O
product O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
otoacoustic O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
emissions O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
DPOAEs O B_DISEASE/B_LOCATION
) O O
were O O
monitored O O
systematically O O
over O O
time O B_TIME[MEASURE]/B_LOCATION
in O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
rabbits O B_BIO/B_PERSON
, O O
with O O
each O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiencing O O
a O O
unique O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
paradigm O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
incorporated O O
repeated O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O O
the O O
low O B_MEASURE/B_COLOR
- O O
frequency O B_MEASURE/B_LOCATION
tone O I_MEASURE/I_LOCATION
. O O

Analysis O O
of O O
1 O O
Mb O O
of O O
published O O
sequence O O
from O O
the O O
region O O
of O O
conserved O O
synteny O O
on O O
human O O
chromosome O O
5q31 O O
- O O
q33 O O
identified O O
45 O O
gene O O
candidates O O
, O O
including O O
35 O O
expressed O O
genes O O
in O O
the O O
human B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
IL I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
4 I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
cytokine I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
gene I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
cluster O O
. O O

There O O
is O O
no O O
indication O O
from O O
these O O
experiments O O
that O O
linker B B_PERSON/B_GENE
histones I I_PERSON/I_GENE
bind O O
fundamentally O O
differently O O
to O O
5 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
S I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
bulk O O
nucleosomes O O
. O O

Km O O
values O O
of O O
the O O
uncoupled O O
enzymes O O
IIGlc B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
glucose O O
ranged O O
from O O
0 O O
. O O
5 O O
to O O
2 O O
. O O
5 O O
mM O O
, O O
2 O O
orders O O
of O O
magnitude O O
higher O O
than O O
the O O
value O O
of O O
normal O O
IIGlc B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Cytochrome B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bd I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
biosynthesis O O
in O O
Escherichia O O
coli O O
: O O
the O O
sequences O O
of O O
the O O
cydC B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cydD B B_LOCATION/B_GENE
genes I I_LOCATION/I_GENE
suggest O O
that O O
they O O
encode O O
the O O
components O O
of O O
an O O
ABC B B_ENZYME[GENE]/B_BIO
membrane I I_ENZYME[GENE]/I_BIO
transporter I I_ENZYME[GENE]/I_BIO
. O O

Historically O O
, O O
Cyps B B_BIO/B_PERSON
were O O
first O O
identified O O
by O O
their O O
ability O O
to O O
bind O O
the O O
immunosuppressive O O
agent O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
with O O
high O O
affinity O O
; O O
they O O
later O O
were O O
found O O
to O O
have O O
peptidyl B B_ENZYME[GENE]
- I I_ENZYME[GENE]
prolyl I I_ENZYME[GENE]
cis I I_ENZYME[GENE]
- I I_ENZYME[GENE]
trans I I_ENZYME[GENE]
isomerase I I_ENZYME[GENE]
( O O
PPIase B B_GENE/B_LOCATION
) O O
activity O O
, O O
which O O
catalyzes O O
the O O
folding O O
of O O
oligopeptides O O
at O O
proline O O
- O O
peptide O O
bonds O O
in O O
vitro O O
and O O
may O O
be O O
important O O
for O O
protein O O
folding O O
in O O
vivo O O
. O O

Thus O O
, O O
oxyR B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutants I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
locked O O
on O O
for O O
Ag43 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
, O O
whereas O O
dam B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutants I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
locked O O
off O O
for O O
Ag43 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
. O O

A O O
rare O O
tRNA B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
Arg I I_GENE/I_MEASURE
( I I_GENE/I_MEASURE
CCU I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
that O O
regulates O O
Ty1 B B_DISEASE_ADJECTIVE[DISEASE]
element I I_DISEASE_ADJECTIVE[DISEASE]
ribosomal O O
frameshifting O O
is O O
essential O O
for O O
Ty1 B B_GENE
retrotransposition O O
in O O
Saccharomyces O O
cerevisiae O O
. O O

Several O O
35 O O
- O O
mm O O
slides O O
of O O
dystrophin B B_GENE
- O O
, O O
laminin B B_GENE
- O O
, O O
and O O
concanavalin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ConA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
- O O
stained O O
muscle O O
sections O O
were O O
used O O
to O O
calculate O O
myofiber O O
cross O O
- O O
sectional O O
areas O O
and O O
to O O
compare O O
different O O
techniques O O
and O O
settings O O
of O O
an O O
image O O
capture O O
system O O
. O O

In O O
addition O O
, O O
both O O
inhibitors O O
blocked O O
phosphatidylcholine O O
hydrolysis O O
and O O
protein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
C I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
translocation O O
. O O

p93 B B_GENE/B_PERSON
appears O O
to O O
be O O
antigenically O O
related O O
to O O
stat91 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_VIRUS[BIO]
. O O

When O O
single O O
- O O
point O O
mutation O O
was O O
introduced O O
to O O
each O O
GC O O
box O O
, O O
EBS B B_DISEASE/B_GENE
, O O
and O O
GT O O
box O O
in O O
PFP9a20 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
at O O
least O O
3 O O
- O O
fold O O
less O O
CAT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity O O
was O O
observed O O
in O O
CTLL O O
- O O
R8 O O
cells O O
. O O

Thus O O
, O O
STK1 B B_NUMBER[MEASURE]/B_PERSON
is O O
most O O
likely O O
the O O
human B B_PERSON/B_GENE
homologue I I_PERSON/I_GENE
of I I_PERSON/I_GENE
MO15 I I_PERSON/I_GENE
. O O

BACKGROUND O O
: O O
Recent O O
iterative O O
methods O O
for O O
sequence O O
alignment O O
have O O
indicated O O
that O O
the O O
380 O O
kDa O O
motor O O
unit O O
of O O
dynein B B_BACTERIUM[BIO]/B_GENE
belongs O O
to O O
the O O
AAA B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
class I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
chaperone B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
like I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
ATPases I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Intramolecular O O
interaction O O
is O O
believed O O
to O O
result O O
in O O
the O O
formation O O
of O O
MxA B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
monomers I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
, O O
whereas O O
intermolecular O O
interaction O O
may O O
induce O O
the O O
formation O O
of O O
large B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
MxA I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
oligomers I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
psbA B B_GENE
gene I I_GENE
encodes O O
the O O
D1 B B_PROTEIN[GENE]/B_PERSON
protein I I_PROTEIN[GENE]/I_PERSON
of O O
photosystem B B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_BIO/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
synthesized O O
at O O
very O O
high O O
rates O O
in O O
the O O
light O O
in O O
order O O
to O O
replace O O
photodamaged O O
protein O O
. O O

These O O
Tlr B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
family I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
members I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
unlike O O
others O O
reported O O
to O O
date O O
, O O
were O O
identified O O
within O O
a O O
genomic O O
database O O
. O O

We O O
have O O
used O O
the O O
chloramphenicol B B_GENE
acetyltransferase I I_GENE
( O O
CAT B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
reporter O O
gene O O
system O O
to O O
study O O
the O O
effect O O
of O O
T B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
the O O
long O O
terminal O O
repeats O O
( O O
LTRs O O
) O O
of O O
a O O
large O O
family O O
of O O
human O O
endogenous O O
retrovirus O O
- O O
like O O
sequences O O
, O O
RTVL O O
- O O
H O O
. O O

Based O O
on O O
the O O
requirement O O
for O O
CREM B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
ICER B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
Rad6B B B_GENE
proteins I I_GENE
in O O
spermatogenesis O O
, O O
we O O
determined O O
expression O O
of O O
Cdc34 B B_GENE
, O O
Rad6B B B_GENE/B_BACTERIUM[BIO]
, O O
CREM B B_LOCATION/B_DISEASE
/ O O
ICER B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms O O
, O O
and O O
the O O
Skp1 B B_GENE
- O O
Cullin B B_PROTEIN[GENE]/B_DISEASE
- O O
F O O
- O O
box O O
ubiquitin B B_GENE/B_BIO
protein O O
ligase O O
subunits O O
Cul B B_GENE
- I I_GENE
1 I I_GENE
and O O
Cul B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
2 I I_PROTEIN[GENE]/I_MEASURE
, O O
which O O
are O O
associated O O
with O O
Cdc34 B B_GENE
activity O O
during O O
murine O O
testicular O O
development O O
. O O

Transcription B B_GENE
factor I I_GENE
IIIC I I_GENE
( O O
TFIIIC B B_PROTEIN[GENE]/B_DISEASE
) O O
is O O
required O O
for O O
the O O
assembly O O
of O O
a O O
preinitiation O O
complex O O
on O O
5S B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
tRNA O O
, O O
and O O
adenovirus B B_VIRUS[BIO]/B_PERSON
VA I I_VIRUS[BIO]/I_PERSON
RNA O O
genes O O
and O O
contains O O
two O O
separable O O
components O O
, O O
TFIIIC1 B B_PROTEIN[GENE]/B_DISEASE
and O O
TFIIIC2 B B_PROTEIN[GENE]
. O O

MGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
novel O O
member O O
of O O
the O O
cytokine B B_ORGANIZATION/B_LOCATION
- I I_ORGANIZATION/I_LOCATION
regulated I I_ORGANIZATION/I_LOCATION
transcription I I_ORGANIZATION/I_LOCATION
factor I I_ORGANIZATION/I_LOCATION
gene I I_ORGANIZATION/I_LOCATION
family I I_ORGANIZATION/I_LOCATION
. O O

This O O
result O O
, O O
together O O
with O O
the O O
fact O O
that O O
unrearranged B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
V I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
kappa I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
genes I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
transcriptionally O O
silent O O
, O O
suggests O O
that O O
structural O O
features O O
of O O
both O O
the O O
V B B_PROTEIN[GENE]
kappa I I_PROTEIN[GENE]
and O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loci I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contribute O O
to O O
the O O
overall O O
transcriptional O O
efficiency O O
of O O
a O O
rearranged O O
V B B_MEASURE/B_DISEASE
kappa I B_MEASURE/I_DISEASE
- O O
C B B_GENE
kappa I I_GENE
gene O O
. O O

An O O
X O O
- O O
linked O O
zinc B B_GENE/B_DISEASE
finger I B_GENE/I_DISEASE
gene I B_GENE/I_DISEASE
mapping O O
to O O
Xq21 O O
. O O
1 O O
- O O
q21 O O
. O O
3 O O
closely O O
related O O
to O O
ZFX B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ZFY B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O O
possible O O
origins O O
from O O
a O O
common O O
ancestral O O
gene O O
. O O

The O O
pineal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
melatonin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
MLT O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
able O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
exert O O
an O O
oncostatic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
action O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
both O O
ADN O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
eliminated O O
the O O
remaining O O
sigmoidal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
correlation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
between O O
MAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
RSNA O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
further O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
resting O O
MAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
RSNA O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
relationship O O
between O O
donor O O
status O O
for O O
antibody O O
to O O
hepatitis B B_DISEASE
B I I_DISEASE
core I I_DISEASE
antigen I I_DISEASE
and O O
the O O
occurrence O O
of O O
non O O
- O O
A O O
, O O
non O O
- O O
B O O
posttransfusion O O
hepatitis O O
in O O
the O O
recipient O O
was O O
prospectively O O
studied O O
in O O
112 O O
patients O O
undergoing O O
open O O
- O O
heart O O
surgery O O
who O O
were O O
followed O O
for O O
6 O O
. O O
5 O O
months O O
after O O
surgery O O
. O O

By O O
sequencing O O
of O O
exonuclease B B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
III I I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
deletion O O
clones O O
an O O
open O O
reading O O
frame O O
of O O
405 O O
nucleotides O O
was O O
found O O
coding O O
for O O
a O O
protein O O
of O O
135 O O
amino O O
acids O O
with O O
a O O
molecular O O
mass O O
of O O
15 O O
kDa O O
. O O

Treatment O O
of O O
steroid O O
resistant O O
rejection O O
following O O
renal O O
transplantation O O
: O O
benefits O O
and O O
risks O O
of O O
OKT3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
therapy O O
. O O

SH3A B B_GENE
competes O O
with O O
the O O
SH3 B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Grb2 B B_GENE
in O O
binding O O
to O O
mSos1 B B_GENE
, O O
and O O
the O O
intersectin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mSos1 B B_GENE
complex O O
can O O
be O O
separated O O
from O O
Grb2 B B_GENE
by O O
sucrose O O
gradient O O
centrifugation O O
. O O

This O O
resulted O O
in O O
a O O
shift O O
of O O
C1 O O
/ O O
C2 O O
, O O
so O O
that O O
the O O
effect O O
of O O
collagen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
more O O
pronounced O O
( O O
maximal O O
increase O O
of O O
C1 O O
/ O O
C2 O O
= O O
134 O O
% O O
) O O
than O O
ADP O O
( O O
maximal O O
increase O O
of O O
C1 O O
/ O O
C2 O O
= O O
79 O O
% O O
) O O
. O O

Several O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
waveforms O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
both O O
the O O
somatosensory O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
N20 O B_LOCATION/B_PROTEIN[GENE]
, O O
P O B_OTHER/B_PROTEIN[GENE]
/ O O
N O B_MEASURE/B_PROTEIN[GENE]
30 O I_MEASURE/I_PROTEIN[GENE]
, O O
and O O
P200 O B_PROTEIN[GENE]/B_MEASURE
) O O
and O O
the O O
brainstem O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
auditory O I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
evoked O O
response O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
I O B_OTHER/B_PROTEIN[GENE]
, O O
III O B_TIME[MEASURE]/B_PROTEIN[GENE]
, O O
IV O B_TIME[MEASURE]/B_PROTEIN[GENE]
, O O
and O O
V O B_OTHER/B_PROTEIN[GENE]
) O O
demonstrated O O
shorter O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
p O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
latencies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
growth O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
retarded O O
fetuses O B_PERSON
relative O I_PERSON
to O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
sized O B_BIO/B_TIME[MEASURE]
fetuses O B_BIO/I_TIME[MEASURE]
. O O

GH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
signals O O
by O O
interacting O O
with O O
GH B B_GENE
receptor I I_GENE
( O O
GHR B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Ultraviolet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
crosslinking O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
element O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O O
the O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
binding O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
two O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
approximately O O
43 O B_MEASURE
and O O
80 O B_MEASURE
kDa O I_MEASURE
. O O

Brome B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mosaic I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polymerase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
like O O
protein B B_GENE
2a I I_GENE
is O O
directed O O
to O O
the O O
endoplasmic O O
reticulum O O
by O O
helicase B B_GENE
- O O
like O O
viral B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
protein I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
1a I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O O

A O O
DNA O B_GENE/B_LOCATION
binding O I_GENE/I_LOCATION
protein O I_GENE/I_LOCATION
was O O
identified O O
which O O
binds O O
to O O
two O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
novel O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
like O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
( O O
i O O
) O O
at O O
the O O
5 O B_NUMBER[MEASURE]
' O O
flanking O O
site O B_LOCATION/B_MEASURE
of O O
the O O
breakpoint O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
junction O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
chromosome O B_GENE/B_DISEASE
8 O I_GENE/I_DISEASE
in O O
a O O
patient O B_PERSON/B_LOCATION
with O O
T O B_PROTEIN[GENE]/B_DISEASE
- O O
acute O B_DISEASE
lymphoblastic O I_DISEASE
leukemia O I_DISEASE
( O O
ALL O B_DISEASE/B_NUMBER[MEASURE]
) O O
carrying O O
the O O
t O B_DISEASE/B_GENE
( O O
8 O B_NUMBER[MEASURE]
; O O
14 O B_MEASURE
) O O
( O O
q24 O O
; O O
q11 O O
) O O
rearrangement O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
and O O
( O O
ii O B_TIME[MEASURE]/B_PROTEIN[GENE]
) O O
on O O
chromosome O B_GENE/B_MEASURE
1 O I_GENE/I_MEASURE
in O O
three O B_NUMBER[MEASURE]/B_PERSON
of O O
five O B_DISEASE/B_PROTEIN[GENE]
T O B_DISEASE/I_PROTEIN[GENE]
- O O
ALL O B_LOCATION/B_DISEASE
patients O I_LOCATION/I_DISEASE
with O O
the O O
t O B_DISEASE/B_GENE
( O O
1 O B_NUMBER[MEASURE]
; O O
14 O B_MEASURE
) O O
( O O
p32 O B_MEASURE/B_GENE
; O O
q11 O B_MEASURE
) O O
rearrangement O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O O

The O O
mutant O O
strain O O
carries O O
three O O
tandem O O
copies O O
of O O
the O O
18 O O
bp O O
sequence O O
that O O
is O O
duplicated O O
in O O
the O O
amdI66 B B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutation O O
. O O

Of O O
3841 O O
serum O O
samples O O
from O O
sows O O
received O O
from O O
the O O
Tennessee O O
State O O
Diagnostic O O
Laboratory O O
in O O
1991 O O
- O O
1992 O O
, O O
1130 O O
were O O
positive O O
for O O
Toxoplasma B B_DISEASE
gondii I I_DISEASE
antibody I I_DISEASE
. O O

In O O
this O O
group O O
of O O
patients O O
, O O
the O O
mean O O
LH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
9 O O
. O O
3 O O
+ O O
/ O O
- O O
5 O O
. O O
9 O O
IU O O
/ O O
l O O
) O O
and O O
sex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
hormone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
globulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SHBG B B_GENE/B_LOCATION
) O O
( O O
54 O O
. O O
5 O O
+ O O
/ O O
- O O
22 O O
. O O
9 O O
nmol O O
/ O O
l O O
) O O
concentrations O O
were O O
significantly O O
greater O O
than O O
those O O
of O O
five O O
normal O O
control O O
subjects O O
( O O
4 O O
. O O
7 O O
+ O O
/ O O
- O O
1 O O
. O O
11 O O
IU O O
/ O O
l O O
and O O
26 O O
. O O
0 O O
+ O O
/ O O
- O O
7 O O
. O O
0 O O
nmol O O
/ O O
l O O
respectively O O
) O O
. O O

To O O
facilitate O O
the O O
characterization O O
of O O
NF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
functions O O
in O O
human O O
cells O O
, O O
we O O
isolated O O
cDNAs O O
encoding O O
two O O
members O O
of O O
the O O
small B B_PERSON/B_BIO
Maf I B_PERSON/I_BIO
family I B_PERSON/I_BIO
, O O
MafK B B_LOCATION/B_GENE
and O O
MafG B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
. O O

Radioactively O O
labeled O O
microspheres O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
used O O
to O O
determine O O
and O O
compare O O
the O O
hemodynamic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitroprusside O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SNP O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
nitroglycerin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NTG O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
and O O
deep O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
enflurane O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
anesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
oral O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
tissues O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
during O O
controlled O O
hypotension O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
when O O
compared O O
with O O
controls O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CYP51P1 B B_GENE
is O O
96 O O
. O O
5 O O
% O O
identical O O
to O O
the O O
human B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
CYP51 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
coding O O
sequence O O
and O O
is O O
not O O
interrupted O O
with O O
introns O O
but O O
has O O
six O O
in O O
- O O
frame O O
stop O O
codons O O
resulting O O
from O O
point O O
mutations O O
. O O

Three O O
RasV12 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutants I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
S35 B B_PROTEIN[GENE]
, O O
G37 B B_PROTEIN[GENE]
, O O
and O O
C40 B B_PROTEIN[GENE]/B_MEASURE
) O O
which O O
differ O O
by O O
their O O
ability O O
to O O
bind O O
to O O
Ras B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
effectors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Raf B B_GENE/B_DISEASE
, O O
Ral B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GEFs I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
p110 B B_GENE/B_PERSON
subunit I I_GENE/I_PERSON
of I I_GENE/I_PERSON
PI I I_GENE/I_PERSON
3 I I_GENE/I_PERSON
- I I_GENE/I_PERSON
kinase I I_GENE/I_PERSON
, O O
respectively O O
) O O
were O O
able O O
to O O
induce O O
sustained O O
NR O O
cell O O
proliferation O O
, O O
although O O
none O O
of O O
these O O
mutants O O
was O O
reported O O
to O O
transform O O
NIH O O
3T3 O O
cells O O
. O O

Using O O
the O O
interaction O O
- O O
trap O O
assay O O
to O O
identify O O
candidate O O
proteins O O
that O O
bind O O
the O O
cytoplasmic O O
region O O
of O O
the O O
LAR B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
transmembrane I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PT B B_LOCATION/B_GENE
- I I_LOCATION/I_GENE
Pase I I_LOCATION/I_GENE
) O O
, O O
we O O
isolated O O
a O O
cDNA O O
encoding O O
a O O
2861 O O
- O O
amino O O
acid O O
protein O O
termed O O
Trio B B_GENE/B_ENT
that O O
contains O O
three O O
enzyme O O
domains O O
: O O
two O O
functional O O
GEF B B_LOCATION/B_PERSON
domains I I_LOCATION/I_PERSON
and O O
a O O
protein B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
serine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
threonine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PSK B B_GENE/B_LOCATION
) O O
domain O O
. O O

We O O
have O O
isolated O O
two O O
H19 B B_GENE
cDNAs I I_GENE
( O O
AP B B_LOCATION
and O O
ES B B_LOCATION/B_PROTEIN[GENE]
) O O
that O O
contain O O
this O O
ORF4 O O
and O O
correspond O O
to O O
incomplete O O
copies O O
of O O
the O O
unique O O
2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
H19 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
combined O O
in O O
vitro O O
effects O O
of O O
ethanol O O
wih O O
methaqualone O O
, O O
phenobarbital O O
, O O
pyrazole O O
or O O
disulfiram O O
were O O
studied O O
using O O
rat B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
brain I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microsomal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
K I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ATPase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Here O O
we O O
report O O
that O O
components O O
of O O
the O O
Ras B B_GENE/B_DISEASE
/ O O
Raf B B_GENE/B_DISEASE
/ O O
MAPK B B_GENE/B_LOCATION
pathway O O
are O O
constitutively O O
activated O O
in O O
these O O
lck B B_VIRUS[BIO]/B_DISEASE
- O O
transformed O O
immature O O
thymoblasts O O
. O O

Analysis O O
of O O
the O O
DNA O O
sequence O O
upstream O O
of O O
the O O
narQ B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
encodes O O
the O O
second O O
nitrate O O
- O O
responsive O O
sensor O O
- O O
transmitter O O
protein O O
in O O
Escherichia O O
coli O O
, O O
revealed O O
an O O
open O O
reading O O
frame O O
( O O
ORF O O
) O O
whose O O
product O O
shows O O
a O O
high O O
degree O O
of O O
similarity O O
to O O
a O O
number O O
of O O
iron B B_GENE/B_BIO
- I I_GENE/I_BIO
sulfur I I_GENE/I_BIO
proteins I I_GENE/I_BIO
as O O
well O O
as O O
to O O
the O O
beta O O
subunit O O
of O O
glutamate B B_ENZYME[GENE]
synthase I I_ENZYME[GENE]
( O O
gltD B B_DISEASE/B_LOCATION
) O O
of O O
E O O
. O O
coli O O
. O O

We O O
suggest O O
that O O
the O O
responses O O
to O O
types B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
II I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
collagen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
caused O O
by O O
a O O
cross O O
- O O
reaction O O
with O O
type B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
III I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
collagen I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
peptides O O
. O O

The O O
influence O O
of O O
different O O
temperatures O O
between O O
13 O O
degrees O O
C O O
and O O
45 O O
degrees O O
C O O
on O O
coagulation O O
factors O O
in O O
vitro O O
was O O
studied O O
by O O
measuring O O
clotting O O
time O O
with O O
the O O
recalcification O O
time O O
, O O
partial O O
thromboplastin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
time O O
( O O
PTT O O
) O O
, O O
and O O
thromboplastin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
time O O
test O O
. O O

Thus O O
, O O
transgene O O
expression O O
directed O O
by O O
both O O
the O O
human O O
and O O
mouse B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Rb I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
promoters I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
restricted O O
to O O
a O O
subset O O
of O O
tissues O O
in O O
which O O
Rb B B_GENE/B_DISEASE
is O O
normally O O
expressed O O
during O O
embryogenesis O O
. O O

The O O
sequence O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immediately O O
upstream O O
of O O
the O O
translation O B_GENE
start O I_GENE
site O I_GENE
was O O
G O B_PROTEIN[GENE]/B_LOCATION
+ O O
C O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
rich O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
greater O B_MEASURE
than O O
75 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
and O O
contained O O
a O O
consensus O B_GENE
CCAAT O I_GENE
sequence O I_GENE
despite O O
the O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
TATA O B_GENE
box O I_GENE
. O O

For O O
O3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
the O O
correlation O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
personal O B_LOCATION/B_ORGANIZATION
exposures O I_LOCATION/I_ORGANIZATION
and O O
ambient O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
weakest O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
in O O
the O O
winter O B_TIME[MEASURE]/B_LOCATION
for O O
residential O B_PERSON/B_LOCATION
microenvironments O I_PERSON/I_LOCATION
( O O
rs O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
0 O B_MEASURE
. O O
05 O B_MEASURE
, O O
p O B_MEASURE
> O B_MEASURE/B_LOCATION
0 O I_MEASURE
. O O
05 O B_MEASURE
) O O
, O O
and O O
was O O
strongest O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
summer O B_TIME[MEASURE]
for O O
outdoor O B_LOCATION/B_ORGANIZATION
near O O
- O O
roadway O B_LOCATION/B_ORGANIZATION
microenvironments O I_LOCATION/I_ORGANIZATION
( O O
rs O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
0 O B_MEASURE
. O O
91 O B_MEASURE
, O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_NUMBER[MEASURE]
. O O
05 O B_MEASURE
) O O
. O O

We O O
have O O
shown O O
that O O
the O O
human O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
MRC O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
closely O O
resembles O O
the O O
murine O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
MRC O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
in O O
both O O
its O O
protein O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
composition O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
its O O
fractionation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
chromatographic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Under O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
conditions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
lithium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
7 O B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O I_ENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
did O O
not O O
modify O O
the O O
hyperlocomotion O B_DISEASE_ADJECTIVE[DISEASE]
produced O O
by O O
d O B_PROTEIN[GENE]/B_DISEASE
- O O
amphetamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Ultra O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
energy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
UHE O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
imaging O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
usually O O
performed O O
in O O
simultaneous O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
18 O B_MEASURE
FDG O I_MEASURE
/ O O
Tc O B_PROTEIN[GENE]/B_LOCATION
- O O
99m O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
MIBI O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
studies O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Unlike O O
these O O
contaminant O O
- O O
responsive O O
T O O
cells O O
, O O
those O O
that O O
are O O
truly O O
specific O O
for O O
natural O O
AChR B B_DISEASE
epitopes I I_DISEASE
appear O O
less O O
heterogeneous O O
and O O
therefore O O
more O O
suitable O O
targets O O
for O O
selective O O
immunotherapy O O
. O O

In O O
one O O
trial O O
, O O
116 O O
subjects O O
with O O
transfusion O O
- O O
related O O
chronic O O
hepatitis O O
C O O
were O O
treated O O
with O O
lymphoblastoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interferon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
5 O O
MU O O
/ O O
m2 O O
three O O
times O O
a O O
week O O
for O O
2 O O
mo O O
, O O
then O O
3 O O
MU O O
/ O O
m2 O O
three O O
times O O
a O O
week O O
for O O
4 O O
or O O
10 O O
mo O O
) O O
. O O

A O O
derived O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
RA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
resistant O B_LOCATION/B_GENE
line O I_LOCATION/I_GENE
, O O
NT2 O B_PROTEIN[GENE]/B_LOCATION
/ O O
D1 O B_LOCATION/B_PROTEIN[GENE]
- O O
R1 O B_MEASURE/B_PERSON
, O O
is O O
deficient O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
this O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
is O O
co O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
resistant O B_DISEASE_ADJECTIVE[DISEASE]
to O O
cisplatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
region O B_GENE/B_LOCATION
showed O O
it O O
contained O O
five O B_MEASURE/B_LOCATION
potential O B_MEASURE/I_LOCATION
copies O B_MEASURE/I_LOCATION
of O O
the O O
sterol O B_GENE
regulatory O I_GENE
element O I_GENE
( O O
SRE O B_PROTEIN[GENE]/B_DISEASE
- O O
1 O B_NUMBER[MEASURE]
) O O
( O O
Smith O B_PERSON
, O O
J O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
R O B_OTHER/B_LOCATION
. O O
, O O
Osborne O B_PERSON/B_ORGANIZATION
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
F O B_OTHER/B_LOCATION
. O O
, O O
Brown O B_PERSON
, O O
M O B_LOCATION
. O O
S O B_OTHER/B_LOCATION
. O O
, O O
Goldstein O B_PERSON
, O O
J O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
L O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
and O O
Gil O B_PERSON
, O O
G O B_OTHER/B_PERSON
. O O

Therefore O O
, O O
we O O
have O O
reevaluated O O
the O O
age O O
- O O
related O O
changes O O
in O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
leptin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
and O O
their O O
relationship O O
with O O
adiposity O O
and O O
androgen O O
levels O O
in O O
a O O
large O O
group O O
of O O
community O O
dwelling O O
men O O
. O O

Plasma B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
renin I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
activity O O
in O O
end O O
- O O
stage O O
kidney O O
disease O O
. O O

Smectic O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
A O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ordering O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
at O O
a O O
liquid O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
vapor O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interface O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

During O O
the O O
last O B_TIME[MEASURE]/B_ENT
three O I_TIME[MEASURE]/I_ENT
days O I_TIME[MEASURE]/I_ENT
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
mean O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urine O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
osmolality O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Uosm O B_LOCATION/B_PROTEIN[GENE]
) O O
and O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reabsorption O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TCH2O O B_PROTEIN[GENE]/B_LOCATION
) O O
increased O O
significantly O O
: O O
[ O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
formula O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
see O O
text O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Although O O
indomethacin O O
is O O
useful O O
for O O
examining O O
the O O
role O O
of O O
cyclooxygenase B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
asthmatic O O
responses O O
, O O
it O O
should O O
not O O
be O O
considered O O
in O O
the O O
treatment O O
of O O
asthma O O
. O O

The O O
salt O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sensitivity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
interaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
that O O
two O B_NUMBER[MEASURE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ion O I_NUMBER[MEASURE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pairs O I_NUMBER[MEASURE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
involved O O
in O O
the O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Zn2 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
NC O B_DISEASE/B_PROTEIN[GENE]
- O O
F1 O B_PROTEIN[GENE]/B_MEASURE
) O O
with O O
polynucleotide O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
one O B_NUMBER[MEASURE]/B_PERSON
ion O I_NUMBER[MEASURE]/I_PERSON
pair O I_NUMBER[MEASURE]/I_PERSON
is O O
found O O
in O O
the O O
metal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
nucleic O B_PROTEIN[GENE]
acid O I_PROTEIN[GENE]
complex O I_PROTEIN[GENE]
. O O

Investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O O
the O O
asymmetrical O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induced O O
yields O B_DISEASE
in O O
90Sr O B_LOCATION/B_PROTEIN[GENE]
- O O
90Y O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
beta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
irradiated O O
D O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
and O O
L O B_PROTEIN[GENE]/B_LOCATION
- O O
alanines O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Serum O O
levels O O
of O O
total O O
and O O
specific B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoglobulin I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IgE B B_PROTEIN[GENE]/B_LOCATION
) O O
have O O
been O O
determined O O
by O O
radioimmunoassays O O
in O O
sixty O O
- O O
nine O O
allergic O O
subjects O O
. O O

IgE B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
Psocoptera O O
were O O
determined O O
by O O
immunoblotting O O
experiments O O
. O O

We O O
also O O
show O O
that O O
the O O
products O O
of O O
both O O
the O O
GIY B B_TIME[MEASURE]/B_GENE
- I I_TIME[MEASURE]/I_GENE
YIG I I_TIME[MEASURE]/I_GENE
ORF O O
and O O
the O O
non O O
- O O
canonical O O
LAGLI B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_VIRUS[BIO]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
DADG I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
GIY I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
YIG I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
ORF O O
, O O
which O O
is O O
generated O O
by O O
its O O
integration O O
, O O
have O O
endonuclease O O
activities O O
which O O
recognize O O
and O O
cut O O
the O O
insertion O O
site O O
of O O
the O O
optional O O
sequence O O
. O O

Identification O O
of O O
a O O
putative O O
infC B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
rpmI B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
rplT B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
operon O O
flanked O O
by O O
long O O
inverted O O
repeats O O
in O O
Mycoplasma O O
fermentans O O
( O O
incognitus O O
strain O O
) O O
. O O

Neurological O B_DISEASE
toxicity O I_DISEASE
occurred O O
in O O
8 O B_MEASURE
/ O O
219 O B_MEASURE
patients O I_MEASURE
treated O O
with O O
fludarabine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
FAMP O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
30 O B_MEASURE
mg O I_MEASURE
/ O O
m2 O B_MEASURE
per O O
day O B_TIME[MEASURE]
and O O
cytosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arabinoside O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Ara O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- O O
C O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
0 O B_MEASURE
. O O
5 O B_MEASURE
g O I_MEASURE
/ O O
m2 O O
per O O
hour O B_TIME[MEASURE]/B_ENT
for O O
2 O B_NUMBER[MEASURE]
- O O
6 O B_TIME[MEASURE]/B_SPORT[ENT]
hours O I_TIME[MEASURE]/I_SPORT[ENT]
for O O
5 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
for O O
new O B_DISEASE_ADJECTIVE[DISEASE]
or O O
relapsed O B_DISEASE_ADJECTIVE[DISEASE]
acute O I_DISEASE_ADJECTIVE[DISEASE]
leukemia O I_DISEASE_ADJECTIVE[DISEASE]
or O O
myelodysplasia O B_DISEASE
. O O

Evaluation O O
of O O
gamma B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
glutamyl I I_DISEASE_ADJECTIVE[DISEASE]
transpeptidase I I_DISEASE_ADJECTIVE[DISEASE]
in O O
myocardial O O
infarction O O
. O O

The O O
influence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
high O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
n O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PUFA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
intake O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
measures O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
lipid O B_DISEASE/B_GENE
peroxidation O I_DISEASE/I_GENE
has O O
been O O
equivocal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

An O O
anoerxiant O O
, O O
mazindol O O
suppresses O O
food O O
intake O O
by O O
1 O O
) O O
stimulating O O
beta B B_DISEASE/B_ORGANISM_FUNCTION
- I I_DISEASE/I_ORGANISM_FUNCTION
adrenergic I I_DISEASE/I_ORGANISM_FUNCTION
receptors I I_DISEASE/I_ORGANISM_FUNCTION
, O O
2 O O
) O O
inhibiting O O
the O O
feeding O O
center O O
and O O
, O O
3 O O
) O O
stimulating O O
the O O
satiety O O
center O O
in O O
the O O
hypothalamus O O
. O O

Hydropathy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
deduced O B_GENE
A4 O I_GENE
amino O I_GENE
acid O I_GENE
sequence O I_GENE
revealed O O
four O B_MEASURE/B_LOCATION
putative O B_MEASURE/I_LOCATION
membrane O B_MEASURE/I_LOCATION
- O O
spanning O O
alpha O B_PROTEIN[GENE]/B_NUMBER[MEASURE]
- O O
helices O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
surface O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
methodology O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
employed O O
to O O
describe O O
the O O
relationship O B_PERSON/B_MEASURE
between O O
soman O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
induced O O
incapacitation O B_DISEASE
and O O
the O O
ATR O B_LOCATION/B_PROTEIN[GENE]
/ O O
DZ O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
ATR O B_LOCATION/B_PROTEIN[GENE]
/ O O
SCP O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dosages O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
brains O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
bisected O O
and O O
T1 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
T2 O B_PROTEIN[GENE]/B_LOCATION
relaxation O I_PROTEIN[GENE]/I_LOCATION
times O I_PROTEIN[GENE]/I_LOCATION
were O O
determined O O
for O O
the O O
right O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O O
left O O
hemispheres O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
MR O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
spectroscopy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
immediately O O
after O O
dissection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Enzymatic O B_GENE
and O O
chemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
structure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
probing O O
revealed O O
mainly O O
the O O
conserved O B_LOCATION/B_MEASURE
terminal O I_LOCATION/I_MEASURE
part O I_LOCATION/I_MEASURE
( O O
termed O O
3 O B_NUMBER[MEASURE]
' O O
C O B_PROTEIN[GENE]/B_LOCATION
) O O
of O O
the O O
DI9c O B_MEASURE
3 O I_MEASURE
' O O
UTR O B_GENE/B_LOCATION
containing O O
distinctive O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
RNA O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
motifs O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
i O O
. O O
e O O
. O O
, O O
a O O
stable O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
stem O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- O O
loop O B_LOCATION/B_ORGANIZATION
, O O
SL O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
I O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
near O O
the O O
RNA O B_NUMBER[MEASURE]
3 O I_NUMBER[MEASURE]
' O O
terminus O B_LOCATION/B_MEASURE
and O O
a O O
considerably O O
less O O
stable O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
stem O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- O O
loop O B_LOCATION
, O O
SL O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
II O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
that O O
forms O O
the O O
5 O B_NUMBER[MEASURE]
' O O
portion O B_MEASURE/B_LOCATION
of O O
3 O B_NUMBER[MEASURE]
' O O
C O B_GENE/B_LOCATION
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
4 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
cyclosporin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
7 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
per O O
day O B_TIME[MEASURE]/B_PERSON
) O O
( O O
CyA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
on O O
the O O
survival O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
vascularized O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
osteochondral O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
grafts O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O O
rat O B_PERSON/B_LOCATION
strains O I_PERSON/I_LOCATION
[ O I_PERSON
DA O I_PERSON
( O O
donor O B_PERSON
) O O
and O O
Lewis O B_PROTEIN[GENE]/B_BIO
( O O
recipient O B_PERSON/B_BIO
) O O
] O B_OTHER/B_DISEASE
and O O
the O O
presence O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
and O O
significance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
host O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immune O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tolerance O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
graft O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antigen O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
modulation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
cessation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
immunosuppression O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
examined O O
. O O

In O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
mean O O
z O B_MEASURE
- O O
score O B_MEASURE/B_ENT
for O O
GFR O B_NUMBER[MEASURE]/B_PERSON
was O O
- O O
0 O B_MEASURE
. O O
27 O B_MEASURE
( O O
94 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
normal O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
in O O
group O B_MEASURE/B_PERSON
2 O I_MEASURE/I_PERSON
mean O I_MEASURE/I_PERSON
z O O
- O O
score O B_MEASURE/B_ENT
was O O
- O O
1 O B_MEASURE
. O O
51 O B_MEASURE
( O O
72 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
normal O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
kidneys O I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
) O O
( O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
022 O B_MEASURE
, O O
Mann O B_PERSON
- O O
Whitney O B_PERSON
U O I_PERSON
- O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
. O O

The O O
model O O
of O O
the O O
complex O O
provides O O
a O O
rationale O O
for O O
conserved O O
ITAM B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
residues O O
, O O
substrate O O
specificity O O
, O O
and O O
suggests O O
that O O
substrate O O
binds O O
only O O
the O O
active O O
conformation O O
of O O
the O O
Src B B_ENZYME[GENE]
family I I_ENZYME[GENE]
tyrosine I I_ENZYME[GENE]
kinase I I_ENZYME[GENE]
, O O
unlike O O
the O O
ATP O O
cofactor O O
, O O
which O O
can O O
bind O O
the O O
inactive O O
form O O
. O O

S O O
- O O
phase O O
- O O
promoting O O
cyclin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Cdks B B_GENE/B_LOCATION
) O O
and O O
the O O
kinase O O
Dbf4 B B_GENE
- O O
Cdc7 B B_MEASURE
then O O
act O O
to O O
initiate O O
replication O O
. O O

An O O
incorrect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
enhanced O O
the O O
accuracy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
in O O
the O O
left O B_TIME[MEASURE]/B_LOCATION
visual O I_TIME[MEASURE]/I_LOCATION
field O I_TIME[MEASURE]/I_LOCATION
( O O
LVF O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

A O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
feature O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
genomic O B_GENE
sequence O I_GENE
is O O
the O O
presence O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
first O B_GENE
intron O I_GENE
( O O
Il O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
215 O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
bp O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
long O O
, O O
located O O
48 O B_LOCATION
bp O I_LOCATION
downstream O I_LOCATION
of O O
the O O
translation O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
start O O
ATG O B_LOCATION/B_GENE
codon O I_LOCATION/I_GENE
. O O

Experimental O O
studies O O
and O O
clinical O O
application O O
of O O
plasma B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ACTH I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
radioimmunoassay O O
kit O O
without O O
extraction O O
process O O

With O O
stimulation O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
beyond O O
the O O
theta O B_PROTEIN[GENE]/B_MEASURE
- O O
range O B_MEASURE/B_LOCATION
three O B_MEASURE/I_LOCATION
phenomena O B_MEASURE/I_LOCATION
occurred O O
: O O
shift O O
of O O
the O O
burst O B_MEASURE
frequencies O I_MEASURE
to O O
higher O B_MEASURE/B_LOCATION
or O O
lower O B_MEASURE
harmonics O I_MEASURE
of O O
stimulation O B_MEASURE/B_ENT
frequencies O I_MEASURE/I_ENT
; O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
interactions O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
basic O B_MEASURE
background O I_MEASURE
frequency O I_MEASURE
with O O
rhythm O B_TIME[MEASURE]/B_ENT
of O O
stimulation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
" O O
beating O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
" O O
) O O
; O O
return O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
background O O
theta O O
- O O
burst O B_MEASURE/B_LOCATION
frequency O I_MEASURE/I_LOCATION
in O O
spite O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
continuing O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
" O O
escape O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
) O O
. O O

Here O O
, O O
we O O
report O O
the O O
isolation O O
of O O
a O O
new O O
spindle O O
checkpoint O O
gene O O
, O O
mph1 B B_GENE/B_DISEASE
( O O
Mps1p B B_LOCATION/B_SPECIES[BIO]
- I B_LOCATION/I_SPECIES[BIO]
like I B_LOCATION/I_SPECIES[BIO]
pombe I B_LOCATION/I_SPECIES[BIO]
homolog I B_LOCATION/I_SPECIES[BIO]
) O O
, O O
in O O
the O O
fission O O
yeast O O
Schizosaccharomyces O O
pombe O O
, O O
that O O
is O O
required O O
for O O
checkpoint O O
activation O O
in O O
response O O
to O O
spindle O O
defects O O
. O O

Reduced O O
concentrations O O
of O O
antithrombin B B_GENE
III I I_GENE
, O O
plasminogen B B_GENE
, O O
( O O
free O O
) O O
protein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
S I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
and O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
found O O
in O O
some O O
patients O O
but O O
were O O
not O O
associated O O
with O O
either O O
thrombosis O O
or O O
lupus O O
anticoagulant O O
. O O

R O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
chest O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
wall O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
maximum O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
35 O B_MEASURE
. O O
6 O B_MEASURE
cmH2O O I_MEASURE
. O O
L O B_OTHER/B_MEASURE
- O O
1 O B_MEASURE/B_LOCATION
. O O
sec O B_ORGANIZATION/B_MEASURE
- O O
1 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
2 O B_MEASURE
. O O
2 O B_MEASURE/B_LOCATION
SE O I_MEASURE/I_LOCATION
) O O
at O O
0 O B_MEASURE
. O O
2 O B_MEASURE
Hz O I_MEASURE
- O O
10 O B_MEASURE/B_LOCATION
ml O I_MEASURE/I_LOCATION
and O O
decreased O O
with O O
increasing O O
f O O
and O O
VT O B_PROTEIN[GENE]/B_MEASURE
, O O
although O O
the O O
VT O B_MEASURE/B_DISEASE
effect O I_MEASURE/I_DISEASE
diminished O O
at O O
the O O
higher O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
f O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
unusual O O
properties O O
of O O
TRAC B B_ENZYME[GENE]/B_MEASURE
activity O O
and O O
its O O
relationship O O
, O O
if O O
any O O
, O O
with O O
the O O
enigmatic O O
Ku B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
protein I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
are O O
discussed O O
. O O

We O O
have O O
isolated O O
and O O
determined O O
the O O
complete O O
nucleotide O O
sequence O O
of O O
another O O
operon O O
, O O
cpeCD B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O O
that O O
encodes O O
the O O
linker O O
proteins O O
associated O O
with O O
phycoerythrin B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
hexamers I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
phycobilisome B B_BIO
. O O

A B B_PERSON/B_LOCATION
. I I_PERSON/I_LOCATION
thaliana I I_PERSON/I_LOCATION
cystathionine I I_PERSON/I_LOCATION
beta I I_PERSON/I_LOCATION
- I I_PERSON/I_LOCATION
lyase I I_PERSON/I_LOCATION
exhibits O O
22 O O
% O O
sequence O O
identity O O
with O O
the O O
E O O
. O O
coli O O
corresponding O O
enzyme O O
and O O
contains O O
a O O
70 O O
amino O O
acid O O
N O O
- O O
terminal O O
additional O O
sequence O O
compared O O
with O O
the O O
bacterial O O
protein O O
. O O

Role O O
of O O
double B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stranded I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
mediating O O
hypersensitivity O O
of O O
Fanconi O O
anemia O O
complementation O O
group O O
C O O
cells O O
to O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
tumor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
double O O
- O O
stranded O O
RNA O O
. O O

Our O O
results O O
suggest O O
a O O
dose O O
- O O
dependent O O
activity O O
of O O
lysine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
vasopressin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O O
the O O
EEG O O
, O O
which O O
might O O
be O O
similar O O
to O O
that O O
observed O O
in O O
animal O O
and O O
man O O
after O O
administration O O
of O O
nicotine O O
. O O

Reaction O O
of O O
aromatic O O
/ O O
heterocyclic O O
sulfonamides O O
possessing O O
free O O
amino O O
, O O
imino O O
or O O
hydrazino O O
moieties O O
with O O
7 O O
- O O
chloro O O
- O O
4 O O
- O O
chloromethylcoumarin O O
afforded O O
a O O
series O O
of O O
N O O
- O O
[ O O
( O O
7 O O
- O O
chloro O O
- O O
4 O O
- O O
coumarinyl O O
) O O
- O O
methyl O O
] O O
- O O
derivatives O O
which O O
showed O O
effective O O
inhibition O O
of O O
three O O
carbonic B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
anhydrase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CA B B_LOCATION/B_ORGANIZATION
) O O
isozymes O O
. O O

It O O
is O O
noteworthy O O
that O O
under O O
more O O
physiological O O
conditions O O
mimicking O O
the O O
cellular O O
GDP O O
/ O O
GTP O O
ratio O O
, O O
Raf B B_GENE/B_DISEASE
enhances O O
the O O
GEF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
stimulated O O
GDP O O
/ O O
GTP O O
exchange O O
on O O
Ha B B_GENE
- I I_GENE
Ras I I_GENE
, O O
in O O
agreement O O
with O O
the O O
sequestration O O
of O O
Ras B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
GTP I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
Raf B B_GENE/B_DISEASE
. O O

When O O
O O O
- O O
2A O O
/ O O
c B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
myc I I_PROTEIN[GENE]/I_MEASURE
cells O O
underwent O O
terminal O O
differentiation O O
APprog B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
lost O O
and O O
conventional O O
AP B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
DNA O O
- O O
binding O O
activity O O
became O O
evident O O
, O O
particularly O O
in O O
astrocytes O O
. O O

The O O
mammalian O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
UPR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
is O O
mediated O O
by O O
the O O
cis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
acting O O
ER O B_GENE/B_LOCATION
stress O I_GENE/I_LOCATION
response O I_GENE/I_LOCATION
element O I_GENE/I_LOCATION
consisting O O
of O O
19 O B_MEASURE/B_GENE
nt O B_MEASURE/I_GENE
( O O
CCAATN O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
9 O B_NUMBER[MEASURE]/B_LOCATION
) O O
CCACG O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
) O O
, O O
the O O
CCACG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
part O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
which O O
is O O
considered O O
to O O
provide O O
specificity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Site O O
- O O
directed O O
mutagenesis O O
of O O
the O O
conserved O O
cysteine O O
residue O O
( O O
tom1C3235A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
in O O
the O O
hect B B_GENE
- I I_GENE
domain I I_GENE
, O O
supposed O O
to O O
be O O
necessary O O
for O O
thioester O O
- O O
bond O O
formation O O
with O O
ubiquitin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
, O O
abolished O O
the O O
gene O O
function O O
. O O

The O O
two O O
SH3 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
separated O O
by O O
a O O
54 O O
amino O O
acid O O
linker O O
region O O
, O O
whose O O
length O O
is O O
highly O O
conserved O O
in O O
xenopus O O
, O O
chicken O O
, O O
and O O
mamalian B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Crk I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
II I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
this O O
report O O
, O O
we O O
establish O O
that O O
the O O
heteromeric O O
CCAAT B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
binding I I_PROTEIN[GENE]/I_LOCATION
factor I I_PROTEIN[GENE]/I_LOCATION
CBF B I_PROTEIN[GENE]/I_LOCATION
is O O
the O O
major O O
component O O
of O O
the O O
C1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
C1F B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
in O O
human O O
cells O O
. O O

Mutant B B_PERSON/B_GENE
M I I_PERSON/I_GENE
proteins I I_PERSON/I_GENE
were O O
tested O O
for O O
their O O
ability O O
to O O
complement O O
growth O O
of O O
the O O
temperature O O
- O O
sensitive O O
M B B_DISEASE/B_SPECIES[BIO]
protein I B_DISEASE/I_SPECIES[BIO]
mutant I B_DISEASE/I_SPECIES[BIO]
virus O O
tsO23 O O
at O O
the O O
nonpermissive O O
temperature O O
. O O

The O O
yjr041c B B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
delta I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
haploid O O
cells O O
gave O O
rise O O
to O O
microcolonies O O
comprising O O
about O O
20 O O
to O O
50 O O
cells O O
. O O

Two O O
mutants O O
, O O
mapping O O
at O O
the O O
HindIII B B_LOCATION/B_MEASURE
site I I_LOCATION/I_MEASURE
( O O
between O O
the O O
consensus O O
sequences O O
) O O
of O O
the O O
pSC101 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tetA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
were O O
studied O O
: O O
MA2 O O
corresponds O O
to O O
a O O
4 O O
bp O O
deletion O O
between O O
positions O O
- O O
12 O O
and O O
- O O
15 O O
; O O
B30 O O
bears O O
a O O
44 O O
bp O O
insertion O O
C O O
( O O
TA O O
) O O
21 O O
G O O
at O O
the O O
HindIII B B_LOCATION
site I I_LOCATION
. O O

Effects O O
of O O
timepidium O O
bromide O O
( O O
TB O O
; O O
anticholinergic O O
agent O O
) O O
, O O
acetylcholine O O
( O O
ACh O O
) O O
and O O
neostigmine O O
( O O
Neost O O
) O O
on O O
gastric O O
and O O
duodenal O O
blood O O
flow O O
distribution O O
were O O
studied O O
by O O
the O O
use O O
of O O
131I O O
- O O
labeled O O
macroaggregated O O
human O O
serum O O
albumin O O
( O O
MAA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
in O O
rabbits O O
. O O

Here O O
, O O
we O O
describe O O
the O O
three O B_NUMBER[MEASURE]
- O O
dimensional O B_MEASURE/B_LOCATION
structure O B_MEASURE/I_LOCATION
of O O
the O O
enzyme O B_ENZYME[GENE]/B_LOCATION
from O O
Escherichia O B_BACTERIUM[BIO]
colidetermined O O
and O O
refined O O
to O O
2 O B_MEASURE
. O O
0 O B_MEASURE
A O O
resolution O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

However O O
, O O
the O O
MCMI O B_LOCATION/B_DISEASE
- O O
III O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
significantly O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
magnitude O B_MEASURE
compared O O
with O O
the O O
MCMI O B_LOCATION/B_DISEASE
- O O
II O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
. O O

The O O
exact O O
function O O
of O O
IP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
30 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
yet O O
known O O
, O O
but O O
it O O
may O O
play O O
a O O
role O O
in O O
gamma B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O O
immune O O
reactions O O
. O O

The O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
products O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expressed O O
from O O
these O O
chimeric O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
COS O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
were O O
assessed O O
by O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
by O O
metabolic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
labeling O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
proteins O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
followed O O
by O O
immunoprecipitation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
SDS O B_PROTEIN[GENE]/B_DISEASE
- O O
PAGE O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
H5 B B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
: O O
DH5 B B_PROTEIN[GENE]
( O O
all O O
amino O O
acids O O
in O O
D O O
configuration O O
) O O
and O O
H5F B B_PROTEIN[GENE]/B_BIO
( O O
where O O
all O O
His O O
are O O
replaced O O
by O O
Phe O O
at O O
positions O O
3 O O
, O O
7 O O
, O O
8 O O
, O O
15 O O
, O O
18 O O
, O O
19 O O
, O O
21 O O
) O O
. O O

When O O
targeted O O
to O O
the O O
GAL1 B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
promoter I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
by O O
fusing O O
with O O
the O O
Gal4p B B_GENE
DNA I I_GENE
- I I_GENE
binding I I_GENE
domain I I_GENE
, O O
Sko1p B B_GENE
acts O O
as O O
an O O
Ssn6 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Tup1p B B_MEASURE/B_BIO
- O O
dependent O O
repressor O O
regulated O O
by O O
osmotic O O
stress O O
. O O

Only O O
the O O
native O O
structure O O
of O O
phosphorylated O O
ERK B B_GENE
was O O
recognized O O
by O O
VHR B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
was O O
inactivated O O
with O O
a O O
second O O
- O O
order O O
rate O O
constant O O
of O O
40 O O
, O O
000 O O
M O O
- O O
1 O O
s O O
- O O
1 O O
. O O

6 O B_MEASURE/B_LOCATION
h O O
after O O
ingestion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
aspirin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O O
day O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
1 O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
day O B_TIME[MEASURE]
14 O I_TIME[MEASURE]
, O O
both O O
TX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
PGI2 O B_LOCATION/B_PROTEIN[GENE]
levels O I_LOCATION/I_PROTEIN[GENE]
also O O
significantly O O
decreased O O
( O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
0001 O B_MEASURE
) O O
. O O

Joint O O
ultrasonography O O
demonstrating O O
thickening O O
of O O
synoviae O O
and O O
tendons O O
has O O
become O O
a O O
useful O O
non O O
- O O
invasive O O
diagnostic O O
tool O O
, O O
although O O
it O O
is O O
not O O
specific O O
for O O
beta B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
M I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amyloidosis O O
, O O
and O O
results O O
depend O O
on O O
observer O O
experience O O
. O O

Immunofluorescence O O
tests O O
for O O
Borrelia B B_DISEASE/B_VIRUS[BIO]
burgdorferi I B_DISEASE/I_VIRUS[BIO]
serum I B_DISEASE/I_VIRUS[BIO]
antibodies I B_DISEASE/I_VIRUS[BIO]
had O O
positive O O
results O O
, O O
but O O
G O O
- O O
penicillin O O
treatment O O
was O O
ineffective O O
. O O

The O O
size O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
the O O
predicted O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_GENE/B_LOCATION
sequence O B_GENE/I_LOCATION
of O O
the O O
mouse O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
confirmed O O
experimentally O O
. O O

The O O
herpesvirus B B_GENE
entry I I_GENE
mediator I I_GENE
C I I_GENE
( O O
HveC B B_LOCATION/B_DISEASE
) O O
, O O
previously O O
known O O
as O O
poliovirus B B_GENE
receptor I I_GENE
- I I_GENE
related I I_GENE
protein I I_GENE
1 I I_GENE
( O O
PRR1 B B_GENE/B_LOCATION
) O O
, O O
and O O
the O O
herpesvirus B B_GENE
Ig I I_GENE
- I I_GENE
like I I_GENE
receptor I I_GENE
( O O
HIgR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
are O O
the O O
bona O O
fide O O
receptors O O
employed O O
by O O
herpes O O
simplex O O
virus O O
- O O
1 O O
and O O
- O O
2 O O
( O O
HSV O O
- O O
1 O O
and O O
- O O
2 O O
) O O
for O O
entry O O
into O O
the O O
human O O
cell O O
lines O O
most O O
frequently O O
used O O
in O O
HSV O O
studies O O
. O O

4 O O
- O O
Hydroxyproline O O
assays O O
were O O
performed O O
to O O
determine O O
collagen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
content O O
. O O

In O O
addition O O
, O O
we O O
mapped O O
a O O
putative O O
hnRNP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
U5 B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
RNA I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
demonstrated O O
that O O
p40CRS B B_GENE
( O O
hnRNP B B_PROTEIN[GENE]/B_MEASURE
A1 I I_PROTEIN[GENE]/I_MEASURE
) O O
binding O O
to O O
that O O
site O O
correlates O O
with O O
CRS B B_DISEASE/B_GENE
function O O
. O O

Sequence O O
comparisons O O
reveal O O
that O O
the O O
P B B_GENE/B_BIO
. I I_GENE/I_BIO
woesei I I_GENE/I_BIO
GTP I I_GENE/I_BIO
- I I_GENE/I_BIO
binding I I_GENE/I_BIO
protein I I_GENE/I_BIO
is O O
strikingly O O
related O O
in O O
sequence O O
to O O
eubacterial B B_SPECIES[BIO]/B_GENE
FtsZ I I_SPECIES[BIO]/I_GENE
and O O
is O O
marginally O O
more O O
similar O O
to O O
eukaryotic B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
tubulins I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
than O O
are O O
bacterial B B_SPECIES[BIO]/B_GENE
FtsZ I I_SPECIES[BIO]/I_GENE
proteins I I_SPECIES[BIO]/I_GENE
. O O

The O O
possible O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
equivalency O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
a O O
short O B_MEASURE/B_PERSON
form O B_MEASURE/I_PERSON
and O O
the O O
long O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
form O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
Multiple O B_TIME[MEASURE]/B_DISEASE
Affect O O
Adjective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Check O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
List O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
Revised O O
( O O
MAACL O B_LOCATION/B_DISEASE
- O O
R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
Zuckerman O B_PERSON
& O O
Lubin O B_PERSON
, O O
1985 O B_MEASURE
) O O
was O O
studied O O
by O O
correlating O O
both O O
forms O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
MAACL O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
R O B_OTHER/B_PROTEIN[GENE]
with O O
the O O
State O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Trait O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Personality O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Inventory O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
Spielberger O B_PERSON
, O O
1995 O B_MEASURE
) O O
; O O
the O O
Affect O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Balance O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Scale O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Bradburn O B_PERSON
, O O
1969 O B_MEASURE
) O O
; O O
and O O
the O O
Sensation O B_DISEASE/B_GENE
Seeking O O
Scale O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Zuckerman O B_PERSON
, O O
1978 O B_MEASURE
) O O
. O O

In O O
addition O B_MEASURE/B_LOCATION
, O O
269 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
a O O
( O O
Mus O B_DISEASE/B_PROTEIN[GENE]
spretus O B_DISEASE/I_PROTEIN[GENE]
x O O
C57BL O B_BIO/B_PROTEIN[GENE]
/ O O
6J O B_MEASURE
) O O
F1 O B_PROTEIN[GENE]/B_SPECIES[BIO]
x O O
C57BL O B_BIO/B_PROTEIN[GENE]
/ O O
6J O B_MEASURE/B_PERSON
interspecific O I_MEASURE/I_PERSON
backcross O I_MEASURE/I_PERSON
were O O
also O O
used O O
to O O
order O O
marker O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loci O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
calculate O O
intergene O B_MEASURE/B_GENE
distances O I_MEASURE/I_GENE
for O O
this O O
region O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
animals O O
were O O
followed O O
over O O
a O O
1 O O
- O O
to O O
6 O O
- O O
h O O
posttraumatic O O
course O O
, O O
and O O
processed O O
for O O
the O O
LM O O
and O O
TEM O O
visualization O O
of O O
HRP B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Of O O
these O O
four O O
PP2C B B_GENE/B_LOCATION
genes I I_GENE/I_LOCATION
, O O
the O O
expression O O
of O O
the O O
PP2Cbeta B B_SEQUENCE[MEASURE]/B_PERSON
gene I I_SEQUENCE[MEASURE]/I_PERSON
has O O
been O O
reported O O
to O O
be O O
tissue O O
- O O
specific O O
and O O
development O O
- O O
dependent O O
. O O

Moreover O O
, O O
antibody O O
binding O O
to O O
the O O
same O O
two O O
determinants O O
was O O
also O O
inhibited O O
when O O
ZAP B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
70 I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
the O O
SH2 B B_PROTEIN[GENE]/B_BIO
domains I I_PROTEIN[GENE]/I_BIO
bound O O
to O O
the O O
zeta O O
chain O O
or O O
to O O
a O O
2pY B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ITAM I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
IR4 O O
ORF O O
exhibits O O
significant O O
homology O O
to O O
the O O
immediate B B_GENE/B_BIO
- I I_GENE/I_BIO
early I I_GENE/I_BIO
gene I I_GENE/I_BIO
US1 B I_GENE/I_BIO
( O O
ICP22 B B_PROTEIN[GENE]/B_LOCATION
) O O
of O O
herpes O O
simplex O O
virus O O
type O O
1 O O
and O O
to O O
the O O
ICP22 B B_SPECIES[BIO]/B_MEASURE
homologs O O
of O O
varicella O O
- O O
zoster O O
virus O O
( O O
ORF63 B B_PROTEIN[GENE]/B_VIRUS[BIO]
) O O
, O O
pseudorabies O O
virus O O
( O O
RSp40 B B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
and O O
equine O O
herpesvirus O O
4 O O
( O O
ORF4 O O
) O O
. O O

These O O
include O O
not O O
only O O
antioxidants O O
, O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
methyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
D I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aspartate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antagonists O O
, O O
inhibitors O O
of O O
glutamate O O
release O O
, O O
calcium O O
channel O O
blockers O O
, O O
polyamine O O
antagonists O O
, O O
and O O
nitric B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O O
, O O
but O O
cannabinoids O O
, O O
aspirin O O
, O O
melatonin O O
, O O
and O O
vitamin O O
B O O
- O O
12 O O
. O O

A O O
series O O
of O O
mutations O O
were O O
constructed O O
within O O
the O O
E2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
open O O
reading O O
frame O O
which O O
delete O O
various O O
regions O O
of O O
the O O
conserved O O
DNA O O
binding O O
and O O
transactivation O O
domains O O
as O O
well O O
as O O
the O O
internal O O
hinge O O
region O O
. O O

Two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
sensory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inhibition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
employed O O
, O O
S2 O B_PROTEIN[GENE]/B_MEASURE
/ O O
S1 O B_MEASURE
x O O
100 O B_MEASURE
amplitude O I_MEASURE
ratio O I_MEASURE
and O O
S1 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
S2 O B_MEASURE
amplitude O I_MEASURE
difference O I_MEASURE
. O O

For O O
large O B_DISEASE/B_MEASURE
breasts O I_DISEASE/I_MEASURE
( O O
> O O
70 O B_MEASURE
mm O I_MEASURE
) O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
X O B_PROTEIN[GENE]/B_NUMBER[MEASURE]
- O O
ray O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
sets O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
such O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
the O O
IGE O B_PRODUCT[OBJECT]/B_ENT
DMR O I_PRODUCT[OBJECT]/I_ENT
, O O
which O O
automatically O O
select O O
the O O
beam O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
quality O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
for O O
each O O
breast O B_BIO/B_DISEASE
, O O
resulted O O
in O O
lower O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O O
with O O
sets O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
using O O
manual O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tube O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
potential O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
selection O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Sequence O O
analysis O O
revealed O O
that O O
Hv B B_GENE/B_BIO
- I I_GENE/I_BIO
p68 I I_GENE/I_BIO
belongs O O
to O O
the O O
large O O
family O O
of O O
FAD B B_ENZYME[GENE]/B_BIO
- I I_ENZYME[GENE]/I_BIO
dependent I I_ENZYME[GENE]/I_BIO
glucose I I_ENZYME[GENE]/I_BIO
methanol I I_ENZYME[GENE]/I_BIO
choline I I_ENZYME[GENE]/I_BIO
oxidoreductases I I_ENZYME[GENE]/I_BIO
and O O
that O O
it O O
shares O O
significant O O
sequence O O
identity O O
( O O
> O O
67 O O
% O O
) O O
with O O
the O O
alcohol B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
oxidases I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
methylotrophic O O
yeasts O O
. O O

In O O
the O O
HIV B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
LTR I B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
this O O
region O O
has O O
been O O
demonstrated O O
to O O
have O O
both O O
positive O O
and O O
negative O O
regulatory O O
effects O O
on O O
HIV O O
gene O O
expression O O
. O O

Small B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
t I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
also O O
inhibited O O
the O O
dephosphorylation O O
of O O
cAMP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PKA B B_GENE/B_LOCATION
) O O
- O O
phosphorylated O O
CREB B B_GENE
in O O
rat O O
liver O O
nuclear O O
extracts O O
. O O

Increased O O
platelet B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derived I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
production O O
and O O
intimal O O
thickening O O
during O O
healing O O
of O O
Dacron O O
grafts O O
in O O
a O O
canine O O
model O O
. O O

The O O
differences O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
percentages O B_DISEASE_ADJECTIVE[DISEASE]
for O O
HIV O B_DISEASE
- O O
1 O B_DISEASE/B_GENE
infection O I_DISEASE/I_GENE
in O O
intravenous O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
drug O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
users O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IVDU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
were O O
67 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
in O O
non O B_MEASURE/B_PERSON
IVDU O B_MEASURE/I_PERSON
were O O
3 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
with O O
a O O
significant O B_MEASURE/B_DISEASE
statistical O B_MEASURE/I_DISEASE
difference O B_MEASURE/I_DISEASE
( O O
chi O B_PROTEIN[GENE]/B_PERSON
2 O I_PROTEIN[GENE]/I_PERSON
= O O
557 O B_MEASURE
. O O
5 O B_MEASURE
; O O
p O O
< O O
0 O B_MEASURE
. O O
0001 O B_MEASURE
) O O
. O O

One O O
of O O
the O O
ORFs O O
in O O
the O O
Methanococcus O O
jannaschii O O
genome O O
possesses O O
high O O
similarity O O
to O O
the O O
M B B_SPECIES[BIO]/B_SEQUENCE[MEASURE]
. I I_SPECIES[BIO]/I_SEQUENCE[MEASURE]
aeolicus I I_SPECIES[BIO]/I_SEQUENCE[MEASURE]
ilvB I I_SPECIES[BIO]/I_SEQUENCE[MEASURE]
, O O
indicating O O
that O O
it O O
is O O
an O O
authentic O O
AHAS B B_GENE/B_MEASURE
. O O

HrpE B B_BACTERIUM[BIO]/B_LOCATION
is O O
similar O O
to O O
YscL B B_BIO/B_GENE
of O O
Yersinia O O
spp O O
. O O

DESIGN O O
: O O
Activating B B_GENE
protein I I_GENE
- I I_GENE
1 I I_GENE
( O O
AP B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
) O O
and O O
Tat B B_GENE
- O O
induced O O
transcription O O
were O O
assessed O O
using O O
Jun B B_PERSON/B_MEASURE
and O O
hybrid O O
Tat B B_GENE
/ O O
Jun B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
expression O O
plasmids O O
and O O
reporter O O
gene O O
constructs O O
which O O
contained O O
AP B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
sites I I_GENE/I_LOCATION
upstream O O
of O O
the O O
rat B B_GENE
prolactin I I_GENE
TATAA I I_GENE
element I I_GENE
or O O
an O O
HIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
construct I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
which O O
AP B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
binding I I_GENE/I_MEASURE
sites I I_GENE/I_MEASURE
replaced O O
the O O
TAR O O
element O O
. O O

A O O
protein O O
which O O
promotes O O
DNA O O
strand O O
transfer O O
between O O
linear O O
double O O
- O O
stranded O O
M13mp19 O O
DNA O O
and O O
single O O
- O O
stranded O O
viral O O
M13mp19 O O
DNA O O
has O O
been O O
isolated O O
from O O
recA B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E O O
. O O
coli O O
. O O

IgE B B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibody I I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
twelve O O
common O O
food O O
and O O
inhalant O O
allergens O O
was O O
measured O O
by O O
enzyme O O
- O O
linked O O
immunosorbent O O
assay O O
( O O
ELISA O O
) O O
in O O
the O O
sera O O
of O O
thirteen O O
atopic O O
patients O O
with O O
one O O
or O O
more O O
allergic O O
disorders O O
( O O
asthma O O
occurring O O
in O O
eleven O O
; O O
rhinitis O O
in O O
ten O O
; O O
eczema O O
in O O
six O O
; O O
urticaria O O
in O O
four O O
; O O
mouth O O
and O O
gastro O O
- O O
intestinal O O
symptoms O O
in O O
six O O
) O O
, O O
of O O
twelve O O
non O O
- O O
atopic O O
patients O O
with O O
various O O
clinical O O
symptoms O O
( O O
asthma O O
in O O
four O O
; O O
rhinitis O O
in O O
four O O
; O O
eczema O O
in O O
one O O
; O O
urticaria O O
in O O
two O O
; O O
mouth O O
and O O
gastro O O
- O O
intestinal O O
symptoms O O
in O O
four O O
) O O
and O O
sixteen O O
cord O O
blood O O
sera O O
. O O

Significant O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reductions O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
noted O O
in O O
vertical O B_MEASURE/B_LOCATION
GRFs O I_MEASURE/I_LOCATION
per O O
newton O B_PERSON/B_MEASURE
of O O
body O B_MEASURE/B_DISEASE
weight O I_MEASURE/I_DISEASE
exerted O O
at O O
10 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
( O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
0009 O B_MEASURE
) O O
and O O
20 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
( O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
0383 O B_MEASURE
) O O
of O O
stance O B_MEASURE/B_LOCATION
phase O I_MEASURE/I_LOCATION
and O O
in O O
anteroposterior O B_MEASURE/B_PERSON
GRFs O I_MEASURE/I_PERSON
exerted O O
at O O
10 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
( O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
0009 O B_MEASURE
) O O
and O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
0033 O B_MEASURE
) O O
of O O
stance O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
phase O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
when O O
ambulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
was O O
compared O O
with O O
and O O
without O O
the O O
orthotic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PRODUCT[OBJECT]
device O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PRODUCT[OBJECT]
. O O

Database O O
searches O O
revealed O O
a O O
50 O O
- O O
63 O O
% O O
similarity O O
and O O
34 O O
- O O
42 O O
% O O
identity O O
with O O
several O O
families O O
of O O
serine B B_BIO/B_GENE
proteases I I_BIO/I_GENE
, O O
in O O
particular O O
the O O
trypsin B B_BIO/B_ENZYME[GENE]
- I I_BIO/I_ENZYME[GENE]
like I I_BIO/I_ENZYME[GENE]
proteases I I_BIO/I_ENZYME[GENE]
, O O
members O O
of O O
the O O
glandular B B_PERSON/B_BIO
kallikrein I I_PERSON/I_BIO
family I I_PERSON/I_BIO
( O O
including O O
prostate B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
specific I I_GENE/I_DISEASE
antigen I I_GENE/I_DISEASE
, O O
nerve B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
epidermal B B_GENE
growth I I_GENE
factor I I_GENE
- I I_GENE
binding I I_GENE
protein I I_GENE
) O O
and O O
the O O
activators O O
for O O
the O O
kringle B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
family I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
including O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tissue I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasminogen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hepatocyte I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Manifestation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
superfluidity O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
an O O
evolving O O
bose O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- O O
einstein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
condensed O I_PERSON
Gas O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
We O O
study O O
the O O
generation O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
excitations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
due O O
to O O
an O O
" O O
impurity O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
( O O
static O B_PROTEIN[GENE]/B_LOCATION
perturbation O I_PROTEIN[GENE]/I_LOCATION
) O O
placed O O
into O O
an O O
oscillating O O
Bose O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Einstein O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
condensed O B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gas O B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
time O B_MEASURE/B_LOCATION
- O O
dependent O B_LOCATION/B_MEASURE
trapping O I_LOCATION/I_MEASURE
field O I_LOCATION/I_MEASURE
. O O

Zta B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O O
the O O
HAT B B_ENZYME[GENE]/B_DISEASE
activity O O
of O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
had O O
been O O
partially O O
purified O O
or O O
immunoprecipitated O O
from O O
mammalian O O
cells O O
as O O
well O O
as O O
from O O
affinity O O
- O O
purified O O
, O O
baculovirus O O
expressed O O
CBP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Expression O O
of O O
the O O
Hox B B_GENE/B_DISEASE
genes I I_GENE/I_DISEASE
egl B I_GENE/I_DISEASE
- I I_GENE/I_DISEASE
5 I I_GENE/I_DISEASE
and O O
mab B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
5 I I_MEASURE/I_GENE
is O O
reduced O O
in O O
lin B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
49 I I_GENE/I_LOCATION
and O O
lin B B_MEASURE/B_PERSON
- I I_MEASURE/I_PERSON
59 I I_MEASURE/I_PERSON
mutants I I_MEASURE/I_PERSON
, O O
suggesting O O
lin B B_GENE/B_PERSON
- I I_GENE/I_PERSON
49 I I_GENE/I_PERSON
and O O
lin B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
59 I I_MEASURE/I_GENE
regulate O O
HOM B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
in O O
C O O
. O O
elegans O O
as O O
the O O
trx B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
G I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
genes I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
do O O
in O O
Drosophila O O
. O O

Interleukin B B_PERSON/B_LOCATION
- I I_PERSON/I_LOCATION
1 I I_PERSON/I_LOCATION
increased O O
the O O
noradrenaline O O
release O O
. O O

3 O O
patients O O
with O O
acute O O
leukaemia O O
, O O
HLA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies O O
and O O
thrombocytopenia O O
refractory O O
to O O
random O O
donor O O
platelet O O
transfusions O O
were O O
treated O O
with O O
high O O
- O O
dose O O
i O O
. O O
v O O
. O O
immunoglobulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Two O O
genes O O
( O O
ptsI B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
and O O
ptsA B B_PROTEIN[GENE]/B_LOCATION
) O O
that O O
encode O O
homologues O O
of O O
the O O
energy O O
coupling O O
Enzyme B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
phosphoenolpyruvate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependent I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sugar I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transporting I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphotransferase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O O
( O O
PTS O O
) O O
have O O
previously O O
been O O
identified O O
on O O
the O O
Escherichia O O
coli O O
chromosome O O
. O O

BACKGROUND O O
: O O
Murine B B_GENE/B_PERSON
Nramp I I_GENE/I_PERSON
is O O
a O O
candidate O O
for O O
the O O
macrophage O O
resistance O O
gene O O
Ity B B_LOCATION/B_PERSON
/ O O
Lsh B B_LOCATION/B_PERSON
/ O O
Bcg B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

In O O
cases O O
in O O
which O O
it O O
was O O
identified O O
, O O
insulitis O O
affected O O
23 O O
% O O
of O O
islets O O
containing O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
affected O O
only O O
1 O O
% O O
of O O
islets O O
which O O
were O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deficient O O
, O O
thus O O
supporting O O
the O O
concept O O
that O O
insulitis O O
represents O O
an O O
immunologically O O
mediated O O
destruction O O
of O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
secreting O O
B O O
cells O O
. O O

Eighteen O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
advanced O B_DISEASE
epidermoid O I_DISEASE
carcinoma O I_DISEASE
of O O
the O O
head O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
neck O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
were O O
entered O O
into O O
a O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
II O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
N O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Methylformamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NMF O B_DISEASE/B_MEASURE
) O O
, O O
800 O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
M2 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IV O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O O
for O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
every O O
4 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
. O O

Using O O
a O O
set O O
of O O
sera O O
for O O
which O O
full O O
chlamydial O O
micro O O
- O O
immunofluorescence O O
results O O
suggested O O
a O O
clear O O
diagnosis O O
, O O
we O O
have O O
evaluated O O
the O O
Chlamydia O O
Spot O O
- O O
IF O O
test O O
( O O
bioMerieux O O
) O O
, O O
which O O
allows O O
a O O
comparison O O
of O O
titres O O
to O O
Chlamydia B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trachomatis I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
psittaci I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigens I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
single O O
copy O O
flotillin B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
is O O
located O O
at O O
6p21 O O
. O O
3 O O
in O O
the O O
MHC B B_SPECIES[BIO]/B_MEASURE
class I I_SPECIES[BIO]/I_MEASURE
I I I_SPECIES[BIO]/I_MEASURE
region I I_SPECIES[BIO]/I_MEASURE
and O O
consists O O
of O O
13 O O
exons O O
over O O
15 O O
kb O O
. O O

The O O
in O O
vivo O O
response O O
of O O
the O O
PacC B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
like I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
decamers I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
to O O
external O O
pH O O
was O O
dependent O O
on O O
the O O
status O O
of O O
the O O
pH O O
- O O
regulated O O
activator O O
YlRim101p B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
homologous O O
to O O
the O O
A O O
. O O
nidulans O O
PacC B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regulator O O
. O O

In O O
the O O
univariate O O
models O O
of O O
either O O
fixed O O
or O O
time O O
dependent O O
covariates O O
, O O
many O O
variables O O
were O O
significantly O O
associated O O
with O O
risk O O
of O O
progression O O
to O O
AIDS O O
( O O
T4 O O
cell O O
count O O
, O O
T4 O O
/ O O
T8 O O
ratio O O
, O O
blastogenic O O
responses O O
to O O
phytohemagglutinin B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
concanavalin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
pokeweed B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mitogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
serum B B_DISEASE
IgA I I_DISEASE
, O O
appearance O O
of O O
p24 B B_DISEASE/B_GENE
antigen I I_DISEASE/I_GENE
, O O
and O O
the O O
development O O
of O O
oral O O
hairy O O
leukoplakia O O
, O O
thrush O O
, O O
or O O
herpes O O
zoster O O
) O O
. O O

Polar O O
effects O O
of O O
transposon O O
insertions O O
demonstrated O O
that O O
all O O
of O O
these O O
mRNAs O O
arose O O
from O O
a O O
single O O
promoter O O
region O O
, O O
where O O
transcription O O
initiated O O
80 O O
bp O O
5 O O
' O O
to O O
nifH B B_TIME[MEASURE]/B_LOCATION
. O O

VBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
a1 B B_GENE
/ I I_GENE
EBP I I_GENE
could O O
mediate O O
the O O
high O O
rates O O
of O O
ALV O O
and O O
RSV B B_DISEASE/B_VIRUS[BIO]
LTR I B_DISEASE/I_VIRUS[BIO]
- O O
enhanced O O
transcription O O
in O O
bursal O O
lymphoma O O
cells O O
and O O
many O O
other O O
cell O O
types O O
. O O

One O B_PERSON/B_ENT
hundred O I_PERSON/I_ENT
men O I_PERSON/I_ENT
who O O
received O O
alpha O B_PROTEIN[GENE]
- O O
tocopherol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
matched O O
on O O
age O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
study O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
center O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
length O B_MEASURE/B_LOCATION
of O O
time O B_TIME[MEASURE]/B_DISEASE
between O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_NUMBER[MEASURE]
draws O O
to O O
100 O B_PERSON/B_SPORT[ENT]
men O I_PERSON/I_SPORT[ENT]
who O O
received O O
a O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

The O O
contribution O O
of O O
residues O O
outside O O
the O O
Ras B B_LOCATION/B_PERSON
binding I I_LOCATION/I_PERSON
domain I I_LOCATION/I_PERSON
of O O
Raf B B_GENE/B_DISEASE
( O O
RafRBD B B_PROTEIN[GENE]/B_LOCATION
) O O
to O O
Ras B B_GENE/B_DISEASE
- O O
Raf B B_GENE/B_DISEASE
interaction O O
and O O
Ras B B_GENE/B_DISEASE
- O O
dependent O O
Raf B B_GENE/B_DISEASE
activation O O
has O O
remained O O
unresolved O O
. O O

After O O
dialysis O O
online O O
, O O
lactate O O
was O O
converted O O
by O O
means O O
of O O
lactate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxidase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
immobilized O O
to O O
porous O O
glass O O
, O O
and O O
the O O
depletion O O
of O O
oxygen O O
was O O
registered O O
by O O
means O O
of O O
a O O
Clark O O
electrode O O
. O O

The O O
deduced O O
amino O O
- O O
acid O O
sequence O O
of O O
the O O
mature O O
enzyme O O
showed O O
very O O
low O O
homology O O
( O O
< O O
20 O O
. O O
4 O O
% O O
identity O O
) O O
to O O
those O O
of O O
known O O
pectinolytic O O
enzymes O O
in O O
the O O
large O O
pectate B B_LOCATION/B_PERSON
lyase I I_LOCATION/I_PERSON
superfamily I I_LOCATION/I_PERSON
( O O
the O O
polysaccharide B B_PERSON/B_LOCATION
lyase I I_PERSON/I_LOCATION
family I I_PERSON/I_LOCATION
1 I I_PERSON/I_LOCATION
) O O
. O O

Despite O O
this O O
loss O O
, O O
YEpFAS1 B B_PERSON
is O O
still O O
able O O
to O O
complement O O
a O O
fas1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutation O O
at O O
the O O
enoyl B B_PROTEIN[GENE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
reductase I B_PROTEIN[GENE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
domain O O
. O O

Hepatitis B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immune I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulins I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
HIV B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
contrast O O
, O O
a O O
similar O O
fusion O O
protein O O
( O O
hGH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
LDLR B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
DAF17 B B_GENE
, O O
abbreviated O O
HLD B B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
) O O
containing O O
a O O
fragment O O
of O O
the O O
serine O O
/ O O
threonine O O
- O O
rich O O
domain O O
of O O
the O O
LDL B B_GENE
receptor I I_GENE
( O O
LDLR B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
place O O
of O O
the O O
DAF B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
derived I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
serine I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
threonine I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
rich I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
does O O
not O O
become O O
GPI O O
anchored O O
. O O

To O O
assess O O
whether O O
thallium O B_LOCATION
- O O
201 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
thallous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
chloride O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
Tl O B_PROTEIN[GENE]/B_LOCATION
) O O
can O O
detect O O
childhood O B_DISEASE
tumors O I_DISEASE
and O O
whether O O
diagnostic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effectiveness O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improves O O
with O O
combined O O
blood O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
28 O B_PERSON/B_ENT
children O I_PERSON/I_ENT
( O O
1 O B_MEASURE
. O O
0 O B_MEASURE
- O O
18 O B_NUMBER[MEASURE]
. O O
6 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
) O O
were O O
studied O O
using O O
single O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
photon O B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
emission O B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
computed O O
tomography O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SPECT O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
: O O
Tl O B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O B_MEASURE
. O O
3 O B_MEASURE
- O O
1 O B_MEASURE
. O O
8 O B_MEASURE
mCi O I_MEASURE
intravenously O O
) O O
, O O
followed O O
in O O
13 O B_NUMBER[MEASURE]
of O O
the O O
patients O B_PERSON/B_MEASURE
by O O
technetium O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
99m O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
hexamethylpropyleneamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
oxime O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
( O O
99mTc O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
HMPAO O B_MEASURE/B_DISEASE
; O O
8 O B_NUMBER[MEASURE]
- O O
18 O B_TIME[MEASURE]/B_LOCATION
mCi O I_TIME[MEASURE]/I_LOCATION
intravenously O O
) O O
. O O

Forty O B_NUMBER[MEASURE]
- O O
five O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
with O O
recent O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
onset O B_DISEASE/B_ORGANISM_FUNCTION
hyperthyroidism O I_DISEASE/I_ORGANISM_FUNCTION
( O O
< O B_PROTEIN[GENE]/B_LOCATION
12 O I_PROTEIN[GENE]/I_LOCATION
weeks O I_PROTEIN[GENE]/I_LOCATION
) O O
were O O
sex O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
menopause O B_PERSON/B_MEASURE
stratified O O
and O O
randomly O O
allocated O O
to O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
carbimazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Neotomizol O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
carbimazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
low O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
dose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
CT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O O
Calsynar O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
; O O
100 O B_MEASURE/B_LOCATION
IU O I_MEASURE/I_LOCATION
/ O O
day O B_TIME[MEASURE]
, O O
2 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
/ O O
week O B_TIME[MEASURE]
) O O
, O O
or O O
carbimazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
high O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CT O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Calsynar O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
; O O
100 O B_MEASURE
IU O I_MEASURE
/ O O
day O B_TIME[MEASURE]
, O O
14 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
/ O O
month O B_TIME[MEASURE]
) O O
. O O

This O O
mechanism O O
seems O O
to O O
be O O
involved O O
in O O
VIP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
PRL B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
gene I B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
regulation O O
. O O

Mean O O
concentration O O
of O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
maternal O O
plasma O O
across O O
all O O
sampling O O
times O O
was O O
higher O O
in O O
ethanol O O
treated O O
animals O O
. O O

Minor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
changes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
within O O
the O O
transmembrane O B_PROTEIN[GENE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains O B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TMs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
sometimes O O
produced O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
effects O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
more O O
drastic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
TMs O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
ablated O O
surface O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expression O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
entirely O O
. O O

The O O
tau O B_PROTEIN[GENE]/B_MEASURE
v O B_PROTEIN[GENE]/I_MEASURE
at O O
rest O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
4 O B_MEASURE
. O O
06 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
2 O B_NUMBER[MEASURE]
. O O
16 O B_MEASURE
s O I_MEASURE
and O O
decreased O O
to O O
2 O B_MEASURE
. O O
44 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
. O O
07 O B_TIME[MEASURE]
s O I_TIME[MEASURE]
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
at O O
1 O B_TIME[MEASURE]/B_LOCATION
Hz O I_TIME[MEASURE]/I_LOCATION
and O O
to O O
1 O B_MEASURE
. O O
81 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
4 O B_MEASURE/B_LOCATION
s O I_MEASURE/I_LOCATION
at O O
5 O B_MEASURE/B_LOCATION
Hz O I_MEASURE/I_LOCATION
. O O

Using O O
in O O
vivo O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
genomic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dimethyl O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sulfate O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
KMnO4 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
footprinting O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
we O O
showed O O
that O O
the O O
promoter O B_ENZYME[GENE]/B_LOCATION
region O I_ENZYME[GENE]/I_LOCATION
is O O
differentially O O
protected O O
, O O
depending O O
upon O O
which O O
holoenzyme O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
is O O
bound O O
. O O

The O O
testes O O
of O O
8 O O
specimens O O
of O O
Triturus O O
marmoratus O O
were O O
collected O O
during O O
each O O
month O O
of O O
1987 O O
and O O
processed O O
for O O
electron O O
microscopy O O
and O O
light O O
microscopy O O
demonstration O O
of O O
testosterone O O
( O O
T O O
) O O
following O O
the O O
ABC B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
avidin B B_LOCATION
- I I_LOCATION
biotin I I_LOCATION
peroxidase I I_LOCATION
complex I I_LOCATION
) O O
method O O
. O O

In O O
stage O B_ENT/B_MEASURE
I O O
, O O
histochemistry O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
copper O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
11 O B_NUMBER[MEASURE]
out O O
of O O
21 O B_MEASURE
cases O I_MEASURE
: O O
6 O B_MEASURE
cases O I_MEASURE
were O O
T O B_PROTEIN[GENE]/B_DISEASE
+ O I_PROTEIN[GENE]/I_DISEASE
; O O
1 O B_PERSON/B_PROTEIN[GENE]
case O B_PERSON/I_PROTEIN[GENE]
R O B_PERSON/I_PROTEIN[GENE]
+ O B_PERSON/I_PROTEIN[GENE]
and O O
2 O B_DISEASE
cases O I_DISEASE
O O I_DISEASE
+ O I_DISEASE
; O O
2 O B_NUMBER[MEASURE]/B_PERSON
cases O I_NUMBER[MEASURE]/I_PERSON
were O O
T O B_GENE
+ O I_GENE
, O O
R O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
O O B_LOCATION/B_MEASURE
+ O I_LOCATION/I_MEASURE
. O O

The O O
non B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
major I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
histocompatibility I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
complex I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
MHC B B_GENE/B_LOCATION
) O O
- O O
encoded O O
CD1 B B_GENE/B_LOCATION
family I I_GENE/I_LOCATION
has O O
recently O O
emerged O O
as O O
a O O
new O O
antigen O O
- O O
presenting O O
system O O
that O O
is O O
distinct O O
from O O
either O O
MHC B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
class I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
I I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
or I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
class I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
II I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
molecules I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

The O O
predicted O O
amino O O
acid O O
sequence O O
of O O
Pst1p B B_GENE/B_MEASURE
possessed O O
high O O
sequence O O
homology O O
with O O
the O O
Sin3 B B_LOCATION/B_GENE
family I I_LOCATION/I_GENE
of O O
proteins O O
, O O
known O O
for O O
their O O
interaction O O
with O O
histone B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
deacetylases I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Removal O O
of O O
ink4a B B_GENE
dramatically O O
reduces O O
the O O
lymphoid O O
and O O
neurological O O
defects O O
seen O O
in O O
bmi B B_GENE
- I I_GENE
1 I I_GENE
- O O
deficient O O
mice O O
, O O
indicating O O
that O O
ink4a B B_GENE
is O O
a O O
critical O O
in O O
vivo O O
target O O
for O O
Bmi B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Early O O
complement O O
components O O
, O O
C1q B B_PROTEIN[GENE]
and O O
C4 B B_PROTEIN[GENE]
, O O
and O O
IgA B B_NUMBER[MEASURE]/B_PERSON
secretory O O
piece O O
were O O
absent O O
. O O

Using O O
a O O
dominant O O
negative O O
form O O
of O O
Sp3 B B_GENE
and O O
transcriptional O O
activation O O
assays O O
in O O
Schneider O O
SL O O
- O O
2 O O
insect O O
cells O O
, O O
it O O
was O O
confirmed O O
that O O
ERalpha B B_GENE/B_LOCATION
- O O
Sp3 B B_GENE/B_LOCATION
interactions O O
define O O
a O O
pathway O O
for O O
E2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mediated O O
inhibition O O
of O O
gene O O
expression O O
, O O
and O O
this O O
represents O O
a O O
new O O
mechanism O O
for O O
decreased O O
gene O O
expression O O
by O O
E2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

From O O
the O O
supposition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O O
there O O
exists O O
a O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
connection O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
certain O B_DISEASE
psychopathological O I_DISEASE
symptoms O I_DISEASE
, O O
and O O
/ O O
or O O
syndromes O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
e O B_PROTEIN[GENE]/B_DISEASE
. O O
g O B_DISEASE/B_MEASURE
. O O
, O O
hallucinations O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
regional O B_DISEASE
cerebral O I_DISEASE
dysfunction O I_DISEASE
, O O
patients O B_PERSON/B_BIO
suffering O O
from O O
auditory O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
tactile O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hallucinations O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
investigated O O
, O O
in O O
a O O
symptom O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
oriented O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
using O O
the O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
technetium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
99m O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Hexamethyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
propylenamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Oxime O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
99m O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Tc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
HMPAO O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
Single O B_LOCATION/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Photon O B_LOCATION/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Emission O B_LOCATION/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Computed O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tomography O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SPECT O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
) O O
and O O
compared O O
with O O
normal O B_PERSON/B_BIO
controls O I_PERSON/I_BIO
. O O

The O O
false O B_MEASURE/B_DISEASE
positive O I_MEASURE/I_DISEASE
fraction O I_MEASURE/I_DISEASE
( O O
FPF O B_PROTEIN[GENE]/B_LOCATION
) O O
decreased O O
significantly O O
if O O
the O O
count O B_MEASURE/B_DISEASE
density O I_MEASURE/I_DISEASE
increased O O
; O O
no O O
difference O B_MEASURE
in O O
FPF O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
found O O
for O O
a O O
change O B_MEASURE
in O O
lesion O B_MEASURE/B_PERSON
tracer O I_MEASURE/I_PERSON
concentration O I_MEASURE/I_PERSON
. O O

Human B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
plastin I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
genes I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

C B B_GENE
/ I I_GENE
EBP I I_GENE
delta I I_GENE
( O O
NFIL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
was O O
not O O
detected O O
in O O
complexes O O
utilizing O O
extracts O O
from O O
the O O
IL B B_TIME[MEASURE]/B_SPECIES[BIO]
- I I_TIME[MEASURE]/I_SPECIES[BIO]
1 I I_TIME[MEASURE]/I_SPECIES[BIO]
nonproducing O O
T O O
cell O O
line O O
. O O

Here O O
, O O
we O O
describe O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
detailed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aimed O O
at O O
identifying O O
the O O
gene O B_GENE
or O O
genes O B_PROTEIN[GENE]/B_LOCATION
responsible O I_PROTEIN[GENE]/I_LOCATION
for O O
the O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
growth O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
- O O
arrest O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O O
with O O
human O B_GENE/B_LOCATION
chromosome O I_GENE/I_LOCATION
- O O
9 O B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
focused O O
on O O
two O B_NUMBER[MEASURE]/B_PERSON
platyrrhine O I_NUMBER[MEASURE]/I_PERSON
( O O
New O B_PROTEIN[GENE]/B_SPECIES[BIO]
World O I_PROTEIN[GENE]/I_SPECIES[BIO]
monkey O I_PROTEIN[GENE]/I_SPECIES[BIO]
) O O
species O B_BIO/B_LOCATION
: O O
the O O
common O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
marmoset O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Callithrix O B_SPECIES[BIO]/B_LOCATION
jacchus O I_SPECIES[BIO]/I_LOCATION
) O O
and O O
the O O
brown O B_SPECIES[BIO]
capuchin O I_SPECIES[BIO]
monkey O I_SPECIES[BIO]
( O O
Cebus O B_SPECIES[BIO]
apella O I_SPECIES[BIO]
) O O
, O O
each O O
of O O
which O O
has O O
paired O O
, O O
non O B_DISEASE/B_NUMBER[MEASURE]
- O O
allelic O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
gamma O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
loci O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
( O O
5 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
gamma O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
gamma O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_MEASURE
' O O
) O O
. O O

A O O
phase O O
II O O
clinical O O
trial O O
on O O
MDS O O
was O O
conducted O O
in O O
a O O
cooperative O O
study O O
with O O
orally O O
administrable O O
ara O O
- O O
C O O
analogue O O
, O O
PLAC O O
, O O
which O O
is O O
resistant O O
to O O
cytidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
deaminase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
had O O
shown O O
an O O
anti O O
- O O
tumor O O
activity O O
on O O
various O O
experimental O O
tumors O O
by O O
oral O O
route O O
. O O

To O O
address O O
this O O
question O O
with O O
respect O O
to O O
skeletal O O
muscle O O
, O O
we O O
have O O
examined O O
the O O
effects O O
of O O
the O O
Providence O O
mutation O O
in O O
cultured O O
muscle O O
cells O O
, O O
after O O
adoptive O O
gene O O
transfer O O
to O O
adult O O
mice O O
, O O
and O O
in O O
two O O
infants O O
homozygous O O
for O O
spectrin B B_DISEASE/B_PERSON
Providence I I_DISEASE/I_PERSON
. O O

It O O
was O O
found O O
that O O
both O O
versions O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
brief O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SL O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
& O O
amp O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
; O O
shy O B_PERSON/B_LOCATION
; O O
ASIA O B_LOCATION/B_PERSON
had O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
target O B_MEASURE
variables O I_MEASURE
as O O
the O O
full O B_LOCATION/B_PROTEIN[GENE]
scale O I_LOCATION/I_PROTEIN[GENE]
SL O I_LOCATION/I_PROTEIN[GENE]
& O O
amp O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
shy O B_PERSON/B_LOCATION
; O O
ASIA O B_LOCATION/B_MEASURE
. O O

Recently O O
, O O
we O O
and O O
other O O
laboratories O O
have O O
identified O O
a O O
family O O
of O O
caveolin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O O
caveolin B B_LOCATION/B_PERSON
has O O
been O O
re O O
- O O
termed O O
caveolin B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
. O O

Role O O
of O O
zinc B B_GENE
- I I_GENE
finger I I_GENE
proteins I I_GENE
Sp1 I I_GENE
and O O
zif268 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
egr B B_MEASURE
- I I_MEASURE
1 I I_MEASURE
in O O
transcriptional O O
regulation O O
of O O
the O O
human B B_GENE
synaptobrevin I I_GENE
II I I_GENE
gene I I_GENE
. O O

First O O
, O O
mutations O O
in O O
the O O
IFNgamma B B_GENE/B_BIO
- I I_GENE/I_BIO
activated I I_GENE/I_BIO
sequence I I_GENE/I_BIO
( O O
GAS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
, O O
either O O
multimerized O O
or O O
in O O
the O O
context O O
of O O
the O O
1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
7 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IRF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
failed O O
to O O
mediate O O
a O O
PRL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response O O
, O O
showing O O
that O O
the O O
IRF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
GAS B I_GENE/I_DISEASE
is O O
a O O
target O O
of O O
PRL B B_GENE
signaling O O
. O O

The O O
protein O B_ENZYME[GENE]/B_BACTERIUM[BIO]
was O O
overexpressed O O
in O O
Escherichia O B_BIO
coli O I_BIO
and O O
purified O O
to O O
homogeneity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

A O O
360 O O
- O O
bp O O
DNA O O
fragment O O
located O O
over O O
500 O O
bp O O
upstream O O
from O O
the O O
cfl B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcriptional O O
start O O
site O O
was O O
used O O
in O O
DNase B B_GENE
I I I_GENE
protection O O
assays O O
to O O
define O O
the O O
specific O O
bases O O
bound O O
by O O
CorR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
nationwide O O
survey O O
uncovered O O
a O O
tenfold O O
variation O O
between O O
counties O O
in O O
the O O
prescribing O O
of O O
IFNB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

M O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Apps O B_PERSON/B_ORGANIZATION
, O O
D O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
data O O
suggest O O
that O O
weight O O
gain O O
or O O
increased O O
caloric O O
intake O O
, O O
in O O
contrast O O
to O O
its O O
large O O
effect O O
on O O
peripheral O O
thyroid O O
function O O
, O O
has O O
relatively O O
little O O
effect O O
on O O
CNS B B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TRH I I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
. O O

Clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
provides O O
tentative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggestions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
( O O
a O O
) O O
possible O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
additional O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
risk O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cigarette O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
smoking O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
b O B_PROTEIN[GENE]/B_DISEASE
) O O
avoidance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
venography O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
c O B_OTHER/B_PROTEIN[GENE]
) O O
avoidance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
varicose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
vein O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Before O O
and O O
6 O O
and O O
12 O O
months O O
after O O
H O O
. O O
pylori O O
eradication O O
the O O
patients O O
were O O
evaluated O O
for O O
fasting O O
gastrinemia O O
and O O
pepsinogen B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
basal O O
and O O
peak O O
acid O O
output O O
, O O
and O O
detailed O O
histological O O
assessment O O
including O O
the O O
ECL O O
cell O O
proliferative O O
patterns O O
. O O

Defective O O
concanavalin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
suppression O O
in O O
bancroftian O O
filariasis O O
. O O

This O O
result O O
, O O
together O O
with O O
the O O
fact O O
that O O
unrearranged B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
V I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
kappa I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
genes I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
transcriptionally O O
silent O O
, O O
suggests O O
that O O
structural O O
features O O
of O O
both O O
the O O
V B B_PROTEIN[GENE]
kappa I I_PROTEIN[GENE]
and O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loci I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contribute O O
to O O
the O O
overall O O
transcriptional O O
efficiency O O
of O O
a O O
rearranged B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
V I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

NSD1 B B_GENE/B_SPECIES[BIO]
contains O O
a O O
SET B B_MEASURE/B_LOCATION
domain I B_MEASURE/I_LOCATION
and O O
multiple O O
PHD O O
fingers O O
. O O

Among O O
women O O
, O O
plasma B B_LOCATION/B_DISEASE
factor I I_LOCATION/I_DISEASE
VII I I_LOCATION/I_DISEASE
: O O
Ag O O
was O O
inversely O O
associated O O
with O O
income O O
. O O

Symptoms O O
, O O
skin O O
- O O
prick O O
tests O O
( O O
SPT O O
) O O
with O O
environmental O O
allergens O O
and O O
Pt O O
salt O O
, O O
total O O
serum B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IgE I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
lung O O
function O O
, O O
and O O
bronchial O O
hyperresponsiveness O O
were O O
assessed O O
by O O
standard O O
procedures O O
. O O

Binding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sites O B_LOCATION/B_ENT
were O O
mapped O O
for O O
each O O
factor O B_PROTEIN[GENE]
. O O

Complementary O O
DNA O O
libraries O O
from O O
liver O O
and O O
ovary O O
of O O
an O O
immature O O
female O O
channel O O
catfish O O
were O O
screened O O
with O O
a O O
homologous B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ERalpha I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probe O O
. O O

Our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
direct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
enantiomeric O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
separation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
mephenytoin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
obtained O O
by O O
using O O
a O O
chiral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
capillary O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
column O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
the O O
retention O B_MEASURE/B_LOCATION
times O I_MEASURE/I_LOCATION
for O O
S O B_PROTEIN[GENE]/B_DISEASE
- O O
and O O
R O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
mephenytoin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
25 O B_MEASURE
. O O
5 O B_MEASURE
and O O
26 O B_MEASURE
. O O
2 O B_MEASURE/B_PERSON
min O I_MEASURE/I_PERSON
respectively O O
, O O
with O O
a O O
detection O B_MEASURE
limit O I_MEASURE
less O I_MEASURE
than O O
50 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
of O O
mephenytoin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
conclude O O
that O O
GRF1 B B_GENE/B_DISEASE
and O O
GRF2 B B_GENE/B_DISEASE
can O O
form O O
homo O O
- O O
and O O
hetero O O
- O O
oligomers O O
via O O
their O O
DH B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
that O O
mutational O O
inactivation O O
of O O
oligomer O O
formation O O
by O O
GRF1 B B_GENE
is O O
associated O O
with O O
impaired O O
biological O O
and O O
signaling O O
activities O O
, O O
and O O
that O O
in O O
293T O O
cells O O
GRF1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mediates O O
at O O
least O O
two O O
pathways O O
for O O
Raf B B_GENE/B_DISEASE
activation O O
: O O
one O O
a O O
constitutive O O
signal O O
that O O
is O O
mainly O O
Ras B B_GENE/B_DISEASE
- O O
dependent O O
, O O
and O O
one O O
an O O
ionomycin O O
- O O
induced O O
signal O O
that O O
cooperates O O
with O O
the O O
constitutive O O
signal O O
without O O
further O O
augmenting O O
the O O
level O O
of O O
GTP B B_GENE
- I I_GENE
Ras I I_GENE
. O O

Bedbug O O
( O O
Cimex O O
lectularius O O
) O O
samples O O
adult O O
and O O
nymphs O O
either O O
engorged O O
or O O
starved O O
from O O
Central O O
Security O O
Forces O O
sleeping O O
wards O O
, O O
laboratory O O
animal O O
house O O
and O O
control O O
samples O O
from O O
laboratory O O
reared O O
colonies O O
were O O
ground O O
and O O
subjected O O
to O O
ELISA O O
test O O
of O O
hepatitis B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surface I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigen I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
together O O
with O O
276 O O
serum O O
samples O O
from O O
the O O
recruits O O
slept O O
in O O
those O O
wards O O
. O O

Multiple O O
attempts O O
aimed O O
at O O
disruption O O
of O O
the O O
chromosomal B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fabG I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O O
unsuccessful O O
. O O

Thus O O
, O O
the O O
mutants O O
are O O
deficient O O
in O O
production O O
of O O
the O O
O B B_ENZYME[GENE]/B_SPECIES[BIO]
- I I_ENZYME[GENE]/I_SPECIES[BIO]
antigen I I_ENZYME[GENE]/I_SPECIES[BIO]
polymerase I I_ENZYME[GENE]/I_SPECIES[BIO]
and O O
were O O
termed O O
rfc B B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
mutants I I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
. O O

The O O
D443N B B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
substitution I I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
is O O
an O O
activating O O
mutation O O
that O O
increases O O
the O O
activity O O
of O O
SCAP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
renders O O
it O O
resistant O O
to O O
inhibition O O
by O O
25 O O
- O O
hydroxycholesterol O O
. O O

Central O O
( O O
heart O O
rate O O
, O O
VE O O
, O O
VO2 O O
) O O
or O O
local O O
( O O
muscle O O
and O O
blood O O
lactate O O
, O O
adenosine O O
triphosphate O O
, O O
creatine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phosphokinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
glycogen O O
) O O
cues O O
highlighted O O
in O O
these O O
studies O O
demonstrate O O
both O O
the O O
complexity O O
of O O
effort O O
perception O O
, O O
and O O
the O O
need O O
for O O
better O O
understanding O O
of O O
the O O
physiological O O
components O O
upon O O
which O O
it O O
is O O
based O O
. O O

The O O
gene O B_GENE/B_MEASURE
is O O
predicted O O
to O O
encode O O
an O O
880 O B_NUMBER[MEASURE]
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
acid O B_PROTEIN[GENE]
protein O I_PROTEIN[GENE]
which O O
contains O O
two O B_GENE
C2H2 O I_GENE
zinc O I_GENE
fingers O I_GENE
, O O
a O O
nuclear O B_GENE
localization O I_GENE
sequence O I_GENE
and O O
two O B_GENE
transcriptional O I_GENE
activation O I_GENE
domains O I_GENE
. O O

Regulation O O
of O O
activating B B_GENE
transcription I I_GENE
factor I I_GENE
- I I_GENE
1 I I_GENE
and O O
the O O
cAMP B B_GENE/B_TIME[MEASURE]
response I I_GENE/I_TIME[MEASURE]
element I I_GENE/I_TIME[MEASURE]
- I I_GENE/I_TIME[MEASURE]
binding I I_GENE/I_TIME[MEASURE]
protein I I_GENE/I_TIME[MEASURE]
by O O
Ca2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
+ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
calmodulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dependent I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
type I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
II I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
IV I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
nucleotide O O
sequence O O
of O O
a O O
PCR O O
- O O
amplified O O
SMT3A B B_SPECIES[BIO]/B_GENE
genomic O O
DNA O O
fragment O O
was O O
found O O
to O O
be O O
identical O O
to O O
that O O
of O O
SMT3A B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
cDNA I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
indicating O O
the O O
absence O O
of O O
intron O O
( O O
s O O
) O O
in O O
its O O
protein O O
coding O O
region O O
. O O

The O O
Ixodes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
fauna O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
in O O
the O O
Michourin O B_LOCATION
region O I_LOCATION
, O O
where O O
the O O
pastures O B_LOCATION/B_SPECIES[BIO]
in O O
1971 O B_TIME[MEASURE]/B_LOCATION
were O O
grazed O O
only O O
by O O
sheep O B_SPECIES[BIO]
, O O
shows O O
the O O
following O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trends O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
H O B_PROTEIN[GENE]/B_LOCATION
. O O
punctata O B_SPECIES[BIO]/B_DISEASE
and O O
R O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
turanicus O B_SPECIES[BIO]/B_DISEASE
ticks O I_SPECIES[BIO]/I_DISEASE
, O O
which O O
are O O
preferably O O
parasitising O O
in O O
sheep O B_SPECIES[BIO]/B_LOCATION
, O O
increase O O
their O O
relative O B_MEASURE/B_LOCATION
share O I_MEASURE/I_LOCATION
. O O

The O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
respective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
time O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
C5 O B_PROTEIN[GENE]
, O O
C10 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
C15 O B_PROTEIN[GENE]/B_MEASURE
) O O
were O O
injected O O
with O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
cDNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clones O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O O
human O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gamma O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
revealed O O
an O O
open O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reading O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
frame O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
predicting O O
a O O
protein O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
of O O
299 O B_MEASURE
amino O I_MEASURE
acids O I_MEASURE
( O O
approximately O O
32 O B_MEASURE
kDa O I_MEASURE
) O O
, O O
half O O
the O O
size O B_MEASURE/B_LOCATION
of O O
the O O
bovine O B_GENE
gamma O I_GENE
subunit O I_GENE
. O O

A O O
positive O O
FTA B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ABS I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
19S I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IgM I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O O
indicates O O
the O O
necessity O O
of O O
treatment O O
. O O

Our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
some O O
defects O B_DISEASE
observed O O
in O O
BS O B_LOCATION/B_DISEASE
, O O
WS O B_DISEASE/B_PROTEIN[GENE]
or O O
RTS O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
the O O
consequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
unrestrained O B_DISEASE
recombination O I_DISEASE
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
chromatic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
processing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
areas O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
V1 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
V2 O B_PROTEIN[GENE]/B_LOCATION
is O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
V4 O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lesions O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
, O O
together O O
with O O
the O O
behavioural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
that O O
these O O
areas O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
sufficient O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
some O O
basic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
aspects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
colour O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
perception O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Mutations O O
of O O
SIN4 B B_GENE
, O O
ROX3 B B_GENE
, O O
SRB8 B B_GENE
, O O
SRB9 B B_GENE
, O O
SRB10 B B_GENE
, O O
SRB11 B B_GENE
, O O
and O O
two O O
novel O O
genes O O
, O O
NUT1 B B_GENE/B_DISEASE
and O O
NUT2 B B_GENE/B_DISEASE
, O O
relieve O O
the O O
requirement O O
of O O
Swi4p B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
for O O
expression O O
of O O
this O O
reporter O O
. O O

Attenuated O O
serum O O
cortisol O O
responses O O
were O O
found O O
in O O
six O O
of O O
the O O
patients O O
despite O O
a O O
normal O O
ACTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
test O O
. O O

The O O
screen O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
identifies O O
mutants O B_DISEASE/B_BIO
whose O O
growth O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depends O O
on O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
expression O B_GENE
of O O
that O O
gene O B_ENZYME[GENE]/B_MEASURE
. O O

The O O
efficiency O O
of O O
transfections O O
was O O
normalized O O
relative O O
to O O
the O O
net O O
amount O O
of O O
CAT B B_BIO/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
plasmid O O
actually O O
transfected O O
into O O
recipient O O
cells O O
, O O
determined O O
by O O
a O O
modified O O
Southern O O
hybridization O O
procedure O O
. O O

Allergen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
stimulated O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
PGD2 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
1274 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
565 O B_MEASURE
versus O I_MEASURE
1468 O I_MEASURE
+ O I_MEASURE
/ O O
- O O
679 O B_MEASURE
after O O
prednisone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
; O O
likewise O O
, O O
allergen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
stimulated O O
5 O B_MEASURE
- O O
HETE O B_PROTEIN[GENE]
levels O I_PROTEIN[GENE]
were O O
95 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
21 O B_MEASURE
versus O I_MEASURE
82 O I_MEASURE
+ O I_MEASURE
/ O O
- O O
21 O B_MEASURE
; O O
those O O
of O O
LTE4 O B_GENE/B_MEASURE
were O O
54 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
20 O B_MEASURE
versus O I_MEASURE
91 O I_MEASURE
+ O I_MEASURE
/ O O
- O O
51 O B_MEASURE
; O O
and O O
those O O
of O O
15 O B_NUMBER[MEASURE]
- O O
HETE O B_MEASURE/B_PROTEIN[GENE]
were O O
63 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
19 O B_MEASURE
versus O I_MEASURE
60 O I_MEASURE
+ O I_MEASURE
/ O O
- O O
25 O B_MEASURE
. O O

Furthermore O O
, O O
we O O
demonstrate O O
that O O
in O O
myeloid O O
and O O
B O O
cell O O
extracts O O
, O O
PU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
forms O O
a O O
novel O O
, O O
specific O O
, O O
more O O
slowly O O
migrating O O
complex O O
( O O
PU B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
SF I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
when O O
binding O O
the O O
GM B B_GENE/B_DISEASE
- I B_GENE/I_DISEASE
CSF I B_GENE/I_DISEASE
receptor I B_GENE/I_DISEASE
alpha I B_GENE/I_DISEASE
promoter O O
PU B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site O O
. O O

A O O
third O B_SEQUENCE[MEASURE]
- O O
order O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
polynominal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
fit O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O O
a O O
good O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
the O O
parameter O B_MEASURE/B_PROTEIN[GENE]
Q O B_MEASURE/I_PROTEIN[GENE]
* O O
and O O
MTT O B_PROTEIN[GENE]/B_MEASURE
, O O
whereas O O
T O B_GENE/B_MEASURE
and O O
SImax O B_LOCATION/B_MEASURE
were O O
found O O
to O O
have O O
a O O
poor O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlation O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

The O O
difference O O
between O O
the O O
results O O
in O O
the O O
high O O
dose O O
AHLG B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O O
in O O
the O O
control O O
group O O
was O O
significant O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

Reduction O O
of O O
p53 B B_GENE/B_DISEASE
protein I I_GENE/I_DISEASE
was O O
detected O O
after O O
1 O O
day O O
of O O
OM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
and O O
reached O O
maximal O O
suppression O O
of O O
10 O O
- O O
20 O O
% O O
of O O
control O O
after O O
3 O O
days O O
in O O
H3922 O O
and O O
40 O O
% O O
of O O
control O O
after O O
4 O O
days O O
in O O
MCF O O
- O O
7 O O
cells O O
. O O

However O O
, O O
it O O
was O O
observed O O
that O O
storage O B_MEASURE/B_DISEASE
time O B_MEASURE/I_DISEASE
affected O O
significantly O O
the O O
biochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
occurring O O
in O O
the O O
constituents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
carrots O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
exposed O O
to O O
gamma O B_PROTEIN[GENE]
- O O
irradiation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Suppression O O
of O O
the O O
cka1 B B_DISEASE_ADJECTIVE[DISEASE]
delta I I_DISEASE_ADJECTIVE[DISEASE]
cka2 I I_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
8 I I_DISEASE_ADJECTIVE[DISEASE]
mutant I I_DISEASE_ADJECTIVE[DISEASE]
phenotype O O
occurs O O
by O O
interaction O O
of O O
CKB1 B B_GENE
with O O
the O O
defective O O
, O O
cka2 B B_GENE
- I I_GENE
8 I I_GENE
- O O
encoded O O
, O O
catalytic O O
subunit O O
. O O

Thomas O B_PERSON
, O O
S O B_PROTEIN[GENE]/B_DISEASE
. O O
S O B_OTHER/B_DISEASE
. O O

Transient O O
transfection O O
assays O O
indicated O O
that O O
the O O
( O O
- O O
4551 O O
) O O
UCP1 B B_GENE/B_LOCATION
- O O
CAT B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
construct O O
, O O
containing O O
the O O
5 O O
' O O
- O O
regulatory O O
region O O
of O O
the O O
rat B B_GENE
ucp I I_GENE
- I I_GENE
1 I I_GENE
gene I I_GENE
, O O
was O O
activated O O
by O O
PPARalpha B B_GENE
co O O
- O O
transfection O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
and O O
this O O
activation O O
was O O
potentiated O O
by O O
Wy O O
14 O O
, O O
643 O O
and O O
retinoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
X I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

These O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O O
further O O
examined O O
with O O
regard O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
modulation O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
discharge O B_MEASURE/B_BIO
rate O I_MEASURE/I_BIO
i O O
) O O
during O O
motor O B_DISEASE/B_PROTEIN[GENE]
activity O B_DISEASE/I_PROTEIN[GENE]
in O O
W O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
ii O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
at O O
the O O
transitional O B_TIME[MEASURE]/B_LOCATION
phase O I_TIME[MEASURE]/I_LOCATION
from O O
SS O B_DISEASE/B_PROTEIN[GENE]
to O O
paradoxical O B_DISEASE
sleep O I_DISEASE
( O O
PS O B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
iii O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
during O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]
eye O I_DISEASE_ADJECTIVE[DISEASE]
movements O I_DISEASE_ADJECTIVE[DISEASE]
( O O
REMs O B_DISEASE/B_LOCATION
) O O
in O O
PS O B_LOCATION/B_PROTEIN[GENE]
, O O
and O O
iv O B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
) O O
following O O
electrical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
the O O
midbrain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
reticular O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
formation O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MRF O B_LOCATION/B_PROTEIN[GENE]
) O O
. O O

Likewise O O
, O O
the O O
consensus O O
signal O O
believed O O
to O O
be O O
involved O O
in O O
terminating O O
VV B B_GENE
early I I_GENE
gene I I_GENE
transcription O O
, O O
TTTTTNT O O
, O O
was O O
evident O O
at O O
the O O
3 O O
' O O
- O O
boundary O O
of O O
both O O
the O O
N2 O O
and O O
M1 O O
ORFs O O
suggesting O O
that O O
these O O
genes O O
may O O
be O O
VV B B_DISEASE_ADJECTIVE[DISEASE]
early I I_DISEASE_ADJECTIVE[DISEASE]
genes I I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
radiolabeled O O
, O O
900 O B_MEASURE
- O O
bp O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
amplicon O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
used O O
as O O
a O O
hybridization O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probe O B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
screen O O
a O O
cDNA O B_GENE
library O I_GENE
constructed O O
from O O
poly O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
( O O
+ O B_PROTEIN[GENE]/B_DISEASE
) O O
RNA O B_GENE/B_BIO
isolated O O
from O O
induced O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
Taxus O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
from O O
which O O
a O O
full O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
length O B_GENE/B_MEASURE
transacetylase O I_GENE/I_MEASURE
sequence O I_GENE/I_MEASURE
was O O
obtained O O
. O O

Low O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
temperature O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
8 O B_PROTEIN[GENE]/B_LOCATION
degrees O I_PROTEIN[GENE]/I_LOCATION
C O I_PROTEIN[GENE]/I_LOCATION
) O O
impairs O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secretory O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
again O O
independently O O
of O O
the O O
photoperiod O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
selected O O
. O O

Although O O
the O O
QT O B_MEASURE
duration O I_MEASURE
was O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
p O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
0001 O B_MEASURE
) O O
at O O
night O B_MEASURE/B_LOCATION
, O O
the O O
beat O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
to O O
- O O
beat O B_MEASURE/B_LOCATION
variability O I_MEASURE/I_LOCATION
of O O
this O O
interval O B_MEASURE
was O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
: O O
in O O
the O O
time O B_MEASURE/B_LOCATION
domain O I_MEASURE/I_LOCATION
( O O
decreased O O
standard O B_MEASURE
deviation O I_MEASURE
, O O
p O O
= O O
0 O B_NUMBER[MEASURE]
. O O
0005 O B_MEASURE
) O O
, O O
in O O
the O O
frequency O B_MEASURE/B_LOCATION
domain O I_MEASURE/I_LOCATION
( O O
decreased O O
low O B_MEASURE/B_DISEASE
- O O
frequency O B_MEASURE
power O I_MEASURE
of O O
the O O
spectra O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
p O O
= O O
0 O B_MEASURE
. O O
004 O B_MEASURE
) O O
, O O
and O O
the O O
chaotic O B_MEASURE/B_LOCATION
domain O I_MEASURE/I_LOCATION
( O O
tighter O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clustering O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
points O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
the O O
Poincare O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
plots O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

The O O
biological O O
functions O O
of O O
rat O O
surfactant B B_GENE
protein I I_GENE
A I I_GENE
( O O
SP B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
A I I_DISEASE/I_LOCATION
) O O
, O O
an O O
oligomer O O
composed O O
of O O
18 O O
polypeptide O O
subunits O O
derived O O
from O O
a O O
single O O
gene O O
, O O
are O O
dependent O O
on O O
intact O O
disulfide O O
bonds O O
. O O

A O O
V1 B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
mutant I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
generated O O
in O O
vivo O O
with O O
11 O O
of O O
the O O
14 O O
N O O
- O O
terminal O O
amino O O
acids O O
altered O O
, O O
was O O
viable O O
and O O
produced O O
symptoms O O
typical O O
of O O
a O O
wild O O
- O O
type O O
infection O O
. O O

We O O
have O O
demonstrated O O
that O O
the O O
specific O O
determination O O
and O O
identification O O
of O O
plasma O O
FbDP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alone O O
is O O
not O O
sufficient O O
to O O
follow O O
the O O
effectiveness O O
of O O
thrombolytic O O
therapy O O
. O O

Coronary O O
vasoconstriction O O
caused O O
by O O
endothelin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
enhanced O O
by O O
ischemia O O
- O O
reperfusion O O
and O O
by O O
norepinephrine O O
present O O
in O O
concentrations O O
typically O O
observed O O
after O O
neonatal O O
cardiopulmonary O O
bypass O O
. O O

We O O
have O O
previously O O
demonstrated O O
that O O
pyrene O O
in O O
diesel O O
- O O
exhaust O O
particles O O
( O O
DEP O O
) O O
has O O
an O O
adjuvant O O
activity O O
on O O
immunoglobulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
IgE B B_PROTEIN[GENE]/B_LOCATION
) O O
antibody O O
production O O
in O O
mice O O
immunized O O
with O O
Japanese O O
cedar O O
pollen O O
allergen O O
( O O
JCPA O O
) O O
or O O
ovalbumin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
OA B B_LOCATION/B_DISEASE
) O O
intraperitoneally O O
. O O

( O O
LH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
P O O
< O O
0 O O
. O O
05 O O
, O O
LH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
FSH B B_GENE
P O O
< O O
0 O O
. O O
01 O O
) O O
. O O

Inhibition O O
of O O
Raf B B_GENE
- I I_GENE
1 I I_GENE
signaling O O
by O O
a O O
monoclonal O O
antibody O O
, O O
which O O
interferes O O
with O O
Raf B B_GENE
- I I_GENE
1 I I_GENE
activation O O
and O O
with O O
Mek B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
substrate O O
binding O O
. O O

The O O
classic O O
sterol O O
regulatory O O
cis O O
element O O
( O O
sre O O
- O O
1 O O
) O O
in O O
the O O
LDL B B_GENE
receptor I I_GENE
promoter O O
mediates O O
sterol B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulatory I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SREBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
- O O
binding O O
and O O
the O O
effects O O
of O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
platelet B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
derived I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PDGF B B_GENE
) O O
. O O

The O O
isoproterenol O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
infusion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
was O O
adjusted O O
so O O
that O O
heart O B_MEASURE/B_LOCATION
rate O B_MEASURE/I_LOCATION
( O O
HR O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
was O O
at O O
least O O
30 O B_MEASURE
beats O I_MEASURE
/ O O
min O B_TIME[MEASURE]/B_LOCATION
greater O I_TIME[MEASURE]/I_LOCATION
than O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

This O O
is O O
probably O O
because O O
, O O
in O O
vivo O O
, O O
some O O
bacteria O O
( O O
perhaps O O
dormant O O
forms O O
) O O
are O O
not O O
entirely O O
dependent O O
upon O O
urease B B_BACTERIUM[BIO]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
survival O O
. O O

The O O
system O O
consists O O
of O O
a O O
microcomputer O O
and O O
six O O
laboratory O O
analyzers O O
: O O
a O O
blood O O
gas O O
analyzer O O
, O O
a O O
flame O O
photometer O O
, O O
a O O
plasma O O
osmotic O O
pressure O O
meter O O
, O O
a O O
chloride O O
ion O O
titrator O O
, O O
a O O
blood O O
sugar O O
analyzer O O
, O O
and O O
a O O
hemoglobin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentration O O
and O O
saturation O O
meter O O
. O O

These O O
results O O
suggest O O
that O O
the O O
Reg1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
Glc7 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phosphatase O O
is O O
a O O
cytoplasmic O O
component O O
of O O
the O O
machinery O O
responsible O O
for O O
returning O O
Snf1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
to O O
its O O
basal O O
level O O
and O O
reestablishing O O
glucose O O
repression O O
. O O

The O O
structure O O
of O O
the O O
mAR B B_DISEASE_ADJECTIVE[DISEASE]/B_SEQUENCE[MEASURE]
ORF O O
was O O
confirmed O O
by O O
sequence O O
analysis O O
of O O
mAR B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
cDNA O O
fragments O O
, O O
which O O
were O O
obtained O O
by O O
PCR O O
amplification O O
of O O
mouse O O
testis O O
cDNA O O
, O O
using O O
mAR B B_NUMBER[MEASURE]/B_BIO
specific O O
primers O O
. O O

The O O
Thrombolysis O O
in O O
Myocardial O O
Infarction O O
( O O
TIMI O O
) O O
Phase O O
II O O
Trial O O
randomized O O
3 O O
, O O
339 O O
patients O O
to O O
either O O
an O O
invasive O O
( O O
INV O O
, O O
n O O
= O O
1 O O
, O O
681 O O
) O O
or O O
a O O
conservative O O
( O O
CON O O
, O O
n O O
= O O
1 O O
, O O
658 O O
) O O
strategy O O
after O O
intravenous O O
recombinant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tissue I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
type I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
plasminogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
rt B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PA I I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
for O O
acute O O
myocardial O O
infarction O O
. O O

An O O
analogue O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
calcium O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
strontium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Sr O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
89 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
rapidly O O
cleared O O
from O O
the O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
after O O
i O O
. O O
v O B_PROTEIN[GENE]/B_LOCATION
. O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Patients O O
with O O
the O O
chronic O O
photosensitivity O O
dermatitis O O
with O O
actinic O O
reticuloid O O
syndrome O O
have O O
high O O
total O O
serum O O
IgE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentrations O O
. O O

The O O
sequence O B_LOCATION/B_MEASURE
of O O
the O O
25 O B_MEASURE
- O O
kDa O B_PROTEIN[GENE]/B_MEASURE
chain O I_PROTEIN[GENE]/I_MEASURE
of O O
the O O
alpha O B_GENE
subunit O I_GENE
was O O
found O O
in O O
a O O
cDNA O B_GENE
clone O I_GENE
, O O
and O O
the O O
amino O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
deduced O O
from O O
the O O
cDNA O B_GENE
establishes O O
the O O
complete O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
25 O B_MEASURE
- O O
kDa O B_PROTEIN[GENE]/B_MEASURE
chain O I_PROTEIN[GENE]/I_MEASURE
. O O

Characterization O O
of O O
the O O
chromosome O O
19 O O
breakpoint O O
region O O
revealed O O
that O O
the O O
transcription B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
encoding I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
USF2 I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
is O O
affected O O
. O O

Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
active O O
Tax B B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
able O O
to O O
abrogate O O
the O O
G1 O O
arrest O O
and O O
apoptosis O O
induced O O
by O O
p53 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
this O O
effect O O
does O O
not O O
correlate O O
with O O
an O O
altered O O
localization O O
of O O
nuclear B B_GENE
p53 I I_GENE
or O O
with O O
the O O
disruption O O
of O O
p53 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
lowest O B_MEASURE
PaCO2 O I_MEASURE
values O I_MEASURE
were O O
significantly O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
MCE O B_PROTEIN[GENE]/B_MEASURE
than O O
in O O
the O O
F O B_PROTEIN[GENE]/B_DISEASE
, O O
W O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
D O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
F O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
W O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
controls O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
translational O O
product O O
of O O
UL26 B B_GENE/B_TIME[MEASURE]
. I I_GENE/I_TIME[MEASURE]
5 I I_GENE/I_TIME[MEASURE]
is O O
infected B B_GENE
- I I_GENE
cell I I_GENE
protein I I_GENE
35c I I_GENE
, I I_GENE
d I I_GENE
( O O
ICP35c B B_NUMBER[MEASURE]/B_LOCATION
, I I_NUMBER[MEASURE]/I_LOCATION
d I I_NUMBER[MEASURE]/I_LOCATION
) O O
( O O
F O O
. O O

The O O
mouse B B_GENE/B_LOCATION
tapasin I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
was O O
mapped O O
about O O
70 O O
kilobases O O
from O O
H2 B B_LOCATION/B_PERSON
- I I_LOCATION/I_PERSON
K I I_LOCATION/I_PERSON
at O O
the O O
centromeric O O
end O O
of O O
the O O
mouse B B_GENE/B_LOCATION
MHC I I_GENE/I_LOCATION
. O O

Subsequent O O
analysis O O
revealed O O
that O O
MyD88 B B_GENE
possesses O O
a O O
unique O O
modular O O
structure O O
, O O
which O O
consists O O
of O O
an O O
N O O
- O O
terminal O O
" O O
death O O
domain O O
, O O
" O O
similar O O
to O O
the O O
intracellular O O
segments O O
of O O
TNF B B_GENE
receptor I I_GENE
1 I I_GENE
and O O
Fas B B_GENE/B_MEASURE
, O O
and O O
a O O
C O O
- O O
terminal O O
region O O
related O O
to O O
the O O
cytoplasmic O O
domains O O
of O O
the O O
Drosophila B B_SPECIES[BIO]
morphogen I I_SPECIES[BIO]
Toll I I_SPECIES[BIO]
and O O
vertebrate O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

PtdIns B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
4 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
5 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
P2 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
synthesis O O
, O O
on O O
the O O
other O O
hand O O
, O O
is O O
only O O
moderately O O
affected O O
even O O
in O O
fab1Delta B B_PERSON/B_DISEASE
mutants I I_PERSON/I_DISEASE
. O O

We O O
found O O
that O O
48 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
patients O B_PERSON/B_BIO
had O O
their O O
thoracolumbar O B_DISEASE_ADJECTIVE[DISEASE]
blood O I_DISEASE_ADJECTIVE[DISEASE]
supply O I_DISEASE_ADJECTIVE[DISEASE]
based O O
on O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anterior O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radiculospinal O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arteries O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
lowest O B_SEQUENCE[MEASURE]/B_LOCATION
of O O
which O O
was O O
located O O
at O O
, O O
or O O
lower O B_TIME[MEASURE]
than O O
, O O
T12 O B_PROTEIN[GENE]
, O O
and O O
the O O
second O B_SEQUENCE[MEASURE]/B_LOCATION
and O O
higher O B_SEQUENCE[MEASURE]
one O I_SEQUENCE[MEASURE]
between O O
T6 O B_PROTEIN[GENE]
and O O
T10 O B_MEASURE/B_PROTEIN[GENE]
. O O

The O O
plants O O
were O O
then O O
brought O O
to O O
our O O
Houston O O
laboratory O O
where O O
they O O
were O O
measured O O
and O O
analyzed O O
for O O
lignin O O
and O O
protein O O
content O O
and O O
for O O
phenylalanine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
ammonia I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
lyase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PAL B B_DISEASE/B_LOCATION
) O O
and O O
peroxidase B B_ENZYME[GENE]/B_DISEASE
activities O O
. O O

Pax B B_GENE/B_TIME[MEASURE]
- I I_GENE/I_TIME[MEASURE]
6 I I_GENE/I_TIME[MEASURE]
constructs O O
lacking O O
the O O
C O O
- O O
terminal O O
activation O O
domain O O
repressed O O
betaB1 B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
crystallin I I_GENE/I_DISEASE
promoter I I_GENE/I_DISEASE
activity O O
as O O
effectively O O
as O O
the O O
full O O
- O O
length O O
protein O O
, O O
but O O
the O O
PD B B_DISEASE/B_GENE
alone O O
or O O
Pax B B_GENE/B_MEASURE
- I B_GENE/I_MEASURE
6 I B_GENE/I_MEASURE
( I B_GENE/I_MEASURE
5a I B_GENE/I_MEASURE
) I B_GENE/I_MEASURE
, O O
a O O
splice O O
variant O O
with O O
an O O
altered O O
PD B B_DISEASE/B_LOCATION
affecting O O
its O O
DNA O O
binding O O
specificity O O
, O O
did O O
not O O
. O O

The O O
predicted O O
amino O O
acid O O
sequence O O
contained O O
all O O
consensus O O
regions O O
for O O
S B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
adenosyl I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
methionine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
methyltransferases I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
presented O O
26 O O
% O O
identity O O
with O O
Saccharomyces B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
cerevisiae I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
DHHB I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
methyltransferase I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
38 O O
% O O
identity O O
with O O
the O O
rat O O
protein O O
, O O
as O O
well O O
as O O
with O O
a O O
bacterial O O
( O O
Escherichia O O
coli O O
and O O
Salmonella O O
typhimurium O O
) O O
methyltransferase B B_ENZYME[GENE]/B_BIO
encoded O O
by O O
the O O
UBIG B B_GENE
gene I I_GENE
. O O

Two O O
plasmids O O
, O O
one O O
containing O O
the O O
amino O O
terminus O O
of O O
P O O
fused O O
to O O
the O O
DNA O O
- O O
binding O O
domain O O
of O O
the O O
yeast O O
transactivator O O
, O O
GAL4 B B_GENE/B_SPECIES[BIO]
, O O
and O O
the O O
other O O
containing O O
the O O
amino O O
terminus O O
of O O
NP B B_PROTEIN[GENE]/B_DISEASE
fused O O
to O O
the O O
herpesvirus O O
transactivator O O
, O O
VP16 B B_GENE/B_LOCATION
, O O
were O O
transfected O O
in O O
COS O O
- O O
1 O O
cells O O
along O O
with O O
a O O
chloramphenicol B B_ENZYME[GENE]
acetyltransferase I I_ENZYME[GENE]
( O O
CAT B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
reporter O O
plasmid O O
containing O O
GAL4 B B_NUMBER[MEASURE]/B_PERSON
DNA O O
- O O
binding O O
sites O O
. O O

For O O
the O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
phase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
it O O
was O O
12 O B_MEASURE
. O O
5 O B_MEASURE
wk O I_MEASURE
for O O
RIR O B_PROTEIN[GENE]/B_PERSON
and O O
10 O B_NUMBER[MEASURE]
for O O
WL O B_PERSON/B_PROTEIN[GENE]
males O I_PERSON/I_PROTEIN[GENE]
, O O
whereas O O
it O O
was O O
5 O B_MEASURE
wk O I_MEASURE
for O O
RIR O B_LOCATION/B_PROTEIN[GENE]
and O O
6 O B_MEASURE
for O O
WL O B_PERSON
females O I_PERSON
. O O

During O O
normoxic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
exercise O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
at O O
a O O
mean O B_MEASURE
O2 O I_MEASURE
uptake O I_MEASURE
( O O
VO2 O B_PROTEIN[GENE]/B_LOCATION
) O O
of O O
4 O B_MEASURE
. O O
0 O B_MEASURE/B_LOCATION
l O I_MEASURE/I_LOCATION
/ O O
min O B_TIME[MEASURE]/B_PERSON
, O O
almitrine O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O O
arterial O B_PROTEIN[GENE]/B_LOCATION
PO2 O I_PROTEIN[GENE]/I_LOCATION
( O O
PaO2 O B_MEASURE/B_PROTEIN[GENE]
) O O
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
, O O
SaO2 O B_MEASURE/B_PROTEIN[GENE]
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
, O O
and O O
VE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
and O O
decreased O O
arterial O B_PROTEIN[GENE]/B_DISEASE
PCO2 O I_PROTEIN[GENE]/I_DISEASE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
, O O
without O O
affecting O O
pulmonary O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hemodynamics O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
ventilation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
perfusion O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distributions O B_DISEASE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
expression O O
of O O
the O O
leukocyte B B_GENE
EL I I_GENE
- I I_GENE
246 I I_GENE
antigen I I_GENE
was O O
regulated O O
in O O
the O O
same O O
manner O O
as O O
L B B_GENE
- I I_GENE
selectin I I_GENE
and O O
EL B B_TIME[MEASURE]/B_PERSON
- I I_TIME[MEASURE]/I_PERSON
246 I I_TIME[MEASURE]/I_PERSON
recognized O O
anti B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
L I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
selectin I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mAb I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
affinity O O
- O O
purified O O
antigen O O
in O O
SDS O O
/ O O
PAGE O O
Western O O
blot O O
analysis O O
. O O

The O O
entire O O
coding O O
region O O
of O O
an O O
ovine B B_GENE
endometrial I I_GENE
oxytocin I I_GENE
receptor I I_GENE
( O O
OTR B B_LOCATION/B_GENE
) O O
cDNA O O
was O O
generated O O
by O O
PCR O O
, O O
subcloned O O
into O O
the O O
SV40 B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
major I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
late I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
vector O O
pSVLJ O O
and O O
transiently O O
expressed O O
in O O
Cos O O
- O O
7 O O
cells O O
. O O

These O O
operons O O
encode O O
subunits O O
of O O
photosystems B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
I I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
( O O
psa B B_DISEASE/B_LOCATION
) O O
and O O
II O O
( O O
psb B B_DISEASE/B_LOCATION
) O O
, O O
the O O
cytochrome B B_ENZYME[GENE]
bGf I I_ENZYME[GENE]
complex I I_ENZYME[GENE]
( O O
pet B B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
the O O
plastid O O
NAD B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
P I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
H I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ndh B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
, O O
and O O
the O O
unidentified O O
open O O
reading O O
frame O O
ycf9 B B_GENE/B_MEASURE
. O O

Transcriptional O O
modulation O O
of O O
the O O
anti B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
apoptotic I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
BCL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
XL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
the O O
paired B B_GENE
box I I_GENE
transcription I I_GENE
factors I I_GENE
PAX3 B I_GENE
and O O
PAX3 B B_GENE/B_LOCATION
/ O O
FKHR B B_MEASURE
. O O

The O O
level O O
of O O
expression O O
of O O
the O O
PDE B B_GENE
protein I I_GENE
was O O
monitored O O
by O O
immunoblot O O
analysis O O
using O O
two O O
specific O O
cAMP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PDE I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polyclonal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
by O O
measuring O O
the O O
PDE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
activity O O
. O O

Since O O
UmuD B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
proteolytically O O
processed O O
to O O
an O O
active O O
form O O
( O O
UmuD B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
* I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
a O O
RecA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
* O O
- O O
dependent O O
fashion O O
, O O
and O O
MucA B B_TIME[MEASURE]/B_BACTERIUM[BIO]
shares O O
extensive O O
amino O O
acid O O
homology O O
with O O
UmuD B B_GENE/B_BIO
, O O
we O O
examined O O
whether O O
MucA B B_BACTERIUM[BIO]/B_PERSON
is O O
similarly O O
processed O O
in O O
the O O
cell O O
, O O
using O O
antiserum O O
against O O
a O O
LacZ B B_MEASURE/B_GENE
' I I_MEASURE/I_GENE
- O O
' B B_GENE/B_BACTERIUM[BIO]
MucA I I_GENE/I_BACTERIUM[BIO]
fusion O O
protein O O
. O O

These O O
studies O O
reveal O O
that O O
CREM B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
tissue O O
- O O
specific O O
factor O O
, O O
is O O
expressed O O
and O O
regulated O O
by O O
gonadotropins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
ovary O O
, O O
that O O
the O O
predominant O O
CREM B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
transcripts O O
encode O O
the O O
repressor B B_GENE/B_MEASURE
protein I I_GENE/I_MEASURE
ICER I I_GENE/I_MEASURE
, O O
and O O
that O O
ICER B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
capable O O
of O O
inhibiting O O
cAMP O O
- O O
induced O O
expression O O
of O O
the O O
inhibin B B_GENE/B_MEASURE
alpha I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
subunit I I_GENE/I_MEASURE
gene I I_GENE/I_MEASURE
. O O

While O O
these O O
could O O
be O O
unusual O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
chronic O B_DISEASE/B_GENE
non O I_DISEASE/I_GENE
- O O
A O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
non O B_DISEASE/B_LOCATION
- O O
B O B_DISEASE
hepatitis O I_DISEASE
, O O
this O O
can O O
be O O
only O O
speculation O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
until O O
a O O
serologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
non O B_DISEASE/B_GENE
- O O
A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
non O B_DISEASE/B_LOCATION
- O O
B O B_DISEASE/B_PROTEIN[GENE]
hepatitis O B_DISEASE/I_PROTEIN[GENE]
becomes O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Acanthamoeba B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myosin I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heavy I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MIHCK B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
phosphorylates O O
the O O
heavy O O
chains O O
of O O
amoeba B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
myosins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
increasing O O
their O O
actin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O O
activated O O
ATPase B B_ENZYME[GENE]
activities O O
. O O

We O O
propose O O
that O O
unc B B_PERSON/B_LOCATION
- I I_PERSON/I_LOCATION
37 I I_PERSON/I_LOCATION
may O O
be O O
regulated O O
by O O
unc B B_GENE
- I I_GENE
4 I I_GENE
. O O

Adenovirus O O
infection O O
of O O
hepatoma O O
cells O O
inhibited O O
transcription O O
of O O
the O O
phosphoenolpyruvate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
carboxykinase I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
GTP O O
) O O
( O O
EC B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
4 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
32 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
( O O
PEPCK B B_GENE/B_SPECIES[BIO]
) O O
gene O O
and O O
virtually O O
eliminated O O
transcription O O
of O O
a O O
chimeric O O
gene O O
which O O
contained O O
the O O
PEPCK B B_GENE
promoter I I_GENE
linked O O
to O O
the O O
structural O O
gene O O
for O O
chloramphenicol B B_GENE
acetyltransferase I I_GENE
( O O
CAT B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Choline B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
acetyltransferase I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
immunohistochemistry O O
combined O O
with O O
the O O
retrograde O O
transport O O
of O O
horseradish B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
peroxidase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
showed O O
that O O
the O O
reticular O O
and O O
mediodorsal O O
thalamic O O
nuclei O O
of O O
the O O
cat O O
receive O O
an O O
important O O
input O O
from O O
cholinergic O O
and O O
non O O
- O O
cholinergic O O
neurons O O
of O O
substantia O O
innominata O O
and O O
adjacent O O
structures O O
in O O
the O O
basal O O
forebrain O O
. O O

( O O
i O O
) O O
The O O
chimeric O O
gene O O
consisting O O
of O O
the O O
coding O O
and O O
5 O O
' O O
nontranslated O O
leader O O
regions O O
of O O
the O O
TK B B_GENE
gene I I_GENE
fused O O
to O O
portions O O
of O O
the O O
domain O O
of O O
alpha B B_GENE
gene I I_GENE
0 I I_GENE
extending O O
largely O O
upstream O O
from O O
the O O
site O O
of O O
initiation O O
of O O
transcription O O
of O O
alpha B B_GENE
gene I I_GENE
0 I I_GENE
was O O
regulated O O
in O O
the O O
same O O
fashion O O
as O O
the O O
alpha B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
4 I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
and I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
27 I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
TK I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
chimeras O O
. O O

For O O
the O O
albino O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
both O O
the O O
ST1 O B_PROTEIN[GENE]/B_LOCATION
and O O
ST2 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
spatial O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
responses O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
peak O O
at O O
around O O
0 O B_MEASURE
. O O
3 O B_MEASURE/B_LOCATION
cycles O I_MEASURE/I_LOCATION
deg O I_MEASURE/I_LOCATION
- O O
1 O B_MEASURE
, O O
and O O
both O O
curves O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O O
displaced O O
considerably O O
to O O
the O O
low O B_LOCATION/B_MEASURE
spatial O I_LOCATION/I_MEASURE
frequency O I_LOCATION/I_MEASURE
side O I_LOCATION/I_MEASURE
of O O
the O O
normal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
ST2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
spatial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

From O O
a O O
chromosomal O O
cosmid O O
library O O
of O O
Streptomyces O O
argillaceus O O
, O O
a O O
Mtm B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
producer O O
, O O
a O O
clone O O
( O O
cosAR7 O O
) O O
was O O
isolated O O
by O O
homology O O
to O O
the O O
actI B B_GENE
/ I I_GENE
III I I_GENE
region I I_GENE
of O O
S O O
. O O
coelicolor O O
and O O
the O O
strDEM B B_GENE/B_BIO
genes I I_GENE/I_BIO
of O O
S O O
. O O
griseus O O
. O O

Thirty O B_NUMBER[MEASURE]
- O O
three O B_NUMBER[MEASURE]
small O I_NUMBER[MEASURE]
glottic O I_NUMBER[MEASURE]
carcinomas O I_NUMBER[MEASURE]
( O O
T1 O B_PROTEIN[GENE]
and O O
small O B_PROTEIN[GENE]/B_DISEASE
T2 O I_PROTEIN[GENE]/I_DISEASE
; O O
UICC O B_PERSON
, O O
1978 O B_MEASURE
) O O
were O O
examined O O
by O O
malignancy O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
grading O O
using O O
the O O
8 O B_NUMBER[MEASURE]
- O O
factor O B_MEASURE/B_LOCATION
system O I_MEASURE/I_LOCATION
proposed O O
by O O
Jakobsson O B_PERSON/B_ORGANIZATION
et O I_PERSON/I_ORGANIZATION
al O I_PERSON/I_ORGANIZATION
. O O

In O O
marked O O
contrast O O
to O O
the O O
previously O O
published O O
human B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CD6 I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
mouse O O
sequence O O
predicts O O
a O O
long O O
cytoplasmic O O
tail O O
that O O
is O O
not O O
closely O O
related O O
to O O
other O O
proteins O O
and O O
possesses O O
two O O
proline O O
- O O
rich O O
motifs O O
containing O O
the O O
SH3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consensus I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
three O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphorylation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motifs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
nine O O
casein B B_GENE/B_LOCATION
kinase I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
phosphorylation I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
motifs I I_GENE/I_LOCATION
, O O
and O O
a O O
serine O O
- O O
threonine O O
- O O
rich O O
motif O O
repeated O O
three O O
times O O
. O O

ET B B_PERSON/B_DISEASE
- I I_PERSON/I_DISEASE
1 I I_PERSON/I_DISEASE
limited O O
the O O
electrocardiographic O O
evidence O O
of O O
subendocardial O O
ischemia O O
and O O
attenuated O O
contractile O O
dysfunction O O
compared O O
with O O
mechanical O O
stenosis O O
at O O
the O O
same O O
coronary O O
flows O O
, O O
even O O
though O O
lactate O O
flux O O
was O O
similar O O
. O O

Our O O
results O O
are O O
consistent O O
with O O
TCOF1 B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leading O O
to O O
the O O
Treacher O O
Collins O O
syndrome O O
phenotype O O
. O O

Blood O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ammonia O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
males O B_PERSON/B_BIO
at O O
70 O B_MEASURE
, O O
80 O B_MEASURE
and O O
90 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
VO2 O B_PERSON/B_MEASURE
peak O I_PERSON/I_MEASURE
. O O

HCVR O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
L O B_PROTEIN[GENE]/B_LOCATION
significantly O O
increased O O
dVAS O B_DISEASE/B_PROTEIN[GENE]
/ O O
dPCO2 O B_MEASURE/B_PROTEIN[GENE]
to O O
4 O B_MEASURE
. O O
9 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
7 O B_MEASURE
mm O I_MEASURE
/ O O
Torr O B_MEASURE/B_PERSON
compared O O
to O O
HCVR O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
S O B_PROTEIN[GENE]/B_DISEASE
( O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

[ O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
OP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
2Cu O B_LOCATION
] O O
+ O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
detected O O
protections O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
the O O
C O B_PROTEIN[GENE]/B_NUMBER[MEASURE]
alpha O B_PROTEIN[GENE]/I_NUMBER[MEASURE]
- O O
helix O B_LOCATION
, O O
the O O
interdomain O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
hinge O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
strands O B_PROTEIN[GENE]/B_LOCATION
2 O I_PROTEIN[GENE]/I_LOCATION
- O O
7 O B_MEASURE
. O O

Vertebrate O O
U6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
small I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
snRNA O O
) O O
loci O O
exemplify O O
a O O
novel O O
class O O
of O O
polymerase B B_DISEASE/B_LOCATION
III I I_DISEASE/I_LOCATION
- O O
transcribed O O
genes O O
that O O
lack O O
an O O
intragenic O O
control O O
region O O
( O O
ICR O O
) O O
. O O

Elements O O
of O O
the O O
hAT B B_GENE/B_LOCATION
transposon I I_GENE/I_LOCATION
family I I_GENE/I_LOCATION
, O O
such O O
as O O
the O O
maize B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Ac B B_DISEASE/B_LOCATION
) O O
, O O
have O O
been O O
discovered O O
in O O
a O O
large O O
number O O
of O O
eukaryotic O O
species O O
. O O

Correlation O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coefficients O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
SF O B_MEASURE/B_LOCATION
thickness O B_MEASURE/I_LOCATION
and O O
NIR O B_MEASURE
optical O I_MEASURE
density O I_MEASURE
readings O I_MEASURE
at O O
940 O B_MEASURE
nm O I_MEASURE
( O O
OD1 O B_PROTEIN[GENE]/B_MEASURE
) O O
and O O
950 O B_MEASURE
nm O I_MEASURE
( O O
OD2 O B_PROTEIN[GENE]/B_MEASURE
) O O
wavelengths O B_LOCATION/B_DISEASE
ranged O O
from O O
r O B_PROTEIN[GENE]/B_MEASURE
= O O
- O O
0 O B_NUMBER[MEASURE]
. O O
30 O B_MEASURE
( O O
subscapula O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
) O O
to O O
r O B_PROTEIN[GENE]/B_MEASURE
= O O
- O O
0 O B_NUMBER[MEASURE]
. O O
67 O B_MEASURE
( O O
biceps O B_BODY_PART_OR_ORGAN_COMPONENT
) O O
for O O
OD1 O B_PROTEIN[GENE]/B_DISEASE
and O O
r O B_MEASURE/B_LOCATION
= O I_MEASURE/I_LOCATION
- O O
0 O B_NUMBER[MEASURE]
. O O
39 O B_MEASURE
( O O
axilla O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
) O O
to O O
r O B_PROTEIN[GENE]/B_MEASURE
= O O
- O O
0 O B_NUMBER[MEASURE]
. O O
68 O B_MEASURE
( O O
biceps O B_BODY_PART_OR_ORGAN_COMPONENT
) O O
for O O
OD2 O B_PROTEIN[GENE]/B_DISEASE
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
domain O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
deletion O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
mutants O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
demonstrated O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synergy O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
RRM O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O O
a O O
central O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
degenerate O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RRM O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
binding O O
to O O
RNA O B_GENE/B_BIO
. O O

Sequence O O
analysis O O
of O O
the O O
catfish O O
JH B B_PROTEIN[GENE]/B_LOCATION
- O O
CH B B_LOCATION/B_DISEASE
intron O O
suggests O O
that O O
several O O
sequences O O
are O O
present O O
which O O
appear O O
similar O O
to O O
important O O
transcriptional O O
regulatory O O
elements O O
found O O
within O O
JH B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
CH B B_LOCATION/B_DISEASE
introns O O
of O O
higher O O
vertebrates O O
. O O

However O O
, O O
the O O
pre3 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
2 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
strengthened O O
phenotypes O O
induced O O
by O O
other O O
20 B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteasomal I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
indicating O O
that O O
the O O
peptidylglutamyl O O
peptide O O
- O O
hydrolyzing O O
activity O O
has O O
to O O
fulfill O O
some O O
rescue O O
functions O O
. O O

The O O
use O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pharmacokinetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
parameters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
t1 O B_LOCATION/B_PROTEIN[GENE]
/ O O
2 O B_NUMBER[MEASURE]
and O O
Cltp O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O O
as O O
indices O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
elimination O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
ability O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
are O O
discussed O O
. O O

No O O
cleavage O O
of O O
gp B B_GENE
130 I I_GENE
was O O
observed O O
in O O
analogous O O
pulse O O
- O O
chase O O
radiolabelling O O
of O O
Ad O O
- O O
gB B B_LOCATION/B_DISEASE
- O O
infected O O
human O O
fibroblasts O O
, O O
even O O
though O O
these O O
cells O O
are O O
permissive O O
for O O
HCMV O O
replication O O
and O O
can O O
process O O
the O O
native B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecule I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
include O O
the O O
genes O O
, O O
undefined B B_PROTEIN[GENE]
1 I I_PROTEIN[GENE]
( O O
UD1 B B_GENE/B_DISEASE
) O O
, O O
UD2 B B_GENE/B_DISEASE
, O O
and O O
UD3 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
each O O
coding O O
for O O
proteins O O
of O O
unknown O O
function O O
, O O
the O O
ken B B_PERSON/B_GENE
gene I I_PERSON/I_GENE
encoding O O
a O O
new O O
Kruppel B B_ENZYME[GENE]
- I I_ENZYME[GENE]
like I I_ENZYME[GENE]
putative I I_ENZYME[GENE]
transcription I I_ENZYME[GENE]
factor I I_ENZYME[GENE]
, O O
the O O
fly O O
homologues O O
of O O
the O O
mammalian B B_ENZYME[GENE]/B_BIO
mitochondrial I I_ENZYME[GENE]/I_BIO
trifunctional I I_ENZYME[GENE]/I_BIO
enzyme I I_ENZYME[GENE]/I_BIO
( O O
thiolase B B_LOCATION/B_GENE
) O O
, O O
and O O
the O O
TAR B B_BIO/B_GENE
DNA I I_BIO/I_GENE
- I I_BIO/I_GENE
binding I I_BIO/I_GENE
protein I I_BIO/I_GENE
- I I_BIO/I_GENE
43 I I_BIO/I_GENE
( O O
TBPH B B_DISEASE/B_GENE
) O O
, O O
the O O
first O O
nonvertebrate O O
member O O
of O O
the O O
transmembrane B B_GENE
4 I I_GENE
superfamily I I_GENE
( O O
TM4SF B B_GENE/B_MEASURE
) O O
gene O O
, O O
a O O
new O O
homeodomain B B_GENE/B_BIO
gene I I_GENE/I_BIO
, O O
and O O
a O O
gene O O
coding O O
for O O
a O O
putative O O
nuclear O O
binding O O
protein O O
( O O
PNBP O O
) O O
that O O
is O O
homologous O O
to O O
maleless B B_PERSON/B_BIO
, O O
and O O
a O O
Copia B B_GENE/B_BIO
- I I_GENE/I_BIO
like I I_GENE/I_BIO
element I I_GENE/I_BIO
. O O

This O O
incompatibility O O
phenotype O O
requires O O
the O O
global O O
transcriptional O O
repressor O O
, O O
KorB B B_GENE/B_BACTERIUM[BIO]
, O O
and O O
the O O
target O O
for O O
incC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- O O
mediated O O
incompatibility O O
is O O
a O O
KorB B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
site I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
O I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
B I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

UICC O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
for O O
VM O B_DISEASE/B_LOCATION
and O O
35 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
for O O
VE O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
not O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

The O O
central O B_LOCATION/B_MEASURE
region O I_LOCATION/I_MEASURE
of O O
the O O
sarcomere O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
coincident O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
with O O
the O O
M O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
line O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
selectively O O
labeled O O
with O O
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
the O O
short O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
terminal O B_LOCATION/B_MEASURE
form O I_LOCATION/I_MEASURE
. O O

Despite O O
this O O
dependency O O
, O O
however O O
, O O
a O O
B B B_DISEASE_ADJECTIVE[DISEASE]
. I I_DISEASE_ADJECTIVE[DISEASE]
japonicum I I_DISEASE_ADJECTIVE[DISEASE]
fixK I I_DISEASE_ADJECTIVE[DISEASE]
mutant I I_DISEASE_ADJECTIVE[DISEASE]
did O O
not O O
have O O
the O O
phenotypic O O
characteristics O O
of O O
B B B_LOCATION/B_BIO
. I I_LOCATION/I_BIO
japonicum I I_LOCATION/I_BIO
fixL I I_LOCATION/I_BIO
and O O
fixJ B B_DISEASE/B_LOCATION
mutants I I_DISEASE/I_LOCATION
: O O
the O O
fixK B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
mutant I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
was O O
neither O O
Fix O O
- O O
in O O
symbiosis O O
with O O
soybean O O
plants O O
nor O O
defective O O
in O O
anaerobic O O
respiration O O
with O O
nitrate O O
as O O
the O O
terminal O O
electron O O
acceptor O O
. O O

Screening O O
of O O
a O O
human O O
foetal O O
brain O O
genomic O O
DNA O O
library O O
allowed O O
us O O
to O O
isolate O O
an O O
EcoRI B B_GENE/B_DISEASE
- O O
EcoRI B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fragment O O
containing O O
6 O O
kb O O
of O O
the O O
5 O O
' O O
- O O
flanking O O
region O O
, O O
the O O
open O O
reading O O
frame O O
and O O
4 O O
kb O O
of O O
the O O
3 O O
' O O
- O O
flanking O O
region O O
of O O
the O O
alpha2C4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
carboxyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
terminal O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
75 O B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
amino O B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
acids O B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
two O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
contain O O
the O O
bHLH O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motif O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
differ O O
from O O
each O O
other O B_NUMBER[MEASURE]/B_PERSON
by O O
only O O
three O B_NUMBER[MEASURE]/B_LOCATION
conservative O I_NUMBER[MEASURE]/I_LOCATION
amino O I_NUMBER[MEASURE]/I_LOCATION
acid O I_NUMBER[MEASURE]/I_LOCATION
changes O I_NUMBER[MEASURE]/I_LOCATION
, O O
while O O
the O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
portions O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
are O O
markedly O O
divergent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O O
each O O
other O B_NUMBER[MEASURE]/B_PERSON
. O O

In O O
a O O
rat O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
SAH O B_DISEASE
, O O
we O O
assessed O O
BBB O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
by O O
means O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
quantitative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
[ O O
14C O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
alpha O B_PROTEIN[GENE]
- O O
aminoisobutyric O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
technique O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Time O B_TIME[MEASURE]/B_PERSON
between O O
tests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
usually O O
less O B_MEASURE
than O O
one O B_TIME[MEASURE]
year O I_TIME[MEASURE]
) O O
did O O
not O O
affect O O
the O O
correlations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
but O O
MMPI O B_MEASURE/B_LOCATION
response O I_MEASURE/I_LOCATION
- O O
set O B_MEASURE/B_LOCATION
variables O I_MEASURE/I_LOCATION
( O O
L O B_OTHER/B_PROTEIN[GENE]
, O O
F O B_LOCATION/B_DISEASE
, O O
K O B_OTHER/B_LOCATION
, O O
F O B_PROTEIN[GENE]/B_DISEASE
- O O
K O B_OTHER/B_PROTEIN[GENE]
) O O
did O O
. O O

The O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
binding O O
( O O
Kdapp O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
incorporation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
extension O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
kinetics O B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
8 O B_NUMBER[MEASURE]
- O O
oxo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- O O
dGTP O B_PROTEIN[GENE]/B_LOCATION
compared O O
to O O
normal O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
dNTP O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
incorporation O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
at O O
template O B_MEASURE
8 O I_MEASURE
- O O
oxo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- O O
G O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
adducts O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicate O O
that O O
polymerase O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fidelity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O O
not O O
depend O O
solely O O
upon O O
the O O
overall O B_LOCATION/B_MEASURE
geometry O I_LOCATION/I_MEASURE
of O O
Watson O B_PERSON/B_LOCATION
- O O
Crick O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
base O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
pairs O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
and O O
reflects O O
the O O
asymmetry O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
the O O
enzyme O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
active O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
constant O O
expression O O
profile O O
, O O
coupled O O
with O O
the O O
observation O O
that O O
over O O
- O O
expression O O
of O O
mSin3A B B_GENE
does O O
not O O
augment O O
the O O
anti B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Myc I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
of O O
Mxi1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
SR O O
in O O
the O O
rat O O
embryo O O
fibroblast O O
( O O
REF O O
) O O
transformation O O
assay O O
, O O
suggests O O
that O O
mSin3A B B_GENE
is O O
not O O
a O O
limiting O O
factor O O
in O O
the O O
regulation O O
of O O
Myc B B_GENE/B_BIO
superfamily I I_GENE/I_BIO
function O O
. O O

Amongst O B_MEASURE/B_LOCATION
53 O I_MEASURE/I_LOCATION
" O O
inoperable O B_DISEASE_ADJECTIVE[DISEASE]
" O O
( O O
T4 O B_PROTEIN[GENE]/B_DISEASE
, O O
N0 O B_PROTEIN[GENE]
, O O
N1 O B_PROTEIN[GENE]
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
N2 O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
N3 O B_PROTEIN[GENE]/B_DISEASE
) O O
cases O B_PERSON/B_DISEASE
, O O
5 O B_MEASURE
( O O
10 O B_MEASURE
% O I_MEASURE
) O O
had O O
a O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scan O I_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
5 O B_NUMBER[MEASURE]
a O O
doubtful O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
scan O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

It O O
was O O
observed O O
that O O
muscle O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
infarction O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
IPC O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
24 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
2 O B_MEASURE
% O I_MEASURE
) O O
and O O
preischemic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
LMK O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
21 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
2 O B_MEASURE
% O I_MEASURE
) O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
were O O
smaller O B_MEASURE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
than O O
that O O
in O O
the O O
control O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
42 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
2 O B_MEASURE
% O I_MEASURE
) O O
. O O

High O O
- O O
affinity O O
binding O O
was O O
also O O
observed O O
with O O
recombinant B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SH2 I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
v B B_GENE
- I I_GENE
src I I_GENE
and O O
v B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fps I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
raising O O
the O O
possibility O O
of O O
protein O O
- O O
protein O O
interactions O O
between O O
various O O
members O O
of O O
the O O
cytoplasmic B B_GENE/B_BIO
PTK I I_GENE/I_BIO
family I I_GENE/I_BIO
. O O

Fluorescence O O
in O O
situ O O
hybridization O O
was O O
used O O
to O O
investigate O O
the O O
physical O O
distribution O O
and O O
revealed O O
that O O
both O O
retrotransposon O O
families O O
are O O
present O O
on O O
all O O
sugar O O
beet O O
chromosomes O O
and O O
largely O O
excluded O O
from O O
chromosomal O O
regions O O
harbouring O O
the O O
18S B B_GENE/B_DISEASE
- O O
5 B B_MEASURE/B_LOCATION
. I I_MEASURE/I_LOCATION
8S I I_MEASURE/I_LOCATION
- O O
25S B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rRNA O O
genes O O
. O O

The O O
organelles O O
synthesize O O
their O O
own O O
set O O
of O O
Fe B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
they O O
initiate O O
the O O
generation O O
of O O
extramitochondrial B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Fe I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
S I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
genomic O O
clone O O
of O O
the O O
chicken B B_GENE
osteopontin I I_GENE
- I I_GENE
encoding I I_GENE
gene I I_GENE
( O O
opn B B_GENE
) O O
was O O
isolated O O
and O O
found O O
to O O
be O O
organized O O
as O O
follows O O
: O O
an O O
untranslated O O
5 O O
' O O
exon O O
; O O
a O O
signal O O
peptide O O
; O O
a O O
recognition O O
sequence O O
for O O
phosphorylation O O
by O O
casein B B_GENE
kinase I I_GENE
II I I_GENE
; O O
a O O
domain O O
containing O O
a O O
possible O O
O O O
- O O
linkage O O
site O O
for O O
glycosylation O O
; O O
a O O
second O O
casein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphorylation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O O
an O O
exon O O
containing O O
three O O
functional O O
regions O O
, O O
the O O
poly O O
- O O
Asp O O
sequence O O
of O O
seven O O
consecutive O O
Asp O O
residues O O
, O O
the O O
RGD B B_LOCATION/B_TIME[MEASURE]
integrin I B_LOCATION/I_TIME[MEASURE]
recognition I B_LOCATION/I_TIME[MEASURE]
site I B_LOCATION/I_TIME[MEASURE]
and O O
a O O
potential O O
N O O
- O O
linkage O O
site O O
for O O
glycosylation O O
; O O
and O O
a O O
large O O
C O O
- O O
terminal O O
exon O O
which O O
also O O
contains O O
a O O
potential O O
N O O
- O O
linkage O O
site O O
for O O
glycosylation O O
. O O

In O O
treatments O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
R1 O I_PROTEIN[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
R2 O B_PROTEIN[GENE]
, O O
feed O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
quality O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
was O O
restricted O O
by O O
withholding O O
concentrates O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
3 O B_NUMBER[MEASURE]
and O O
4 O B_MEASURE
. O O
5 O B_MEASURE/B_PERSON
mo O I_MEASURE/I_PERSON
, O O
respectively O O
. O O

SCOF B B_GENE/B_PERSON
- I I_GENE/I_PERSON
1 I I_GENE/I_PERSON
localized O O
to O O
the O O
nucleus O O
but O O
did O O
not O O
bind O O
directly O O
to O O
either O O
C O O
- O O
repeat O O
/ O O
dehydration O O
( O O
CRT O O
/ O O
DRE O O
) O O
or O O
ABA O O
responsive O O
element O O
( O O
ABRE O O
) O O
, O O
cis O O
- O O
acting O O
DNA O O
regulatory O O
elements O O
present O O
in O O
COR B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoters I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

On O O
the O O
basis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
these O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
we O O
suggest O O
that O O
the O O
acceptor O B_PROTEIN[GENE]
peptide O I_PROTEIN[GENE]
binds O O
the O O
transferase O B_ENZYME[GENE]
in O O
a O O
beta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
like O B_LOCATION
conformation O I_LOCATION
and O O
that O O
penultimate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
residue O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
side O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
chain O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
steric O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
interactions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
may O O
play O O
a O O
role O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
determining O O
extent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
that O O
a O O
given O O
Ser O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
Thr O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
is O O
glycosylated O O
. O O

The O O
concentration O B_MEASURE
of O O
vitamin O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B1 O I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
B2 O B_PROTEIN[GENE]
and O O
B6 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
found O O
to O O
be O O
9 O B_MEASURE
. O O
96 O B_MEASURE
, O O
9 O B_MEASURE
. O O
92 O B_MEASURE
and O O
3 O B_MEASURE
. O O
01 O B_MEASURE
mg O I_MEASURE
, O O
respectively O O
in O O
240 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
capsule O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
powder O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
of O O
a O O
standard O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
company O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
name O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
has O O
not O O
been O O
disclosed O O
due O O
to O O
secrecy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
purpose O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
) O O
. O O

mCoch B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
5B2 I I_GENE/I_DISEASE
was O O
genetically O O
mapped O O
in O O
the O O
mouse O O
to O O
chromosome O O
12 O O
, O O
in O O
a O O
region O O
of O O
homologous O O
synteny O O
with O O
human O O
14q11 O O
. O O
2 O O
- O O
q13 O O
, O O
which O O
contains O O
the O O
asp1 B B_PROTEIN[GENE]/B_DISEASE
( O O
audiogenic B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
seizure I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
prone I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
) O O
locus O O
in O O
the O O
mouse O O
. O O

The O O
local O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
median O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ranges O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
of O O
the O O
above O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tests O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
as O O
follows O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
AMT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
: O O
9 O B_MEASURE
( O O
6 O B_SEQUENCE[MEASURE]
- O O
10 O B_MEASURE
) O O
; O O
CMMS O B_LOCATION/B_DISEASE
: O O
25 O B_MEASURE
( O O
16 O B_MEASURE
- O O
28 O B_MEASURE
) O O
; O O
SBT O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
2 O B_MEASURE
( O O
0 O B_MEASURE
- O O
10 O B_MEASURE
) O O
; O O
WL O B_DISEASE/B_PROTEIN[GENE]
- O O
i O B_DISEASE/B_PROTEIN[GENE]
: O O
17 O B_MEASURE
( O O
8 O B_MEASURE
- O O
27 O B_MEASURE
) O O
; O O
WL O B_DISEASE/B_PROTEIN[GENE]
- O O
d O B_PROTEIN[GENE]/B_DISEASE
: O O
5 O B_MEASURE
( O I_MEASURE
0 O I_MEASURE
- O O
10 O B_MEASURE
) O O
; O O
WL O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
r O B_PROTEIN[GENE]/B_LOCATION
: O O
9 O B_MEASURE
( O O
1 O B_MEASURE
- O O
10 O B_MEASURE
) O O
; O O
ST O B_LOCATION/B_DISEASE
: O O
13 O B_MEASURE
( O O
6 O B_MEASURE
- O O
25 O B_MEASURE
) O O
; O O
BNT O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O O
14 O B_MEASURE
( O O
10 O B_MEASURE
- O O
15 O B_MEASURE
) O O
; O O
CPT O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
1 O B_MEASURE
( O O
0 O B_MEASURE
- O O
3 O B_MEASURE
) O O
; O O
BDT O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
19 O B_MEASURE
( O O
0 O B_MEASURE
- O O
42 O B_MEASURE
) O O
; O O
OAT O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
20 O B_MEASURE
( O O
3 O B_MEASURE
- O O
33 O B_MEASURE
) O O
. O O

Antigen O B_TIME[MEASURE]/B_LOCATION
dose O I_TIME[MEASURE]/I_LOCATION
- O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
curves O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
drawn O O
, O O
and O O
the O O
cumulative O B_MEASURE/B_LOCATION
dose O I_MEASURE/I_LOCATION
required O O
for O O
a O O
35 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
reduction O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
specific O B_DISEASE
airway O I_DISEASE
conductance O I_DISEASE
was O O
calculated O O
and O O
designated O O
Provocation O B_MEASURE/B_LOCATION
Dose O B_MEASURE/I_LOCATION
( O O
PD35 O B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

Furthermore O O
, O O
CL100 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
suppresses O O
the O O
[ O O
val12 O O
] O O
ras B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
activation O O
of O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
cell O O
- O O
free O O
system O O
from O O
Xenopus O O
oocytes O O
. O O

The O O
Xenopus B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homeobox I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
twin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mediates O O
Wnt B B_GENE
induction O O
of O O
goosecoid B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
establishment O O
of O O
Spemann O O
' O O
s O O
organizer O O
. O O

The O O
data O O
also O O
suggest O O
that O O
gamma B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
CACCC I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
box I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
mediate O O
LCR B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
- I B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
gamma I B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
interactions O O
which O O
normally O O
enhance O O
gamma B B_GENE
- I I_GENE
globin I I_GENE
and O O
suppress O O
beta B B_GENE
- I I_GENE
globin I I_GENE
gene I I_GENE
expression O O
in O O
fetal O O
erythroid O O
cells O O
. O O

The O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
betamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
duodenal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
calcium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
absorption O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
1 O B_MEASURE
, O O
25 O B_MEASURE
- O O
dihydroxy O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
vitamin O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
D3 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
production O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
chick O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

We O O
have O O
previously O O
identified O O
LIT1 B B_GENE/B_LOCATION
, O O
a O O
paternally O O
expressed O O
antisense O O
RNA O O
within O O
the O O
KvLQT1 B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
locus I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
through O O
a O O
positional O O
screening O O
approach O O
using O O
human O O
monochromosomal O O
hybrids O O
. O O

Comparative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicate O O
that O O
the O O
5 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
peripheral O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domain O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exhibits O O
a O O
75 O B_MEASURE/B_LOCATION
- O O
bp O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
length O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphism O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
near O O
sequences O B_LOCATION
associated O O
with O O
the O O
termination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
the O O
H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
- O O
strand O B_GENE/B_LOCATION
replication O I_GENE/I_LOCATION
. O O

We O O
have O O
documented O O
previously O O
that O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormones O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
modulate O O
the O O
posttranslational O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
localization O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cell O B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
surface O I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
mouse O I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
mammary O I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
tumor O I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus O I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MMTV O B_VIRUS[BIO]/B_DISEASE
) O O
glycoproteins O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
viral O B_DISEASE/B_VIRUS[BIO]
- O O
infected O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
M1 O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O O
54 O B_TIME[MEASURE]/B_DISEASE
rat O I_TIME[MEASURE]/I_DISEASE
HTC O I_TIME[MEASURE]/I_DISEASE
hepatoma O I_TIME[MEASURE]/I_DISEASE
cell O I_TIME[MEASURE]/I_DISEASE
line O I_TIME[MEASURE]/I_DISEASE
. O O

Oligomers O O
corresponding O O
to O O
the O O
region O O
of O O
the O O
mlc B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
/ I I_GENE/I_LOCATION
3 I I_GENE/I_LOCATION
enhancer I I_GENE/I_LOCATION
, O O
which O O
encompasses O O
this O O
conserved O O
sequence O O
, O O
bound O O
MEF B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
competed O O
for O O
its O O
binding O O
to O O
the O O
mck B B_SPECIES[BIO]/B_GENE
enhancer O O
. O O

This O O
difference O O
between O O
SP B B_GENE
- I I_GENE
1 I I_GENE
and O O
SP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
peptides I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
not O O
due O O
to O O
their O O
differential O O
uptake O O
by O O
cell O O
, O O
since O O
approximately O O
100 O O
times O O
more O O
SP B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
2 I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
peptide I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
could O O
be O O
found O O
in O O
cytoplasmic O O
extracts O O
than O O
SP B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
experiments O O
using O O
radiolabeled O O
peptides O O
. O O

We O O
found O O
a O O
prevalence O O
of O O
eating O O
disorders O O
of O O
5 O O
. O O
9 O O
% O O
( O O
lifetime O O
prevalence O O
of O O
10 O O
% O O
) O O
, O O
irrespective O O
of O O
gender O O
and O O
type O O
of O O
diabetes O O
; O O
4 O O
. O O
1 O O
% O O
of O O
the O O
whole O O
sample O O
reported O O
intentional O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
undertreatment O O
or O O
omission O O
. O O

We O O
constructed O O
a O O
series O O
of O O
chimeric O O
genes O O
containing O O
part O O
of O O
the O O
first O O
exon O O
and O O
increasingly O O
longer O O
5 O O
' O O
flanking O O
sequences O O
of O O
the O O
ODC B B_GENE
gene I I_GENE
fused O O
to O O
either O O
bacterial B B_ENZYME[GENE]
chloramphenicol I I_ENZYME[GENE]
acetyltransferase I I_ENZYME[GENE]
( O O
CAT B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
or O O
luciferase B B_GENE
reporter I I_GENE
genes I I_GENE
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
A O O
spatial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
counting O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
which O O
the O O
location O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
each O O
and O O
every O O
PN O B_LOCATION/B_PROTEIN[GENE]
and O O
NP O B_LOCATION/B_PROTEIN[GENE]
in O O
the O O
stratum O B_LOCATION/B_MEASURE
pyramidale O I_LOCATION/I_MEASURE
of O O
sectors O B_PROTEIN[GENE]/B_LOCATION
CA1 O I_PROTEIN[GENE]/I_LOCATION
- O O
4 O B_MEASURE
was O O
applied O O
to O O
11 O B_MEASURE
normal O I_MEASURE
control O I_MEASURE
( O O
CONs O B_LOCATION/B_PROTEIN[GENE]
) O O
and O O
10 O B_MEASURE/B_PERSON
SZs O I_MEASURE/I_PERSON
matched O O
for O O
age O B_TIME[MEASURE]/B_DISEASE
and O O
postmortem O B_MEASURE/B_DISEASE
interval O I_MEASURE/I_DISEASE
, O O
as O O
well O O
as O O
4 O B_DISEASE
manic O I_DISEASE
depressive O I_DISEASE
( O O
MD O B_DISEASE/B_PROTEIN[GENE]
) O O
subjects O B_PERSON/B_LOCATION
matched O O
for O O
age O B_TIME[MEASURE]/B_PERSON
. O O

Cytostatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
some O O
essential O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oils O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
against O O
HEp O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_PROTEIN[GENE]/B_MEASURE
cells O I_PROTEIN[GENE]/I_MEASURE
. O O

Analysis O O
of O O
rat O O
brain O O
, O O
heart O O
, O O
lung O O
, O O
liver O O
, O O
kidney O O
and O O
skeletal O O
muscle O O
revealed O O
psi B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PKC I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
zeta I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
in O O
brain O O
. O O

Furthermore O O
, O O
the O O
rapid O O
light O O
- O O
mediated O O
increase O O
of O O
CPRF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
insensitive O O
to O O
transcriptional O O
inhibitors O O
, O O
suggesting O O
that O O
a O O
post O O
- O O
transcriptional O O
mechanism O O
controls O O
CPRF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
accumulation O O
. O O

In O O
those O O
patients O O
who O O
before O O
transplantation O O
were O O
serological O O
negative O O
for O O
CMV O O
but O O
had O O
received O O
organs O O
from O O
CMV B B_DISEASE
- I I_DISEASE
IgG I I_DISEASE
positive O O
donors O O
, O O
the O O
incidence O O
of O O
the O O
disease O O
was O O
highest O O
. O O

The O O
BDU O B_LOCATION/B_PROTEIN[GENE]
neurons O I_LOCATION/I_PROTEIN[GENE]
and O O
the O O
ALM O B_LOCATION/B_DISEASE
touch O I_LOCATION/I_DISEASE
neurons O I_LOCATION/I_DISEASE
are O O
lineal O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
sister O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
cells O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
the O O
AB O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
a O O
lineage O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
the O O
VA O B_LOCATION/B_PROTEIN[GENE]
and O O
VB O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
motor O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
neurons O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
are O O
lineal O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sister O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
AB O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
p O B_GENE/B_LOCATION
lineage O I_GENE/I_LOCATION
. O O

We O O
compared O O
retrospectively O O
the O O
efficacy O O
of O O
granulocyte B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulating I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
G B B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CSF I I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
alone O O
with O O
chemotherapy O O
plus O O
G B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CSF I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mobilizing O O
CD34 B B_GENE
- O O
positive O O
cells O O
in O O
patients O O
with O O
malignant O O
lymphoma O O
. O O

Cervical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
CT O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
revealed O O
an O O
irregular O B_DISEASE/B_LOCATION
low O I_DISEASE/I_LOCATION
density O I_DISEASE/I_LOCATION
at O O
the O O
periphery O B_LOCATION/B_MEASURE
of O O
the O O
cervical O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
vertebra O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
from O O
the O O
C2 O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
to O O
C4 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
level O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
now O O
show O O
that O O
purified O O
recombinant O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
PDGF B B_GENE
can O O
induce O O
this O O
binding O O
activity O O
which O O
we O O
have O O
termed O O
SIF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
for O O
sis B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
inducible I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
orthologs O O
of O O
the O O
Y B B_GENE/B_MEASURE
( I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
and O O
Y B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
subtypes I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
display O O
high O O
amino O O
acid O O
sequence O O
identities O O
between O O
pig O O
, O O
human O O
, O O
and O O
mouse O O
( O O
92 O O
% O O
- O O
94 O O
% O O
) O O
, O O
whereas O O
the O O
Y B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
Y B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
y B B_MEASURE/B_BIO
( I I_MEASURE/I_BIO
6 I I_MEASURE/I_BIO
) I I_MEASURE/I_BIO
subtypes I I_MEASURE/I_BIO
display O O
lower O O
identities O O
( O O
76 O O
% O O
- O O
87 O O
% O O
) O O
. O O

Influence O O
of O O
huanglian O O
used O O
in O O
combination O O
with O O
huangqin O O
and O O
gancao O O
on O O
the O O
erythrocytic O O
osmotic O O
fragilitas O O
of O O
experimental O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
deficiency O O
in O O
rats O O
] O O
OBJECTIVE O O
: O O
To O O
study O O
the O O
influence O O
of O O
common O O
combination O O
of O O
Huanglian O O
( O O
Coptis O O
chinensis O O
) O O
on O O
the O O
erythrocytic O O
osmotic O O
fragilitas O O
of O O
glucose B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphate I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
G6PD B B_GENE/B_LOCATION
) O O
deficiency O O
in O O
rats O O
. O O

Two O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
were O O
submitted O O
to O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
different O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hypoxia O B_DISEASE
( O O
FiO2 O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
05 O B_MEASURE
, O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
F5 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
FiO2 O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
1 O B_MEASURE
, O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
F10 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
and O O
the O O
third O B_SEQUENCE[MEASURE]/B_PERSON
to O O
normoxia O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
FiO2 O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_MEASURE/B_LOCATION
. O O
21 O B_MEASURE
, O O
group O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F21 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
a O O
thermoneutral O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
controlled O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
environment O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Magnetic O B_DISEASE/B_MEASURE
force O I_DISEASE/I_MEASURE
and O O
torque O B_MEASURE/B_DISEASE
at O O
1 O B_MEASURE
. O O
5 O B_MEASURE/B_LOCATION
T O I_MEASURE/I_LOCATION
did O O
not O O
dislodge O O
the O O
GF O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
result O O
in O O
perforation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
canine O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
IVC O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
by O O
the O O
GF O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

LCCH1 B B_GENE/B_PERSON
was O O
identical O O
to O O
the O O
Rdl B B_GENE
gene I I_GENE
, O O
a O O
known O O
GABA B B_GENE/B_PERSON
receptor I I_GENE/I_PERSON
subunit I I_GENE/I_PERSON
gene I I_GENE/I_PERSON
from O O
D O O
. O O
melanogaster O O
, O O
whereas O O
LCCH2 B B_GENE/B_PERSON
and O O
LCCH3 B B_PROTEIN[GENE]/B_MEASURE
were O O
novel O O
D O O
. O O
melanogaster O O
sequences O O
that O O
exhibited O O
structural O O
similarity O O
to O O
other O O
members O O
of O O
the O O
ligand B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
gated I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
chloride I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
channel I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
family I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

During O O
subsequent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CS O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
alone O O
trials O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
the O O
responses O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
( O O
+ O B_MEASURE/B_DISEASE
) O O
MK O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
801 O B_NUMBER[MEASURE]
- O O
injected O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
extinguished O O
as O O
easily O O
as O O
those O O
of O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
injected O O
mice O B_BIO/B_PERSON
. O O

In O O
addition O O
to O O
loss O O
of O O
digit O O
identity O O
and O O
varying O O
degrees O O
of O O
polydactyly O O
, O O
proximal O O
skeletal O O
elements O O
are O O
severely O O
shortened O O
in O O
Xt B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
ld B B_DISEASE/B_MEASURE
double O O
homozygous O O
limbs O O
. O O

The O O
NH2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_PROTEIN[GENE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragments O B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
tested O O
for O O
susceptibility O B_DISEASE
to O O
modification O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
Nalpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
( O O
3 O B_MEASURE
- O O
maleimidylpropionyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
biocytin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
which O O
attaches O O
a O O
biotin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
group O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
cysteine O O
sulfhydryls O B_MEASURE/B_BIO
. O O

The O O
flanking O B_GENE/B_LOCATION
open O I_GENE/I_LOCATION
reading O I_GENE/I_LOCATION
frames O I_GENE/I_LOCATION
in O O
pARGC2 O B_BIO/B_MEASURE
showed O O
no O O
homologies O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
arginine O O
biosynthetic O B_ENZYME[GENE]
genes O I_ENZYME[GENE]
. O O

The O O
specificity O O
of O O
the O O
transcriptional O O
activation O O
by O O
ISGF3 B B_GENE
is O O
mediated O O
by O O
specific O O
elements O O
termed O O
IFN B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stimulatory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ISRE B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
located O O
in O O
the O O
promoter O O
region O O
of O O
IFN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
inducible O O
genes O O
. O O

It O O
appears O O
that O O
the O O
K O B_OTHER/B_PROTEIN[GENE]
- O O
ABC O B_PROTEIN[GENE]/B_DISEASE
is O O
a O O
relatively O O
nonbiased O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suitable O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
evaluation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
both O O
gifted O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O O
nongifted O B_PERSON/B_ORGANIZATION
children O I_PERSON/I_ORGANIZATION
regardless O O
of O O
race O B_SPORT[ENT]/B_PERSON
or O O
gender O B_PERSON/B_LOCATION
. O O

Spinophilin B B_MEASURE/B_LOCATION
, O O
a O O
novel O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
localized O O
to O O
dendritic O O
spines O O
. O O

he O O
formulated O O
' O O
Haber O B_PERSON/B_COLOR
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
rule O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
' O O
, O O
also O O
known O O
as O O
C O B_PROTEIN[GENE]/B_MEASURE
x O O
T O B_PROTEIN[GENE]/B_OTHER
= O O
constant O B_MEASURE/B_DISEASE
in O O
order O B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
characterize O O
the O O
toxicity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
an O O
inhalant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
major O B_GENE/B_LOCATION
transcription O I_GENE/I_LOCATION
start O I_GENE/I_LOCATION
site O I_GENE/I_LOCATION
, O O
designated O O
as O O
+ O B_PROTEIN[GENE]
1 O I_PROTEIN[GENE]
, O O
was O O
determined O O
by O O
RACE O B_DISEASE/B_GENE
( O O
rapid O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
amplification O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cDNA O B_GENE
ends O I_GENE
) O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
human O B_GENE
liver O I_GENE
cDNA O I_GENE
and O O
was O O
found O O
to O O
be O O
located O O
50 O B_MEASURE/B_LOCATION
bp O B_MEASURE/I_LOCATION
upstream O O
from O O
the O O
translation O B_LOCATION/B_ORGANIZATION
start O I_LOCATION/I_ORGANIZATION
site O I_LOCATION/I_ORGANIZATION
. O O

The O O
MIC90 O O
of O O
ABK O O
against O O
coagulase B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
type I B_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
IV I B_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
strains O O
was O O
rather O O
high O O
, O O
12 O O
. O O
5 O O
micrograms O O
/ O O
ml O O
. O O

HC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
toxin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
exerts O O
a O O
potent O O
cytostatic O O
effect O O
on O O
plant O O
and O O
animal O O
cells O O
by O O
inhibiting O O
histone B B_GENE
deacetylase I I_GENE
. O O

The O O
delta O B_PROTEIN[GENE]/B_MEASURE
mean O O
VAF O B_DISEASE/B_PROTEIN[GENE]
and O O
delta O B_PROTEIN[GENE]/B_MEASURE
mean O O
SABP O B_DISEASE
indicated O O
varied O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mean O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
VAF O B_DISEASE/B_PROTEIN[GENE]
and O O
SABP O B_DISEASE/B_PROTEIN[GENE]
, O O
respectively O O
. O O

Azoospermia O B_DISEASE/B_SPECIES[BIO]
was O O
graded O O
in O O
the O O
following O O
way O B_LOCATION
: O O
adequate O B_DISEASE_ADJECTIVE[DISEASE]
spermatozoa O I_DISEASE_ADJECTIVE[DISEASE]
( O O
A1 O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
scanty O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
rare O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spermatozoa O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
A2 O B_PROTEIN[GENE]
) O O
, O O
spermatid O B_DISEASE/B_ORGANISM_FUNCTION
arrest O I_DISEASE/I_ORGANISM_FUNCTION
( O O
B1 O B_PROTEIN[GENE]
) O O
, O O
spermatocyte O B_DISEASE/B_ORGANISM_FUNCTION
arrest O I_DISEASE/I_ORGANISM_FUNCTION
( O O
B2 O B_PROTEIN[GENE]
) O O
, O O
Sertoli O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cell O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
- O O
only O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pattern O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
C O B_PROTEIN[GENE]
) O O
and O O
sclerosis O B_DISEASE
( O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

